---
document_datetime: 2023-09-21 17:23:25
document_pages: 162
document_pathfilename: www.ema.europa.eu/en/documents/assessment-report/kisplyx-epar-public-assessment-report_en.pdf
document_name: kisplyx-epar-public-assessment-report_en.pdf
version: success
processing_time: 130.7974853
conversion_datetime: 2025-12-28 19:34:04.253472
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

21 July 2016 EMA/578759/2016 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Kisplyx

International non-proprietary name: lenvatinib

Procedure No. EMEA/H/C/004224/0000

## Note

Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure..............................................                                | 7                                                                                                        |
|-------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier .....................................................................................7   |                                                                                                          |
| 1.2. Steps taken for the assessment of the product                                                                      | ........................................................8                                                |
| 2. Scientific discussion................................................................................                | 9                                                                                                        |
| 2.1. Problem statement...............................................................................................9  |                                                                                                          |
| 2.1.1. Disease or condition                                                                                             | ..........................................................................................9              |
| 2.1.2. Epidemiology, clinical presentation, diagnosis and stage/prognosis..........................9                    |                                                                                                          |
| 2.1.3. Biologic features and pathogenesis......................................................................9        |                                                                                                          |
| 2.1.4. Clinical presentation, diagnosis and stage/prognosis............................................                 | 10                                                                                                       |
| 2.1.5. Management...................................................................................................    | 10                                                                                                       |
| 2.2. Quality aspects .................................................................................................. | 13                                                                                                       |
| 2.2.1. Introduction.................................................................................................... | 13                                                                                                       |
| 2.2.2. Active Substance.............................................................................................    | 13                                                                                                       |
| 2.2.3. Finished Medicinal Product................................................................................       | 15                                                                                                       |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects..............................                      | 17                                                                                                       |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                               | ...................... 18                                                                                |
| 2.2.6. Recommendation(s) for future quality development.............................................                    | 18                                                                                                       |
| 2.3. Non-clinical aspects............................................................................................   | 18                                                                                                       |
| 2.3.1. Introduction.................................................................................................... | 18                                                                                                       |
| 2.3.2. Pharmacology.................................................................................................    | 18                                                                                                       |
| 2.3.3. Pharmacokinetics                                                                                                 | ............................................................................................ 28          |
| 2.3.4. Toxicology...................................................................................................... | 35                                                                                                       |
| 2.3.5. Ecotoxicity/environmental risk assessment.........................................................               | 47                                                                                                       |
| 2.3.6. Discussion on non-clinical aspects .....................................................................         | 48                                                                                                       |
| 2.3.7. Conclusion on the non-clinical aspects                                                                           | ............................................................... 49                                       |
| 2.4. Clinical aspects                                                                                                   | .................................................................................................. 50    |
| 2.4.1. Introduction.................................................................................................... | 50                                                                                                       |
| 2.4.2. Pharmacokinetics                                                                                                 | ............................................................................................ 51          |
| 2.4.3. Pharmacodynamics..........................................................................................       | 64                                                                                                       |
| 2.4.4. Discussion on clinical pharmacology...................................................................           | 69                                                                                                       |
| 2.4.5. Conclusions on clinical pharmacology.................................................................            | 71                                                                                                       |
| 2.5. Clinical efficacy                                                                                                  | .................................................................................................. 72    |
| 2.5.1. Dose response studies .....................................................................................      | 72                                                                                                       |
| 2.5.2. Main study                                                                                                       | ..................................................................................................... 74 |
| 2.5.3. Discussion on clinical efficacy..........................................................................        | 103                                                                                                      |
| 2.5.4. Conclusions on the clinical efficacy ..................................................................          | 105                                                                                                      |
| 2.6. Clinical safety .................................................................................................. | 105                                                                                                      |
| 2.6.1. Discussion on clinical safety............................................................................        | 139                                                                                                      |
| 2.6.2. Conclusions on the clinical safety                                                                               | .................................................................... 144                                 |

<div style=\"page-break-after: always\"></div>

2.7. Risk Management Plan  ...................................................................................... 145

2.8. Pharmacovigilance ........................................................................................... 155

2.9. Product information  .......................................................................................... 155

2.9.1. User consultation .......................................................................................... 155

2.9.2. Additional monitoring  ..................................................................................... 155

3. Benefit-Risk Balance ........................................................................... 155

3.1. Therapeutic Context ......................................................................................... 155

3.1.1. Disease or condition ...................................................................................... 155

3.1.2. Available therapies and unmet medical need  ..................................................... 156

3.1.3. Main clinical studies  ....................................................................................... 156

3.2. Favourable effects  ............................................................................................ 157

3.3. Uncertainties and limitations about favourable effects  ........................................... 157

3.4. Unfavourable effects  ......................................................................................... 157

3.5. Uncertainties and limitations about unfavourable effects ....................................... 158

3.6. Effects Table  .................................................................................................... 158

3.7. Benefit-risk assessment and discussion  ............................................................... 160

3.7.1. Importance of favourable and unfavourable effects  ............................................ 160

3.7.2. Balance of benefits and risks .......................................................................... 161

3.7.3. Additional considerations on the benefit-risk balance ......................................... 161

3.8. Conclusions  ..................................................................................................... 161

4. Recommendations  ............................................................................... 161

<div style=\"page-break-after: always\"></div>

## List of abbreviations

| AE adverse event                                                                                                        |
|-------------------------------------------------------------------------------------------------------------------------|
| ALT alanine aminotransferase                                                                                            |
| AST aspartate aminotransferase                                                                                          |
| ATC anaplastic thyroid cancer                                                                                           |
| AUC area under the concentration-time curve                                                                             |
| AUC0-24 area under the concentration-time curve from time zero to 24 hours                                              |
| BID bis in die , twice daily                                                                                            |
| BOR best overall response                                                                                               |
| CHMP Committee for Medicinal Products for Human Use                                                                     |
| CI confidence interval                                                                                                  |
| Cmax maximum observed plasma concentration                                                                              |
| CNS central nervous system                                                                                              |
| CPMP Committee for Proprietary Medicinal Products                                                                       |
| CR complete response                                                                                                    |
| CRF case report form                                                                                                    |
| CSE clinically significant event                                                                                        |
| CSR Clinical Study Report                                                                                               |
| CTCAE Common Terminology Criteria for Adverse Events                                                                    |
| CVA cerebrovascular accident                                                                                            |
| dc discontinuation                                                                                                      |
| decr decreased                                                                                                          |
| DTC differentiated thyroid cancer                                                                                       |
| ECOG PS Eastern Cooperative Oncology Group Performance Status                                                           |
| EMA European Medicines Agency                                                                                           |
| EF ejection fraction                                                                                                    |
| ESMO European Society for Medical Oncology                                                                              |
| EU European Union EVER Everolimus                                                                                       |
| FAMHP Federal Agency for Medicines and Health Products FDA Food and Drug Administration                                 |
| FGF fibroblast growth factor                                                                                            |
| FGFR fibroblast growth factor receptor                                                                                  |
| FLT1 fms-like tyrosine kinase 1 (alternate name for VEGFR1) FLT4 fms-like tyrosine kinase 4 (alternate name for VEGFR3) |
| genl phys general physical                                                                                              |
| GI gastrointestinal                                                                                                     |
| Hgb hemoglobin                                                                                                          |
| HR hazard ratio                                                                                                         |
| HUVEC human umbilical vein endothelial cell                                                                             |
| IBD International Birth Date                                                                                            |
| IC50 half maximal inhibitory concentration                                                                              |
| ICH International Conference on Harmonisation                                                                           |
| ICR Independent Central Review                                                                                          |

<div style=\"page-break-after: always\"></div>

| IFN-α interferon-α                                                                |
|-----------------------------------------------------------------------------------|
| IIR independent imaging review                                                    |
| IL-2 interleukin-2                                                                |
| ILD interstitial lung disease                                                     |
| incr increased                                                                    |
| IPCW inverse probability of censoring weighted (analysis)                         |
| ISS Integrated Summary of Safety                                                  |
| ITT intent-to-treat                                                               |
| KDR kinase insert domain receptor (VEGFR2)                                        |
| KIT a stem cell factor receptor                                                   |
| LENV lenvatinib                                                                   |
| MAA marketing authorisation application                                           |
| MAPK mitogen activated kinase                                                     |
| MedDRA Medical Dictionary for Regulatory Activities                               |
| MHRA Medicines and Healthcare Regulatory Agency                                   |
| MTC medullary thyroid cancer                                                      |
| MI myocardial infarction                                                          |
| mRCC metastatic renal cell carcinoma                                              |
| MSKCC Memorial Sloan-Kettering Cancer Center MTD maximum tolerated dose           |
| mTOR mammalian target of rapamycin                                                |
| NAv not available                                                                 |
| NCCN National Comprehensive Cancer Network                                        |
| NE not estimable                                                                  |
| ORR objective response rate                                                       |
| received placebo in the double-blind Randomization Phase in Study 303)            |
| OS overall survival                                                               |
| PD progressive disease or disease progression                                     |
| PDGF platelet-derived growth factor PDGFR platelet-derived growth factor receptor |
| PFS progression-free survival PK pharmacokinetic(s)                               |
| PopPK population PPE palmar-plantar erythrodysesthesia (syndrome)                 |
| pharmacokinetics                                                                  |
| PRAC Pharmacovigilance Risk Assessment Committee                                  |
| PR partial response                                                               |
| PRES posterior reversible encephalopathy syndrome                                 |
| QD quaque die , once daily                                                        |
| RCC renal cell carcinoma                                                          |
| RECIST Response Evaluation Criteria in Solid Tumors resp respiratory              |
| RP2 recommended Phase 2 (dose) depending on context                               |
| RR radioiodine-refractory or rate ratio, RTK receptor tyrosine kinase             |

<div style=\"page-break-after: always\"></div>

SAE serious adverse event SD stable disease or standard deviation, depending on context SGQ sponsor-generated query SmPC Summary of Product Characteristics SMQ standard MedDRA query SY subject-year TC thyroid cancer TEAE treatment-emergent adverse event TKI tyrosine kinase inhibitor TSH thyroid-stimulating hormone US United States VEGF vascular endothelial growth factor VEGFR vascular endothelial growth factor receptor

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

The applicant Eisai Europe Ltd. submitted on 11 January 2016 an application for marketing authorisation to the European Medicines Agency (EMA) for Kisplyx, through the centralised procedure falling within the Article 3(1) and point 3 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 21 May 2015. The acceptability of an accelerated review was agreed upon by the EMA/CHMP on 19 November 2015.

The applicant applied for the following indication: Kisplyx is indicated in combination with everolimus for the treatment of adult patients with unresectable advanced or metastatic renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.

## The legal basis for this application refers to:

Article 8(3) of Directive 2001/83/EC - complete and independent application.

The application submitted is composed of administrative information, complete quality data, non-clinical and clinical data based on applicants' own tests and studies and/or bibliographic literature substituting/supporting certain tests or studies.

This application is submitted as a multiple of Lenvima authorised on 28 May 2015 in accordance with Article 82(1) of Regulation (EC) No 726/2004.

## Information on Paediatric requirements

Pursuant to Article 7 of Regulation (EC) No 1901/2006, the application included an EMA Decision CW/1/2011 on the granting of a class waiver.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the applicant did submit a critical report addressing the possible similarity with authorised orphan medicinal products.

## Applicant's request for consideration

## Scientific Advice

The applicant did not seek scientific advice at the CHMP for the pivotal study in this indication..

## Licensing status

The product was not licensed in this indication in any country at the time of submission of the application.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur: Bart Van der Schueren Co-Rapporteur:  Robert James Hemmings

- The application was received by the EMA on 11 January 2016.
- Accelerated Assessment procedure was agreed upon by CHMP on 19 November 2015
- The procedure started on 28 January 2016.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 19 April 2016. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 15 April 2016. The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on 29 April 2016. In accordance with Article 6(3) of Regulation (EC) No 726/2004, the Rapporteur and Co-Rapporteur declared that they had completed their assessment report in less than 80 days.
- During the meeting on 13 May 2016, the PRAC agreed on the PRAC Assessment Overview and Advice to CHMP.
- During the meeting on 26 May 2016, the CHMP agreed on the consolidated List of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 30 May 2016.
- The applicant submitted the responses to the CHMP consolidated List of Questions on 21 June 2016.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 08 July 2016.
- During the meeting on 21 July 2016, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation to Kisplyx.
- The CHMP adopted the similarity report on 21 July 2016.

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

Lenvatinib is an oral multiple kinase inhibitor. It was approved as an orphan medicine in the EU under the tradename of Lenvima in the treatment of adult patients with differentiated thyroid cancer (DTC) on 28 May 2015.

## 2.1.1. Disease or condition

Renal cell carcinomas are kidney tumours which represent approximately 90% of cases of kidney cancer in adults (Wahal and Mardi, 2014). These tumours arise from the cells of the proximal renal tubular epithelium.

The applicant applied for the following indication:

Kisplyx is indicated in combination with everolimus for the treatment of adultpatients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.

According to the American Joint Committee on Cancer, both metastatic (M1 - distant metastasis present) and locally unresectable (T4 - tumor invades beyond Gerota's fascia; N - any; M0) RCC are classified as Stage IV (Edge, et al., 2010). The terms 'unresectable advanced RCC' and 'metastatic RCC' are used interchangeably, and since both represent Stage IV RCC, the treatment of adult patients with advanced RCC is stated in the approved indications for second-line agents.

## 2.1.2. Epidemiology, clinical presentation, diagnosis and stage/prognosis

Kidney cancer represents approximately 3% of all cancers worldwide (Cohen, et al., 2005, Garcia and Rini, 2007). The incidence of RCC has been rising steadily and the 5-year prevalence of RCC in the EU-28 (plus Iceland and Norway) in 2015 was estimated to be 229,465 cases (adapted from Globocan 2012). Despite substantial progress in the understanding and treatment of mRCC in recent years, its incidence is increasing, and  the  disease  is  still  considered  incurable.  Smoking  and  obesity  are  established  risk  factors  for  RCC development. RCC also appears to be more common in patients with end-stage renal failure, acquired renal cystic disease and tuberous sclerosis. Approximately 2%-3% of RCC are hereditary and several autosomal dominant syndromes are described, each with a distinct genetic basis and phenotype, the most common one being Von Hippel Lindau (VHL) disease. In recent years, many new genes associated with RCC have been reported (such as PBRM1, SETD2, BAP1) (ESMO guidelines, 2014; NCCN guidelines 2016).

## 2.1.3. Biologic features and pathogenesis

Clear cell RCC is the most frequent pathological subtype of sporadic RCC in adults (70%-85%), with loss of 3p and the classical clear aspect of the cells due to glycogen and lipids in their cytoplasm. Other subtypes historically  called  non  clear  RCC  include  papillary  RCC  (7%-15%)  shows  distribution  of  malignant  cells around capillary cores (papillae), chromophobe RCC (5%-10%) is made up of typical polygonal cells with a clear  delimitation  of  the  cytoplasmic  membrane  and  reticular  cytoplasm,  renal  medullary  carcinoma,  etc (Escudier et al, 2014). Due to a better understanding of the correlation between chromosomal alterations,

<div style=\"page-break-after: always\"></div>

histological  subtypes  and  molecular  pathway  abnormalities,  new  morphological  variants  of  RCC  are  now recognised  according  to  the  Vancouver  classification  (Escudier  et  al,  2014).  Each  of  the  most  frequent morphological  genetic  RCC  subtypes  correlates  with  a  specific  molecular  pathway.  Examples  include  the hypoxia-inducible pathway (clear-cell, papillary type II through the FH gene), the mTOR signalling pathway (clear-cell and papillary type II), the c Met-RAF-MEK-ERK pathway (papillary type I and translocation RCC).

Inactivation  of  the  von  Hippel-Lindau  (VHL)  tumour  suppressor  protein  is  a  characteristic  of  clear  cell tumours, resulting in the deregulation of the VEGF signalling pathway. VEGFRs are typical receptor tyrosine kinases with an extracellular domain for ligand binding, a transmembrane domain and a cytoplasmic domain, including a tyrosine kinase domain. Activation of VEGF signalling pathways promotes the growth of tumour blood cells. The major pro-angiogenic signal is generated from the ligand-activated VEGFR-2.

## 2.1.4. Clinical presentation, diagnosis and stage/prognosis

More than 50% of RCCs are currently detected incidentally. However, some patients with RCC still present with  clinical  symptoms,  such  as  flank  pain,  gross  haematuria  and  palpable  abdominal  mass  (the  classical triad);  metastatic  symptoms  like  bone  pain  or  lung  nodules;  or  paraneoplastic  syndromes,  such  as hypercalcaemia, unexplained fever, erythrocytosis or wasting syndromes (Escudier et al, 2014). About 30% of patients with RCC have metastatic disease at the time of diagnosis, and a significant proportion of patients with  localized  disease  treated  with  curative  nephrectomy  relapse  subsequently  with  metastatic  disease. Metastatic RCC is associated with a high quality-of-life burden, based on physical, psychological, and social criteria, and drastically reduced survival; only about 8% to 22.5% of mRCC patients survive for five years or more as compared to 90% of patients with localized renal cancer. The extent of tumour burden and site of metastasis  contribute  to  local  symptoms.  The  most  frequent  locations  of  metastases  are  the  lungs, mediastinum, bone, liver,  and  brain.  Among  solid  cancer  types,  RCC  has  the  second  highest  incidence  of brain metastases.

Risks assessment models have been developed to provide prognostic information for patients and to inform on  eligibility  and  risk  stratification  factors  for  clinical  trials.  The  Memorial  Sloan-Kettering  Cancer  Centre (MSKCC) stratifies patients by favourable, intermediate and poor risk according to 6 prognostic risk factors; Karnofsky  performance  status  (KPS),  haemoglobin  level,  corrected  serum  calcium,  time  from  diagnosis  to treatment, platelets and neutrophil levels. Subsequently established and validated in first-line and secondline setting International mRCC  Database  Consortium  (IMDC) model  includes 3 prognostic factors (haemoglobin level, corrected serum calcium and performance status) to stratify patients to risk groups.

## 2.1.5. Management

Management of local disease includes partial or radical nephrectomy. The role of neo-adjuvant or adjuvant therapy  is  not  yet  established.  In  the  advanced  disease  setting  systemic  therapy  is  used.  Until  the development of agents that target tumour angiogenesis and other signaling pathways, systemic therapy with the cytokines interleukin 2 (IL-2) or interferon (IFN)-α was the main treatment for advanced RCC. However, the use of both agents has declined substantially since the introduction of molecular targeted therapies.

Current approved treatments for metastatic RCC in the first-line setting comprise targeted therapies, either tyrosine  kinase  inhibitors  (TKI:  sunitinib  and  pazopanib)  or  mammalian  target  of  rapamycin  (mTOR) inhibitors  (temsirolimus)  administered  as  single  agents,  bevacizumab  +  interferon  (IFN),  or  high-dose interleukin-2 (IL-2) (ESMO guidelines, 2014; NCCN guidelines, 2016).

<div style=\"page-break-after: always\"></div>

Approved second-line agents include TKIs: sorafenib, sunitinib, axitinib, and pazopanib; the mTOR inhibitor everolimus.

A novel immunotherapeutic agent, Opdivo (nivolumab), belonging to a class of immune checkpoint inhibitors (PD-1/PD-L1), has been recently granted approval by EC on 19/06/2015 for the treatment of advanced renal cell carcinoma after prior therapy in adults.

Afinitor  is  indicated  for  the  treatment  of  patients  with  advanced  renal  cell  carcinoma,  whose  disease  has progressed on or after treatment with VEGF-targeted therapy. The recommended dose is 10 mg everolimus once daily. Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs.

Relapsed RCC is an aggressive tumor and the optimal sequencing of therapies, or combination of therapies which would lead to durable responses and minimize relapse remains a challenge. Current strategies have focused  on  the  development  of  new  therapeutic  agents,  optimal  sequencing,  and  combinations  of  these agents  to  maximize  their  impact  on  clinical  outcomes.  To  date,  however,  results  of  combination-therapy studies (ie, temsirolimus  plus bevacizumab,  temsirolimus  plus  sunitinib, erlotinib  plus  bevacizumab, everolimus  plus  bevacizumab)  have  shown  no  advantage  in  PFS  over  monotherapy  with  approved  single agents and, in some cases, an unacceptably high degree of toxicity (Bukowski et al., 2007; Dorff, et al., 2014;  Feldman,  et  al.,  2009;  Graves,  et  al.,  2013;  Hainsworth,  et  al.,  2010;  Kanesvaran,  et  al.,  2015; Negrier,  et  al.,  2011;  Powles,  et  al.,  2014;  Ravaud,  et  al.,  2013).  Therefore,  there  remains  a  significant unmet medical need for more effective treatment options, including possible combination therapies, with a manageable safety profile in patients with advanced RCC.

Table 1 Approved indications of Second line therapies in advanced RCC:

| INN        | Date Authorized   | Indication                                                                                                                                                   |
|------------|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Sorafenib  | Jul 2006          | Treatment of patients with advanced RCC who have failed prior interferon-alpha- or interleukin 2-based therapy or are considered unsuitable for such therapy |
| Everolimus | Aug 2009          | Treatment of patients with advanced RCC, whose disease has progressed on or after treatment with VEGF-targeted therapy                                       |
| Pazopanib  | Jun 2010          | In adults for the first-line treatment of advanced RCC and for patients who have received prior cytokine therapy for advanced disease                        |
| Axitinib   | Sep 2012          | Treatment of adult patients with advanced RCC after failure of prior treatment with sunitinib or a cytokine                                                  |
| Nivolumab  | Apr 2016          | Treatment of advanced RCC after prior therapy in adults                                                                                                      |

## About the product

Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), in addition to other proangiogenic and oncogenic pathway-related RTKs including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4, the platelet derived growth factor (PDGF) receptor PDGFRα, KIT, and RET.  The combination of lenvatinib and everolimus showed increased antiangiogenic and antitumor activity as demonstrated by decreased human endothelial cell proliferation, tube formation, and VEGF signaling in vitro and tumor volume in mouse xenograft models of human renal cell cancer greater than each drug alone.

<div style=\"page-break-after: always\"></div>

In the scope of this application, everolimus (Afinitor) is intended to be used in combination with lenvatinib.

## Indication and dosage

Lenvima is formulated in 2 strengths of hypromellose hard capsules containing lenvatinib mesilate equivalent to either 4 mg or 10 mg of lenvatinib.

The applicant applied for the following indication:

'Lenvatinib  is  indicated  in  combination  with  everolimus  for  the  treatment  of  patients  with  unresectable advanced  or  metastatic  renal  cell  carcinoma  (RCC)  following  one  prior  vascular  endothelial  growth  factor (VEGF)-targeted therapy'.

The approved indication further to the CHMP review is:

'Kisplyx is indicated in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one vascular endothelial growth factor (VEGF)-targeted prior therapy'.

The proposed recommended daily dose of lenvatinib is 18 mg (one 10 mg capsule and two 4 mg capsules) once daily in combination with 5 mg of everolimus once daily. The daily doses of lenvatinib and, if necessary, everolimus are to be modified as needed according to the dose/toxicity management plan.

If a patient misses a dose, and it cannot be taken within 12 hours, then that dose should be skipped and the next dose should be taken at the usual time of administration.

Treatment should continue as long as there is clinical benefit or until unacceptable toxicity occurs.

## Type of Application and aspects on development

The CHMP agreed to the applicant's request for an accelerated assessment as the product was considered to be of major public health interest. This was based on:

- The benefit-risk balance is expected to be positive.
- The applicant has provided comprehensive data.
- Unmet medical needs will be addressed, as there is a need to develop strategies that may increase the degree of the antitumor effects and impedes the onset of/ or eliminates refractory disease. Combinations of  targeted  agents  may  be  one  method  to  achieve  these  goals.  Hence  the  proposed  combination  of lenvatinib and everolimus in the 2nd line setting could be seen as addressing an area of unmet medical need. The results of the Phase 2 part of the conducted pivotal Study E7080-G000-205 suggest that the proposed combination of lenvatinib with everolimus is a successful combination therapy in the treatment of metastatic renal cancer which could have an impact on medical practice. The presented data appear to  support  a  therapeutic  advantage  for  efficacy  in  favor  of  the  proposed  lenvatinib-everolimus combination over existing monotherapies.
- The intended drug combination is of major interest from the point of view of public health with regards to the number of patients that would benefit from improved treatment strategies for metastatic renal cancer.

<div style=\"page-break-after: always\"></div>

## 2.2. Quality aspects

## 2.2.1. Introduction

The proposed product is identical from a quality point of view to the Lenvima (EU/1/15/1002) approved on 28 May 2015 via Centralised procedure. An updated Module 3 has been submitted to support this application, as this considered a stand-alone application due to different indications and another trade name.

The finished product is presented as hard capsules in 2 strengths, containing lenvatinib mesilate equivalent to 4 mg and 10 mg lenvatinib as active substance.

## Other ingredients are:

Capsule  contents:  calcium  carbonate,  mannitol,  microcrystalline  cellulose,  hydroxypropylcellulose,  lowsubstituted hydroxypropylcellulose and talc;

Capsule shell: hypromellose, titanium dioxide (E171), yellow iron oxide (E172) and red iron oxide (E172);

Printing ink containing: shellac, black iron oxide (E172), potassium hydroxide and propylene glycol

The product is available in blisters of polyamide/aluminium/PVC with a push through aluminium foil lidding.

## 2.2.2. Active Substance

## General information

The chemical name of lenvatinib is 4-[3-Chloro-4-( N '-cyclopropylureido)phenoxy]-7-methoxyquinoline-6carboxamide methanesulfonate and it has the following structure:

<!-- image -->

The active substance is a white, non-hygroscopic, crystalline powder, slightly soluble in water and practically insoluble in ethanol . The structure of lenvatinib mesilatewas elucidated by using elemental analysis, ultraviolet-visible (UV-Vis) spectroscopy, infrared spectroscopy, 1 H and  13 C nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry. Lenvatinib is achiral.

Lenvatinib mesilate exhibits polymorphism. Polymorphism is controlled during the manufacturing process of the active substance.

<div style=\"page-break-after: always\"></div>

## Manufacture, characterisation and process controls

The manufacturing process of lenvatinib mesilate consists of two synthetic steps followed by salt formation. Five  crystallisations  ensure  the  control  of  the  impurity  profile  of  lenvatinib  mesilate.  Well  defined  starting materials with acceptable specifications are used.

A quality by design (QbD) approach was used in the process development of lenvatinib mesilate. A quality target product profile (QTPP) was defined for the finished product and the properties of the active substance shown  to  impact  on  this  were  defined  as  critical  quality  attributes  (CQAs).  Active  substance  CQAs  are impurities, residual solvents, residual genotoxins, particle size, and polymorphic form.

Critical  process  parameters  (CPPs)  in  the  synthetic  process  were  identified  by  risk  assessment  (including failure mode effects analysis, FMEA), process knowledge, and both uni- and multi-variate experiments. Each of the 3 steps contains CPPs and thus all are considered critical. Proven acceptable ranges (PARs) for all the CPPs have been defined. However, no design space is claimed by the applicant so for each step, only one CPP may be moved within its PAR with other CPPs held at their target set-point.

The quality of the active substance is assured by a control strategy composed of the above-mentioned PARs and a series of in process controls designed to limit impurities and residual solvents. Adequate in-process controls are applied during the synthesis. The specifications and control methods for intermediate products, starting  materials  and  reagents  have  been  presented.  Despite  the  QbD  approach  to  development,  the applicant employs traditional release testing to ensure the quality of the active substance. Data from the first process validation batch of lenvatinib mesilate is provided. The CPPs were all controlled within the PARs and the  lenvatinib  mesilate  thus  produced  was  of  adequate  quality  and  in  line  with  the  active  substance specification.

The characterisation of the active substance and its impurities are in accordance with the EU guideline on chemistry of new active substances. Potential and actual impurities were well discussed with regards to their origin  and  characterised. All  potential  impurities  and  the  starting  material  (SM)  itself  have  been  evaluated according  to  CHMP  guidelines  on  genotoxic  impurities.  This  analysis  is  based  on  experimental  and computational SAR analysis using DEREK and MCASE software systems and Ames-test. There have been no impurities detected above the reporting threshold (0.05%) in 10 batches. A HPLC method was developed to detect the 16 potential impurities. Specifications for only 2 from 16 potential impurities have been defined based  on  spiking  studies.  The  spike  study  of  genotoxic  impurity  demonstrates  that  during  manufacturing process is able to purge to levels below the TTC of 60ppm, from 0.30% to 3ppm, in the intermediate. The genotoxic impurities show no detectable levels in 10 batches.

Adequate in-process  controls  are  applied  during  the  synthesis.  The  specifications  and  control  methods  for intermediate products, starting materials and reagents have been presented.

Lenvatinib mesilate is packed inside linear low-density polyethylene (LLDPE) film on the inside and a nylon film on the outside and secured with a cable.

## Specification

The  active  substance  specification  includes  tests  for  appearance,  identification  (IR,  XRPD),  assay  (HPLC), related  substances  (HPLC),  genotoxic  impurities  (HPLC),  residual  solvents  (GC,  HPLC),  residual  benzene (GC), water content (KF), heavy metals (USP), methanesulfonic acid content (ion chromatography), particle size (light diffraction measurement) and microbial limits (Ph Eur).

<div style=\"page-break-after: always\"></div>

Impurities  present  at  higher  than  the  qualification  threshold  according  to  ICH  Q3A  were  qualified  by toxicological and clinical studies and appropriate specifications have been set.

The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines. Satisfactory information regarding the reference standards used for impurities testing has been presented.

Batch analysis data (6 commercial scale batches) of the active substance are provided. The results are within the specifications and consistent from batch to batch.

## Stability

Stability data on 3 commercial scale batches of active substance from the proposed manufacturer stored in the intended commercial package for up to 36 months under long term conditions at 5 ºC ± 3 ºC  and for up to 6 months under accelerated conditions at 25 °C ± 2 ºC /60 ± 5 % RH  according to the ICH guidelines were provided. The following parameters were tested: description, identification (XRPD), related substances, genotoxic impurities, water content and assay. No significant changes to any of the measured parameters were observed.

Stress testing on the active substance in the solid state was performed under conditions of heat (60 ºC), light exposure (ICH photostability conditions) and high humidity (30 ºC/75 % RH). Under the stress conditions of light exposure and high humidity, no degradation products were observed and therefore the active substance can be considered photostable and non-hygroscopic.  Genotoxic impurities remain below LOQ or unchanged at 5°C and slightly increases at 25°C/60%RH.

The stability results indicate that the drug substance manufactured by the proposed supplier is sufficiently stable. The stability results justify the proposed retest period in the proposed container.

## 2.2.3. Finished Medicinal Product

## Description of the product and Pharmaceutical development

Lenvatinib mesilate is a tyrosine kinase inhibitor which works as an anticancer drug. The aim was to develop and oral immediate release form which allows patients to administer the drug themselves, easy to handle, and  obtain  desired  bioability.  The  product  is  presented  in  multiple  strengths  easily  distinguished  by combination of shape, color, shape and prints to allow dose adjustments and minimizes risk of side effects and the mix-up of strengths and products.

The  active  substance  stability,  solubility,  polymorphism  and  particle  size  characteristics  were  taken  into account  during  the  pharmaceutical  development.  Lenvatinib  mesilate,  potentially  includes  a  genotoxic impurity and degradant, which is also a synthetic intermediate of lenvatinib. It was found to increase in the active substance by decomposition by heat stress. In addition, lenvatinib mesilate forms a gel when it is in contact with dissolution media. Therefore, the related substances and dissolution were designated as critical quality attributes for lenvatinib capsules.

Film-coated tablets were first developed and used in the early clinical trials. However, it was found that the excipients  and  process  used  to  manufacture  this  pharmaceutical  form  had  a  negative  impact  on  related substances  and  increased  the  level  of  the  genotoxic  impurity  in  the  finished  product.  Because  of  these

<div style=\"page-break-after: always\"></div>

concerns, development of another formulation for commercial production was initiated. A capsule formulation was  developed in order to address the manufacturability issues associated with the initial tablet manufacturing process. These were used for pivotal clinical studies and selected as the pharmaceutical form of  the  marketed  product.  During  development,  it  was  decided  to  have  multiple  strengths  to  enable  dose reduction  during  treatment  and  to  minimize  occurrence  of  side  effects  and  exposure  to  genotoxic  process impurities.

The excipients for Kisplyx were selected to ensure both appropriate stability and dissolution of the finished product. Therefore, compatibility of the active substances with excipients, their functions, and their relative concentrations were studied.

Non-hygroscopic  excipients  were  chosen  to  limit  the  level  of  water  and  reduce  the  risk  of  degradation  of lenvatinib  mesilate.  Calcium  carbonate  was  selected  as  a  water  insoluble  inorganic  diluent,  which  could effectively avoid gelation of the active substance without preventing dispersion of drug substance particles.

All excipients are well known pharmaceutical ingredients and for the majority, their quality is compliant with Ph Eur standards. The only non-pharmacopeial excipients are low-substituted hydroxypropyl cellulose and the hypromellose capsule shells. The specification for low-substituted hydroxypropyl cellulose complies with the National Formulary (NF) and is considered to be acceptable. The components of the capsules comply with the Ph Eur with the exception of butyl alcohol for which no Ph Eur monograph exists. This component complies with the NF monograph. There are no novel excipients used in the finished product formulation. The list of excipients is included in section 6.1 of the SmPC.

The formulation used during clinical studies is the same as that proposed for commercialization.

A  bioequivalence  study  was  performed  between  capsules  and  tablets,  which  concluded  that  the  same strength of capsules (10mg) could be used for pivotal clinical studies.

The manufacturing process is a standard process consisting of mixing, granulation, drying, milling, blending and encapsulation steps. An initial risk assessment for the manufacturing process at commercial production scale was performed so as to identify process parameters that were likely to have an impact on the CQAs of lenvatinib  capsules.  Development  and  formal  validation  data  are  convincing  that  the  physical  state  of  the active  substance  is  under  control  throughout  manufacturing  of  the  capsules.  Nevertheless,  the  CHMP recommended  testing  the  first  10  commercial  batches  intended  for  marketing  in  order  to  determine  the physical state of lenvatinib mesilate in the finished product.

Lenvatinib capsules are packaged in polyamide and polyvinyl chloride (PVC) laminated aluminium film with push-through aluminium foil blisters (Alu/Alu blisters). Specifications for the forming film and lidding foil have been provided. The specifications contain an IR identification test. The forming lid is stated to comply with Ph. Eur. 3.1.11, EC Directive 2002/72EC and EC Directive 78/142/EEC. The lidding foil is stated to comply with EC Directive 2002/72EC and EC Directive 78/142/EEC.

## Manufacture of the product and process controls

The finished product is manufactured in two manufacturing sites.

The manufacturing process of the finished product consists in a conventional wet granulation of nine steps: mixing,  granulation,  drying,  milling,  blending,  encapsulation,  weight-sorting,  bulk  packaging,  and  blister packaging. The process is considered to be a standard manufacturing process.

<div style=\"page-break-after: always\"></div>

Major  steps  of  the  manufacturing  process  have  been  validated  by  a  number  of  studies.  It  has  been demonstrated that the manufacturing process is capable of producing the finished product of intended quality in a reproducible manner. The in-process controls are adequate for this type of manufacturing process.

Proven  acceptable  ranges  have  been  defined  for  the  following  steps  of  the  medicinal  product:    drying, encapsulation, weight sorting and blister packaging. The available development data, the proposed control strategy and batch analysis data from commercial scale batches fully support the proposed PARs.

## Product specification

The finished product release specifications include appropriate tests for this kind of dosage form: description, identification (UV, HPLC, HPLC-PDA), related substances (HPLC), assay (HPLC), dissolution (Ph Eur), water content (Ph Eur), uniformity of dosage units (Ph Eur), and microbial limits (Ph Eur).

Batch analysis results are provided for 3 commercial scale batches for each strength confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification. All batches were manufactured at the proposed manufacturing site.

The finished product is released on the market based on the above release specifications, through traditional final product release testing.

## Stability of the product

Stability data on 3 (1 commercial scale and 2 pilot scale) batches per strength of finished product stored under long term conditions for up to 24 months at 25 ºC / 60% RH and for up to 6 months under accelerated conditions at 40 ºC / 75% RH according to the ICH guidelines were provided. The batches of medicinal product are identical to those proposed for marketing and were packed in the primary packaging proposed for marketing. Samples were tested for description, dissolution, related substances, assay, water content and microbiological limits. The analytical procedures used are stability indicating.

In addition, 1 batch was exposed to light as defined in the ICH Guideline on Photostability Testing of New Drug Substances and Products. Under long term and accelerated conditions after 24 months and 6 months respectively, no significant changes were observed and there was no difference between the 4 and 10 mg capsule strengths. During photostability studies no changes were observed in comparison to the initial timepoint or to a control sample stored in an open dish in the dark.

Based on available stability data, the proposed shelf-life of 36 months and the following storage condition 'do not store above 25°C' as stated in the SmPC (section 6.3) are acceptable.

## Adventitious agents

No excipients derived from animal or human origin have been used.

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner. The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

<div style=\"page-break-after: always\"></div>

The applicant has applied QbD principles in the development of the active substance and finished product and their manufacturing process. However, no design space was claimed for the manufacturing process of the active substance and finished product. PARs are claimed for CPPs identified in both active substance and finished product manufacturing processes.

At the time of the CHMP opinion, there were a number of minor unresolved quality issues having no impact on the Benefit/Risk ratio of the product.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

## 2.2.6. Recommendation(s) for future quality development

In the context of the obligation of the MAHs to take due account of technical and scientific progress, the CHMP recommends the following points for investigation:

- To test the first 10 commercial batches intended for marketing to determine the physical state of lenvatinib mesilate in the finished product.

## 2.3. Non-clinical aspects

## 2.3.1. Introduction

All pivotal toxicology studies and the battery of safety pharmacology studies were conducted in accordance with Good Laboratory Practice (GLP) regulations. In addition, all GLP studies were conducted by laboratories in countries that adhere to the Organisation for Economic Co-operation and Development (OECD) system for mutual acceptance of chemical safety data.

Pharmacodynamic, pharmacokinetic, preliminary and dose-range finding (DRF) toxicology studies were generally non-GLP studies.

Nonclinical studies of lenvatinib were generally conducted using lenvatinib mesilate, and doses are expressed in terms of the mesilate salt.

## 2.3.2. Pharmacology

## Primary pharmacodynamic studies

The primary pharmacodynamic effects of lenvatinib were evaluated in in vitro kinase inhibition (profiling) assays, kinetic interaction studies, X-ray analysis of the crystal structure of the VEGFR2-lenvatinib complex, and in vitro cell-based assays evaluating the effects of lenvatinib on VEGF- and FGF-driven cellular activities in endothelial cells as well as the direct antitumor activity of lenvatinib.

<div style=\"page-break-after: always\"></div>

The following new studies were conducted in addtioion to non-clinical data provided during the Lenvima MAA (EMEA/H/C/3727) procedure:

## In vitro studies

- Inhibition of FGF-driven cellular functions of endothelial cells
- Inhibition of VEGF- and FGF-driven cellular functions of endothelial cells when combined with everolimus
- Direct antiproliferative effects on H460 and Colo205 cancer cells

## In vivo studies:

- Inhibitory activity in an in vivo angiogenesis model
- Evidence for FGFR inhibition in vivo
- Antitumor effects in human tumor xenograft models in combination with other anticancer agents

## In vitro studies

Kinase Inhibition Profiling Studies

## Studies 1 and 2 (Studies W-2012086 and W-20120814)

Two  kinase  inhibition  profiling  studies  (W-20120816  &amp;  W-20120814)  targeting  66  purified  recombinant protein  kinases  demonstrated  that  lenvatinib  is  a  potent  multiple  kinase  inhibitor.  IC50  values  were determined by measuring the cell-free kinase activities with lenvatinib (0.3 - 10,000 nmol/L) by enzymelinked immunosorbent assay (ELISA) or mobility shift assay under optimized condition for each kinase. The profile for sorafenib, another multikinase inhibitor in clinical use, was also studied under the same condition as a reference (see table 4).

<div style=\"page-break-after: always\"></div>

Table 2. Kinase inhibition profile of lenvatinib and sorafenib against 66 kinases

<!-- image -->

Other kinases with ICso values above 10,000 mmol/L for lenvatinib and sorafenib include: AKT1, CDK2/CycE1, PKACa,PLK1,PRKX,SGK3,WEE1. Kinases listed are in order of low to high based on the ICso values for lenvatinib. Kinases with superscripts are known mutants with single amino acid substihutions. ICso = half-maximal inhibitory concentration.

Source: Study Nos. W-20120816 and W-20120814.

## Kinase Inhibition Profiling Study 3 (Study No. W-20120815)

A study was also conducted to determine inhibition constants (Ki) for selected kinases (W-20120815). The Ki values were calculated using a Dixon Plot of the inhibition by lenvatinib (0.3 - 260 nmol/L) under 6 different concentrations of ATP (see table 3).

<div style=\"page-break-after: always\"></div>

Table 3. Kinase inhibition profile of lenvatinib against 10 kinases

| Kinase        |               | K; (nmol/L)   |
|---------------|---------------|---------------|
| VEGF receptor | VEGFR1 (FLT1) | 1.3           |
| VEGF receptor | VEGFR2 (KDR)  | 0.74          |
| VEGF receptor | VEGFR3 (FLT4) | 0.71          |
| FGF receptor  | FGFR1         | 22            |
| FGF receptor  | FGFR2         | 8.2           |
| FGF receptor  | FGFR3         | 15            |
| FGF receptor  | FGFRK650E     | 28            |
| FGF receptor  | FGFR3K650M    | 62            |
| RET           | RET           | 1.5           |
| KIT           | KIT           | II            |

FGF = fibroblast growth factor. K= imhibition constant,VEGF = vascular endothelial growth factor.

Source: Study No.W-20120815.

## Results:

Lenvatinib selectively inhibited tyrosine kinase activities of VEGF receptors (VEGFR1-3) and RET with halfmaximal inhibitory concentration (IC50) values below 10 nmol/L (table 4) and inhibition constant (Ki) values of approximately 1 nmol/L.

Secondly, lenvatinib also inhibited other proangiogenic and oncogenic pathway-related RTKs including FGFR14, PDGFRα, and KIT with IC 50 values between 10 and 100 nmol/L. The Ki values were higher: respectively 22, 8.2, 15 and 11 nmol/L for FGFR1, 2 and 3, and KIT. The inhibition mode against these kinases was found to be competitive. Ki values for FGFR-4 and PDGFRα were not determined.

Against  VEGFR1  -  3  and  FGFR1  -  3,  IC50  values  for  lenvatinib  were  several-fold  lower  than  those  of sorafenib. In particular, the IC50 of lenvatinib against FGFR4 was approximately 80-fold lower than that of sorafenib. In contrast, the IC50 values for lenvatinib against PDGFRα, PDGFRβ and RAF1 were higher than those of sorafenib. In these assays, lenvatinib was more selective to VEGF receptors and FGF receptors and less selective to PDGF receptors and RAF1 compared to sorafenib.

## Kinetic Interaction Analysis against VEGFR2 (Study No. W-20140526)

This  study  determined  the  dissociation  rate  constant  (koff  =  1/  residence  time),  association  rate  constant (kon), and equilibrium dissociation constant (Kd = koff / kon) for VEGFR2. These values for the binding of lenvatinib  and  sorafenib  against  human  recombinant  protein  of  VEGFR2  including  kinase  domain  (Leu834Asn1162) were measured using a reporter displacement assay (Neumann, et al., 2011).  The Kd value for lenvatinib  against  VEGFR2  was  2.1  nmol/L,  which  is  about  16  fold  lower  than  that  of  sorafenib.    This difference is due to the balance for koff and kon values of lenvatinib, which are about 3.8-fold and 60-fold higher than for sorafenib, respectively. These results suggested that lenvatinib dissociated sooner from the target, but associated much more rapidly to the active site of VEGFR2, and the overall result was a superior binding affinity (based on a lower Kd value) to the target compared to sorafenib.

<div style=\"page-break-after: always\"></div>

## Crystal Structure of VEGFR2-Lenvatinib Complex (Study No. W-20140522)

X-ray  analysis  for  the  crystal  structure  of  the  VEGFR2-lenvatinib  complex  showed  that  lenvatinib  binds  to both the adenosine triphosphate (ATP)-binding site and the neighboring allosteric region in the kinase domain adopting an 'aspartic acid-phenylalanine-glycine (DFG)-in' configuration, suggesting a different binding mode compared to sorafenib.

The amino acid residues located in the vicinity of lenvatinib or sorafenib with a maximum distance of 3.9 Å were identified as those belonging to an ATP-binding site including a gate-keeper residue (common site for protein  kinases),  or  the  neighboring  region,  a  non-conserved  allosteric  region  (Traxler  and  Furet,  1999). Among  the  total  of  25  amino  acid  residues,  16  residues  were  common  for  lenvatinib  and  sorafenib. Lenvatinib and sorafenib binded to the ATP-binding site at their common core from the urea group to the quinoline ring (lenvatinib) and pyridine (sorafenib). They binded to the neighboring allosteric region via the cyclopropane ring (lenvatinib) or the 4-chloro-3-(trifluoromethyl) phenyl ring (sorafenib).  This suggested a strong hydrophobic interaction between the cyclopropane ring of lenvatinib and the phenyl ring of Phe1047. Both compounds could exert their kinase inhibitory activity through binding to the ATP-binding site, while enhancing kinase selectivity through binding to the neighboring region (Liao, 2007; Zuccotto, et al., 2010; McTigue, et al., 2012).

## Effects  on  VEGF-Driven  VEGFR2  Phosphorylation,  Proliferation,  and  Tube  Formation  in  the  HUVEC  Model (Studies M03008, M03006, M03005, W-20100606)

Four  studies  were  conducted  to  evaluate  the  effects  of  lenvatinib  on  VEGF-driven  cellular  functions  of HUVECs, which could be considered as in  vitro angiogenesis  models,  specifically  VEGFR2  phosphorylation, proliferation, and three-dimensional organization for tube formation.

Lenvatinib  inhibited  VEGF-driven  VEGFR2  phosphorylation,  proliferation,  and  tube  formation  in  the  HUVEC model in concentration-dependent manners (IC50HUVECphosphorylation=0.25 nM (0.11 ng/ml); IC50HUVECproliferation=  3.4  nM  (1.28  ng/ml);  IC50HUVECtube  formation=  2.1  nM  (0.90  ng/ml).  In  the fourth study (Study No. W-20100606) the effect of lenvatinib on HUVEC proliferation driven by both VEGF (20 ng/mL) and hepatocyte growth factor (HGF, a MET ligand [30 ng/mL]) was also studied.  Lenvatinib (0.3 -  300  nmol/L)  showed  a  concentration  dependent,  but  partial  inhibition  (approximately  60%  at  300 nmol/mL), as predicted by the kinase inhibitory profile in which lenvatinib strongly inhibited VEGFR2 but not MET.

## Effects of Lenvatinib Metabolites on VEGF-Driven Proliferation of HUVECs (Study No. M06002)

Primary pharmacodynamic effects of lenvatinib metabolites M1, M2, and M3 produced by liver microsomes were evaluated by measuring the inhibitory effects on VEGF-driven proliferation of HUVECs M1, M2, and M3 showed concentration-dependent  antiproliferative  activity,  with  IC50  values  of  57 nmol/L  (95%  confidence interval  [CI]:    18 - 180),  250 nmol/L  (95%  CI:    240 - 270)  and  230 nmol/L  (95%  CI:    120 - 440), respectively, against the VEGF-driven proliferation of HUVECs, suggesting that VEGFR2 inhibitory activities of M1, M2, and M3 were 6%, 1%, and 1%, respectively, of the activity of lenvatinib.

## Effect of Lenvatinib on FGF-Driven Tube Formation of Endothelial Cells (Study No. M14012)

This study examined the inhibitory activity of lenvatinib against FGF-driven tube formation of HUVECs. The activity of sorafenib was also evaluated.

Effect of lenvatinib in combination with everolimus on VEGF- or FGF-driven cellular functions of endothelial cells (Study No. BIOMT-2015-009, Study No. BIOMT-2015-010, Study No. M15015, Study No. M15016)

<div style=\"page-break-after: always\"></div>

Four studies were conducted to evaluate the effects of lenvatinib in combination with everolimus on VEGF- or FGF-driven cellular activities in HUVECs.

In the first study (Study No. BIOMT-2015-009), the effects of lenvatinib and everolimus on VEGF-activated intracellular signaling in HUVECs were examined, specifically the phosphorylation of Erk1/2 (p44/42 MAPK), S6K (p70 S6 kinase), and S6 (S6 ribosomal protein). Erk1/2 is a signaling molecule involved in the MAPK pathway (RAS-RAF-MEK-Erk1/2 pathway) and S6K and S6 are signaling molecules involved in the mTORS6K-S6 pathway. Both pathways are downstream of RTKs including VEGFR and FGFR.

Combination of lenvatinib and everolimus inhibited the phosphorylation of Erk1/2(Thr202/Tyr204), S6K(Thr389),  S6K(Thr421/Ser424),  and  S6(Ser235/Ser236).  Specifically  in  mTOR-S6K-S6  pathway,  the combination showed greater inhibition than each single agent for the phosphorylation of S6K(Thr421/Ser424) and  S6(Ser235/Ser236).  S6K(Thr389)  directly  downstream  of  the  mTOR  complex  was  already  maximally inhibited by everolimus

In the second study (Study No. BIOMT-2015-010), the effects of lenvatinib and everolimus on FGF-activated intracellular  signaling  in  HUVECs  were  examined;  specifically  the  phosphorylation  of  Erk1/2,  S6K,  and  S6 were evaluated.

The combination of lenvatinib and everolimus also inhibited the phosphorylation of Erk1/2(Thr202/Tyr204), S6K(Thr389), S6K(Thr421/Ser424), and S6(Ser235/Ser236). The combination showed greater inhibition than each single agent for the phosphorylation of S6K(Thr421/Ser424) and S6(Ser235/Ser236), similar to what was observed with VEGFstimulated phosphorylation.

In the third study (Study No. M15015), the effects of lenvatinib in combination with everolimus on VEGFdriven proliferation of HUVECs were examined. Dilutions of lenvatinib mesilate alone, everolimus alone, and their mixtures (molar ratios of 2.5:1, 5:1, 10:1, and 20:1 (lenvatinib: everolimus)), were added to HUVECs on tissue culture plates.

The combination of lenvatinib and everolimus at the different molar ratios resulted in combination indexes of 0.80, 1.11, 1.12, and 1.17, respectively, indicating moderate synergistic or additive effects.

In  the  fourth  study  (Study  No.  M15016), the effects of lenvatinib in combination with everolimus on FGFdriven tube formation of HUVECs were evaluated. Dilutions of lenvatinib alone, everolimus alone, and their mixtures with molar ratios of 1:4, 1:8, 1:12, and 1:16 (lenvatinib : everolimus) were added to HUVECs.

The combination of lenvatinib and everolimus resulted in combination indexes of 0.47, 0.56, 0.61, and 0.74, respectively, indicating synergistic or moderate synergistic effects.

## Direct Anti-proliferative Activities against Cancer Cells

Two studies were conducted to evaluate the effects of lenvatinib on in vitro proliferation of human cancer cell lines. Lenvatinib exhibited weak, direct anti-proliferative activity in vitro against the H460 human non-small cell lung cancer (NSCLC) and Colo205 human colorectal cancer cell lines, with IC50 values of 14.000 and 26.000 nmol/L (~ 7321 ng/ml and 13597 ng/ml), respectively (Study No. M03007).

In a second study, lenvatinib exhibited a weak anti-proliferative activity against the A-498 human RCC cell line with an IC50 value above 10,000 nmol/L, while everolimus inhibited the growth of A-498 cells with an IC50 value of 4.6 nmol/L (95% CI: 2.4 - 8.7) (Study No. M15005).

<div style=\"page-break-after: always\"></div>

## In vivo studies

The inhibitory activity of lenvatinib was evaluated in an in vivo angiogenesis model and the antitumor activity of lenvatinib as monotherapy or in combination with other anticancer agents was evaluated in various human tumor xenograft models in athymic mice.

## Antiangiogenesis activity of lenvatinib in VEGF- and FGF-induced angiogenesis model in mice (DAS Model)

This  study  examined  the  inhibitory  activity  of  lenvatinib  against  VEGF-  or  FGF-induced  angiogenesis  in  a murine DAS model (Yamamoto, et al., 2014). The activity of sorafenib was also evaluated. Recombinant KP-1 human pancreatic cancer cells expressing human VEGF or murine FGF (KP-1/VEGF cells or KP-1/FGF cells) were packed in Millipore chambers with collagen gels, and the chambers were embedded in dorsal air sacs of C57BL/6  mice  (Day  1)  in  order  to  induce  angiogenesis  in  the  skin  attached  to  the  chamber  membrane (Funahashi, et al.,  1999).  Then,  vehicle  for  lenvatinib  (distilled  water),  lenvatinib  mesilate  (3,  10,  and  30 mg/kg) or sorafenib tosylate (100 and 300 mg/kg) was orally administered to the mice (3 - 5/group) once daily for 4 days (Day 1 - 4). Angiogenesis was evaluated on Day 5 by measuring the pre-radiolabelled red blood cell  content  in  the  skin  attached  to  the  chamber  membrane,  and  treatment/  control  (T/C)  (%)  was calculated.

Angiogenesis was markedly induced in the skin of mice bearing the Millipore chamber with KP-1/VEGF or KP1/FGF cells compared to those bearing the Millipore chamber with KP-1 mock cells (mock-transfected cells) or collagen only, demonstrating that in vivo angiogenesis was induced by VEGF or FGF secreted from the tumor cells.  In  this  model,  lenvatinib  at  doses  of  10  and  30  mg/kg  significantly  inhibited  both  VEGF-  and  FGFinduced in vivo angiogenesis. Sorafenib (100 and 300 mg/kg) also significantly inhibited the VEGFinduced angiogenesis, but did not inhibit the FGF-induced angiogenesis.

## Effects of Lenvatinib on Plasma FGF23 Levels in Mice

FGF23, a protein hormone regulating mineral metabolism, is a potential pharmacodynamics marker for FGFR inhibition  in  vivo,  since  its  plasma  level  is  elevated  as  a  compensatory  response  when  intracellular  FGFR signaling is blocked (Wöhrle, et al., 2011; Kim, et al., 2011). This study examined the effect of lenvatinib on plasma FGF23 levels in mice in order to obtain evidence for FGFR inhibition in vivo (Study No. W-20140842). Sorafenib  was  also  evaluated.    Seven-week-old  female  non-tumor-bearing  BALB/c  mice  (8/group)  were administered a single oral dose of the vehicle for lenvatinib (distilled water), lenvatinib mesilate (3 and 10 mg/kg), or sorafenib tosylate (9 and 30 mg/kg). Twenty-four hours after dosing, blood was collected from the abdominal aorta and the concentration of FGF23 in the plasma fraction was measured by ELISA.

The  plasma  FGF23  concentration  increased  dose-dependently  in  mice  treated  with  lenvatinib,  with  a significant increase confirmed at a dose of 10 mg/kg compared to the vehicle-control group; no significant increase in FGF23 concentration associated with treatment with sorafenib was observed. The result provides evidence that lenvatinib is able to inhibit the FGFR signaling pathway in mice, whereas sorafenib does not show such activity.

## Combination therapy with everolimus

## Antitumor Effects of Lenvatinib in Combination With Everolimus in the A-498 Human RCC Xenograft Model in Athymic Mice

The  antitumor  effects  of  lenvatinib,  everolimus,  and  lenvatinib  in  combination  with  everolimus,  were evaluated in the A-498 human RCC xenograft model in athymic mice (Study No. M14026).

<div style=\"page-break-after: always\"></div>

A-498  cells  were  inoculated  subcutaneously  into  8-week-old  female  mice.  At  21  days  after  inoculation, vehicle, lenvatinib mesilate (10 mg/kg), everolimus (30 mg/kg), or lenvatinib mesilate in combination with everolimus were orally administered to the mice (10/group) once daily for 14 days (Day 1 - 14). The TV and body weight were measured twice a week.

Lenvatinib monotherapy, everolimus monotherapy, and the combination of the 2 agents showed significant inhibition of tumor growth compared to vehicle control with T/C values of 26%, 0%, and -20% on Day 15, respectively.  The  combination  resulted  in  growth  inhibition  with  tumor  shrinkage,  which  was  significantly greater than that for each monotherapy.

## Antitumor Effects of Lenvatinib in Combination With Everolimus in the Caki-1 Human RCC Xenograft Model in Athymic Mice

The  antitumor  effects  of  lenvatinib,  everolimus,  and  lenvatinib  in  combination  with  everolimus,  were evaluated in the Caki-1 human RCC xenograft model in athymic mice (Study No. W-20110629).

Caki-1 cells were inoculated subcutaneously into 7-week-old female mice. At 48 days after inoculation (Day 1),  vehicle,  lenvatinib  mesilate  (10  mg/kg),  everolimus  (30  mg/kg),  or  lenvatinib  mesilate  in  combination with everolimus were orally administered to the mice (5/group) once daily for 14 days (Day 1 - 14).

The  TV  and  body  weight  were  measured  twice  a  week.  The  TV  was  calculated  according  to  the  formula: length × width2 × ½, and described as the RTV compared with that on Day 1.

Lenvatinib monotherapy, everolimus monotherapy, and the combination of the 2 agents showed significant inhibition  of  tumor  growth  compared  to  vehicle  control  with  T/C  values  of  2%,  -23%,  and  -86%, respectively,  on  Day  15.  The  combination  resulted  in  tumor  shrinkage,  and  the  antitumor  activity  was significantly  greater  than  that  for  lenvatinib  monotherapy.  It  was  also  numerically  greater  than  that  for everolimus monotherapy, but the difference was not significant (P=0.0683).

## Antitumor Effects of Lenvatinib in Combination With Everolimus in the KP-1/VEGF Xenograft Model in Athymic Mice

The  antitumor  effects  of  lenvatinib,  everolimus,  and  lenvatinib  in  combination  with  everolimus,  were evaluated  in  the  KP-1/VEGF  xenograft  model  in  athymic  mice  (Study  No.  M15012),  where  VEGF-induced tumor  angiogenesis  and  resulting  tumor  growth  were  expected  to  be  enhanced  due  to  the  excess  VEGF secreted from the recombinant KP-1/VEGF cells (Yamamoto, et al., 2014). KP-1/VEGF cells were inoculated subcutaneously into 6-week-old female mice. At 14 days after inoculation, vehicle, lenvatinib mesilate (7.5 and  10  mg/kg),  everolimus  (15  and  30  mg/kg),  or  lenvatinib  mesilate  (7.5  mg/kg)  in  combination  with everolimus (15 mg/kg) were orally administered to the mice (5/group) once daily for 14 days. The TV and body weight were measured twice a week.

Lenvatinib  monotherapy,  everolimus  monotherapy,  and  their  combination  showed  significant  inhibition  of tumor growth compared to vehicle control on Day 15. The combination of lenvatinib mesilate (7.5 mg/kg) and  everolimus  (15  mg/kg)  showed  significantly  greater  antitumor  effect  than  either  monotherapy.  The antitumor  effect  of  the  combination  was  also  significantly  greater  than  with  the  higher  dose  of  either lenvatinib mesilate (10 mg/kg) or everolimus (30 mg/kg) monotherapy.

## Combination therapy with other compounds

- Combination of lenvatinib with:
- o temozolomide  (TMZ)  (Study  No  K08038)  or  eribulin  (Study  No  JW1012)  in  the  A375  melanoma xenograft model,

<div style=\"page-break-after: always\"></div>

- o cisplatin or carboplatin in the A549 NSCLC xenograft model (Study No K06053),
- o paclitaxel in the MKN-74 gastric cancer xenograft model (Study No K06008), and
- o golvatinib in the SEKI melanoma, KP-4 pancreatic cancer, IM95m gastric cancer, and A2780 ovarian cancer (Study No W-20100607)
- o human xenograft models in athymic mice showed greater antitumor effects as compared with each monotherapy.

· Tumor regression has  occurred  for  the  combination  of  lenvatinib  with  eribulin,  ciplatin/carboplatin  and golvatinib:

- The combination of lenvatinib with eribulin (3.0 mg/kg, Q7D×2) showed greater antitumor effects than the monotherapy, which resulted in tumor regression.

- The antitumor effects of the combinations of lenvatinib with carboplatin were of similar magnitude to the combination  with  cisplatin.  The  effects  were  greater  than  each  monotherapy,  although  not  statistically significantly different from the lenvatinib monotherapy. Tumor regression was observed in the combinations of lenvatinib (10 and 30 mg/kg) with cisplatin and lenvatinib (10 mg/kg) with carboplatin.

- Golvatinib (an investigational multiple kinase inhibitor) is a potent inhibitor of MET, while lenvatinib showed little  inhibitory  activity  against  MET.  The  combination  of  lenvatinib  and  golvatinib  showed  significant  and greater  inhibition  of  tumor  growth  as  compared  to  each  monotherapy.  Regression  of  IM95m  tumors  was observed in mice treated with the combination.

## · Body weight loss

- Lenvatinib (10, 30 mg/kg) weakly enhanced the transient BWL caused by TMZ (80 mg/kg).

- When given in combination with 3.0 mg/kg eribulin (QD×7), lenvatinib weakly enhanced the BWL caused by eribulin.

-  Lenvatinib  (10  and  30  mg/kg)  enhanced  the  transient  BWL  caused  by  carboplatin.  The  combination  of lenvatinib (30 mg/kg) with carboplatin (100 mg/kg) was lethal in this model.

- Lenvatinib at each dose weakly enhanced the transient BWL caused by paclitaxel.

-  In  the  SEKI  and  A2780  xenograft  models  for  golvatinib  where  BWL  was  observed  in  the  vehicle  group (attributed to tumor burden), lenvatinib had no effect on, or weakly enhanced, this BWL.

## Secondary pharmacodynamic studies

To evaluate the potential secondary pharmacodynamic effects of lenvatinib, the binding of lenvatinib (1 and 10 μmol/L) to a panel of 50 non-kinase receptors (ExpresSProfile) known to play significant biological roles was determined. With the exception of binding to the 5-hydroxytryptamine (serotonin) receptor 1B (58%) and human norepinephrine (noradrenalin) transporter (50%) at 10 μmol/L (5.2 µg/ml), no significant binding (greater  than  50%  inhibition)  of  lenvatinib  to  any  of  the  50  receptors  was  observed  at  the  tested concentrations. These are not considered relevant at human therapeutic dose levels.

## Safety pharmacology programme

The safety pharmacology of lenvatinib was evaluated in in vitro and in vivo studies.

Table 4: Overview of safety pharmacology studies

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Type of Study and Test System                                                                | GLP Compliance   | StudyNumber   |
|----------------------------------------------------------------------------------------------|------------------|---------------|
| Effect onhERG Tail Current Recorded fromStably Transfected HEK293 Cells                      | Yes              | DJNR1029      |
| EffectsonActionPotentialParametersinIsolated Papillary Muscles of Guinea-Pig                 | Yes              | B030403       |
| Effects on Cardiovascular System andBodyTemperature by Oral Administration in Conscious Dogs | Yes              | B030402       |
| Effects on Respiratory Function by Oral Administration in Rats                               | Yes              | S03019        |
| Effects on General Physical Condition and Behavior by Oral Admimistration in Rats            | Yes              | B030401       |

## Central Nervous system

Effects of lenvatinib on general physical condition and behavior were evaluated in SD rats after a single oral administration of lenvatinib mesilate at 10, 30, and 100 mg/kg using Irwin's method (Study No. B030401). Lenvatinib, up to 100 mg/kg, showed no effect on general physical condition and behavior in rats.

The effects of a single oral dose of lenvatinib mesilate (6 and 30 mg/kg) on body temperature were assessed in beagle dogs (Study No. B030402). Lenvatinib did not cause body temperature changes at any dose in dogs.

## Cardiovascular system

Two in vitro electrophysiology studies were conducted to assess the effect of lenvatinib on hERG tail current or action potential parameters (Study Nos. DJNR1029 and B030403). No significant adverse effects were observed in these studies except for a weak inhibitory effect on hERG potassium current (IC50 = 11.89 μmol/L). The effects of a single oral dose of lenvatinib mesilate (6 and 30 mg/kg) on heart rate, mean blood pressure, and ECG (PR interval, QRS duration, and QT interval) were assessed in beagle dogs (Study No. B030402). Lenvatinib at doses up to 30 mg/kg had no significant effect on heart rate, mean blood pressure, or ECG (including QT) except for a minimal increase in mean blood pressure within the normal biologic range.

## Respiratory System

The effects of a single oral dose of lenvatinib mesilate (10, 30, and 100 mg/kg) on respiratory function (respiratory rate, tidal volume, and minute volume) in SD rats were evaluated using unrestrained whole body plethysmography (Study No. S03019). Lenvatinib at doses up to 100 mg/kg showed no effects on respiratory rate, tidal volume, or minute volume in rats.

## Pharmacodynamic drug interactions

No pharmacodynamic drug interaction studies were submitted. In vivo xenograft studies of lenvatinib in combination with other anticancer agents that evaluate pharmacodynamic interactions were conducted (please see in vivo pharmacology studies above).

<div style=\"page-break-after: always\"></div>

## 2.3.3. Pharmacokinetics

The pharmacokinetic profile of lenvatinib was evaluated by in vivo studies with athymic mice (BALB/c AnNCrjnu/nu), Sprague Dawley (SD) rats, beagle dogs, and cynomolgus monkeys. The strains and species evaluated were those used in pharmacology and toxicity studies. For assessments of metabolic characteristics, in vitro studies using hepatocytes, recombinant metabolic enzymes, liver microsomes or other subcellular fractions of the liver were also conducted.

## Method

A method using HPLC with UV detection was validated for quantification of lenvatinib in plasma samples of mice, rats, dogs, and cynomolgus monkeys. In these validation studies, plasma concentration of lenvatinib was expressed in terms of the mesilate salt.  Radiolabeled lenvatinib mesilate ([14C] lenvatinib mesilate and [14C]CB-lenvatinib mesilate) were synthesized to conduct mass balance and metabolite identification studies. The concentration of radioactivity derived from carbon 14 in the blood, plasma, tissues, urine, bile, and faeces was determined by LSC with external standard method.  The concentration of radioactivity was expressed as the equivalent of lenvatinib mesilate (µg eq./mL or g).

## Absorption

The pharmacokinetic profiles of lenvatinib in mice, rats, dogs, and cynomolgus monkeys were characterized by a low total plasma clearance (100.2 - 368.3 mL/h/kg) and a small to moderate volume of distribution (391.5 - 1610.0 mL/kg). The terminal elimination phase half-life after intravenous administration was 2.05 to 5.27 hours. After oral administration of lenvatinib mesilate at 3 mg/kg as a solution, lenvatinib was absorbed rapidly and had absolute bioavailability in mice (64.4%), rats (68.7%), dogs (70.4%), and monkeys (78.4%).

<div style=\"page-break-after: always\"></div>

Table 5: Pharmacokinetic Parameters for Lenvatinib in animals

| Species/ Strain/ Gender               | Dosing Route   |   Doses a (mg/kg) |   AUC (0-inf) (µg·h/mL ) | CL p (mL/h/ kg)   | V ss (mL/k g)   |   t ½ (h) | C max (µg/ mL)   | t max (h)   | F (%)   |
|---------------------------------------|----------------|-------------------|--------------------------|-------------------|-----------------|-----------|------------------|-------------|---------|
| Mouse / BALB/c AnNCrj- nu/nu / Female | IV             |                 3 |                    8.686 | 345.4             | 714.3           |      2.05 | 7.054 2 b        | NA          | NA      |
|                                       | PO             |                 3 |                    5.596 | NA                | NA              |      2.09 | 1.965 1          | 0.5         | 64.4    |
|                                       | PO             |                10 |                   27.72  | NA                | NA              |      1.74 | 10.51 00         | 0.5         | NC      |
|                                       | PO             |                30 |                  118.198 | NA                | NA              |      1.85 | 31.25 65         | 1           | NC      |
| Rat/SD/Male                           | IV             |                 3 |                   30.107 | 100.2             | 391.5           |      3.65 | 14.05 67 b       | NA          | NA      |
|                                       | PO             |                 3 |                   20.697 | NA                | NA              |      3.61 | 6.167 1          | 0.5         | 68.7    |
|                                       | PO             |                10 |                   78.321 | NA                | NA              |      5.27 | 16.64 50         | 0.5         | NC      |
|                                       | PO             |                30 |                  145.58  | NA                | NA              |      4.95 | 23.20 15         | 1           | NC      |
| Dog/Beagle/ Male                      | IV             |                 3 |                    8.417 | 368.3             | 1610.0          |      5.27 | 2.288 9 b        | NA          | NA      |
|                                       | PO             |                 3 |                    5.481 | NA                | NA              |      4.76 | 1.271 7          | 2           | 70.4    |
| Monkey/ Cynomolgus/ Male              | IV             |                 3 |                   12.9   | 237.7             | 793.7           |      4.28 | 4.642 7 b        | NA          | NA      |
|                                       | PO             |                 3 |                   10.272 | NA                | NA              |      4.07 | 2.501 3          | 2           | 78.4    |

Doses and plasma concentrations for lenvatinib were expressed as those of the mesilate salt, and related parameters were calculated.  In mice, each parameter except tmax was calculated with the average concentration of 3 animals, and in other species, each value except tmax represents the mean of 4 animals.  The tmax represents the mode value, except for mice.  F was calculated using the formula: AUC(0-inf) in oral dosing / AUC(0-inf) in intravenous dosing × 100.

AUC(0-inf) = area under the concentration-time curve from zero time extrapolated to infinite time, CLp = total plasma clearance, Cmax = maximum observed concentration, F = absolute bioavailability, IV = intravenous, NA = not applicable, NC = not calculated, PO = oral, SD = Sprague Dawley, t1/2 = terminal elimination phase half-life, tmax = time at which the highest drug concentration occurs, Vss = volume of distribution at steady state.

a:  Lenvatinib mesilate was administered as solution in all administration groups.

b:  Concentration at 5 minutes for intravenous dosing.

Source:  Study Nos. B03014 (mouse), B03015 (rat), B03016 (dog), and B04003 (monkey).

Overall, repeated-dose toxicokinetic studies of lenvatinib in male and female rats, dogs, and cynomolgus monkeys conducted with once daily oral doses for up to 26, 4, and 39 weeks, respectively, indicated no systemic accumulation of lenvatinib in the toxicology studies.  Systemic exposures in males and females were generally comparable in each species. With the exception of rats, systemic exposure of lenvatinib was not affected by repeated administration in these species. In dogs at doses &lt; 30 mg/kg, the systemic exposure generally increased in a dose-proportional manner. The systemic exposure increased in a less than doseproportional manner at higher dose levels in rats (&gt;10 mg/kg). In contrast, in monkeys, systemic exposure

<div style=\"page-break-after: always\"></div>

increased in a more than a dose-proportional manner at low dose levels (0.1 - 3 mg/kg). Unlike the rat or the monkey, the systemic exposure in humans increased in a dose-proportional manner (see clinical pharmacokinetics section).

## Distribution

Tissue distribution of radioactivity was investigated after a single oral administration of 14C-lenvatinib mesilate (3 mg/kg) to male SD rats and male cynomolgus monkeys and after a single oral administration of 14C-CB-lenvatinib mesilate (3 mg/kg) to male cynomolgus monkeys.

In rats, the highest concentrations of radioactivity were found at 0.5 hours postdose (Tmax) in most tissues (the small intestine, liver, adrenal gland, and stomach showed concentrations 1.19 to 2.59 times higher than that in plasma), and decreased almost in parallel with that in blood. Elimination half-life was 1.9 days.

In monkeys, the highest concentrations of 14C-lenvatinib-radioactivity were found at 4 hours postdose (Tmax) in the bile in gall bladder, being 556.73 times that in the plasma. The mean concentrations of radioactivity in the urine in bladder, gall bladder, liver, choroid, ciliary body, and renal cortex were next highest, being 57.85-10.11 times that in the plasma. At 24 hr postdose, the choroid, iris, large intestine, sclera, cornea, and lens reached their maxima.

The mean concentrations of radioactivity in many tissues decreased almost in parallel with that in the plasma. Elimination half-life was 3.43 days.

In monkeys, the highest concentrations of 14C-CB-lenvatinib-radioactivity were found at 2 hours postdose (Tmax). The radioactive concentrations in the bile in gall bladder and urine in bladder were the highest, being 33.59 and 24.55 times those in the plasma, respectively. The radioactive concentrations in the choroid and liver were the next highest, being 7.14 and 7.02 times those in the plasma, respectively. The radioactive concentrations in the gall bladder, iris, renal cortex, kidney, ciliary body, renal medulla, and lung were 3.28 to 1.49 times those in the plasma. The radioactive concentration in the central nervous system was 0.07 time or lower than that in the plasma. Elimination half-life was 3.70 days.

## Protein Binding and Distribution in Blood Cells

To clarify the nature of covalently-bound lenvatinib-related material with human plasma proteins and to evaluate its reversibility, the effect of the nucleophiles GSH and cysteine was examined.  Covalent binding of lenvatinib to human plasma protein occurred in vitro, and GSH and cysteine successfully released lenvatinibrelated components bound to plasma protein as conjugates in the same manner as the 2-ME conjugates in previous studies (E7080 E044 104 and AE-6748-G).  Since abundant amounts of GSH and cysteine exist in humans, the covalent binding observed in human plasma is expected to be reversible in vivo.

The plasma protein binding of lenvatinib mesilate (0.3 to 30 μg/mL) in athymic mice, SD rats, beagle dogs, cynomolgus monkeys, and humans was determined by equilibrium dialysis in vitro (Study No. B09009). Incubation was conducted for 72 hours at 37 °C. Among the species tested, lenvatinib exhibited the highest plasma protein binding in human, independent of concentrations (97.87% to 98.62%), followed by rat (97.70% to 98.20%), athymic mouse (96.28% to 96.92%), monkey (95.90% to 96.17%), and dog (89.71% to 91.75%).

To assess the specific proteins that bind lenvatinib in human plasma, protein binding of lenvatinib mesilate (0.3 to 30 μg/mL) to albumin, α1-acid glycoprotein, and γ-globulin was determined by equilibrium dialysis in vitro (Study No. B09011). Lenvatinib mainly bound to albumin, and the contribution of α1-acid glycoprotein and γ-globulin to lenvatinib protein binding was minor in human plasma. Based on the results at the lowest

<div style=\"page-break-after: always\"></div>

lenvatinib mesilate concentration tested (0.3 μg/mL), the contributions of albumin, α1-acid glycoprotein, and γ-globulin to the human plasma protein binding of lenvatinib were estimated to be 93.2%, 6.1%, and 0.7%, respectively.

Blood to plasma concentration ratios (Rb) of 14C-lenvatinib mesilate (0.1 to 10 μg/mL) in athymic mice, SD rats, beagle dogs, cynomolgus monkeys, and humans were determined in vitro after a 30-minute incubation at 37 °C. A species difference in the Rb of 14C-lenvatinib was observed, and ranked from highest to lowest as follows: dog &gt; monkey = mouse ≥ rat &gt; human. The Rb values in animals declined with increasing concentration; however, in human, the Rb was constant between 0.1 and 10 μ g/mL.

The in vitro transfer ratios of 14C-lenvatinib mesilate to blood cell were 23.1%, 22.1%, and 18.8% in the mouse; 8.86%, 7.59%, and 4.36% in the rat; 51.4%, 44.3%, and 42.1% in the dog; 29.7%, 21.9%, and 18.3% in the monkey; and 17.2%, 14.5%, and 14.8% in the human at the spiked 14C- lenvatinib mesilate blood concentration of 0.1, 1, and 10 μg/mL, respectively.

As for the stability of 14C-lenvatinib mesilate in the blood, the radiochemical purity declined in the dog blood. The decreased rate was low as approximately 10%, but taking account of dog showing higher Rb than other species, it could not be fully excluded that decomposed 14C-lenvatinib mesilate in dog blood may be distributed to blood cells more than unchanged 14C-E7080.

## Placental transfer studies

Placental transfer was investigated after a single oral administration of 14C-lenvatinib mesilate (3 mg/kg) to pregnant rats (Study No. AE-6750-G). On Days 13 and 18 of pregnancy, the concentrations of radioactivity in fetuses were low, and were 2% or less of the concentration in maternal plasma at 0.5 hours post-dose, the first sampling time point. The distribution of radioactivity for each foetus was 0.02% or less of the dosed radioactivity.

Placental transfer of lenvatinib mesilate in rats (on day 13 and 18 of pregnancy) was low (2% or less of the concentration in maternal plasma).

## Metabolism

The applivant demonstrated that no glutathione metabolites with the quinolone form were identified in the monkey or human studies and that exposure is likely to be very low in humans. In addition, the levels of the aniline metabolite are low and probably similar to those seen for other tyrosine kinase inhibitors. This was raised during the review of Lenvima.

In vitro and in vivo studies using lenvatinib, [14C] lenvatinib, or [14C]CB-lenvatinib were conducted to determine the metabolic profile of lenvatinib.

Lenvatinib mesilate (final concentration: 10 μg/mL) was incubated at 37°C for 60 minutes in mouse, rat, dog, monkey, and human liver microsomes (protein concentration: 1 mg/mL) with or without the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), and the reaction mixtures were analyzed by liquid chromatography coupled with mass spectrometry (LC/MS) to investigate the in vitro metabolism of lenvatinib (Study No. B03025).

8 metabolites (M1, M2, M3, M4, M5, M6, M7, and M8) were detected in at least one animal species as well as in human liver microsomes. M1, M2, and M3 were identified as decyclopropylated, demethylated, and Noxidated forms of lenvatinib, respectively. M1 could be a chemical (or non-enzymatic) degradation product, as M1 was detected in lenvatinib solution and in the incubation mixtures without microsomes or NADPH. M4

<div style=\"page-break-after: always\"></div>

was proposed as a hydroxylated form at the cyclopropyl group of lenvatinib, M5 was proposed as the quinoline form, formed by O-dearylation, M6 was proposed as a form hydroxylated at the cyclopropyl group of M2, M7 was proposed as a form doubly hydroxylated at cyclopropyl group, and M8 was proposed as the Noxidated form of M2.

Six metabolites (M1, M2, M3, M4, M5, and M7) were common among the species tested. M6 and M8 were detected in monkey and human liver microsomes but not in mouse, rat, and dog liver microsomes. In the were also qualitatively represented in monkey liver microsomes. Six metabolites out of eight (M1, M2, M3, M4, M5, and M7) were also detected in rat liver microsomes.

human liver microsomes, M2 appeared to be a major metabolite. All metabolites in human liver microsomes To determine the CYP-mediated metabolism of lenvatinib in humans in vitro, lenvatinib was incubated with recombinant human CYPs. CYP3A4 was the predominant ( ≥ 80%) isoform contributing to the CYP-dependent metabolism of lenvatinib in humans in vitro over the concentration range of 0.005 to 10 µg/mL, followed by CYP1A2 (2.4% to 7.6%) and CYP2B6 (3.0% to 6.7%). To further evaluate CYP isoforms responsible for the CYP dependent metabolism of lenvatinib, the effects of CYP isoform-specific inhibitors on lenvatinib metabolism were also assessed in HLMs. The results obtained further showed that CYP3A4 was a major CYP isoform involved in the CYP-dependent metabolism of lenvatinib in HLM. In addition, aldehyde oxidase (AO) contributes to the formation of M2´ and M3', the major metabolites in human feces. To clarify the metabolic profiles of lenvatinib in vivo, the metabolites after oral administration of [14C]lenvatinib mesilate to rats and a single monkey at 30 mg/kg were investigated (Study No. B10006). In this study, 36 radioactive components in total were found in rat and monkey samples, and were assigned serial numbers with the prefix 'Met' (Met 1 to Met 36). Based on comparisons of retention times and mass spectral data with the corresponding references, Met 14 (me37), Met 28 (me88), Met 32-1 (me107), Met 33 (me114), and Met 35 (me116) were identified as M5, M1, M3, M2, and lenvatinib, respectively. In addition to oxidative metabolism, one of the major metabolic pathways for lenvatinib in the rat and monkey appeared to be glutathione conjugation at the quinoline moiety, and 15 glutathione conjugationrelated metabolites including Met 12 (me36) and Met 15 (me40) were detected in this study. Three metabolites were isolated from monkey urine samples, and their chemical structures were determined by NMR to be Met 13 (me33) further oxidized from Met 12 (me36), Met 16 (me45) dimerized of Met 21 (me47), and Met 20 (me49) conjugated from Met 21 (me47) and Met 19-2 (me44) forming disulfide, respectively (Study No. C10320).

The metabolic profiles of lenvatinib were further investigated following single oral administrations of [14C]lenvatinib mesilate to male rats and monkeys at 3 mg/kg (Study No. AE-6748-G). Plasma, liver, kidney, urine, feces, and bile were collected and subjected to metabolite analyses using LC/MS(MSn). In this study, 41 radioactive peaks on HPLC radiochromatograms were found in rat and monkey samples, and the metabolites were assigned serial numbers with the prefix 'm' (m1 to m41).

In these in vivo studies, the presence of the oxidized human metabolites, M1 (me88), M2 (me114), M3 (me107), M5 (me37), M2´(me118), and M3´(me115) were confirmed by LC/MS analysis of rat or monkey samples after single oral administrations of lenvatinib. An additional study was conducted to clarify the metabolic profile of lenvatinib in monkeys using 14C-labeled lenvatinib radio-labeled on the chlorobenzene moiety. After a single oral dose of 14C-CB-lenvatinib at 3 mg/kg to cynomolgus monkeys, radioactive components in biological samples were analyzed. More than 90% of plasma radioactivity was extracted with

<div style=\"page-break-after: always\"></div>

methanol, and major component in plasma was lenvatinib. Unchanged lenvatinib was found in bile and feces but not in urine. The main primary metabolic pathway of lenvatinib was indicated to be the cleavage of O-aryl bond to form mCB31 (ER-236273), and further biotransformations of mCB31 (conjugate with glucuronic acid, sulfuric acid, glutathione, and N-acetyl glucosamine with or without hydroxylation) were confirmed, resulted in forming many kinds of metabolites.

## Study DMPKT2013-017

Pharmacokinetic  parameters  of  total  radioactivity,  extracted  radioactivity,  radioactive  peaks  including lenvatinib, and unextracted radioactivity in monkey plasma obtained in Study Nos. AE-6748-G, AE-6917-G, and  AE-6918-G  were  calculated.  Lenvatinib  was  the  main  fraction  of  total  radioactivity  in  plasma  after administration  of  both  [ 14 C]lenvatinib  mesilate  (Cmax:  89.9%,  AUC(0-inf):  69.7%)  and  [ 14 C]CB-lenvatinib mesilate (Cmax: 78.4%, AUC(0-inf): 60.4%).  After administration of [ 14 C]lenvatinib mesilate, Cmax and AUC(0inf)  of  all  radioactive  metabolite  peaks  did  not  exceed  1.9%  of  the  total  radioactivity  values.    After administration of [ 14 C]CB-lenvatinib mesilate, mCB9a was the major radioactive metabolite, with Cmax and AUC(0-inf)  values  that  were  12.1%  and  17.0%  of  the  total  radioactivity  values,  respectively.    mCB9a  is equivalent  to  me50  (i.e.  glucuronide  of  me92).  With  the  exception  of  mCB9a,  Cmax  and  AUC(0-inf)  of  all radioactive  metabolite  peaks  detected  after  administration  of  [ 14 C]CB-lenvatinib  mesilate  did  not  exceed 4.7% of total radioactivity.  Cmax and AUC(0-inf)  of unextracted radioactivity after administration of [ 14 C]CBlenvatinib mesilate were 0.5% and 2.6% of the total radioactivity, respectively, and were lower than those after administration of [ 14 C]lenvatinib mesilate (Cmax: 7.3%, AUC(0-inf): 22.6%).

## Study W-20140601

In the monkey study, methanol was unable to extract the entire radioactivity in plasma protein.  This was likely  due  to  covalent  binding  of  [ 14 C]lenvatinib.  Treatment  with  nucleophilic  2-mercaptoethanol  (2-ME) recovered additional radioactivity from the modified plasma protein which likely included conjugates between 2-ME and the quinoline moiety of lenvatinib. In the human mass balance study, incorporation of radioactivity originating from [ 14 C]lenvatinib to plasma protein, possibly due to covalent binding was also observed.  To clarify the nature of covalently-bound lenvatinib-related material with human plasma proteins and to evaluate its reversibility, the effect of the nucleophiles GSH and cysteine was examined. Covalent binding of lenvatinib to  human  plasma  protein  occurred  in  vitro,  and  GSH  and  cysteine  successfully  released  lenvatinib-related components bound to plasma protein as conjugates in the same manner as the 2-ME conjugates in previous studies (E7080-E044-104 and AE-6748-G).  Since abundant amounts of GSH and cysteine exist in humans, the covalent binding observed in human plasma is expected to be reversible in vivo.

## Excretion

After oral administration of [14C] lenvatinib mesilate to rats and cynomolgus monkeys or [14C]CB-lenvatinib mesilate to monkeys, greater than or equal to 90% of the radioactive dose was recovered in the excreta by 168 hours post-dose. In rats, fecal excretion via bile was the main route of excretion, while in monkeys fecal and urinary excretion was a major excretion route of radioactivity after dosing of [14C]lenvatinib mesilate and [14C]CB-lenvatinib mesilate, respectively. These results indicated that metabolites derived from the quinoline moiety were excreted mainly in the feces, and those from the chlorobenzyl moiety were excreted primarily in the urine.

<div style=\"page-break-after: always\"></div>

Table 6: Excretion of radioactivity after a single oral administration of lenvatinib to male rats and monkeys

| Data Source         | Species/Strain Test Article/Dose (mg/kg)        | Cumulative Excretion of Radioactivity up to 168 Hour's*   | Cumulative Excretion of Radioactivity up to 168 Hour's*   | Cumulative Excretion of Radioactivity up to 168 Hour's*   |
|---------------------|-------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
| Data Source         | Species/Strain Test Article/Dose (mg/kg)        | Urine                                                     | Feces                                                     | Total                                                     |
| Study No. AE-4150-G | Rat/SD [14C]Lenvatinib mesilate/3               | 12.2                                                      | 87.2                                                      | 99.4                                                      |
| Study No. AE-4151-G | Monkey/Cynomolgus [14C]Lenvatinib mesilate/3    | 17.2                                                      | 72.8                                                      | 90.0                                                      |
| Study No. AE-6917-G | Monkey/Cynomolgus [14C]CB-lenvatinib mesilate/3 | 79.9                                                      | 13.6                                                      | 93.5                                                      |

Dose is expressed as themesilate salt.Values represent the mean values of 3 animals.

CB = chlorobenzene, SD = Sprague Dawley.

a:Value was expressed as percentage of dose.

The excretion of radioactivity into milk was investigated after a single oral administration of 3 mg/kg [14C]lenvatinib mesilate to lactating SD rats (Study No. AE-6750-G). The concentration of radioactivity in milk was higher than that in plasma, indicating a relatively high transfer of lenvatinib into milk. However, the concentration of radioactivity in milk decreased rapidly with a similar time profile as that in plasma, suggesting no tendency for lenvatinib to remain in milk for a long period.

## Pharmacokinetics drug interactions

Protein binding of lenvatinib in human liver microsomes solution was evaluated using an equilibrium dialysis method. The percentages of protein binding of lenvatinib in the human liver microsomes sample (1 mg protein/mL) at 0.3, 1, 3, 10, and 30 μg/mL lenvatinib mesilate were 29.24±0.91%, 26.93±1.26%, 25.49±0.21%, 24.53±0.52%, and 23.85±1.06%, respectively. The mean unbound fraction in the study at 1 mg/mL microsomal protein was 0.74, and DDI simulation using Simcyp was re-evaluated using this value.

The induction of CYPs, UGTs, and P-gp by lenvatinib was evaluated in vitro (Study Nos. XT063020 and XT103078). Treatment of cultured human hepatocytes with up to 3 μmol/L lenvatinib had a tendency to slightly increase CYP3A but had no effect on CYP1A1, CYP1A2, CYP2C9, and P gp did not induce CYP2B6, UGT1A1, UGT1A4, UGT1A6, UGT1A9, and UGT2B7 enzyme activities or mRNA expressions.

Additionally, the inhibition of CYPs and UGTs by lenvatinib was studied in vitro (Study Nos. B03023, PK-Test0072, PK-Test-0040, PK-Test-0079, and XT105084). Lenvatinib mesilate (100 µmol/L) weakly inhibited the activities of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6. Lenvatinib showed virtually no inhibitory effects on CYP2A6 and CYP2E1. Lenvatinib exhibited a potent inhibitory effect on CYP2C8 (IC50 = 10.1 µmol/L) and a weak inhibitory effect on CYP3A (IC50: approximately 100 µmol/L) in human liver microsomes.

The potential inhibitory activity of lenvatinib mesilate (0.03 to 30 μmol/L) on UGTs (UGT1A1, UGT1A4, UGT1A6, UGT1A9, and UGT2B7) was assessed in HLM using UGT isoform specific substrates. Lenvatinib inhibited UGT1A1 and UGT1A4 with IC50 values of 10.6 and 14.0 μmol/L, respectively.  Lenvatinib weakly inhibited UGT1A9, with 31.9% inhibition observed at 30 μmol/L; however, the IC50 value for this enzyme was greater than 30.0 μmol/L.  There was little or no evidence of inhibition of UGT1A6 and UGT2B7 by lenvatinib.

A series of in vitro studies was conducted to assess the substrate recognition and inhibitory activity of lenvatinib on the known human transporters, including P-gp, BCRP, OATPs, OATs, OCTs, and BSEP.

<div style=\"page-break-after: always\"></div>

The roles of P-gp in mediating the membrane permeability of [14C]lenvatinib and the potential inhibition of P-gp-mediated [3H]digoxin transport by lenvatinib were assessed using human P-gp expressing and control LLC-PK1 cell monolayers (Study No. GE-0556-G). These results demonstrated that lenvatinib was a substrate for P-gp. Lenvatinib weakly inhibited P-gp-mediated transport, and the IC50 for the inhibition of [3H]digoxin transport mediated by P-gp was estimated to be more than 30 μmol/L.

The potential of [14C]lenvatinib to serve as a substrate for BCRP and the potential inhibition of BCRPmediated [3H]prazosin transport by lenvatinib were assessed using human BCRP expressing and control LLCPK1 cell monolayers (Study No. GE-0791-G). In this study, it was shown that lenvatinib was a BCRP substrate and it weakly inhibited BCRP-mediated transport (IC50 &gt; 30 µmol/L).

To assess whether lenvatinib is a substrate or inhibitor for OAT1, OAT3, OCT2, OATP1B1, and OATP1B3, the transport of lenvatinib and inhibition of the various transporters by lenvatinib were examined using specific transporter expressing cells (Study No. GE-0791-G). These results indicated that lenvatinib was not a substrate of OAT1, OAT3, OCT2, OATP1B1, and OATP1B3. The inhibition of these transporters by lenvatinib was evaluated by assessing the inhibition of cellular uptake of radiolabeled typical substrates for each transporter. Lenvatinib showed concentration-dependent inhibitory effects on OAT1, OAT3, OCT2, and OATP1B1 with the IC50 values of 7.36, 4.11, 10.8, and 7.29 μmol/L, respectively, and minimal or no inhibitory effect on OATP1B3 (IC50 &gt;30 μmol/L).

The potential for [14C]lenvatinib to be a substrate for OCT1 and BSEP, and the potential of lenvatinib to inhibit these transporters were assessed using OCT1 expressing HEK293 cells and BSEP expressing closed inside-out vesicles (Study No. GE-0942-G), respectively. Lenvatinib was not a substrate for OCT1 and BSEP. Lenvatinib showed concentration-dependent inhibitory effects on OCT1- and BSEP-mediated uptake of each respective radiolabeled typical substrate with IC50 values of 14.9 and 14.2 μmol/L.

In Study No DMPKT2012-004, the potential inhibition of human AO activity by lenvatinib and its metabolites (M1, M2, M3, M2´, M3´, and M5) was evaluated using human liver cytosol. AO specific activity was assessed using phthalazine, known to be a substrate of AO, by measuring the concentration of its metabolite, phthalazone, with liquid chromatography coupled with tandem mass spectrometry (LC/MS/MS). Lenvatinib did not inhibit AO activity (IC50 &gt;100 μmol/L).

## 2.3.4. Toxicology

All pivotal toxicity studies were performed in compliance with Good Laboratory Practice (GLP) regulations, and designed in accordance with the relevant guidelines.

The applicant provided the same as for the Lenvima MAA.

## Single dose toxicity

The single dose toxicity of lenvatinib was evaluated in oral single-dose toxicity studies in rats, followed by a 4-day or 4-week observation period, and in dose escalation studies in dogs and monkeys.

<div style=\"page-break-after: always\"></div>

Table 7: Overview of single dose toxicity studies with lenvatinib mesilate

<!-- image -->

| StudyNumber   | Type of Study/Species/Strain   | Method of Administration   | Durationof Dosing               | Dose (mg/kg)       | GLP   |
|---------------|--------------------------------|----------------------------|---------------------------------|--------------------|-------|
| TKB02006      | Rat/Sprague Dawley             | Oral gavage                | Single                          | 100,300,1000       | No    |
| S04094        | Rat/Sprague Dawley             | Oral gavage                | Single                          | 0,500,1000, 2000   | Yes   |
| TKB02022      | Dog/Beagle                     | Oral capsule               | Single (Dose escalation method) | 100,300,1000       | No    |
| S03060        | Monkey/Cynomolgus              | Oral gavage                | Single (Dose escalation method) | 0,30,100,300, 1000 | No    |

## Rats

In both the oral dose range-finding (DRF) toxicity study (Study No. TKB02006) and the GLP-compliant singledose oral toxicity study (Study No. S04094) lenvatinib mesilate was suspended with 75% polyethylene glycol (PEG) 400 aqueous solution and administered as a single oral dose, by gavage, to male and female SD rats (3 animals/sex/group in the DRF, 5 animals/sex/group in the GLP compliant study) (vehicle control, 75% PEG 400 aqueous solution). In the DRF study, at 1000 mg/kg, decreased food consumption was observed in males, and red spots in the stomach were observed macroscopically in both males and females. Watery contents in the small intestine were observed in 1 female rat at 1000 mg/kg. No abnormalities were observed in any rats administered 100 or 300 mg/kg.

In the GLP-compliant study, a 4-week observation period was included. Delayed deaths (observed from Day 14 onward) were observed in 3 animals administered 1000 or 2000 mg/kg. In these animals, decreased activity, hypothermia, staining of the nose region, chromaturia (reddish urine), or discoloration of the eyeball were observed before death. At necropsy, dilatation, mucosal thickening, and red focus were observed in the stomach and duodenum. In addition, agglomeration of food and test article was found in the stomach or occluded the duodenum. Similar GI changes were observed in surviving animals at 1000 or 2000 mg/kg. White discoloration of incisors, decreased food consumption, and subsequent suppression of body weight gain were observed in these groups. No test article related changes were observed at the dose of 500 mg/kg.

## Dogs

Lenvatinib mesilate was administered orally in gelatin capsules, as a single dose, to 1 male and 1 female beagle dog in a dose escalation study (Study No. TKB02022). Each dog received single doses of 100, 300, or 1000 mg/kg as a 3-fold trituration with lactose with an interval of 1 week between doses in a dose escalation manner.

There  were  no  deaths.  No  toxicologically  significant  changes  in  clinical  signs,  body  weight,  or  food consumption were observed in the dogs orally administered doses up to 300 mg/kg. At 1000 mg/kg, the female dog showed vomiting immediately after administration.

Maximum observed concentration (Cmax) and area under the concentration-time curve from zero time to 24 hours (AUC(0-24)) values increased with dose escalation from 100 to 300 mg/kg. Cmax and AUC(0-24) values at 1000 mg/kg were lower than those at 300 mg/kg.

## Monkeys

Lenvatinib mesilate was administered orally by gavage, as a single dose, to 2 male cynomolgus monkeys at doses of 0 (vehicle control, 75% PEG 400 aqueous solution, 30, 100, 300, or 1000 mg/kg with an interval of

<div style=\"page-break-after: always\"></div>

1 day between each dose in a dose escalation study (Study No. S03060). Both animals were necropsied after completion of the observation period following the final administration.

There were no deaths. No abnormal clinical signs were induced by lenvatinib treatment except for watery stool, which was also present following dosing with the vehicle. One male showed decreased food consumption after administration of 300 mg/kg and higher. Macroscopically, abnormal materials in the stomach and watery contents in the small and large intestine were observed in both animals treated with lenvatinib, while red spots in the stomach were only observed in 1 animal.

Cmax and AUC(0-24) values at 30 mg/kg were 13.31 μg/mL and 95.19 μg·h/mL, respectively. The plasma concentration of lenvatinib 2 hours after administration did not increase proportionally with administered dose between 100 and 1000 mg/kg.

## Repeat dose toxicity

Table 8: Overview of repeat dose toxicity studies in rats with main findings

| Species Number/Group Study ID   | Duration   | Route Dose (mg/kg)                                         | Major findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|---------------------------------|------------|------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| SD Rat 3M/3F TKB02007 Not GLP   | 1 week     | Oral gavage 0, 100, 300, 1000 (75% PEG 400/ suspension)    | ≥ 100 mg/kg:  platelet,  AST and ALT, mineralization in kidney, stomach, heart and aorta,  thickness of epiphysial growth plate, myocardial degeneration, and hypoplasia in bone marrow 1000 mg/kg: Lethality (2F),  activity, soft stool, watery stool,  food consumption and body weight                                                                                                                                                                                                                                                                                                                                                                                                                              |
| SD Rat 3M/3F TKB02008 Not GLP   | 1 week     | Oral gavage 0, 10, 30, 100 (water for injection/ solution) | ≥ 10 mg/kg:  thickness of epiphysial growth plate 100 mg/kg:  platelets (F), mineralization in stomach (M)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| SD Rat 10M/10F S03016 GLP       | 4 weeks    | Oral gavage 0, 10, 30, 100 (75% PEG 400/ suspension)       | 100 mg/kg: Lethality from Day 22 (4M, 2F),  activity, soft stool,  food consumption and body weight  RBC, Hb, Ht, platelet, reticulocyte, albumin, globulin,  AST and ALT, cholesterol, BUN, creatinine, proteinuria All doses: Histologic lesions in bone (  thickness of epiphysial growth plate and cartilage), kidney (glomerulopathy), ovary (follicular atresia), incisor (dysplasia), testes (hypocellularity of seminiferous epithelium) At MD and HD only: liver (sinusoidal dilatation), adrenal gland (sinusoidal dilatation and cortical necrosis), stomach (increased mucous cells), small intestine (duodenal gland inflammation and foamy cell/neutrophil accumulation), and tongue (epithelial atrophy) |

<div style=\"page-break-after: always\"></div>

| SD Rat 10M/10F (LD) 16M/16F (control &HD) S04001 GLP   | 4 weeks +4 weeks recovery (control &HD)   | Oral gavage 0, 1, 15 (75% PEG 400/ suspension)             | 1 mg/kg: incisor dysplasia (1M, 1F) 15 mg/kg: severe anorexia,  platelets, reticulocyte count  ALT, cholesterol, ALP, proteinuria  testes weight Histologic lesions in bone (  thickness of epiphysial growth plate and cartilage), kidney (glomerulopathy), ovary (follicular atresia), incisor (dysplasia), testes (hypocellularity of seminiferous epithelium) Evidence of partial recovery                                                                                                                                                                                                                                                                                                   |
|--------------------------------------------------------|-------------------------------------------|------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| SD Rat 10M/10F S05039 GLP                              | 13 weeks                                  | Oral gavage 0, 0.4 , 2, 10 (water for injection/ solution) | 2 & 10 mg/kg:  RBC, eosinophil, platelet, albumin, globulin  MCV, MCH, neutrophil, monocyte, AST and ALT, cholesterol, glucose, BUN 10 mg/kg:  body weight, proteinuria Histologic lesions in bone (  thickness of epiphysial growth plate and cartilage), kidney (glomerulopathy), ovary (follicular atresia), liver (sinusoidal dilatation), brain (changes in blood vessels of choroid plexus), incisor (dysplasia), testes (hypocellularity of seminiferous epithelium), adrenal gland (sinusoidal dilatation and cortical necrosis), stomach (mucosal hyperplasia), small intestine (duodenal gland inflammation) 2 mg/kg: less severe changes in incisors, ovaries and submaxillary glands |

<div style=\"page-break-after: always\"></div>

| SD Rat 15M/15F S08037 GLP   | 26 weeks   | Oral gavage 0, 0.4 , 2, 10 (water for injection/ solution)   | 10mg/kg: Lethality from Day 84 (8M, 3F), soft stool,  food consumption and body weight Histologic lesions in bone (  thickness of epiphysial growth plate and cartilage), kidney (glomerulopathy and glomerulonephropathy), ovary (follicular atresia), brain (perivascular exudate in choroid plexus), incisor (dysplasia), testes (hypocellularity of seminiferous epithelium,  weight:- 19%), adrenal gland (sinusoidal dilatation and cortical necrosis), small intestine (distension in 13M/11F, duodenal inflammation, cystic dilatation of duodenal glands). Other changes found in bone marrow (hypocellularity), vagina (mucification), epididymides (desquamated seminiferous epithelial cells), pituitary (basophilic cell vacuolation), stomach (mucosal hyperplasia and inflammatory cell infiltration in glandular stomach, medial necrosis of arterioles and erosion), intestine (accumulation of foamy cells and neutrophils, crypt hyperplasia, submucosal edema and decreased goblet cells), submaxillary glands (acinar hypertrophy), thymus (atrophy), heart (adventitial thickening of arterioles), liver (Kupffer cell hypertrophy or hyperplasia and pigmentation of periportal hepatocytes), common bile duct (cholangitis), pancreas (pancreatitis, fatty necrosis and decreased zymogen granules), and spleen (trabecular mineralization and lymphoid depletion) were considered to be secondary effects of the pharmacology- related changes or deteriorated condition. 2 mg/kg: less severe changes in incisors, kidneys, spleen, and adrenal glands 2 & 10 mg/kg:  RBC (-10%),  MCV, MCH (+14%), neutrophil (x2-4), monocyte (x4-5), lymphocyte (x2), ALT (+11%), cholesterol (+122%M, +26%F), BUN  albumin (up to -25%), A/G ratio (up to -18%) proteinuria   |
|-----------------------------|------------|--------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

Note: NOAEL values are indicated in bold and are underlined.

Table 9: Overview of repeat dose toxicity studies in dogs with main findings

| Species Number/Group Study ID     | Duration   | Route Dose (mg/kg)                                              | Major findings                                                                                                                                                                                                                                                                                             |
|-----------------------------------|------------|-----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Beagle dog 1M/1F TKB02027 Not GLP | 7 days     | Oral capsules 0, 30, 100, 300 (3-fold trituration with lactose) | 300 mg/kg: watery stool,  food consumption and body weight,  lymphocytes,  AST and ALT All doses: Histologic lesions in liver (mononuclear cell infiltration, single cell necrosis of hepatocytes), GI tract (  goblet cells, focal acute inflammation in lamina propria, lymphoid depletion/necrosis) |

<div style=\"page-break-after: always\"></div>

| Beagle dog 3M/3F B-5108 GLP                          | 4 weeks (shorten s to 15 days at LD & MD and to 8 days at HD) HD 20- day recovery   | Oral capsules 0, 2, 6, 30 (10-fold trituration with lactose)   | 30 mg/kg: Severe GI toxicity, vomiting, watery stool,  body weight (up to -14.5%) and food consumption, anorexia  reticulocytes  fibrinogen, AST and ALP, cholesterol, BUN 2 & 6 mg/kg: similar clinical signs, helatology and serum chemistry changes, but less severe All doses: Histologic lesions in kidney (glomerulopathy), ovary (follicular atresia), testes (hypocellularity of seminiferous epithelium), adrenal gland (sinusoidal dilatation and cortical necrosis), vascular lesions (arterial fibrinoid necrosis & parenchymal changes in various tissues, a.o. GI tract) Recovery of clinical signs and vascular effects, except for 1M (moribund/sacrificed on day 13 of recovery)   |
|------------------------------------------------------|-------------------------------------------------------------------------------------|----------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Beagle dog 3M/3F (LD) 5M/5F (control &HD) S03077 GLP | 4 weeks + 4 week recovery (control &HD)                                             | Oral capsules 0, 0.1, 0.5 (10-fold trituration with lactose)   | 0.5 mg/kg: watery stool Histologic lesions in kidney (glomerulopathy), arterial fibrinoid necrosis in the gallbladder, lymphoid depletion in jejunum & ileum ≥0.1 mg/kg: testes (hypocellularity of seminiferous epithelium), epididymides (desquamated seminiferous epithelial cells) Full recovery of all effects                                                                                                                                                                                                                                                                                                                                                                                    |

Table 10: Overview of repeat dose toxicity studies in monkeys with main findings

| Species Number/Group Study ID        | Duration   | Route Dose (mg/kg)                                             | Major findings                                                                                                                                                                                                                                                                                                                                                     |
|--------------------------------------|------------|----------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cynomolgus monkey 1M/1F SBL47-83 GLP | 2 weeks    | Oral capsules 0, 1 , 10, 100 (2-fold trituration with lactose) | 100 mg/kg: soft/watery stool,  food consumption and body weight,  AST and ALT, bilirubin, BUN, creatinine Arterial fibrinoid necrosis in gallbladder (M); mucosal atrophy in colon, duodenum, cecum, rectum; inflammation of duodenal glands 10 mg/kg:  food consumption and body weight Arterial fibrinoid necrosis in colon (F), mucosal atrophy in colon (F) |

<div style=\"page-break-after: always\"></div>

| Cynomolgus monkey 3M/3F (LD) 5M/5F (control, MD&HD) SBL47-86 GLP   | 4 weeks + 4 week recovery   | Oral capsules 0, 0.3 , 3, 30 (3-fold trituration with lactose)   | 30 mg/kg: Lethality (1F, Day 21),  food consumption and body weight, anorexia, watery stool, proteinuria  AST, ALT, bilirubin, BUN, creatinine Histologic lesions in kidney (glomerulopathy), testes (hypocellularity of seminiferous epithelium), duodenum (decreased mucus and inflammation of the duodenal glands), vascular lesions (arterial fibrinoid necrosis/degeneration in gallbladder, stomach, cecum, uterus & focal hemorrhages in the intestine, gallbladder and choroid plexus) 3 mg/kg: vascular changes in gallbladder and focal hemorrhage in the choroid plexus (1M) Recovery of all lesions (histologic lesions in testes only partially recovered)                                                                                                                                                                                                               |
|--------------------------------------------------------------------|-----------------------------|------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Cynomolgus monkey 3M/3F SBL47-94 GLP                               | 13 weeks                    | Oral gavage 0, 0.1 , 0.5, 3 (water for injection/ solution)      | 3 mg/kg: Lethality (1F, Day 75), anorexia,  body weight, watery stool Histologic lesions in kidney (glomerulopathy), duodenum (atrophy of duodenal gland), ovaries (follicular atresia) 0.5 mg/kg: follicular atresia in the ovaries                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Cynomolgus monkey 4M/4F SBL038-031 GLP                             | 39 weeks                    | Oral gavage 0, 0.1 , 0.5, 3 (water for injection)                | 3 mg/kg: Lethality (1M, Day 51), anorexia,  body weight, watery stool Histologic lesions in kidney (glomerulopathy), gallbladder (focal arterial degeneration/fibrinoid necrosis, submucosal inflammatory cell infiltration, choroid plexus in the brain (eosinophilic exudate, arterial fibrinoid necrosis), femur (increased thickness of epiphysial growth plate), duodenum (atrophy of duodenal gland, duodenal crypt hyperplasia), ovaries (follicular atresia) Other changes observed in the vagina (epithelial atrophy), pituitary (vacuolation of basophilic cells), and pancreas (decreased zymogen granules) occurred secondary to pharmacology-related changes.  incidence of menstruation 0.5 mg/kg: Histologic lesions in kidneys (glomerulopathy), femur (increased thickness of epiphysial growth plate), and ovaries (follicular atresia)  incidence of menstruation |

Note: NOAEL values are indicated in bold and are underlined.

## Genotoxicity

The genotoxicity of lenvatinib was evaluated in a standard battery of in vitro and in vivo studies. The battery consisted of the in vitro reverse mutation assay in bacteria (Ames test), in vitro mouse lymphoma tk assay, and in vivo micronucleus assay in rats.

<div style=\"page-break-after: always\"></div>

Table 11: Overview of genotoxicity studies with lenvatinib mesilate

| Type of test/study ID/GLP                                               | Test system                                                           | Concentrations/ Metabolising system                                        | Results   |
|-------------------------------------------------------------------------|-----------------------------------------------------------------------|----------------------------------------------------------------------------|-----------|
| Gene mutations in bacteria S03007 GLP                                   | S. typhimurium (TA98, TA100, TA1535, TA1537) + E.coli strain WP2 uvrA | Up to 5000 µg/plate +/- S9                                                 | Negative  |
| Gene mutations and chromosome aberrations in mammalian cells S03008 GLP | L5178Y TK+/- Mouse Lymphoma                                           | 1) 3h treatment +/- S9 100-200 µg/ml 2) 24h treatment -S9 Up to 22.5 µg/ml | Negative  |
| Chromosomal aberrations in vivo S05032 GLP                              | SD Rat, micronuclei in bone marrow                                    | Tested up to the limit dose 2000 mg/kg                                     | Negative  |

## Carcinogenicity

In accordance with the ICH S9 guideline which states that carcinogenicity studies are not warranted to support marketing for therapeutics intended to treat patients with advanced cancer, no study evaluating the carcinogenic potential of lenvatinib was submitted.

## Reproduction Toxicity

In  accordance  with  the  ICH  S9  guideline,  the  reproduction  and  developmental  toxicity  assessment  for lenvatinib is comprised of only EFD studies in both rats and rabbit. Because lenvatinib was teratogenic in the rat  and  rabbit  EFD  studies,  fertility  and  early  embryonic  development  studies,  and  pre-  and  postnatal development toxicity studies were not conducted.

Table 12: Rat embryo-fetal development studies with lenvatinib mesilate

| Species Number/Group Study ID   | Duration                      | Route Dose (mg/kg)                                                                                       | Major findings                                                                                                                                                                                           |
|---------------------------------|-------------------------------|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| SD rat 7F S05104 Not GLP        | Day 6 to Day 17 of pregnan cy | Oral gavage 0, 0.2, 2, 15, 100 (water/ solution up to 15 mg/kg or 75% PEG 400/ suspension for 100 mg/kg) | ≥ 2 mg/kg: Decreased body weight (-18% to -29% on Day 20 of pregnancy) and food consumption 100% post-implantation loss due to early embryo-fetal resorption 0.2 mg/kg: No toxicity in dams and foetuses |

<div style=\"page-break-after: always\"></div>

| SD rat 20F   | Day 6 to Day 17 of   | Oral gavage 0, 0.1, 0.3, 1.0   | 1 mg/kg:  food consumption and body weight (-14% on Day 20 of pregnancy)                                                                                                                                                                                                                                   |
|--------------|----------------------|--------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S05152       | pregnan              |                                | ≥0.3 mg/kg:  fetal body weights                                                                                                                                                                                                                                                                            |
| GLP          | cy                   | (water/ solution)              | ≥0.1 mg/kg: fetal external abnormalities (mandibular macrognathia, cryptophtalmia, abnormal tails, parietal edema) and skeletal abnormalities (discontinued rib cartilage, hemicentric thoracic centrum, split cartilage of thoracic centrum, retardation of fetal ossicifation split of vertebral centrum) |

Table 13: Rabbit embryo-fetal development studies with lenvatinib mesilate

| Species Number/Group Study ID   | Duration                      | Route Dose (mg/kg)                                            | Major findings                                                                                                                                                                                                                                                                                       |
|---------------------------------|-------------------------------|---------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| NZW rabbit 3F S05062 Not GLP    | 4 days                        | Oral gavage 0, 25, 100, 400 (75% PEG 400/ Aqueous solution)   | All doses:  body weights, food consumption (minimal to no on Day 4 at ≥100 mg/kg), reddish gastric mucosa 400 mg/kg: few feces                                                                                                                                                                      |
| NZW rabbit 5F S05063 Not GLP    | Day 6 to Day 18 of pregnan cy | Oral gavage 0, 0.8, 4, 20 (water for injection/ solution)     | 20 mg/kg: Moribund condition (1F), few feces,  activity,  food consumption and body weight 4 mg/kg:  food consumption and body weight, abortion (2F) 0.8 mg/kg: abortion (2F) All doses: complete fetal resorption, vaginal hemorrhage                                                            |
| NZW rabbit 5F S05119 Not GLP    | Day 6 to Day 18 of pregnan cy | Oral gavage 0, 0.03, 0.1, 0.3 (water for injection/ solution) | 0.3 mg/kg: 1 abortion on Day 21 ≥0.1 mg/kg: slight  post-implantation loss,  live fetuses                                                                                                                                                                                                          |
| NZW rabbit 20F S06009 GLP       | Day 6 to Day 18 of pregnan cy | Oral gavage 0, 0.03, 0.1, 0.5 (water for injection/ solution) | 0.5 mg/kg:  food consumption (up to -47%) and body weight (up to -5.8%) abortion (7F), complete resorption (10F) 1 live fetus with multiple anomalies (retroesophageal subclavian artery, fused rib, thoracic hemivertebra and misshapen arch of lumbar vertebra) 0.1 mg/kg: fused rib (each fetus) |

<div style=\"page-break-after: always\"></div>

## A 2-week dose range finding study in juvenile rats

In order to determine the dosing regimen and the dose levels for the pivotal study in juvenile rats, a 2-week dose range-finding study was conducted with 2 phases. Lenvatinib mesilate was administered orally, by gavage, once daily for 2 weeks to male and female SD rats (5 animals/group/sex) at doses of 0 (vehicle control, water for injection), 0.2, 0.4, 1, or 5 mg/kg from postnatal day (PND) 7 (Phase 1) or at doses of 0, 0.4, 1, 5, 25 mg/kg from PND21 (Phase 2).

Cmax and AUC(0-24) increased dose-proportionally, and there were no biologically significant differences in systemic exposure between males and females. Following repeated administration, the systemic exposure on Day 14 was relatively lower than on Day 1; however, these differences were not considered biologically significant by the applicant.

An overview of the findings including toxicokinetics (as mean values of male and female data) is presented below.

Table 14: 2-week dose range-finding study in juvenile rats

| Doses (mg/kg)                         | Toxicities                                                                                                                                                                                                                                                                                                                                                                                                                                           | Cmax (ng/mL)                          | AUC (ng.h/mL)                         |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|---------------------------------------|
| Phase I (dosing initiated on PND 7)   | Phase I (dosing initiated on PND 7)                                                                                                                                                                                                                                                                                                                                                                                                                  | Phase I (dosing initiated on PND 7)   | Phase I (dosing initiated on PND 7)   |
| 0.2                                   | Slight changes in BW, BUN and bone measurement                                                                                                                                                                                                                                                                                                                                                                                                       | D1: 128.09 D14: 77.47                 | 1289.96 737.25                        |
| 0.4                                   | Less severe changes in BW and bone measurement, and increases in BUN and total cholesterol Histology: changes limited to the incisor, kidneys, heart, and adrenals All changes were reversible after 14-day recovery                                                                                                                                                                                                                                 | D1: 203.71 D14: 143.1                 | 2810.07 1122.83                       |
| 1                                     | Mortality : 7 out of 8/sex (day 4-13), attributed to severe intestinal toxicity sometimes accompanied by peritonitis. Decreased BW, changes in bone measurement (shorter/narrower bone) and delayed eyelid opening Histology: incisor (dysplasia), kidneys (glomerulopathy), adrenals (sinusoidal dilatation and cortical necrosis), bone (  epiphysial growth plate), heart (thrombosis), and intestines (mucosal inflammatory cell infiltration). | D1: 481.61 D14: ND                    | 5666.93 ND                            |
| 5                                     | Mortality : 8 out of 8/sex (day 8-12) See 1 mg/kg                                                                                                                                                                                                                                                                                                                                                                                                    | D1: 4051.32 D14: ND                   | 46197.93 ND                           |
| Phase II (dosing initiated on PND 21) | Phase II (dosing initiated on PND 21)                                                                                                                                                                                                                                                                                                                                                                                                                | Phase II (dosing initiated on PND 21) | Phase II (dosing initiated on PND 21) |
| 0.4                                   | No toxicologically significant changes                                                                                                                                                                                                                                                                                                                                                                                                               | D1 : 172.88 D14 : 125.82              | 1404.15 972.58                        |
| 1                                     | No toxicologically significant changes                                                                                                                                                                                                                                                                                                                                                                                                               | D1 : 456.42 D14 : 321.62              | 3298.06 1928.87                       |
| 5                                     | Less severe changes in BW and FC in males and bone measurement in both sexes                                                                                                                                                                                                                                                                                                                                                                         | D1 : 2893.37 D14 :2270.39             | 22007.37 12441.32                     |

<div style=\"page-break-after: always\"></div>

|    | Histology: changes limited to the incisors, adrenals, and bone                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                           |                    |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|--------------------|
| 25 | Moribond condition in 1 out of 8/sex on last day, related to fasting Decreased BW and FC, delayed vaginal opening and shorter/narrower bone  ALT, AST, BUN, total bilirubin, and total cholesterol,  glucose and Ca Histology: incisor (dysplasia), kidneys (glomerulopathy), adrenals (sinusoidal dilatation and cortical necrosis), bone (  epiphysial growth plate), intestines (inflammation/ cystic dilatation in duodenal glands), testes (hypocellularity), and brain (eosinophilic exudate and arterial fibrinoid necrosis in choroid plexus). | D1 :15712.41 D14 :5678.36 | 128762.71 60448.51 |

In phase I, the lowest dose of 0.2 mg/kg can be considered as the NOAEL, while in phase II, the dose of 1 mg/kg was considered to be NOEL.

In  summary, toxicity of lenvatinib was more prominent in PND7 juvenile rats than PND21 rats. Lenvatinib mesilate at doses of 1 mg/kg and higher were lethal in PND7 animals while no death was observed up to 25 mg/kg in PND21 animals.

## An 8-week toxicity study in juvenile rats

Because of the severe toxicities observed in the DRF when dosing the animals from PND7, the pivotal study was conducted with animals of the age of PND 21. Lenvatinib mesilate was administered orally by gavage once a day for 8 weeks to male and female SD rats (10 animals/group/sex) from PND 21 at doses of 0 (vehicle control, water for injection), 0.4, 2, or 10 mg/kg.

The Cmax and AUC(0-24) were increased proportionally. No gender difference and no effect of repeated dosing on  Cmax  and  AUC(0-24)  was  observed.  Differences  in  systemic  exposure  observed  following  repeated administration were not considered biologically significant by the applicant.

An overview of the findings including toxicokinetics (as mean values of male and female data) is presented below.

<div style=\"page-break-after: always\"></div>

Table 15: 8-week toxicity study in juvenile rats with a 4-week recovery period

|   Doses (mg/kg) | Toxicities                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | Cmax (ng/mL)     | AUC (ng.h/mL)   |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------|-----------------|
|             0.4 | No significant changes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | D1:266 D56:235   | 1882 1507       |
|             2   | Broken teeth(incisors)fromDay31,√BWgainandFC In the open field test, the number of rearing was decreased in males. Clinical pathology: 个 WBC, NEU, and ALT. Changes in the bone measurement (short, narrow). Histopathology changes: limited to the incisors, femur, and kidneys.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | D1:1428 D56:1896 | 10857 8575      |
|            10   | Mortality: 6M,7F between Day 26 and Day 51, accompanied by diarrhea,√BW and FC Death/moribundity attributed to primary duodenallesions with complications including occasionalbacterialinfection. Diarrhea and broken teeth (incisors) from Day 18 or 22, blackish stool √ BW and FC resulted in the secondary delay in physical development (prepuce separation/vaginal opening). Open field test: delay in latency, decreased number of square ambulation, and decreased rearing. Clinical pathology: ↓RBC,HGB,HCT, WBC, Glu,TP, AIb, Glo,and Ca 个NEU,ALT,AST, ALP,BUN, and T-Chol Histopathology:incisors (dysplasia)， bones (increased epiphysial  growth plate/cartilage/articular cartilage), kidneys (alomerulopathy and glomerulonephropathy associated with proteinuria), adrenals (sinusoidal dilatation and cortical necrosis), duodenum (cystic dilatation and inflammation of duodenal glands), and brain (perivascular eosinopbilic exudate and arterial fibrinoid necrosis in choroid plexus). Changes in the bone measurement(short/narrow bone）were consideredrelated to growth retardation and/or histologic changes in the bone. After recovery: sporadic diarrhea at 10 mg/kg and broken teeth at 2 mg/kg Tendency to recover butBW, FC of 2 and 10 mg/kg groups still lower than control, proteinuria still present and bone still short/narrow. Minimal residual histologic changes in the incisors,femur,kidneys,adrenals,and duodenum. | D1:7939 D56:6356 | 56492 38510     |

## Toxicokinetic data

## Rats

The median time at which the highest drug concentration occurred (tmax) was between 0.25 and 1.5 hours after administration. No apparent gender difference was observed in the pharmacokinetic parameters. The Cmax and AUC(0-24) of lenvatinib increased approximately dose-proportionally from 0.4 to 10 mg/kg on Days 1 and 181 (149) in males and females, respectively. The pharmacokinetic parameters of lenvatinib were not significantly affected by repeated administration, except at doses of 30 mg/kg and above, the mean systemic exposure decreased after a 4-week administration.

## Dogs

The median tmax was 2 hours after dosing. The mean Cmax and AUC(0-24)  of lenvatinib increased dose proportionally from 0.1 to 0.5 mg/kg. No difference in the pharmacokinetic parameters was observed between males and females in any dosing group. No apparent changes in pharmacokinetic parameters as a result of repeated administration for 4 weeks were observed in males.

## Monkeys

The median tmax values were between 1 and 4 hours after administration. No apparent gender difference in Cmax or AUC(0-24)  was observed. The mean Cmax and AUC(0-24) generally increased in a more than doseproportional manner from 0.1 to 3.0 mg/kg in males and females on Day 1. There were no significant changes in Cmax or AUC(0-24) after repeated administration for up to 39 weeks.

<div style=\"page-break-after: always\"></div>

Table 16: Comparative overview of AUC values at steady state in rats, dogs, monkeys and humans

|                        | Steady StateAUC (ug·h/mL)   | Steady StateAUC (ug·h/mL)   | Steady StateAUC (ug·h/mL)   | Steady StateAUC (ug·h/mL)   | Steady StateAUC (ug·h/mL)   | Steady StateAUC (ug·h/mL)   | Steady StateAUC (ug·h/mL)   |
|------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Species                | Rata                        | Rata                        |                             |                             | Monkeyd                     | Monkeyd                     | Human                       |
| MethodofAdministration | PO                          | PO                          | PO                          | PO                          | PO                          | PO                          | PO                          |
| Gender                 | Male                        | Female                      | Male                        | Female                      | Male                        | Female                      | Maleand Female              |
| Dose(mg/kg)            |                             |                             |                             |                             |                             |                             |                             |
| 0.1                    |                             |                             | 0.1413                      | 0.1329                      | 0.2051                      | 0.2649                      |                             |
| 0.4                    | 3.2102                      | 3.5546                      | 一                           |                             |                             | 一                           |                             |
| 0.5                    |                             |                             | 0.5576                      | 0.5683                      | 1.5418                      | 1.2944                      |                             |
| 2                      | 18.2235                     | 17.0003                     | 2.6325                      | 2.7832                      |                             | 一                           | 4.224095                    |
| 3                      | 一                           |                             |                             |                             | 11.1901                     | 8.3662                      |                             |
| 6                      |                             |                             | 7.1801                      | 7.0213                      | 一                           | 一                           |                             |
| 10                     | 55.6223                     | 71.1701                     | 一                           | 一                           | 一                           | 一                           |                             |
| 30                     | 一                           |                             | 15.3712                     | 39.3136                     | 一                           | 一                           |                             |

AUC=areaundertheconcentration-timecurve.

a:26-weektoxicitystudy(StudyNo.S08037)

b:4-week toxicity study (1) (Study No.B-5108))

c: 4-week toxicity study (2)(Study No.S03077).

- d:39-weektoxicitystudy(StudyNo.SBL038-031)

e:Dose administered was 25 mg,Cycle 2Day1,Study E7080-E044-101.

Table 17: Comparative overview of Cmax values at steady state in rats, dogs, monkeys and humans

|                        | Steady State Cmax (ug/mL)   | Steady State Cmax (ug/mL)   | Steady State Cmax (ug/mL)   | Steady State Cmax (ug/mL)   | Steady State Cmax (ug/mL)   | Steady State Cmax (ug/mL)   | Steady State Cmax (ug/mL)   |
|------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
| Species                | Rata                        | Rata                        | Dogb,c                      | Dogb,c                      | Monkeyd                     | Monkeyd                     | Hunan                       |
| MethodofAdministration | PO                          | PO                          | PO                          | PO                          | PO                          | PO                          | PO                          |
| Gender                 | Male                        | Female                      | Male                        | Female                      | Male                        | Female                      | Male and Female             |
| Dose (mg/kg)           |                             |                             |                             |                             |                             |                             |                             |
| 0.1                    |                             |                             | 0.0191                      | 0.0208                      | 0.0332                      | 0.0388                      |                             |
| 0.4                    | 0.5053                      | 0.9497                      | 一                           |                             | 一                           | 一                           |                             |
| 0.5                    |                             |                             | 0.1045                      | 0.1016                      | 0.2904                      | 0.2310                      |                             |
| 2                      | 4.0121                      | 3.9652                      | 0.3668                      | 0.3771                      |                             |                             | 0.544718                    |
| 3                      | 一                           | 一                           | 一                           | 一                           | 1.8855                      | 1.7407                      |                             |
| 6                      |                             |                             | 0.5244                      | 0.9468                      | 一                           | 一                           |                             |
| 10                     | 10.1696                     | 19.2626                     |                             |                             |                             | 一                           |                             |
| 30                     | 一                           |                             | 1.2482                      | 2.4443                      |                             | 一                           |                             |

=maximumobservedconcentration max

a:26-week toxicity study(StudyNo.S08037)

b:4-week toxicity study(1) (Study No.B-5108)

c:4-week toxicity study (2) (Study No.S03077).

d:39-week toxicity study(StudyNo.SBL038-031)

e:Dose administered was 25 mg,Cycle 2 Day1,StudyE7080-E044-101.

## Local Tolerance

Specific local tolerance studies for lenvatinib have not been conducted. Local tolerance of lenvatinib was assessed by examination of the GI tissues from oral administration studies.

## Other toxicity studies

An  in  vitro  33  NRU  phototoxicity  study  was  conducted  (Study  No.  SBL038-070)  to  assess  the  phototoxic potential of lenvatinib because lenvatinib absorbs light within the range of 290 to 700 nm, and has an affinity to  melanin  based  on  the  slow  elimination  of  radioactivity  in  the  tissues  containing  melanin.  These  results showed that lenvatinib had no phototoxic potential under the conditions employed in the in vitro 3T3 NRU phototoxicity test.

## 2.3.5. Ecotoxicity/environmental risk assessment

An environmental risk assessment has already been performed to evaluate the potential environmental risk resulting from the use of lenvatinib hard capsules in the treatment of patients with progressive, radioiodinerefractory differentiated thyroid cancer (RR-DTC).

<div style=\"page-break-after: always\"></div>

Using a worst-case refined Fpen value of 0.00001 for RR-DTC, the PECSURFACEWATER for lenvatinib has been calculated to be 0.00012 μg/L. This value is ~100 times lower than the action limit of 0.01 μg/L.

A new environmental risk assessment has now been performed to evaluate the additional potential environmental risk resulting from the use of lenvatinib hard capsules in the treatment of patients with advanced and/or metastatic renal cell carcinoma (RCC) with lenvatinib hard capsules in combination with everolimus, following one prior vascular endothelial growth factor (VEGF)-targeted therapy.

Regarding the environmental risk, LogKow was determined to be 3.3 using the shake-flask method. Therefore, an assessment for PBT is not necessary. The applicant provided published data to calculate the prevalence of the disease population targeted by Lenvatinib and this was used to refine Fpen. Using the refined Fpen, a PECsw was calculated that was below the action limit. Therefore lenvatinib is not expected to pose a risk to the environment.

Table 18: Summary of main study results

| Substance (INN/Invented Name): Lenvatinib/Lenvima                   | Substance (INN/Invented Name): Lenvatinib/Lenvima   | Substance (INN/Invented Name): Lenvatinib/Lenvima   | Substance (INN/Invented Name): Lenvatinib/Lenvima   |
|---------------------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| CAS-number: 857890-39-2                                             | CAS-number: 857890-39-2                             | CAS-number: 857890-39-2                             | CAS-number: 857890-39-2                             |
| PBT screening                                                       |                                                     | Result                                              | Conclusion                                          |
| Bioaccumulation potential- log K ow                                 | Shake-flask                                         | 3.30                                                | No Potential PBT                                    |
| PBT-statement :                                                     | The compound is not considered as PBT nor vPvB      | The compound is not considered as PBT nor vPvB      | The compound is not considered as PBT nor vPvB      |
| Phase I                                                             |                                                     |                                                     |                                                     |
| Calculation                                                         | Value                                               | Unit                                                | Conclusion                                          |
| PEC surfacewater , default or refined (e.g. prevalence, literature) | 0.00408                                             | µ g/L                                               | < 0.01 threshold                                    |

## 2.3.6. Discussion on non-clinical aspects

With regard to pharmacology, the applicant has conducted additional in vitro studies in cell-based assays (7 in  total)  and in  vivo studies  in  xenograft  models  with  the  combination  of  lenvatinib  and  everolimus  (4  in total), to support the original data submitted under the previous MAA for lenvatinib mesilate (EMEA/H/C/3727).  The additional in vitro studies showed that lenvatinib inhibited both the MAPK and mTORS6K-S6 pathways and that inhibition of the latter pathway was enhanced by the combination with everolimus in both VEGFand FGF-stimulated HUVECs.  Both lenvatinib and everolimus inhibited VEGF-driven proliferation  in  HUVECs in  vitro ,  with  the  combination  of  lenvatinib  and  everolimus  having  mostly  additive effects for inhibition of VEGF-driven proliferation and mostly synergistic effects for inhibition of FGF-driven tube formation of HUVECs. The human tumour xenograft in vivo studies suggested that lenvatinib may be an effective  anticancer  therapy  for  the  treatment  of  advanced  and/or  metastatic  renal  cell  carcinoma,  in combination with everolimus, following failure of treatment with 1 prior therapy. Results of the nonclinical safety pharmacology studies suggest that lenvatinib has a low potential for exerting adverse effects on the CNS, cardiovascular system or the respiratory system. The lack of effect on ECG parameters in the in vivo study and the weak inhibitory effects of lenvatinib in the hERG assay (IC50 = 11.89 μmol/L or 6,2 µg/ml) at a concentration approximately 20-fold higher than the total maximum observed concentration (Cmax) at the clinical dose of 18 mg (in Study E7080-G000-205) and 1378-fold higher than the free Cmax at the human therapeutic dose, suggest that lenvatinib has a low potential to cause QT prolongation. No significant effects

<div style=\"page-break-after: always\"></div>

on heart rate and mean blood pressure were noted in the in vivo study in dogs. However, hypertension is an identified risk associated with clinical use of lenvatinib and other inhibitors of the VEGF/VEGFR pathway.

According to the ICH S9  guideline, conduct of standalone safety pharmacology studies is not required for advanced  cancer  indications;  however,  the  core  battery  of  stand-alone  safety  pharmacology  studies  was nonetheless conducted.

Results from additional pharmacokinetic studies performed by the applicant showed that lenvatinib was the main fraction of total  radioactivity  in  plasma  after  oral  administration  of  both  [ 14 C]lenvatinib  mesilate  and [ 14 C]CB-lenvatinib  mesilate.  Metabolite  peaks  did  not  exceed  1.9%  of  the  total  radioactivity  values  after administration of [ 14 C]lenvatinib mesilate. No  non-clinical combination pharmacokinetic studies with lenvatinib  and  everolimus  have  been  conducted.  Further  exploration  on  the  potential  interaction  between lenvatinib and everolimus is needed and will be addressed in a post marketing study (Study 109, please see RMP section  2.8).  This  drug-drug  interaction  study  will  investigate  the  potential  of  Lenavtinib  for  CYP3A4 inhibition/induction.

No  new  toxicology  studies  with  lenvatinib  alone  or  in  combination  with  everolimus  have  been  conducted, which  may  be  acceptable  according  to  ICHS9.  This  means  that  all  observed  toxicities  and  corresponding exposures in animals have been compared with clinical exposures at a dose of 24 mg/day, which was the recommended dose for the DTC MAA. For the current MAA, the proposed dose is 18 mg/day (in combination with  everolimus,  5  mg/day).  It  is  not  considered  that  this  would  lead  to  different  overall  conclusions, therefore this can be accepted. However, since the clinical anticipated exposure to lenvatinib is thus lower with the dosing regimen as proposed in the current MAA, all safety margins should in principle be somewhat higher. The administration route of in vivo studies was oral, which is the intended route for clinical use.

In  accordance with the recommendations of the ICH S9 guideline, carcinogenicity studies, fertility studies, and pre-and postnatal toxicity studies were not conducted with lenvatinib to support marketing approval in the proposed advanced cancer indication.

Clinical experience with the combination is limited. Non-clinical combination PD studies in vivo for 15 days give some reassurance on the absence of acute synergistic toxicities. Based on the toxicity profile of each drug  in  nonclinical  studies,  the  kidney,  GI  tract,  and  reproductive  organs  are  the  target  organs  in  which additive  or  synergistic  toxicity  might  be  expected.  The  available  data  overall  suggest  a  low  potential  for additive or synergistic toxicities with the combination, apart from increased toxicities at the level of the GI tract with potential deterioration of general condition.

Regarding the environmental risk, LogKow was determined to be 3.3 using the shake-flask method. Therefore, an assessment for PBT was not necessary. The applicant provided published data to calculate the prevalence of the disease population targeted by Lenvatinib and this was used to refine Fpen. Using the refined Fpen, a PECsw was calculated that was below the action limit. Therefore lenvatinib is not expected to pose a risk to the environment.

## 2.3.7. Conclusion on the non-clinical aspects

The non-clinical data are considered adequate to support a marketing authorisation for Kisplyx. However, further exploration of the potential interaction between lenvatinib and everolimus is needed and will be addressed in a post marketing study (Study 109). This drug-drug interaction study will investigate the potential of Lenvatinib for CYP3A4 inhibition/induction (please see RMP in section 2.8).

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the applicant.

The applicant has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

## · Tabular overview of clinical studies

Table 19: Biopharmaceutics and clinical pharmacology studies in the lenvatinib development program

<!-- image -->

| Study No. and Iype                         | Population                                            | Number of Subjects\"                                     | Treatment (Mfonotherapy or Combination)   |
|--------------------------------------------|-------------------------------------------------------|---------------------------------------------------------|-------------------------------------------|
| Phase l/lb Studies                         | Phase l/lb Studies                                    | Phase l/lb Studies                                      | Phase l/lb Studies                        |
| E7080-A001-001 Comparative bioavailability | Healthy subjects                                      | 20                                                      | NA                                        |
| E7080-A001-002 Thorough QT study           | Healthy subjects                                      | 52 (51 received lenvatinib)                             | NA                                        |
| E7080-A001-003 Food effect study           | Healthy subjects                                      | 16                                                      | NA                                        |
| E7080-A001-004 DDI study with ketoconazole | Healthy subjects                                      | 18                                                      | NA                                        |
| E7080-A001-005 Renal impairment            | Healthy subjects and subjects with renal impaiment    | 8 healthy subjects; 18 subjects with renal impainment   | NA                                        |
| E7080-A001-006 Hepatic Impairment          | Healthy subjects and subjects with hepatic impairment | 8 healthy subjects; 18 subjects with hepatie impairment | NA                                        |
| E7080-A001-007 DDI study with nifampin     | Healthy subjects                                      | 15                                                      | NA                                        |
| E7080-A001-008 Comparative bioequivalence  | Healthy subjects                                      | 60                                                      | NA                                        |
| E7080-E044-104 Mass balance study          | Subjects with solid tumors or lymphomas               | 6                                                       | Monotherapy                               |

<div style=\"page-break-after: always\"></div>

Table 20: Main clinical efficacy and safety studies in the lenvatinib development program

| Study ID (Status)   | Indication                                                    | No. Study Centers (Location)                          | Dates - Study Start a / Clinical Cut-off/ Database Lock   | Study Design                                                                                                                                                                         | Study Treatment: Dose, Route & Regimen                                                                                                                                                          | No. Subjects Treated/ Ongoing (No. on Treatment at Clinical Cut- off)   |
|---------------------|---------------------------------------------------------------|-------------------------------------------------------|-----------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------|
| E7080-G000- 205     | Unresectable or mRCC following 1 prior VEGFtargeted treatment | 37 sites: Czech Republic, Poland, Spain, UK, and USAb | 12 Aug 2010/ 13 Jun 2014                                  | Phase 1/2b, Open-Label, Multicenter with Treatment and Extension Phases. Phase 1b : dose escalation in sequential cohorts to determine MTD and RP2 dose Phase 2 : randomized (1:1:1) | Phase 1b : LENV 12 mg, 18 mg, or 24 mg + EVER 5 mg Phase 2 : Combination Arm : LENV 18 mg + EVER 5 mg, oral, QD Monotherapy arms : LENV 24 mg, oral QD; EVER 10 mg, oral, QD Continuous, 28-day | Phase 1b : 20/0 Phase 2 : 153/23                                        |

EVER = everolimus, mRCC = metastatic renal cell carcinoma, MTD = maximum tolerated dose; LENV = lenvatinib, QD = once daily, RP2 dose =

recommended Phase 2 dose; VEGF = vascular endothelial growth factor.

a: Clinical start date is date of the first subject's signed informed consent.

b: All 4 sites that participated in the Phase 1b portion also participated in the Phase 2 portion of Study E7080-G000-205.

The primary evidence of efficacy of combination treatment with lenvatinib and everolimus in the unresectable advanced of metastatic RCC indication following one prior VEGF-targeted treatment comes from  a single, open-label, Phase 1b/2 study, which is randomised in Phase 2 only  (Study E7080-G000-205 [Study 205]).

## 2.4.2. Pharmacokinetics

A number of in vitro studies were performed to determine the plasma protein binding, the metabolism, and the potential of Lenvatinib to be a substrate of a number of drug transporters.  Lenvatinib was also tested as an inhibitor and inducer of drug metabolising enzymes and drug transporters.

The clinical pharmacology studies included 6 studies in healthy subjects (E7080-A001-001, -002, -003, -004, -007, -008), one study in healthy subjects and subjects with renal impairment (E7080-A001-005), one study in healthy subjects and subjects with hepatic impairment (E7080-A001-006), and one mass balance study in subjects with advanced solid tumours (E7080-E044-104). The clinical pharmacology studies also included

<div style=\"page-break-after: always\"></div>

studies on bioavailability of different formulations, food effect, drug-drug interaction (DDI) and potential effects on the QT interval.

The doses used in the studies ranged from either 0.1 mg to 24 mg twice daily (BID) or 0.2 mg to 32 mg once daily (QD).  Studies were conducted in male and female healthy subjects, individuals of different racial origin (few data on non-Caucasian and non-Asian population) and in subjects with solid tumours or lymphomas.

A population PK (PopPK) analysis (Report CPMS-E7080-007R-v1) for lenvatinib was based on pooled data collected from:

- o Phase 1 trials in healthy subjects (Studies E7080-A001-001, E7080-A001-002, E7080-A001003, E7080-A001-004, E7080-A001-007, E7080-A001-008), plus E7080-A001-005, and E7080-A001-006 which included otherwise healthy renally and hepatically impaired subjects,
- o 3 Phase 1 clinical trials in subjects with solid tumours including lymphoma refractory to existing therapies or for which no treatment is available (Studies E7080-E044-101, E7080A001-102, and E7080-J081-103), an additional Phase 1 trial in subjects with solid tumours (Study E7080-J081-105),
- o a Phase 2 trial in subjects with advanced or recurrent thyroid cancer (Study E7080-J081208),
- o a Phase 2 trial in subjects with medullary and 131 I refractory, unresectable differentiated thyroid cancers (Study E7080-G000-201), and
- o a Phase 3 trial in subjects with 131 I-refractory differentiated thyroid cancer (Study E7080G000-303) was conducted.

This analysis was conducted to describe the PK of lenvatinib and identify covariates explaining intersubject variability in lenvatinib PK.  The covariates included demographics, clinical laboratory data, and tumour type (DTC, MTC, and other).

## Absorption

Lenvatinib, from both tablet and capsule formulations, was rapidly absorbed after oral administration with a time to reach maximum concentration of drug in plasma (tmax) typically observed 1 to 4 hours post-dose. The observed Cmax, AUC0-t and AUC0-∞ after a single dose of 24 mg (SD) in healthy volunteers were 325 (105) ng/mL, 2990 (974) ng.h/mL and 3010 (974) ng.h/mL, respectively (Study A001-005). In patients, Cmax and exposure after administration of a single 24 mg dose appear to be higher than in healthy volunteers: values of 655 (97) ng/mL and 4905 (2145) ng.h/mL have been observed for Cmax and AUC(0-24), respectively (Study A001-102). There were no data after multiple dosing in healthy volunteers.

In the POPPK analysis healthy volunteers had a 15% higher CL/F compared with subjects with malignant solid tumours.

The absolute bioavailability of lenvatinib was not determined.

<div style=\"page-break-after: always\"></div>

## Influence of food

## Study E7080-A001-003

The primary objective of this trial was to determine the effect of food on the bioavailability of lenvatinib following single oral administration of a capsule containing 10 mg E7080 with and without a meal. The study was a Phase I, open-label, randomized, single-dose, 2-treatment (dosing condition), 2-period, 2-sequence, cross-over study in healthy volunteers. Sixteen subjects (12 males and 4 females) received 10 mg of E7080 as a single dose under the two different conditions (fed versus fasting) in a randomised order. Two single dose administrations (one in each of the two consecutive treatment periods) were separated by a washout period of 14 days between the two dosing. 'Fasting' was defined as deprivation of food for ≥ 10 hours (tap water was allowed), whereas 'fed' was defined as administration of the drug 30 minutes after the start of a standard high-fat breakfast (approximately 150 calories of protein, 250 calories of carbohydrate, and 500 to 600 calories of fat).

The administration of a single oral dose of 10 mg lenvatinib with a standard high-fat breakfast was associated with non-significant increases in lenvatinib AUC(0-inf) (ratio%, 90% CI: 106.3, 95.66 to 118.09) and AUC(0-t) fold (ratio%, 90% CI: 103.7, 92.25 to 116.50). However, Cmax point estimate was reduced by approximately 5% compared to that in the fasted state. As the 90% CIs of the ratio of this pharmacokinetic parameter were without the standard bioequivalence range, these results indicated that food delays the rate of absorption in a significant way. In addition, median tmax for lenvatinib was approximately 2-fold increased after administration with food (4.02 h) compared to administration in the fasted state (2.02 h).

## Study E7080-E044-101

Study E7080-E044-101 was an open-label, non-randomized, dose escalation study in eighty-two male and female subjects with solid tumors or lymphomas resistant or refractory to existing therapies or for whom no treatment was available. This Phase 1 study was designed to determine the maximum tolerated dose (MTD) for lenvatinib. A pilot evaluation of the influence of food on lenvatinib pharmacokinetic at the MTD (25 mg) was also conducted in this study.

Eleven subjects entered and completed the food effect pilot study at a once daily lenvatinib dose of 25 mg (2 x 10 mg tablets and 5 x 1.0 mg tablets). These subjects were randomly assigned to receive a single oral dose of  25  mg  lenvatinib  administered  after  a  high-fat  breakfast  (approximately  150  calories  of  protein,  250 calories of carbohydrate, and 600 calories of fat) or following at least a 10 hour fast on the morning or either Cycle  1  Day  15  or  Cycle  1  Day  22.  The  effect  of  food  on  lenvatinib  pharmacokinetics  was  evaluated  by comparing AUC0-24 and Cmax.

Administration of a single oral dose of 25 mg lenvatinib after a standardized high fat breakfast had no impact on the mean plasma exposure (AUC0-24) for lenvatinib. Compared to overnight fasting, the mean maximum plasma concentration (Cmax) of lenvatinib was slightly reduced in the presence of food (2 %). The 90% CIs of the  ratio  of  this  pharmacokinetic  parameter  being  without  the  standard  bioequivalence  range,  it  indicated that food significantly decreases the rate of absorption of lenvatinib. Moreover, tmax was prolonged in the fed conditions  (5  hours,  median  value)  compared  with  the  fasted  conditions  (2  hours,  median  value)  and  the difference  was  statistically  significant  (p  =  0.0146),  indicating  that  dosing  with  food  delays  the  time  to maximum plasma concentrations (tmax).

<div style=\"page-break-after: always\"></div>

## Bioequivalence (BE)

The  relative  bioavailability  of  the  10  mg  capsule  and  10  mg  tablet  was  determined  in  healthy  volunteers (E7080-A001-001 (Relative Bioavailability)). This was a single-centre, single-dose, open-label, randomized, 2-period  cross-over  study  conducted  in  20  healthy  men  under  fasting  conditions.    The  objective  was  to determine the relative bioavailability of a capsule formulation to a tablet formulation.  The subjects received either one 10-mg capsule or one 10 mg tablet on the first day of the first period.  The subjects received the study drug following an overnight fast of at least 10 h.  They received the alternate formulation on the first day of the second period.  There was a 1-week (7-day) washout between the 2 treatment periods.  Nineteen subjects completed the study.

Mean total exposure (AUC(0-inf)) of the 10-mg lenvatinib capsule was approximately 10% less than that of the 10-mg lenvatinib tablet. Mean Cmax for the capsule was approximately 14% lower than that of the tablet. Median tmax was 2.0 hours for both the capsule and tablet. Mean t1/2  values for the capsule and tablet were comparable  (27.6  h  and  29.1  h,  respectively).  The  variability  in  exposures  was  low,  with  the  highest coefficients of variation, Cmax, less than 26% for both formulations. Even though the study was not powered for  BE,  the  90%  confidence  intervals  for  AUC(0-inf)  and  AUC(0-t)  were  within  the  80%  to  125%  confidence interval  typically  used  to  demonstrate  BE.  However,  the  lower  bound  of  the  confidence  interval  for  Cmax (79.84%) was outside the 80% bound.

A bioavailability study comparing the 4-mg to the 10-mg capsule was not done. The 4-mg capsule was shown to  have  a  similar  dissolution  profile  as  10-mg  capsule.    Additionally,  proportionate  increases  in  lenvatinib exposure (based on dose normalized AUC(0-24) and Cmax) following single doses and at steady-state, were seen over the 0.2-mg to 32-mg QD dose range (E7080-E044-101) and the 0.1- to 12-mg BID dose range (E7080-A001-102).  Also,  the  4-mg  strength  capsule  is  proportionally  similar  in  its  active  and  inactive ingredients to the 10-mg strength.

The 4- and 10-mg capsules (and occasionally the 1-mg) were used in most of the Phase 1 and 2 trials.  The 4- and 10-mg capsules were used in the Phase 3 trial and are the intended commercial formulation.

## Distribution

As there is no study with intravenous administration of lenvatinib, the volume of distribution has not been determined. Apparent volume (V/F) was generally not reported in the studies with healthy volunteers. Only in the renal and hepatic impairment studies (Studies A001-005 and A001-006), values were reported. The total values were 428 (153) L and 408 (216) L, respectively, and the unbound values were 6700 (4460) L and 6760 (6370) L, respectively. In the patient studies, the reported Vz/F values ranged from 50.5-92 L (Study E044-101) and 136-312 L (Study J081-103). At steady state, the values ranged from 43.2-121 L (Study E044-101) and 155-261 L (Study J081-103).

The estimated V/F values from the POPPK analysis showed values of 49.3, 30.7 and 37.1 L for the central and 2 peripheral compartments, respectively.

In humans, the in vitro plasma protein binding of lenvatinib (concentration range: 0.3 to 30 μg/mL, mesilate) was 97.87% to 98.62%, with binding mainly to albumin and to a lesser extent to α1-acid-glycoprotein and γglobulin.  Protein  binding  was  linear  across  concentrations.  This  observation  was  confirmed in  vivo ,  with serum protein binding values ranging from 96.6% to 98.2% (Study E7080-J081-103).

<div style=\"page-break-after: always\"></div>

The in vitro blood-to-plasma concentration ratio of lenvatinib remained constant (0.589 to 0.608) in humans over  the  concentration  range  tested  (0.1  to  10  μg/mL  [ 14 C]lenvatinib  mesilate).  The  predominance  of lenvatinib in plasma over blood was also confirmed in the mass balance study, where blood concentrations were 29% and 36% lower than plasma concentrations for total radioactivity and lenvatinib, respectively.

In vitro studies indicate that lenvatinib is a substrate for multidrug resistance protein 1 (MDR1), P-gp, and BCRP.  Lenvatinib is not a substrate for OAT1, OAT3, OATP1B1, OATP1B3, OCT1, OCT2, or the BSEP.

## Elimination

## Excretion

Following Cmax, the plasma concentrations of lenvatinib declined bi-exponentially. The mean terminal elimination half-life (t1/2) of total lenvatinib ranged from 20.6 hours to 34.3 hours in the studies in healthy volunteers. The mean terminal exponential half-life of lenvatinib was approximately 28 hours. The PK of lenvatinib was characterised by an oral clearance of 6.7 L/hour (Study E7080-E044-104). In the population PK analysis, CL/F was 6.56 L/h and its %CV was 25.5%.

After administration of an oral solution of lenvatinib in the mass balance study, 85.5% of the administered dose has been found in urine or as metabolites in faeces. Degradation of lenvatinib in faeces is judged unlikely and urinary excretion of unchanged drug is negligible. Metabolism appeared to be the major elimination pathway for lenvatinib and the excretion of lenvatinib and its metabolites occurred mainly via the faecal route.

## Metabolism

In vitro results with recombinant CYPs indicated that CYP3A4 was the predominant (&gt;80%) isoform contributing to the CYP-dependent metabolism of lenvatinib in humans, followed by CYP1A2 (5.2% to 6.5%) and CYP2B6 (5.2% to 5.7%). Aldehyde oxidase (AO) is responsible for the metabolisation to M3' and M3' glucuronide.

The in vivo metabolism has been studied in a human radiolabelled study E7080-E044-104. In this absorption, distribution, metabolism, excretion (ADME) study, in which 24 mg of  14 C-lenvatinib (approximately 100 µCi (~3.7 MBq)) was administered to 3 men and 3 women with advanced solid tumours or lymphomas, who were unsuitable for, or had failed, existing therapies, most of the recovered radioactivity was found in faeces, 64% of mean total recovery, and 25% of mean total recovery recovered in urine (i.e. 89% of the dose was recovered in the excreta) (see SmPC section 5.2).

In the mass balance study, the mean recovery of  14 C-radioactivity was 89%, with approximately 64% excreted in the feces and 25% in the urine. In urine and faeces, 0.38% and 2.5%, respectively of the radioactive dose was found as lenvatinib. Fractions of the dose eliminated in the urine as unchanged lenvatinib were not dependent on the dose administered. The M3' metabolite was the predominant analyte in excreta (~17% of the dose), followed by M2' (~11% of the dose) and M2 (~4.4% of the dose) (see SmPC section 5.2).

In plasma samples collected up to 24 hours after administration, lenvatinib constituted 97% of the radioactivity in plasma radiochromatograms while the M2 metabolite accounted for an additional 2.5%. Based on AUC(0 - inf), lenvatinib accounted for 60% and 64% of the total radioactivity in plasma and blood, respectively (see SmPC section 5.2).

<div style=\"page-break-after: always\"></div>

Figure 1: Semi-Log plot of mean total radioactivity, E7080 and key metabolites in plasma and blood, study phase, pharmacokinetic analysis set

<!-- image -->

Extraction recovery of radioactivity in plasma samples appeared to decrease in time (with a minimum of 10% 72h after administration) and was, for the later time-points, also highly variable (%CV up to 46%).80% of the recovered radioactivity in excreta (urine and faeces) was identified.

Based on the in vivo data, the following overview of metabolic pathways for lenvatinib in humans has been proposed.

Figure 2: Overview of metabolic pathways for lenvatinib in humans

<!-- image -->

<div style=\"page-break-after: always\"></div>

In total, the contribution to lenvatinib clearance in human is summarized in the table 22 below. The ratio of aldehyde oxidase (AO): CYP3A: non-enzymatic process is approximately 3:4:3 in humans.

Table 21: Contribution to Lenvatinib Clearance in Humans

| Responsible enzyme                              | Contribution%   | Contribution%   |
|-------------------------------------------------|-----------------|-----------------|
| AO                                              | 17.4%           | 17.4%           |
| CYP3A                                           | 20%             | 27.8%           |
| CYP3A (methanol unextractable fraction)         | 7.8% a          | 27.8%           |
| Non-enzymatic (GSH derivative)                  | 6.8%            | 22.8%           |
| Non-enzymatic (methanol unextractable fraction) | 16% a           | 22.8%           |
| Sub total                                       | 68%             | 68%             |
| Unknown (Not recovered)                         | 11%             | 11%             |

AO = aldehyde oxidase, CYP = cytochrome P450, GSH = glutathione.

a:  maximally estimated value.

There is a substantial body of literature confirming that it is possible to observe clinically relevant drug-drug interactions  mediated  by  inhibition  of  AO.  The  article  by  Obach  et  al.,2004  showed  that  there  is  a  wide variety of drugs on the market which are able to inhibit aldehyde oxidase activity and so have the potential to affect exposure of co-administered drugs which are metabolised via this enzyme. However, the proportion of the dose of lenvatinib which is metabolised through AO is quite low (approx. 17%), with the remainder being cleared via other metabolic routes with just a small amount of parent drug excreted unchanged. Conversely, this  means that a large proportion of the dose is eliminated via non-AO mediated mechanisms. There are multiple alternative clearance pathways available for lenvatinib in addition to AO metabolism which are likely to buffer any minor influence of inhibition of the enzyme. Hence, there is no expectation that inhibition of this pathway will lead to clinically significant effects on lenvatinib exposure.

## Inter- and intra-individual variability

In normal healthy subjects, variability (as coefficient of variation [%CV] of AUC, fasted subjects) ranged from about 8% to 20%. In Study E7080-A001-102 (Combination Therapy), PK parameters exhibited moderate to high variability, with %CV estimates ranging from 19.44% to 78%. Compared to normal subjects, subjects with renal or hepatic impairment had greater variability (39% to 45%). In a formal population PK analysis, the %CV of basal apparent total clearance following extravascular administration (CL/F) was 25.5%.

In order to explain inter-individual variability in lenvatinib exposure (AUC), in the POPPK analysis for lenvatinib, the effect of various covariates was tested on CL/F, and formulation, H2-blockers, proton pump inhibitors, antacids, and combined category of pH elevating agents was tested on relative bioavailability. None of these influenced in an important way the pharmacokinetics of lenvatinib.

<div style=\"page-break-after: always\"></div>

## Dose proportionality and time dependencies

## Dose-proportionality

In patients with solid tumours administered single and multiple doses of lenvatinib once daily, exposure to lenvatinib (Cmax and AUC) increased in direct proportion to the administered dose over the range of 3.2 to 32 mg once-daily (QD) (see SmPC section 5.2).

In study E7080-E044-101, the observed t1/2 values decreased with increasing dose. However from a dose of 6.4 mg on, this appeared to be relatively stable.

When data from E7080-E044-101 and E7080-J081-103 were combined, the dose-normalized Cmax was very consistent across doses of 4 mg and higher, although variability was high across the lower doses (less than 4 mg). Cmax showed a linear profile at clinical doses, i.e., 4 mg or higher.  In vitro study data indicate that lenvatinib is a substrate of permeability glycoprotein (P-gp). Thus, a likely explanation of the nonlinearity of Cmax at lower doses is that P-gp expressed in the gut has an efflux functional effect on lenvatinib, which leads to slower absorption of lenvatinib at these doses.

From the POPPK analysis, the CL/F was reported to be 6.56 L/h and this value appeared to be constant upon repeated dosing and through different dosing levels.

For the linearity in CL/F, the PK model was run without the effect of dose on CL/F. There was an increase of 128.176 points in the objective function value, from 64389.472 to 64517.648. In addition, the PK model was run without the effect of dose on F1 and again there was an increase of 62.288 points in the objective function value, from 64389.472 to 64451.76. To further investigate the relationship between dose and CL/F, the final PK model was run using only capsule formulation PK data and without estimating F1. This is of value as the term 'F1' is a relative bioavailability term in the model linking the tablet and to-be-marketed capsule formulations. Adding dose effect on CL/F decreased the objective function value by 5.067 points (from 37346.978 to 37341.901, which is not statistically significant).

## Time-dependency

Upon multiple dosing, steady-state plasma concentrations were achieved within 5 days. Lenvatinib displayed minimimal accumulation at steady state.  Over the dose range 3.2 to 32 mg, the median accumulation index (Rac) ranged from 0.96 (20 mg) to 1.54 (6.4 mg).

This was consistent with the approximately 28 hour half-life of lenvatinib and once daily administration. Apparent clearance and volume of distribution were generally similar between first dose and steady-state and between doses.

## Special populations

In the population PK analysis, apparent total clearance following oral administration (CL/F) was 15% higher in healthy subjects compared to patients and hence the extent of exposure (AUC) was slightly lower for healthy subjects. The PK parameters of lenvatinib were similar in subjects with DTC, medullary thyroid cancer (MTC) and other tumour types.

<div style=\"page-break-after: always\"></div>

## · Elderly

Table 22: Pharmacokinetics in Special Populations: Elderly - Healthy Volunteers

|                                             | Age 65-74 (older subjects number)   | Age 75-84 (older subjects number)   | Age 85+ (older subjects number)   | Total (total number of subjects)   |
|---------------------------------------------|-------------------------------------|-------------------------------------|-----------------------------------|------------------------------------|
| Pharmacokinetic Trials - healthy volunteers |                                     |                                     |                                   |                                    |
| E7080-A001-001                              | 0                                   | 0                                   | 0                                 | 20                                 |
| E7080-A001-002                              | 1                                   | 0                                   | 0                                 | 52                                 |
| E7080-A001-003                              | 0                                   | 0                                   | 0                                 | 16                                 |
| E7080-A001-004                              | 0                                   | 0                                   | 0                                 | 18                                 |
| E7080-A001-005                              | 13                                  | 2                                   | 0                                 | 26                                 |
| E7080-A001-006                              | 0                                   | 0                                   | 0                                 | 26                                 |
| E7080-A001-007                              | 0                                   | 0                                   | 0                                 | 15                                 |
| E7080-A001-008                              | 0                                   | 0                                   | 0                                 | 60                                 |
| Total:                                      | 14                                  | 2                                   | 0                                 | 233                                |

Source: individual clinical study reports.

In the population PK analysis that included data from 196 healthy subjects and 583 patients, age was not a significant covariate that could account for the inter-subject variability in the PK of lenvatinib (CPMS-E7080007R-v1). Median dose and weight adjusted lenvatinib exposure in cancer patients receiving lenvatinib capsules was 3480 ng·h/mL for subjects with age ≤65 years and 3710 ng·h/mL for subjects with age &gt;65 years.

## · Impaired renal function (study E7080-A001-005)

A Phase 1, multicentre, open-Label, non-randomized, single-dose, pharmacokinetic and safety study of E7080 (24 mg) administered to subjects with mild, moderate, and severe renal impairment and to healthy subjects was submitted  to describe and compare the PK of lenvatinib from a single 24-mg oral dose of lenvatinib administered to subjects with mild, moderate, or severe renal impairment (N=6 in each group) and to healthy subjects (N=8) distributionally matched in age, sex, and body mass index (BMI) and to describe the safety of a single 24-mg oral dose of lenvatinib. Both total (bound + unbound) and unbound drug concentrations of lenvatinib were determined. A method using a centrifugal ultrafiltration followed with LCMS/MS was used to determine unbound lenvatinib in plasma.

Cmax, AUC(0-t), and AUC(0-inf) exhibited moderate to high variability. For subjects with mild, moderate, and severe renal impairment, overall exposure (AUC(0-inf)) to lenvatinib was estimated to be 1.01, 0.90, and 1.22

<div style=\"page-break-after: always\"></div>

times that of normal subjects. The half-life for lenvatinib was similar between the normal and the renally impaired subjects. Using a regression method, no statistically significant correlation between lenvatinib exposure and creatinine clearance (CLcr) was observed.

Lenvatinib exposure, based on AUC0-inf data, was 101%, 90%, and 122% of normal for subjects with mild, moderate, and severe hepatic impairment, respectively (see SmPC section 5.2)..

## · Impaired hepatic function (study E7080-A001-006)

A Phase 1, multicentre, open-label, single-dose pharmacokinetic and safety study of lenvatinib in subjects with mild (10 mg) (Child-Pugh A), moderate (10 mg) (Child-Pugh B), and severe hepatic impairment (5 mg) (Child-Pugh C) and normal hepatic function (10 mg) evaluated the PK of lenvatinib from a single oral dose of 10 mg in subjects (N=6) with mild and moderate hepatic impairment and from a single oral dose of 5 mg in subjects (N=6) with severe hepatic impairment compared to a single oral dose of 10 mg in healthy subjects with (N=8) normal hepatic function and to assess the safety of lenvatinib in subjects with hepatic impairment compared to subjects with normal hepatic function.

The median half-life was comparable in subjects with mild, moderate, and severe hepatic impairment as well as those with normal hepatic function and ranged from 26 hours to 31 hours.  The percentage of the dose of lenvatinib excreted in urine was low in all cohorts (&lt;2.16% across treatment cohorts).

Lenvatinib exposure, based on dose-adjusted AUC0-t and AUC0-inf data, was 119%, 107%, and 180% of normal for subjects with mild, moderate, and severe hepatic impairment, respectively.

## · Gender

The effect of gender on the pharmacokinetics of lenvatinib was evaluated in the population PK analysis. No significant differences between sexes were found in lenvatinib exposure.

## · Race

The effect of race on the pharmacokinetics of lenvatinib was evaluated in the population PK analysis. According to this POP PK analysis, the PK of lenvatinib was unaffected by race.

## · Weight

The effect of weight on the pharmacokinetics of lenvatinib was evaluated in the population PK analysis. In this POP PK analysis, weight (37.8 - 178 kg) added as an allometric constant on CL/F and volume parameters showed a statistically significant effect, but only explained 1.2 % of the inter-individual variability on CL/F. PK simulations showed a major overlap in the steady-state exposure in the presence and absence of this covariate.

Subjects with body weight &lt;60 kg had 36% higher exposure compared with subjects &gt;60 kg.

## ● Children

The safety and efficacy of lenvatinib in children aged 2 to &lt;18 years have not yet been established.

<div style=\"page-break-after: always\"></div>

## Pharmacokinetic interaction studies

Based on in vitro metabolism and transporter data (see non-clinical aspects), drug-drug interactions of lenvatinib were designed to assess effects of P-gp inhibition, CYP3A induction and inhibition on lenvatinib as a substrate, and to assess potential for lenvatinib to inhibit CYP2C8 and CYP3A.

## Effects of other drugs on the pharmacokinetics of lenvatinib (as victim)

- Study E7080-A001-004 with ketoconazole (CYP3A4 and PgP inhibitor)

The objective of the study E7080-A001-004 was to assess the influence of simultaneous CYP3A4 and P-gp inhibition  using  ketoconazole  on  lenvatinib  PK  following  single-dose  oral  administration  of  5  mg  lenvatinib (formulated as a capsule) to healthy volunteers and to evaluate the safety, in healthy subjects, of a single dose of 5 mg lenvatinib administered with and without simultaneous CYP3A4/P-gp inhibition (ketoconazole). Ketoconazole  inhibits  CYP3A,  P-gp  and  BCRP.  Ketoconazole  (400  mg  once  daily  for  18  days)  increased lenvatinib AUC about 15% and Cmax increased about 19% following administration of 5 mg lenvatinib on Day 5. The half-life of lenvatinib was not affected suggesting that inhibition of enterocyte P-gp was responsible for the  changes  observed  rather  than  inhibition  of  CYP3A.  In  the  population  PK  analysis,  CYP3A  inhibitors decreased CL/F by 7.8% (CPMS-E7080-007R-v1).

- Study E7080-A001-007 with rifampin (CYP3A4 and PgP inducer)

The objective of the study E7080-A001-004 was to assess the influence of P-gp inhibition and simultaneous P-gp and CYP3A4 induction on lenvatinib PK following single-dose oral administration of 24 mg lenvatinib to healthy volunteers and to evaluate the safety and tolerability of a single dose of 24 mg lenvatinib administered alone, following P-gp inhibition and following simultaneous induction of P-gp and CYP3A4 in healthy subjects.

Coadministration of a single dose of rifampin (600 mg) with 24 mg of lenvatinib increased lenvatinib AUC and Cmax by 31% and 33%, respectively, without prolonging half-life. Following multiple doses of rifampin (600 mg once daily for 21 days) and a single 24 mg dose of lenvatinib on Day 15, lenvatinib AUC and half-life were reduced by 18% and 27%, respectively, while Cmax was unchanged. This result reflected the net effect of  enzyme  induction  and  P-gp  inhibition.  The  effect  of  strong  CYP3A  induction  in  the  absence  of  P-gp inhibition was estimated. As expected, the effect of induction in the absence of P-gp inhibition was slightly greater than the net effect of the combination of the 2 effects of rifampin. This finding represents a worst case  scenario  for  the  effect  of  a  strong  inducer  on  lenvatinib  exposure  since  it  is  assumed  that  the  P-gp inhibition effect on the PK of lenvatinib is similar under induced and non-induced conditions even though it is known that P-gp is also subject to PXR mediated induction. The effect of induction was relatively small, and consistent with in vitro and in vivo metabolism data.

- Temozolomide (TMZ)

As part of a study primarily assessing the benefit of co-administration of lenvatinib with TMZ in subjects with melanoma, lenvatinib's PK parameters were assessed. This study was not designed as a formal DDI study. Coadministration of TMZ with lenvatinib (24 mg QD) did not alter lenvatinib's PK parameters.

- Carboplatin - paclitaxel

As part of a study primarily assessing the benefit of coadministration of lenvatinib with carboplatin and paclitaxel in subjects with non-small-cell lung cancer, the PK parameters of all 3 drugs were assessed (Study E7080-J081-110). This study was not designed as a formal DDI study. Lenvatinib PK parameters following

<div style=\"page-break-after: always\"></div>

coadministered with carboplatin and paclitaxel were similar to those observed with lenvatinib monotherapy. The PK parameters of carboplatin and paclitaxel with coadministration of lenvatinib were generally consistent with historical values observed without lenvatinib coadministration.

- H2-blockers, proton pump inhibitors

In  the  population  PK  analysis  of  lenvatinib  (CPMS-E7080-007R-v1),  for  DDI,  co-administration  of  CYP3A4 inhibitors and inducers, proton pump inhibitors, H2-blockers, antacids and combined category of pH elevating agents were tested. Agents that elevate gastric pH (H2-blockers, proton pump inhibitors, and antacids) did not have a significant effect on the absorption and bioavailability of lenvatinib.

-    Everolimus

In study E7080-G000-205, based on the dose-normalized Cmax and (AUC(0-24)), the mean lenvatinib Cmax was  similar  between  the  combination  and  the  lenvatinib  arms  while  the  mean  systemic  exposure  as measured by AUC(0-24) was approximately 20% lower in the combination arm compared to the lenvatinib arm. These results should be viewed with caution given the small number of subjects in each treatment arm. In the population PK analysis, a log-likelihood ratio test at a P value of 0.01 showed that everolimus did not significantly  affect  lenvatinib  clearance.  Based  on  these  results,  the  sponsor  concluded  that  concomitant everolimus did not have a statistically significant effect on lenvatinib PK

## Effects of lenvatinib on the pharmacokinetics of other drugs (as perpetrator)

- Midazolam as CYP3A4 substrate

A  human  physiologically  based  pharmacokinetic  (PBPK)  model  was  developed  for  lenvatinib  (Study DMPKA2013-156),  to  simulate  the  human  AUC  profiles  of  midazolam  with  or  without  coadministration  of lenvatinib, and to assess the potential risk of drug-drug interaction (DDI) between lenvatinib and the CYP3A4 substrate midazolam.

In the original physiologically based pharmacokinetic (PBPK) model DDI simulation analysis, the fumic was calculated by Simcyp (Prediction Toolbox) based on logPo:w (partition-coefficient, the ratio of concentrations of a compound in the 1-octanol and water at equilibrium) , compound type, pKa, assay pH, and microsomal protein  concentration.  The  fumic  for  CYP3A4  was  calculated  to  be  0.503  based  on  1  mg/mL  microsomal protein concentration in the in  vitro assay condition for CYP3A4 time-dependent inhibition. Fumic was also measured in an in vitro assay at 1 mg/mL microsomal protein concentration and determined to be 0.74. With the new fumic value, DDI simulation for lenvatinib and CYP3A4 substrate midazolam was reevaluated and the geometric mean AUC ratio (AUCR) for midazolam was determined to be 1.18 with 95% CI of 1.16 - 1.20 and 1.22  with  95%  CI  of  1.20  -  1.24,  respectively,  for  co-administration  with  24-mg  and  32-mg  doses  of lenvatinib, indicating low DDI risk.

However, the in vitro data on the potential induction were judged as not sufficient and an in vivo study with midazolam  as  a  probe  substrate  for  CYP3A4  was  required  as  a  PAM  (category  3)  in  the  DTC  MAA  to investigate  adequately  the  potential  of  lenvatinib  for  CYP3A4  induction.  In  the  RMP  for  RCC,  the  study  is listed in the pharmacovigilance studies/activities and planned in March 2018.

- Repaglinide as CYP2C8 substrate

In vitro, lenvatinib exhibited a weak to moderate, reversible inhibition of CYP2C8 (see non-clinical aspects). A human physiologically based pharmacokinetic (PBPK) model was developed for lenvatinib (Study

<div style=\"page-break-after: always\"></div>

DMPKA2013-156),  to  simulate  the  human  AUC  profiles  of  repaglinide  with  or  without  coadministration  of lenvatinib, and to assess the potential risk of drug-drug interaction (DDI) between lenvatinib and the CYP2C8 substrate repaglinide.

For the DDI simulation, repaglinide was given as a 0.25-mg oral dose either alone or concomitantly on Day 1 with lenvatinib 24 mg p.o. dose QDx8 (Day 1-Day 9). In an additional simulation, repaglinide 0.25-mg p.o. was dosed with a supratherapeutic 32-mg p.o. dose of lenvatinib. This was done as a 'worst case' scenario to confirm the effect at excessively high lenvatinib concentrations.

The geometric mean AUCR for repaglinide 0.25-mg p.o. with or without lenvatinib 24-mg and 32-mg were 1.005  and  1.007,  respectively,  suggesting  a  less  than  1%  increase  in  exposure  to  repaglinide  when concomitantly  given  with  lenvatinib.  The  results  of  these  simulations  suggested  no  DDI  risk  between lenvatinib and repaglinide, even at supratherapeutic doses.

- Warfarin

Regarding R-Warfarin and CYP3A4: Lenvatinib is a reversible inhibitor of CYP3A4 with inhibition constants (Ki and Ki´) of 106.4 µmol/L and 57.0 µmol/L, respectively. These constants were derived using a complex type inhibition  model  (Study  No.  B03023).  For  enterocytes  and  according  to  the  EMA  Guideline  on  the Investigation of Drug Interactions, the [I]/Ki was calculated to be 3.9 (24-mg QD dose) using the lower Ki of 57  µmol/L.  As  the  [I]/Ki  was  less  than  10,  DDI  is  not  considered  a  concern  for  the  CYP3A4  reversible inhibition in enterocytes.

Regarding  the  systemic  circulation  relevant  CYP3A4  reversible  inhibition  DDI  concern,  the  [I]/Ki  was calculated to be 0.0004 using Cmax,ss of 518 ng/mL (Study E7080-J081-105) at the maximum clinical dose (24 mg QD) and fu of 0.02 and the lower Ki of 57 µmol/L. As this calculated [I]/Ki value was much less than 0.02, there is no DDI concern for the CYP3A4 reversible inhibition in the systemic circulation.

Lenvatinib also exhibited weak time-dependent inhibition of CYP3A with kinact of 0.0835 minutes-1, and Ki of 72.266 µmol/L (Study PK-TEST-0040). Based on the physiologically based modeling of the CYP3A4 probe substrate  midazolam  (Study  DMPKA2013-156),  lenvatinib  did  not  significantly  inhibit  CYP3A4.  Effects  on warfarin  pharmacologic  effect  via  this  mechanism  would  be  trivial  (lower  potency  enantiomer  marginally affected).

Lenvatinib only slightly increased CYP3A4 mRNA expression (Study XT063020) and thus is not an inducer of CYP3A4 (He et al., 1997).

Regarding R-Warfarin and CYP1A2: The in vitro data indicated lenvatinib neither inhibits nor induces CYP1A2 (Study XT063020, Study B03023, and Study PK-Test-0079).

Regarding S-Warfarin, and CYP2C9: Lenvatinib neither inhibits nor induces CYP2C9 (Study XT063020, Study B03023, and Study PK-Test-0079).

- Levothyroxine

Thyroxine is generally administered to subjects with DTC or medullary thyroid cancer (MTC) as standard of care. In contrast, thyroxine is not generally administered to subjects with other solid tumor types. The PK parameters of lenvatinib were similar in subjects with DTC and MTC compared to subjects with other solid tumor types (CPMS-E7080-007R-v1). This indicated thyroxine did not affect lenvatinib PK.

-    Everolimus

<div style=\"page-break-after: always\"></div>

In study E7080-G000-205, based on the dose-normalized Cmax and AUC(0-24), the mean everolimus Cmax was approximately 30% greater in the combination arm compared with the everolimus monotherapy arm. The mean AUC(0-24) of everolimus was approximately 50% higher in the combination arm compared with the everolimus arm. Several methodological flaws were noted that prevent to draw a clear conclusion with regards  to  the  possible  PK  interaction  between  everolimus  and  lenvatinib  (small  number  of  subjects  who contributed to PK data in study 205, the only intergroup comparison, the fact that everolimus is a narrow therapeutic  index  drug  with  highly  variable  PK).  Further  exploration  on  the  potential  interaction  between lenvatinib and everolimus is still needed and comprehensive data collected in a manner permitting adequate characterization of PK drug-drug interactions between lenvatinib and everolimus will be provided at the time of submission of results of pop PK analysis of post marketing studies (218 and 307) data. The company is requested to ensure that data will be. Studies 218 and 307 are included in the RMP.

## 2.4.3. Pharmacodynamics

## Mechanism of action

Lenvatinib  is  a  small  molecule  that  inhibits  multiple  receptor  tyrosine  kinases  (RTKs)  implicated  in angiogenesis, tumour growth and metastatic progression. The most sensitive kinases for lenvatinib include VEGFR (VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4)), RET, fibroblast growth factor (FGF) receptors (FGFR1,  2,  3,  and  4),  the  platelet  derived  growth  factor  (PDGF)  receptor  PDGFRα,  and  KIT.  The  precise mechanism of action of lenvatinib is not elucidated, but its anti-angiogenic activity appears to be its primary effect, while anti-proliferative activity is rather limited at least in in vitro assays (see non-clinical section).

## Rationale for Development of Combination Lenvatinib/Everolimus for Unresectable, Advanced or Metastatic Renal Cell Carcinoma

The scientific rationale for combining lenvatinib (an RTK inhibitor) and everolimus (an mTOR inhibitor) was to target angiogenesis and tumour cell survival, as well as to escape resistance mechanisms to antiangiogenic therapy.    The  dual  targeting  of  the  mitogen  activated  kinase  (MAPK)  and  mTOR-S6K-S6  pathways  by lenvatinib  and  everolimus  may  contribute  towards  the  increased  anti-tumour  activity  of  the  combination compared to each agent alone.

Angiogenesis has been identified as a key factor in the development of RCC. VEGF is a crucial regulator of both physiologic and pathologic angiogenesis, and increased expression of VEGF is associated with a poor prognosis  in  many  human  tumour  types,  including  RCC.  Accumulated  evidence  suggests  that  fibroblast growth factor (FGF) and its receptor tyrosine kinase, FGFR, also play a role in angiogenesis and contribute to the aggressiveness of RCC.  Recently, FGF-induced angiogenesis has also been reported to be involved in resistance against anti-VEGF/VEGFR therapy; therefore, inhibition of FGF has been postulated to decrease the rate of drug resistance to VEGF/VEGFR-targeting agents, but clinical data are limited to date.

An  alternative  pathway  for  angiogenesis  is  mediated  by  mTOR,  which  is  downstream  of  phosphoinositide 3-kinase and protein kinase B and is regulated by the phosphatase and tensin homolog tumour suppressor gene.  Inhibition of the mTOR pathway can inhibit both angiogenesis and tumour cell proliferation.

<div style=\"page-break-after: always\"></div>

Figure 3: Inhibition of Receptor Tyrosine Kinase and mTOR Pathways by Lenvatinib and Everolimus: Proposed Mechanism of Action

<!-- image -->

Several studies indicate the lack of absolute cross-resistance between TKIs and that sequential VEGF/VEGR TKIs use or sequential use of VEGF/VEGFR TKIs and mTOR inhibitors can provide clinical benefit in mRCC, for instance sorafenib-sunitinib sequential trial in patients with mRCC (Sablin, et al., 2009), the use of sunitinib after bevacizumab (Rini, et al., 2006) or of axitinib after sorafenib (Rini, et al., 2007).  In a Phase 2 study comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with mRCC, similar efficacy outcomes were observed, favouring however sequential sunitinib followed by everolimus use (Motzer, et al., 2014).

Several trials have previously evaluated combinations of a VEGF TKI with an mTOR inhibitor. For clear cell RCC, combinations of TKIs and mTOR inhibitors generally led to earlier onset and more severe toxicity. The most  of  studies  for  VEGFRi-mTORi  combinations  reported  high  unacceptable  toxicity  precluding  further development.  The  majority  of  studies  did  not  comprehensively  evaluate  the  potential  PD  and/or  PK interactions (Patel et al, 2009; Patnaik et al, 2007; Rosenberg et al, 2008; Molina et al, 2012; Poweles et al, 2014).

Although not studied directly, the MOA for the worsening of diarrhea with the combination is postulated to be mediated  by  the  impairment  of  intestinal  function  related  to  the  MOAs  for  the  individual  agents  VEGF/VEGFR and c-KIT inhibition by lenvatinib coupled with mTOR/NHE3 inhibition by everolimus. (see SmPC section 5.1) Mechanisms for other potential worsening of AEs (e.g. renal events, electrolyte abnormalities, constitutional symptoms) are suggested (Launay-Vacher et al. 2015).

The PD interactions have not been studied in the pivotal study 205. The underlying mechanisms of observed toxicity of the lenvatinib-everolimus combination may at least in part be due to PD interactions and enhanced inhibition  of  downstream  targets  of  signaling  pathways  (e.g.  mTOR  pathway).  As  observed  in  non-clinical studies, lenvatinib inhibited the VEGF- and FGF-driven angiogenic signaling by the MAPK and mTOR-S6K- S6 pathways. The inhibition of the mTOR pathway was enhanced by the combination with everolimus, indicating potential for worsening of adverse reactions associated with everolimus (see non-clinical part).

<div style=\"page-break-after: always\"></div>

## Primary pharmacology

The  binding  of  lenvatinib  to  a  panel  of  50  non-kinase  receptors  known  to  play  significant  biological  roles (ExpresSProfile) was evaluated in vitro at concentrations of 1 and 10 μmol/L. No significant binding  (&gt;50% inhibition) to any receptor of the ExpresSProfile was observed at the tested concentrations, except for the 5hydroxytryptamine receptor 1B (58%) and human norepinephrine transporter (50%) at 10 μmol/L.

In human umbilical vein endothelial cell (HUVEC) models, lenvatinib inhibited 2 important intracellular signal pathways  for  angiogenesis:    mitogen  activated  kinase  (MAPK)  and  the  PI3K/AKT/mTOR-S6K-S6  signal transduction pathway (hereafter referred to as mTOR-S6K-S6) (see figure 2 above).  These 2 pathways are triggered  by  activated  VEGFR  and  FGFR.    Since  cross-talk  between  the  VEGF-signalling  pathway  and  the FGF-signalling  pathway  possibly  accelerates  angiogenesis  in  the  tumour,  this  mode  of  dual  inhibition  by lenvatinib may more effectively inhibit tumour angiogenesis.  The anti-tumour activity of lenvatinib may also stem from a direct inhibitory effect on cellular growth of some tumours.

Mammalian target of rapamycin (mTOR) is a serine/threonine kinase involved in integrating growth factoractivated  and  nutrient-sensing  signals  that  regulate  diverse  cellular  processes,  including  growth,  survival, differentiation,  autophagy,  and  metabolism.  The  mTOR  kinase  exerts  its  effects  through  the  regulation  of protein synthesis.  Stimulation of the mTORC1 complex also results in increased VEGF-induced angiogenesis via activation of hypoxia-inducible factor 1α. The deregulation of mTOR signalling has been implicated in a number of cancer types.

Everolimus  is  an  oral  rapamycin  analogue.  Everolimus  inhibits  mTOR  kinase  activity  downstream  of  the PI3K/AKT pathway by forming a complex with an intracellular protein, FKBP-12. This results in inhibition of mTORC1 and loss of mTORC1 substrate interactions.  In addition, everolimus inhibits the expression of HIF-1 and reduces the expression of VEGF.

Inhibition of several kinases is thought to contribute to anti-tumor activity of lenvatinib and to its toxicity. Pharmacodynamic properties  relative  to  efficacy  and  safety  of  lenvatinib  are  expected  to  be  based  on  its mechanism of action (inhibition of VEGFRs, FGFRs and PDGFRs). The safety profile of lenvatinib in patients is largely  similar  to other  VEGFR-targeting TKIs with hypertension and proteinuria being the most prominent adverse reactions. Inhibition of several types of tyrosine kinases (VEGFRs, FGFRs, PDGFRs) may potentially contribute towards the embryotoxicity observed after administration of lenvatinib to pregnant animals during organogenesis  and  towards  impaired  wound  healing.  FGFR  inhibition  causes  antiangiogenic  effects  and therefore embryotoxic/teratogenic effects are possible safety concerns in treatment with FGFR inhibitors (see non-clinical aspects and SmPC section 5.3). Increased inorganic phosphorus can occur as a result of FGFR inhibition  and  hyperphosphatemia  is  a  known  FGFR-inhibition  associated  safety  signal  given  that  FGFR1c signaling in the kidney regulates phosphate reabsorption and calcium homeostasis upon binding to a ligand, FGF-23 (Tacer, et al, 2010; Javier, et al, 2012; Kharitonenkov, et al., 2009; Lanske, et al, 2013).

Lenvatinib  has  also  activity  against  PDGFR  tyrosine  kinases  although  the  IC50s  were  lower  for  PDGFRβ. PDGFRα is expressed on vascular smooth muscle cells and pericytes surrounding vascular endothelial cells, and  has  roles  for  stabilizing  newly  formed  vasculature.  Inhibition  of  PDGFRα  may  contribute  towards  the antiangiogenic activity of lenvatinib and cardiotoxicity.

<div style=\"page-break-after: always\"></div>

## Genetic differences in PD response

Genotyping was performed in relation to metabolism of lenvatinib. Subject phenotype was determined using data  derived  from  the  Affymetrix  drug  metabolizing  enzyme  and  transporter  (DMET  Plus®)  microarray genotyping platform based on DNA extracted from human whole blood from consenting study subjects (both healthy volunteers and subjects with thyroid tumors; report CPMS-E7080-007pheno).

The enzymes chosen were ones for which a clear phenotype could be assigned to the SNP data, and, had been identified pre-clinically  as  being  involved  in  the  metabolism of  lenvatinib  (CYP1A2,  CYP2A6,  CYP3A4, CYP3A5)  or  of  as  potential  interest  (CYP2C19,  study  E7080-E044-104).  Exposure  data  (steady  state  AUC normalized  to  a  24  mg  dose)  were  determined  from  a  previously  developed  population  PK  model  for lenvatinib  (CPMS-E7080-007R).  None  of  the  phenotypes  of  CYP1A2,  CYP3A5,  CYP2A6  or  CYP2C19  have  a significant impact on lenvatinib clearance. For the CYP3A4 phenotypes, 450 subjects from a total of 476 were classified as extensive metabolizers and 26 as unknown, therefore no correlative analyses was possible.

Genetic biomarkers (genetic constitutional variants in the VEGF pathway) could guide patient selection for treatment with the anti-VEGFR therapy. Higher responses to angiogenic drugs have been reported in familial VHL (von Hippel-Lindau) syndrome cases (i.e.  RCC  with  germline VHL mutations).  Given  that  loss  of  VHL expression in tumours is the most frequent molecular event in RCC. Choueri et al (2008) found that patients with an alteration of the VHL gene had a better response to anti-VEGF therapy.

Planned  assessment  in  the  Phase  2  study  205  included  biomarker  discovery  and/or  validation  of  blood  or tumor  biomarkers  that  may  be  useful  to  predict  subject  response  to  study  drug,  evaluation  of  responserelated  and/or  safety-related  outcomes  as  well  as  for  potential  use  in  diagnostic  development.  Glen  et  al (2015)  concluded  based  on  the  results  of  the  submitted  Phase  2  study  that  elevated  levels  of  VEGF  and FGF23 confirmed lenvatinib target inhibition. Further studies on post-treatment changes in FGF23 levels in everolimus and the combination were considered warranted. The OS benefit observed with lenvatinib/everolimus  combination  in  the  high-baseline  ANG2  subgroup  suggested  a  potentially  unique response, overcoming this otherwise poor prognostic characteristic. A complete report with results of these serum  biomarker  and  pharmacogenetic  studies  will  be  submitted  by  the  Applicant  within  6  moths  postmarketing (recommendation).

## Secondary pharmacology

## QT assessment

In the clinical program, a thorough QT study was performed (E7080-A001-002). This study was conducted in 52 healthy volunteers. This was a single center, single-dose, randomized, double-blind, placebo controlled, three treatment, three-way crossover study (each a 14-day period) conducted to evaluate the potential for QT/QTc prolongation by 32 mg lenvatinib using a placebo control and moxifloxacin (Avelox 400 mg) as the positive control.

The  QTcF  change  from  baseline  (ΔΔQTcF)  was  evaluated  from  serial  electrocardiograms.  The  relationship between lenvatinib plasma concentration and QTcF was analysed with linear mixed-effects modeling.

50  subjects  completed  the  study.  Two  subjects  withdrew  consent  prior  to  completion.  The  mean  age  of subjects was 34 (SD = 13.8) years.

<div style=\"page-break-after: always\"></div>

Lenvatinib plasma concentrations were measured; the peak plasma level (arithmetic mean ± SD) of 417 ± 201.8 ng/ml was observed at a median of 3.0 h. At this plasma level, the change in QTcF is projected to 4.83  msec  (90%  CI  -6.12  to  -  3.53).  The  median  half-life  was  21.3  h.  Mean  peak  plasma  levels  of moxifloxacin reached 3.2 μg/ml and were observed at a median of 2.0 h after dosing.

Following  administration  of  a  single  32  mg  dose,  lenvatinib  did  not  exert  a  clinically  relevant  effect  on ΔΔQTcF.  A  small  QTc  shortening  effect  was  observed  and  QTc  prolongation  exceeding  10  ms  could  be confidently excluded. The mean ΔΔQTcF was negative at all time points postdosing with the exception of 23.5 hours and the upper bound of the CI did not exceed 2 ms at any time point. Concentration effect modeling suggested lenvatinib does not cause QTc prolongation at clinically relevant, high plasma levels.

In  the  phase  3  study  303  in  DTC  patients,  QT/QTc  interval  prolongation  has  been  reported  at  a  higher incidence in patients treated with lenvatinib than in patients treated with placebo (see SmPC section 5.1 for Lenvima).  QTc  prolongation  is  currently  considered  as  an  important  potential  risk  addressed  in  the  Risk Management plan. Post-marketing data from patients in DTC showed new cases with positive dechallenge. The electrocardiogram data from the Study 205 do show more cases of maximum QT increase from baseline (&gt; 60 msec) and of maximum postbaseline value (&gt; 500 msec) when lenvatinib is combined with everolimus, compared  with  lenvatinib  alone.  However,  the  QTcF  values  were  machine-read.  Furthermore,  no  case  of torsades de pointes was reported, and no subject discontinued the drugs because of this event.

Given totality of data collected in patients in different indications and uncertainty regarding the effects of the combination  (lenvatinib/everolimus)  on  QTc  due  to  the  limited  number  of  patients  exposed  to  date,  the Applicant comitted to collect ECG data in further studies and to perform a concentration-response analysis for QTc in order to have a better understanding of the impact of the combination on QTc.

## Relationship between plasma concentration and effect

Relationships  between  lenvatinib,  everolimus  and  the  lenvatinib/everolimus  combination  and  efficacy  and safety endpoints in RCC were explored using Population PK/PD analysis.

The  following  efficacy  endpoints  were  explored:    progression  free  survival  (PFS),  overall  survival  (OS), objective response rate (ORR), disease control rate (DCR), clinical benefit rate (CBR), durable stable disease rate, and tumor shrinkage.

The following treatment emergent adverse events (TEAE) were considered: hypertension [during cycle 1], proteinuria,  fatigue,  decreased  appetite,  diarrhoea,  nausea,  vomiting,  renal  events,  hypertriglyceridaemia and hyperglycaemia.

For each of the adverse events in the DTC submission including hypertension, the main analyses were based on data from Phase 3 Study 303, and binary logistic regression analysis was used. In all clinical studies with lenvatinib conducted to date, including DTC and RCC, blood pressure readings showed pronounced diurnal patterns.  The time of day of blood pressure measurement is important in fitting indirect response model; however, the time of blood pressure measurement was not recorded in Study 205.  Moreover, the effect of concomitant  antihypertensive  therapy  needs  to  be  considered  in  the  complex  indirect  model  using  all  the available  blood  pressure  data.    However,  most  subjects  (78.7%)  in  the  RCC  Safety  Set  took  concomitant antihypertensive therapy, which included a wide range of drugs, multiple classes of antihypertensive therapy, and combinations of drugs.  Thus, the doses of each drug or class are not directly comparable. Moreover, antihypertensive  treatment  is  highly  individualized,  with  each  subject  responding  differently  to  the  same dose.    Hence,  the  simple  binary  logistic  regression  model  for  hypertension  as  AE  was  used.  In  order  to

<div style=\"page-break-after: always\"></div>

minimize  the  bias  from  concomitant  antihypertensive  therapy  in  the  exposure-response  relationship  for lenvatinib-related hypertension, data from the first 28 days (1 cycle) only were selected.

Data  were  not  collected  in  a  manner  permitting  more  adequate  modelling  for  toxicity  endpoints  such  as hypertension, hypertriglyceridemia and hyperglycaemia. Empirical binary regression analysis as performed by the applicant is more suitable for descriptive purpose than for predictive use. They can only be acceptable in case there is no possibility to have more informative data as for fatigue, nausea, decreased appetite, and renal  events.  The  Applicant  is  therefore  strongly  advised  to  collect  (systolic  and  diastolic)  blood  pressure, triglyceridemia  (and  cholesterolemia),  and  glycaemia  data  in  an  appropriate  manner  that  will  allow developing predictive models with these endpoints modelled as continuous variables within study 218.

The impact of everolimus exposure on the different endpoints will be assessed in a more robust manner in future studies with the combination therapy of lenvatinib and everolimus (Studies 218 and 307).

The data that has been provided does not allow excluding a possible drug-drug interaction between lenvatinib and everolimus. The power analysis using clinical trial simulations tools for example would be a convincing evidence to show that the available data would allow detecting drug-drug interactions when applicable. The applicant  is  advised  to  perform  power  analysis  as  part  of  study  design  for  study  218.  This  study  will  be designed  in  a  manner  permitting  appropriate  characterization  of  interactions  between  lenvatinib  and everolimus if present.

## PK/PD analyses for efficacy biomarkers and endpoints

In  regard  to  PK/PD  analyses  for  efficacy  biomarkers  and  endpoints,  planned  assessment  in  the  proposed Phase 2 study 218 will include the analysis the exposure (to everolimus and lenvatinib)-biomarkers-clinical endpoint  relationships for drug  efficacy  and  safety  using  integrative  models  and  mechanism-based approaches supported by the knowledge about the disease pathophysiology and the drug pharmacology in order to provide better insight into doses selection that would allow an optimal benefit-risk ratio.

A binary logistic model for any adverse event leading to drug interruption, reduction or discontinuation as well as an Emax model for tumor growth inhibition model by lenvatinib and everolimus has been developed using data from RCC subjects from Study 205. The developed models were then used to simulate AEs and percentage  of  reduction  in  tumor  size  profiles  and,  subsequently,  overall  response  rate  at  6  months  for different doses of lenvatinib in combination with everolimus 5 mg for dose selection in a planned study 218.

## 2.4.4. Discussion on clinical pharmacology

## Pharmacodynamics

There  is  strong  biologic  rationale  supported  by  available  non-clinical  data  for  combining  VEGF  receptor blockade by lenvatinib with mTOR inhibition by everolimus in the treatment of patients with metastatic RCC. Downstream signal transduction inhibition of the PTEN/Akt/mTOR pathway by everolimus may complement upstream VEGF receptor inhibition  by  either  simple  additive  effects  when  both  targets  are  inhibited  or  by downstream blockade of pathways if there is partial resistance to receptor inhibition.

PD biomarkers for efficacy and safety and PD interactions between lenvatinib and everolimus will be further investigated in Studies 218 and 307.

<div style=\"page-break-after: always\"></div>

## Pharmacokinetics

Several methodological flaws prevent to draw a clear conclusion with regards to the possible PK interaction between everolimus and lenvatinib. Further exploration on the potential interaction between lenvatinib and everolimus is needed and comprehensive data should be provided at the time of submission of results of pop PK analysis of post marketing studies (218 and 307) data.

This study 218 will evaluate PK interactions between lenvatinib and everolimus. It will also establish exposure-safety and exposure-efficacy relationships and better inform the choice of the optimal starting dose, the results of the integrated and mechanism-based PK/PD modelling should be submitted at the time of submission of the CSR. Data will be collected in a manner permitting adequate characterization of PK drugdrug interactions between lenvatinib and everolimus (see RMP).

Data from Study 307 will contribute to PK and PD analyses (see RMP).

In addition, as also required for Lenvima, an in vivo study (Study 109) with midazolam as a probe substrate for  CYP3A4  will  assess  the  lenvatinib  potential  for  CYP3A4  induction/inhibition,  including  time-dependency inhibition.  This  is  an  Open-Label  Phase  1  Study  to  Determine  the  Effect  of  Lenvatinib  (E7080)  on  the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in subjects with Advanced Solid Tumours (see RMP).

In line with the Lenvima MA, no adjustment of starting dose is required in patients with mild or moderate renal  impairment  and  no  adjustment  of  starting  dose  is  required  in  patients  with  mild  (Child-Pugh  A)  or moderate (Child-Pugh B) hepatic impairment. However in patients with severe hepatic or renal impairment, the recommended starting dose of lenvatinib should be reduced to 10 mg (see section 4.2 of the SmPC).

The following dose recommendation for hepatic impaired patients is provided in section 4.2 of the SmPC: 'No data with the combination is available in patients with hepatic impairment. No adjustment of starting dose of the combination is required on the basis of hepatic function in patients with mild (Child-Pugh A) or moderate (Child-Pugh  B)  hepatic  impairment.  In  patients  with  severe  (Child-Pugh  C)  hepatic  impairment,  the recommended  starting  dose  of  lenvatinib  is  10 mg  taken  once  daily  in  combination  with  the  dose  of everolimus recommended for patients with severe hepatic impairment in the everolimus SmPC.  Further dose adjustments  may  be  necessary  on  the  basis  of  individual  tolerability.  The  combination  should  be  used  in patients with severe hepatic impairment only if the anticipated benefit exceeds the risk.'

The following statement is provided in section 4.2 of the SmPC: 'No adjustment of starting dose is required on the basis of renal function in patients with mild or moderate renal impairment.  In patients with severe renal impairment, the recommended starting dose is 10 mg of lenvatinib with 5 mg of everolimus taken once daily. Further dose adjustments may be necessary based on individual tolerability.  Patients with end-stage renal disease were not studied, therefore the use of lenvatinib in these patients is not recommended'.

In subjects with hepatic and with renal impairment it is unknown whether there is a change in the plasma protein binding. The correct determination of unbound drug concentrations should be provided to define the appropriate dose-adjustment in patients with severe hepatic and renal impairment

Hence, in order to define correctly the dose-adjustment in patients with severe hepatic and renal impairment, the MAH should conduct and submit the results of Study E7080-A001-010 (entitled \"A Multicenter Phase 0 Study In Healthy Subjects As Well As Subjects With Either Hepatic Or Renal Impairment To Obtain Plasma To Assess In Vitro Lenvatinib Protein Binding\") as reflected in the RMP (see section 2.7).

<div style=\"page-break-after: always\"></div>

## 2.4.5. Conclusions on clinical pharmacology

In  conclusion,  pharmacokinetics  of  lenvatinib  has  been  investigated  to  an  acceptable  extent.  Overall,  the potential  for  in  vivo  DDI  with  lenvatinib  can  be  considered  as  low.  In  vitro,  it  was  shown  that  lenvatinib inhibits CYP3A4, CYP2C8, UGT1A4, UGT1A1, OCT2, OATP1B1, OAT1, OAT3 but clinical relevant inhibition can be excluded.

## Pharmacology

The  potential  interaction  between  lenvatinib  and  everolimus  requires  further  exploration  to  address uncertainties from the available data. The applicant will therefore submit the results of:

- Study 218 will allow to assess two dosing regimens, PK and PK/PD of the two drugs and related drug-drug interactions between lenvatinib and everolimus. It will also establish exposure-safety and exposure-efficacy relationships and better inform the choice of the optimal starting dose. The protocol and the data analysis plan for PK/PD should be submitted by November 2016. The results of the integrated and mechanism-based PK/PD modelling should be submitted at the time of submission of the CSR. Please section 2.7 of the RMP.

- Study 307 will allow to further characterize PK and PK/PD of the two drugs and related interactions and to contribute to integrated and mechanism-based PK/PD modelling. The protocol and the data analysis plan for PK/PD should be submitted by November 2016. Please see section 2.7 of the RMP.

- Study 109 is requested to assess the lenvatinib potential for CYP3A4 induction/inhibition, including timedependency inhibition  (with  midazolam  as  a  probe  substrate  for  CYP3A4).  This  is  an  Open-Label  Phase  1 Study  to  Determine  the  Effect  of  Lenvatinib  (E7080)  on  the  Pharmacokinetics  of  Midazolam,  a  CYP3A4 substrate, in subjects with advanced Solid Tumors. Please see section 2.7 of the RMP.

In subjects with severe hepatic and renal impairment it is unknown whether there is a change in the plasma protein binding and what are the potential implications regarding dose-adjustment. The applicant will submit the results of Study 010, a multicenter Phase 0 study in healthy subjects as well as subjects with either hepatic or renal impairment to obtain plasma samples, to assess in vitro Lenvatinib protein binding and to determe unbound drug concentrations in order to define correctly the dose-adjustment in patients with severe hepatic and renal impairment (see RMP).

## Pharmacodynamics

The  pharmacodynamic  biomarkers  for  efficacy  and  safety  and  PD  interactions  will  be  further  explored  in planned studies (studies 307 and 218).

<div style=\"page-break-after: always\"></div>

## 2.5. Clinical efficacy

Four  Phase  1  studies  (E7080  E044-101,  E7080-A001-102,  E7080-J081-103,  and  E7080-J081-105)  were conducted  to  determine  the  maximum  tolerated  dose  (MTD)  of  lenvatinib  and  the  optimal  frequency  of administration. These studies looked at administration of lenvatinib on its own (monotherapy).

The main study supporting the proposed indication, the study E7080-G000-205, had a Phase 1b part and a Phase-2 part. Dose escalation was performed, during the Phase 1b part of the study, to determine the MTD of lenvatinib in combination with everolimus. The Phase 2 part of the study 205 compare the combination of lenvatinib  with  everolimus  against  the  use  of  lenvatinib  on  its  own  and  everolimus  on  its  own  in  the treatment of unresectable or metastatic renal cell carcinoma.

## 2.5.1. Dose response studies

## Lenvatinib Monotherapy

Four  Phase  1  dose-finding  studies  (E7080-E044-101  (Study  101),  E7080-A001-102  (Study  102),  E7080J081-103  (Study  103)  and  E7080-J081-105  (Study  105))  were  conducted  to  determine  the  maximum tolerated dose (MTD) of lenvatinib and the optimal dosing regimen. These studies examined escalating doses of lenvatinib administered QD or BID using continuous and interrupted dosing schedules.

## Study 101

In Study 101, escalating doses of lenvatinib from 0.2 to 32 mg were given QD in continuous 28-day cycles to 82  subjects  with  advanced  solid  tumours.    In  this  study,  the  MTD  was  determined  to  be  25  mg  QD. Proteinuria was the dose limiting toxicity.

## Study 102

Study 102 (monotherapy portion) was a dose escalation study with 2 dosing schedules (Schedule 1 - dose escalation  from  0.1  mg  BID  to  3.2  mg  BID  in  a  7  days  on/7  days  off  schedule;  then  Schedule  2  -  dose escalation from 3.2 mg BID to 12 mg BID with continuous daily dosing).  The study was conducted in 77 subjects with solid tumours or resistant/refractory lymphomas. The MTD was determined to be 10 mg BID with continuous dosing.

## Study 103

Study 103 was a dose escalation study (0.5 to 20 mg BID) in which 27 subjects with advanced solid tumours were treated with lenvatinib BID in a 2 week on/1 week off schedule.  In Study 103, the MTD was determined to be 13 mg BID. For lenvatinib monotherapy, the MTD from Study 101 (25 mg QD) correlated with a higher drug  exposure  (Cmax,  AUC)  compared  with  the  MTD  from  Study  102  (10  mg  BID)  and  was  chosen  for monotherapy  to  allow  maximum  anti-tumour  activity  with  a  degree  of  hypertension  controllable  by administration of antihypertensive therapy. To simplify drug administration, a dosage of 24 mg QD (two 10 mg  capsules  plus  one  4-mg  capsule)  was  selected  as  the  dose  for  continued  development  of  lenvatinib monotherapy.

## Study 105

Study 105 was a study in 9 Japanese patients with solid tumours resistant to standard therapies. No doselimiting toxicities were reported in either the 20-mg or 24-mg QD group on a once daily dose schedule.

<div style=\"page-break-after: always\"></div>

## Lenvatinib Combination with Everolimus (Phase 1b of study E7080-G000-205)

The primary objective of Phase 1b part of study 205 was to determine the dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of lenvatinib plus everolimus, and establish the optimal recommended Phase 2 (RP2) dose for the combination.

The  dose  for  initiating  combination  therapy  was  a  half  of  the  recommended  single-agent  dose  for  each compound in RCC indication and in DTC indication; that is respectively, half of 10 mg everolimus dose (5 mg) and half of 24 mg lenvatinib dose (12 mg). Priority in terms of escalating dose was given to lenvatinib based on data from previous Phase 1 studies of lenvatinib in which subjects with metastatic RCC demonstrated a median PFS of approximately 9 months. The majority of these subjects (8 of 9) had already shown disease progression after prior anticancer medication. Of the 9 subjects treated, 5 (55%) achieved a PR and a further single subject (11%) had an unconfirmed PR when treated with lenvatinib.

The dose of lenvatinib was planned to be escalated sequentially (12 mg → 18 mg → 24 mg) in combination with a dose of everolimus of 5 mg or 10 mg (only with 24 mg lenvatinib) in subsequent cohorts.

The dose escalations were planned to proceed as shown in Figure 4 below.

<!-- image -->

Figure 4: Phase 1b dose escalation design

A total of 20 subjects were enrolled across 3 cohorts, no recruitment occurred in Cohort 4.

Overall, four (4) subjects had DLTs as follows:

<div style=\"page-break-after: always\"></div>

-  Cohort  1:    one  subject  with  Grade  3  abdominal  pain  out  of  7  treated  subjects  (n=1).  As  of  the  first  3 subjects enrolled one subject had a DLT, per dose escalation scheme, 3 more subjects were enrolled. There was no further DLT in this cohort. One subject had progressive disease early during Cycle 1 of treatment, was discontinued, and was replaced by another subject.

- Cohort 2: one subject with failure to administer &gt;75% of planned dose, due to intolerable Grade 2 fatigue associated with Grade 1 GI reflux and Grade 1 anorexia out of 11 treated subjects. This occurred during the Cohort 2 expansion to confirm MTD and RP2 (n=1). Of the first 3 subjects enrolled into this cohort, none experienced a DLT allowing enrolment into the next dose level. Subsequent the outcome of Cohort 3, Cohort 2 was expanded to treat 8 more subjects.

- Cohort 3: both of the first 2 enrolled subjects had DLTs; one subject with Grade 3 nausea and vomiting, and one subject with failure to administer &gt;75 % of the planned dose of study medication, due to intolerable Grade 2 stomatitis (n=2). Further enrolment of subjects was stopped in Cohort 3.

Testing the dose level Cohort 4 i.e. everolimus 10 mg in combination with lenvatinib 24 mg was considered not feasible.

The dose received by Cohort 2 subjects, i.e. lenvatinib 18 mg QD + everolimus 5 mg QD, was determined by to be both the MTD and the RP2 dose for the subsequent Phase 2 part of Study 205.

## 2.5.2. Main study

## Phase 2 part of Study E7080-G000-205

The Phase 2 part of Study 205 was designed as an open-label, three-arm, randomized and controlled trial.

Eligible  subjects  were  randomized  in  a  1:1:1  ratio  to  receive  in  either  lenvatinib  in  combination  with everolimus  combination  (Arm  A),  lenvatinib  monotherapy  (Arm  B),  or  everolimus  monotherapy  (Arm  C). Description of the study and its design are provided in Table 21 above and Figure 5 below.

## Methods

Both the Phase 1b and Phase 2 portions of the study included a Pre-treatment Phase, a Treatment Phase, and an Extension Phase.

<div style=\"page-break-after: always\"></div>

Figure 5: Study design

<!-- image -->

Tumour  assessments  using  Response  Evaluation  Criteria  in  Solid  Tumours  (RECIST)  1.1  were  performed during the Pre-randomization Phase and then every 8 weeks (or sooner if there was evidence of progressive disease) during the Treatment Phase, and in the Extension Phase by the Investigator-determined response assessments  at  each  time  point  and  represent  the  basis  for  the  primary  analysis  of  efficacy.    As  per agreement with the FDA  and EMA, a post-hoc independent, blinded review of radiology  assessments  was performed to support the primary analysis of the Phase 2 portion of the study.  The Treatment Phase ended at the data cut-off date for the primary efficacy analysis (13 Jun 2014).  Subjects who were receiving study medication  at  the  time  of  the  data  cut-off  continued  to  receive  the  same  treatment  during  the  Extension Phase.  Once the subjects were off treatment, they were followed for survival every 8 weeks. Subjects who discontinued study treatment before disease progression continued to undergo tumour assessments every 8 weeks until documentation of disease progression or start of another anticancer therapy. Subjects who were being followed for survival at the time of data cut-off (i.e. at the end of the Randomization Phase) continued to be followed for survival during the Follow-up Period of the Extension Phase.

## · Study participants

Eligible  subjects  had  advanced  unresectable  RCC,  histological  or  cytological  confirmation  of  predominantly clear  cell  RCC,  radiographic  evidence  of  disease  progression  within  9 months  of  stopping  prior  therapy,  1 prior VEGF-targeted therapy, and measurable disease according to RECIST 1.1. Other key eligibility criteria are presented in Table 23 below.

<div style=\"page-break-after: always\"></div>

## Eligibility criteria

Table 23:  Eligibility criteria in Study 205 (Phase 1b and 2)

| Inclusion criteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Exclusion criteria                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1. Histologically confirmed diagnosis of renal cell carcinoma. 2. Phase 1: Disease progression after prior vascular endothelial growth factor (VEGF)- targeted treatment. 3. Phase 2: Histological or cytological confirmation of predominant clear cell RCC (original tissue diagnosis of RCC is acceptable). 4. Documented evidence of unresectable advanced or metastatic RCC 5. Phase 2: Radiographic evidence of disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1), on or within 9 months of stopping prior therapy. 6. Phase 2: One prior disease progression episode on or after vascular endothelial growth factor (VEGF)-targeted treatment (for example, but not limited to, sunitinib, sorafenib, pazopanib, bevacizumab, axitinib, vatalanib, AV951/ tivozanib) for unresectable advanced or metastatic RCC (not including disease progression after VEGF-targeted adjuvant treatment). 7. Phase 2: Measurable disease meeting the following criteria: a. At least 1 lesion of ≥ 1.5 cm in the longest diameter for a non-lymph node or ≥ 1.5 cm in the short-axis diameter for a lymph node which is serially measurable according to RECIST 1.1 using computerized tomography /magnetic resonance imaging (CT/MRI) or photography b. Lesions that have had external beam radiotherapy (EBRT) or loco-regional therapies such as radiofrequency (RF) ablation must show evidence of progressive disease based on RECIST 1.1 to be deemed a target lesion. | 1. Phase 1b or Phase 2 specific per below: - Phase 1b only: Subjects with untreated or unstable metastases to the central nervous system (CNS) are excluded. Subjects who have completed local therapy and have discontinued the use of steroids for this indication at least 4 weeks prior to commencing treatment and in whom stability has been proven by at least 2 CT or MRI scans obtained at least 4 weeks apart are eligible for Phase 1b only. - Phase 2 only: subjects with CNS (eg, brain or leptomeningeal) metastases are excluded. 2. Phase 2 only: More than one prior disease progression episode on or after VEGF-targeted treatment for unresectable advanced or metastatic RCC (not including disease progression after VEGF-targeted adjuvant treatment). 3. Phase 1b or Phase 2 specific per below: - Phase 1b only: Prior exposure to E7080 -Phase 2 only: Prior exposure to E7080 or mammalian target of rapamycin (mTOR) inhibitor 4. Subjects should not have received any anti- cancer treatment within 21 days or any investigational agent within 30 days prior to the first dose of study drug and should have recovered from any toxicity related to previous anti-cancer treatment. 5. Major surgery within 3 weeks prior to the first dose of study drug 6. Subjects having > 1+ proteinuria on urinalysis will undergo 24-h urine collection for quantitative assessment of proteinuria. Subjects with urine protein ≥ 1 g/24-hour will be ineligible. 7. Uncontrolled diabetes as defined by fasting |

<div style=\"page-break-after: always\"></div>

8.  Subjects  must  have  an  Eastern  Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
9.  Adequately  controlled blood  pressure  with  or without antihypertensive medications, defined as blood pressure (BP) ≥ 150/90 mmHg at screening  and  no  change  in  antihypertensive medications within 1 week prior to Cycle 1 Day 1.
10. Adequate renal function defined as calculated creatinine clearance ≥ 30 mL/min per the Cockcroft and Gault formula.
11.  Adequate  bone  marrow  function:  absolute neutrophil  count  (ANC) ≥ 1500/mm3 ( ≥ 1.5  x 103/µL);  platelets ≥ 100,000/mm3  ( ≥ 100  x 109/L); hemoglobin ≥ 9.0 g/dL.
12. Adequate blood coagulation function as evidenced  by  an  International  Normalized  Ratio (INR) ≤  1.5.
13.  Adequate  liver  function:  bilirubin  ≤    1.5  x the upper  limit  of  normal  (ULN)  except  for unconjugated hyperbilirubinemia of Gilbert's syndrome; alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ≤  3 x ULN (≤  5 x ULN if subject has liver metastases).
14. Males or females age ≥ 18 years at the time of informed consent.
15. All  females must have a negative serum or urine  pregnancy  test  (minimum  sensitivity  25 IU/L or equivalent units of beta-human chorionic gonadotropin  [β-hCG])  at  the  Screening  Visit (and/or within 72 hours of the first dose of study drug).  Females  of  child-bearing  potential,  if  not practicing total abstinence or having a vasectomised partner with confirmed azoospermia,  must  agree  to  use  two  highly effective methods of contraception (shortened).
16. Male subjects who are partners of women of childbearing  potential  must  use  a  condom  + spermicide and their female partners if of childbearing potential must use a highly effective
10. serum glucose &gt; 1.5 x ULN.
8.  Fasting  total  cholesterol  &gt;  7.75  mmol/L  (&gt; 300 mg/dl).
9. Fasting triglyceride level &gt; 2.5 x ULN.
10. Gastrointestinal malabsorption, gastrointestinal anastomosis, or any other condition  that  might  affect  the  absorption  of E7080 or everolimus.
11. Significant cardiovascular impairment: history of congestive heart failure

greater than New York Heart Association (NYHA) Class II (Appendix 4), unstable angina, myocardial infarction  or  stroke  within  6  months of the first dose  of study  drug;  or cardiac arrhythmia requiring medical treatment.

12. Prolongation of QTc interval to &gt; 480 msec.
13.  Bleeding  disorder  or  thrombotic  disorder requiring anticoagulant therapy, such as warfarin, or similar agents requiring therapeutic international  normalized  ratio  (INR)  monitoring (treatment  with  low  molecular  weight  heparin [LMWH] is allowed).
14.  Active  hemoptysis  (bright  red  blood  of  at least  0.5  teaspoon) within 3 weeks prior to the first dose of study drug.
15. Active infection (any infection requiring treatment)
16. Phase 2 only: Active malignancy (except for renal cell carcinoma, melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ  of  the  cervix)  within  the  past 24 months.
17. Known intolerance to any of the study drugs (or any of the excipients) and/or known hypersensitivity  to  rapamycins  (eg,  sirolimus, everolimus, temsirolimus) or any of the excipients.
18.  Phase  1b  only:  Subjects  who  discontinued prior tyrosine kinase inhibitor due to toxicity will

<div style=\"page-break-after: always\"></div>

| method of contraception beginning at least 1 menstrual cycle prior to starting study drug(s), throughout the entire study period, and for 30 days after the last dose of study drug, unless the male subjects are totally sexually abstinent or have undergone a successful vasectomy with confirmed azoospermia or unless the female partners have been sterilized surgically or are otherwise proven sterile. 17. Voluntary agreement to provide written informed consent and the willingness and ability   | be ineligible. 19. Any medical or other condition which, in the opinion of the investigator, would preclude participation in a clinical trial. 20. Females who are pregnant or breastfeeding. 21. Medical need for the continued use of potent inhibitors of CYP3A4   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

## · Treatments

The  RP2  dose  determined  in  the  Phase  1b  part  of  the  study  was  further  investigated  in  the  open-label, randomized Phase 2 part, in which eligible subjects were randomized into 3 arms in a 1:1:1 ratio to receive:

- 1) 18 mg/day lenvatinib + 5 mg/day everolimus (RP2 dose; combination arm A),
- 2) lenvatinib 24 mg/day (lenvatinib arm B), or
- 3) everolimus 10 mg/day (everolimus arm C).

In both Phase 1b and Phase 2, lenvatinib capsules and everolimus tablets were self-administered orally by the  subjects  in  continuous  28-day  cycles.  For  subjects  receiving  combination  therapy,  the  doses  of everolimus  and  lenvatinib  were  taken  at  the  same  time.    Dose  interruption,  dose  reduction,  or  treatment discontinuation were allowed according to the protocol-specified dose management scheme for subjects who experienced lenvatinib toxicity and for subjects in the combination arm who experienced everolimus toxicity. Subjects  who  experienced  everolimus-related  toxicity  in  the  everolimus  arm  had  dose  adjustments (temporary dose interruptions and no dose reduction below 5 mg) according to prescribing information.

## Prior therapy: see 'Baseline data' subsection

## Concomitant therapy

All subjects received at least 1 concomitant medication.

Concomitant antihypertensive medications were taken by a higher percentage of subjects in the combination and lenvatinib arms (82.4% and 86.5%, respectively) than the everolimus arm (60.0%). The most frequently reported  concomitant  antihypertensive  medication  was  amlodipine  (49.0%  combination  arm;  67.3% lenvatinib arm; 28.0% everolimus arm).

Concomitant therapy with the anti-propulsive agent loperamide for diarrhea was highest in the combination arm  (58.8%,  30  subjects),  followed  by  the  lenvatinib  arm  (46.2%,  24  subjects),  and  was  lowest  in  the everolimus arm 12.0% (6 subjects).

<div style=\"page-break-after: always\"></div>

Concomitant therapy with thyroid preparations was used most often in the combination and lenvatinib arms, and less often in the everolimus arm. Thyroid Preparations were used in 27 (52.9%), 32 (61.5%) and 10 (20.0%), respectively, and levothyroxine in 27 (52.9%), 32 (61.5%) and 10 (20.0%), respectively.

## · Objectives

## Primary objective

- To compare the progression-free survival (PFS) of 1) lenvatinib in combination with everolimus at the RP2 dose once daily (QD) (Arm A) and 2) single-agent lenvatinib 24 mg QD (Arm B) to single-agent everolimus 10 mg QD (Arm C) in subjects with unresectable advanced or metastatic RCC and disease progression following 1 prior VEGF-targeted treatment.

## Secondary objectives

- To determine the tolerability and safety profile of lenvatinib in combination with everolimus and of single-agent lenvatinib.
- To compare PFS of Arm A, lenvatinib/everolimus combination therapy to Arm B, single-agent lenvatinib.
- To assess overall survival (OS).
- To assess objective response rate (ORR) (complete response [CR] +partial response [PR]); disease control rate (DCR: CR + PR + stable disease [SD]); durable SD (SD ≥ 23 weeks) and clinical benefit rate (CBR: CR, PR + durable SD rate).
- To assess PK profiles (e.g. AUC, Cmax) of lenvatinib and everolimus during single-agent and combination therapy.
- To assess PK and PD relationship of lenvatinib as single-agent and combination therapy.

## · Outcomes/endpoints

## Primary efficacy endpoint:

PFS  defined  as  the  time  from  the  date  of  randomization  to  the  date  of  first  documentation  of  disease progression or death (whichever occurred first).  The PFS endpoint was based on investigator assessments using RECIST version 1.1.  PFS censoring rules were based on the FDA guidelines.  The date of objective disease progression was defined as the earliest date of radiological disease progression, as assessed by the investigator based on radiographic images.

The primary comparisons for PFS were the combination arm versus the everolimus arm and the lenvatinib arm versus the everolimus arm.

## Secondary efficacy endpoints:

- OS defined as the time from the date of randomization until date of death from any cause.  Subjects who were lost to follow-up or alive at the date of data cut-off (13 Jun 2014 for the collection of the data for

<div style=\"page-break-after: always\"></div>

the primary outcome measure, 10 Dec 2014 cut-off for the first OS update, and 31 Jul 2015 cut-off for the second OS update) were censored at the date the subject was last known alive.

- Objective response rate defined as the proportion of subjects who had best overall response of complete response or partial response (CR + PR) (assessed by investigators).
- Disease control rate (DCR: CR + PR + SD; SD had to be ≥7 weeks after randomization).
- Durable SD (SD ≥23 weeks) rate and clinical benefit rate (CBR: CR, PR + durable SD rate).

## · Sample size

For  the  Phase  2  part,  the  primary  basis  for  the  sample  size  determination  was  a  comparison  of  the progression-free survival based on the following assumptions.

The assumed median PFS for everolimus 10 mg was 5 months based on the historical data. A minimum of a 50% increase in the median PFS (i.e., achieving a median PFS of at least 7.5 months in the investigational Arms A or B) relative to the median PFS of 5 months for everolimus as single agent, would be considered worthy of further investigation. Given that there were no prior clinical data available for the combination of lenvatinib  plus  everolimus,  and  limited  data  for  lenvatinib  alone  in  the  target  population,  it  was  deemed appropriate  to  consider  a  hazard  ratio  (HR)  of  0.67  as  a  clinically  meaningful  improvement  in  PFS.  The planned sample size for the primary analysis required a total of at least 90 PFS events to be observed across all  3  treatment  groups  and  at  least  60  PFS  events  to  be  observed  for  each  of  the  comparisons  of  the combination versus the everolimus arm, and the lenvatinib versus the everolimus arm. PFS events for each of the comparisons of the combination versus the everolimus arm, and the lenvatinib versus the everolimus arm events were required to detect a HR of 0.67 with 70% power using an (1-sided) alpha of 0.15 for the comparison  of  the  combination  arm  (and  lenvatinib  arm)  versus  the  everolimus  arm.  This  trial  was  not designed and powered to primarily investigate differences in OS.

Sample size rationale for the everolimus/Lenvatinib Phase 2 PK Sub Analysis Set assumed a between-subject CV on logarithmically transformed plasma Lenvatinib clearance of 40%. A sample size of 9 to 12 completing subjects in each study arm will provide 68% to 80% power to detect a 1.5-fold change in exposure between Lenvatinib administered alone and Lenvatinib in combination with everolimus.

## · Randomisation

Randomization was performed centrally by an Interactive Voice Response System (IVRS) vendor.

The IVRS randomly assigned eligible subjects in a 1:1:1 ratio to receive either lenvatinib 18 mg QD plus everolimus 5 mg QD (N=51; combination arm), lenvatinib 24 mg QD (N=52; lenvatinib arm), or everolimus 10 mg, QD (N=50; everolimus arm).

Randomisation was stratified by baseline haemoglobin ( ≤ 13 g/dL vs &gt;13 g/dL for males and ≤ 11.5 g/dL vs &gt;11.5 g/dL for females) and corrected serum calcium levels ( ≥ 10 mg/dL vs &lt;10 mg/dL).

## · Blinding (masking)

This was an open-label study; therefore blinding procedures were not applicable.

<div style=\"page-break-after: always\"></div>

## · Statistical methods

## Primary efficacy endpoint: PFS

The primary efficacy variable was PFS, defined as the time from the date of randomisation to the date of first documentation of disease progression or death. The primary PFS was based on investigator review data using RECIST  1.1.  As  requested  by  the  FDA  and  EMA,  a  post-hoc  independent,  blinded  review  of  radiology assessments was performed to support the primary analysis.

The primary comparisons for PFS were the combination arm versus the everolimus arm and the lenvatinib arm versus the everolimus arm. No multiplicity adjustment was planned at the inception of the study. Each null hypothesis of no difference in PFS was evaluated using the stratified log-rank test, and tested at a (2sided) α =0.05 stratified by haemoglobin level ( ≤ 13 g/dL vs &gt;13 g/dL for males and ≤ 11.5 g/dL vs &gt;11.5 g/dL for females) and corrected serum calcium ( ≥ 10 mg/dL vs &lt;10 mg/dL).

There was no prespecified ordering in testing these hypotheses and each null hypothesis was tested at a nominal α=0.05. Kaplan-Meier (K-M) estimates were used to estimate the median PFS.

Hazard ratio (HR) between treatment groups and corresponding 95% CI were estimated using stratified Cox regression  model  with  treatment  as  a  factor.  The  Efron  method  was  used  for  correction  for  tied  events. Three-month, 6-month, 9-month and 1-year PFS rates were estimated from K-M and corresponding 95% CI were calculated using the Greenwood formula. Originally, a pre-planned sensitivity analysis to the primary analysis was planned adjusting for ECOG PS (0 vs. 1) as a factor in the stratified Cox regression model. As decided after database lock, sensitivity analysis to the primary analysis was performed with ECOG PS (0 vs 1) as  an  additional  stratum  in  the  stratified  Cox  regression  model.  For  subgroup  analyses  of  PFS,  the (unstratified) Cox proportional hazard model was used adjusting for treatment and subgroup as factors and treatment-by-subgroup  as  an  interaction  term  in  the  model.  The  HR  was  estimated  for  each  treatment comparison along with 95% CI. The interaction test across different levels of the subgroup for each treatment comparison was also performed by setting up an appropriate contrast for the corresponding interaction test.

## Secondary endpoints: OS, ORR, DCR, CBR, and durable SD

The secondary efficacy variables were OS, ORR, DCR, CBR, and durable SD (SD ≥ 23 weeks). The Median survival time (OS) and the cumulative probability of survival at 12 months, 18 months, and 24 months were calculated using K-M estimates for each treatment arm and presented with 2-sided 95% CIs. K-M survival probabilities  for each  arm were plotted over time. OS was measured from the date of randomization until date of death from any cause.

Subjects who were lost to follow-up and those who were alive at the date of data cut-off were censored. Planned  analyses  were  performed  to  test  null  hypothesis  of  treatment  difference  in  OS  at  a  nominal significance level of 0.05 (2-sided) using the stratified log-rank test using stratification factors. The stratified Cox  proportional  hazard  model  was  performed  to  estimate  HR  between  treatment  groups  and  their corresponding 95% CI.

Objective response rate (ORR), DCR, CBR, and durable SD rate were calculated with exact 95% CIs using the method of Clopper and Pearson Ad-hoc analyses were performed to estimate the crude rate ratio of each treatment comparison and to compute P values using the Fisher's exact (2-sided) test..

<div style=\"page-break-after: always\"></div>

## Results

## · Participant flow

Of the 235 subjects who were screened 82 (34.9%) subjects were screen failures (majority failed to meet entry criteria) and 153 (65.1%) subjects were randomly assigned to treatment as follows:  51 subjects with combination, 52 subjects with lenvatinib and 50 with everolimus. (see Figure 6 below)

Figure 6: Flowchart of Subject Disposition in Phase 2 part of Study 205

<!-- image -->

## · Recruitment

The Phase 2 portion of Study 205 was conducted between 16 March 2012 (when first subject signed informed consent) and 13 June 2014 (data cut-off date for the primary analysis). A total of 37 sites were involved: 24 in Europe (the Czech Republic, Poland, Spain, and the UK) and 13 in the US.

## · Conduct of the study

The original protocol was dated 19 April 2010. Four protocol amendments were issued until the data cut-off date (13 Jun 2014). Amendment 05 (11 Nov 2014) was implemented after the cut-off date for the primary analysis; therefore subject data included in the study report of Phase 2 part of the study were not affected. The final SAP (dated 20 May 2014) included more technical details regarding the original planned analyses in the protocol.

Overall, 9 major protocol deviations were reported for 9 (5.9%) subjects (2 subjects in the combination arm, 3 subjects in the lenvatinib arm, and 4 subjects in the everolimus arm). One subject in the lenvatinib arm did not have predominant clear cell RCC and 7 subjects (2 in the combination, 2 in the lenvatinib, and 3 in the everolimus arm) did not have any brain scans performed. The remaining deviation was in a subject in the

<div style=\"page-break-after: always\"></div>

everolimus arm who took lenvatinib 10 mg QD for 1 cycle as a result of a dispensing error at the site. This major protocol  deviation  occurred  at  a  site  in  the  UK,  and  was  reported  to  the  Medicines  and  Healthcare Products Regulatory Agency on 3 May 2013. The Applicant did not perform the Per Protocol analysis to assess the robustness of the primary analysis since the majority of the deviations (7 out of 8 subjects in total) were not considered necessary to be excluded from the Per Protocol Analysis Set.

## · Baseline data

Table 24: Demographic and Baseline Characteristics - FAS - Phase 2 - Study 205

|                                              | Lenvatinib 18 mg + Everolimus 5 mg (N=51)   | Lenvatinib 24 mg (N=52)   | Everolimus 10 mg (N=50)   | Total (N=153)   |
|----------------------------------------------|---------------------------------------------|---------------------------|---------------------------|-----------------|
| Age (years)                                  |                                             |                           |                           |                 |
| Mean (SD)                                    | 61.7 (8.2)                                  | 63.3 (8.6)                | 58.9 (9.2)                | 61.3 (8.8)      |
| Median                                       | 61.0                                        | 64.0                      | 58.5                      | 61.0            |
| Min, Max                                     | 44, 79                                      | 41, 79                    | 37, 77                    | 37, 79          |
| Age Group (years), n (%)                     |                                             |                           |                           |                 |
| ≤65                                          | 31 (60.8)                                   | 29 (55.8)                 | 39 (78.0)                 | 99 (64.7)       |
| >65                                          | 20 (39.2)                                   | 23 (44.2)                 | 11 (22.0)                 | 54 (35.3)       |
| Sex, n (%)                                   |                                             |                           |                           |                 |
| Male                                         | 35 (68.6)                                   | 39 (75.0)                 | 38 (76.0)                 | 112 (73.2)      |
| Female                                       | 16 (31.4)                                   | 13 (25.0)                 | 12 (24.0)                 | 41 (26.8)       |
| Race, n (%)                                  |                                             |                           |                           |                 |
| White                                        | 50 (98.0)                                   | 52 (100.0)                | 47 (94.0)                 | 149 (97.4)      |
| Asian                                        | 1 (2.0)                                     | 0                         | 2 (4.0)                   | 3 (2.0)         |
| Chinese                                      | 1 (2.0)                                     | 0                         | 0                         | 1 (0.7)         |
| Unknown a                                    | 0                                           | 0                         | 1 (2.0)                   | 1 (0.7)         |
| Ethnicity, n (%)                             |                                             |                           |                           |                 |
| Hispanic or Latino                           | 5 (9.8)                                     | 2 (3.8)                   | 3 (6.0)                   | 10 (6.5)        |
| Not Hispanic or Latino                       | 46 (90.2)                                   | 50 (96.2)                 | 46 (92.0)                 | 142 (92.8)      |
| Unknown a                                    | 0                                           | 0                         | 1 (2.0)                   | 1 (0.7)         |
| ECOG Performance Status, n (%)               |                                             |                           |                           |                 |
| 0                                            | 27 (52.9)                                   | 29 (55.8)                 | 28 (56.0)                 | 84 (54.9)       |
| 1                                            | 24 (47.1)                                   | 23 (44.2)                 | 22 (44.0)                 | 69 (45.1)       |
| Weight (kg)                                  |                                             |                           |                           |                 |
| Mean (SD)                                    | 79.4 (13.5)                                 | 80.4 (15.6)               | 82.7 (15.5)               | 80.8 (14.9)     |
| Median                                       | 80.2                                        | 76.6                      | 81.1                      | 80.0            |
| Min, Max                                     | 55.0, 116.0                                 | 53.0, 129.5               | 50.0, 128.0               | 50.0, 129.5     |
| Haemoglobin, n (%)                           |                                             |                           |                           |                 |
| ≤13 g/dL for males or ≤11.5 g/dL for females | 33 (64.7)                                   | 36 (69.2)                 | 31 (62.0)                 | 100 (65.4)      |
| >13 g/dL for males or >11.5 g/dL for females | 18 (35.3)                                   | 16 (30.8)                 | 19 (38.0)                 | 53 (34.6)       |
| Corrected serum calcium, n (%)               |                                             |                           |                           |                 |
| ≥10 mg/dL                                    | 6 (11.8)                                    | 8 (15.4)                  | 8 (16.0)                  | 22 (14.4)       |
| <10 mg/dL                                    | 45 (88.2)                                   | 44 (84.6)                 | 42 (84.0)                 | 131 (85.6)      |
| MSKCC Risk Group                             |                                             |                           |                           |                 |
| Favourable (Risk Score = 0)                  | 12 (23.5)                                   | 11 (21.2)                 | 12 (24.0)                 | -               |
| Intermediate (Risk Score = 1)                | 19 (37.3)                                   | 18 (34.6)                 | 19 (38.0)                 | -               |
| Poor (Risk Score ≥2)                         | 20 (39.2)                                   | 23 (44.2)                 | 19 (38.0)                 | -               |
| Heng's Risk Group                            |                                             |                           |                           |                 |

<div style=\"page-break-after: always\"></div>

Table 24: Demographic and Baseline Characteristics - FAS - Phase 2 - Study 205

|                                    | Lenvatinib 18 mg + Everolimus 5 mg (N=51)   | Lenvatinib 24 mg (N=52)   | Everolimus 10 mg (N=50)   | Total (N=153)   |
|------------------------------------|---------------------------------------------|---------------------------|---------------------------|-----------------|
| Favourable (Risk Score = 0)        | 8 (16.0)                                    | 7 (13.5)                  | 9 (18.0)                  | -               |
| Intermediate (Risk Score = 1 or 2) | 32 (64.0)                                   | 33 (63.5)                 | 29 (58.0)                 | -               |
| Poor (Risk Score ≥3)               | 10 (20.0)                                   | 12 (23.1)                 | 12 (24.0)                 | -               |

Percentages are based on the total number of subjects in the Full Analysis Set within relevant treatment group.

ECOG = Eastern Cooperative Oncology Group, FAS = full analysis dataset, Max = maximum, Min = minimum, MSKCC = Memorial Sloan Kettering Cancer Centre, NYHA = New York Heart Association, SD = standard deviation.

a:  Race and ethnicity was not recorded for 1 subject in the everolimus arm and is reported as unknown.

Table 25: Number and sites of metastases

|                                        | Lenvatinib 18 mg + Everolimus 5 mg (N=51)   | Lenvatinib 24 mg N=52)                 | Everolimus 10 mg (N=50)                | Total (N=153)                          |
|----------------------------------------|---------------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
| Based on independent review assessment | Based on independent review assessment      | Based on independent review assessment | Based on independent review assessment | Based on independent review assessment |
| Number of Metastases, n(%)             | Number of Metastases, n(%)                  | Number of Metastases, n(%)             | Number of Metastases, n(%)             | Number of Metastases, n(%)             |
| 0                                      | 1 ( 2.0)                                    | 1 ( 1.9)                               | 1 ( 2.0)                               | 3 (2.0)                                |
| 1                                      | 7 ( 13.7)                                   | 3 ( 5.8)                               | 5 ( 10.0)                              | 15 (9.8)                               |
| 2                                      | 13 ( 25.5)                                  | 12 ( 23.1)                             | 7 ( 14.0)                              | 32 (20.9)                              |
| >=3                                    | 30 ( 58.8)                                  | 36 ( 69.2)                             | 37 ( 74.0)                             | 103 (67.3)                             |
| Site of Metastases, n(%)               | Site of Metastases, n(%)                    | Site of Metastases, n(%)               | Site of Metastases, n(%)               | Site of Metastases, n(%)               |
| Bone                                   | 16 ( 31.4)                                  | 23 ( 44.2)                             | 17 ( 34.0)                             | 56 ( 36.6)                             |
| Liver                                  | 15 ( 29.4)                                  | 17 ( 32.7)                             | 16 ( 32.0)                             | 48 ( 31.4)                             |
| Lung                                   | 34 ( 66.7)                                  | 35 ( 67.3)                             | 39 ( 78.0)                             | 108 ( 70.6)                            |
| Lymph Nodes                            | 29 ( 56.9)                                  | 32 ( 61.5)                             | 31 ( 62.0)                             | 92 ( 60.1)                             |
| Visceral Organs                        | 41 ( 80.4)                                  | 49 ( 94.2)                             | 44 ( 88.0)                             | 134 ( 87.6)                            |
| Based on Investigator assessment       | Based on Investigator assessment            | Based on Investigator assessment       | Based on Investigator assessment       | Based on Investigator assessment       |
| Number of Metastases, n(%)             | Number of Metastases, n(%)                  | Number of Metastases, n(%)             | Number of Metastases, n(%)             | Number of Metastases, n(%)             |
| 1                                      | 18 (35)                                     | 9 (17)                                 | 5 (10)                                 | 32 (21)                                |
| 2                                      | 15 (29)                                     | 15 (29)                                | 15 (30)                                | 45 (30)                                |
| >=3                                    | 18 (35)                                     | 28 (54)                                | 30 (60)                                | 76 (50)                                |
| Site of Metastases, n(%)               | Site of Metastases, n(%)                    | Site of Metastases, n(%)               | Site of Metastases, n(%)               | Site of Metastases, n(%)               |
| Bone                                   | 12 (24)                                     | 13 (25)                                | 16 (32)                                | 41 (27)                                |
| Liver                                  | 10 (20)                                     | 14 (27)                                | 13 (26)                                | 37 (24)                                |
| Lung                                   | 27 (53)                                     | 35 (67)                                | 35 (70)                                | 97 (63)                                |
| Lymph Nodes                            | 25 (49)                                     | 31 (60)                                | 33 (66)                                | 89 (58)                                |

## Prior therapy

Nephrectomy was reported in the medical history of 135 subjects (88% overall; respectively 86.3%, 82.7% and 96% in the combination, lenvatinib and everolimus arms). The proportion of subjects who received prior radiotherapy was respectively 11.8%, 21.2% and 22.0% in the combination, lenvatinib and everolimus arms.

All patients received 1 previous VEGF-targeted therapy and the most frequent agent being sunitinib (64.7%) and pazopanib (22.9%). Only 5 subjects received prior treatment with checkpoint inhibitors (anti-PD1).

<div style=\"page-break-after: always\"></div>

Table 26: Prior Cancer Therapies - FAS - Phase 2 - Study 205

|                                                                   | Lenvatinib 18 mg + Everolimus 5 mg (N=51)   | Lenvatinib 24 mg (N=52)   | Everolimus 10 mg (N=50)   | Total (N=153)   |
|-------------------------------------------------------------------|---------------------------------------------|---------------------------|---------------------------|-----------------|
| Prior Therapy Regimens, n (%)                                     |                                             |                           |                           |                 |
| 1                                                                 | 44 (86.3)                                   | 46 (88.5)                 | 41 (82.0)                 | 131 (85.6)      |
| 2                                                                 | 6 (11.8)                                    | 4 (7.7)                   | 9 (18.0)                  | 19 (12.4)       |
| 3                                                                 | 1 (2.0)                                     | 2 (3.8)                   | 0                         | 3 (2.0)         |
| Prior VEGF-Targeted Therapy, n (%)                                |                                             |                           |                           |                 |
| Yes                                                               | 51 (100.0)                                  | 52 (100.0)                | 50 (100.0)                | 153 (100.0)     |
| 1                                                                 | 51 (100.0)                                  | 52 (100.0)                | 50 (100.0)                | 153 (100.0)     |
| Type of Prior VEGF Targeted Therapy [a], n                        | (%)                                         |                           |                           |                 |
| Adjuvant b                                                        | 5 ( 9.8)                                    | 5 ( 9.6)                  | 1 ( 2.0)                  | 11 ( 7.2)       |
| Neo-Adjuvant b                                                    | 0                                           | 0                         | 2 ( 4.0)                  | 2 ( 1.3)        |
| Therapeutic                                                       | 40 ( 78.4)                                  | 43 ( 82.7)                | 44 ( 88.0)                | 127 ( 83.0)     |
| Maintenance                                                       | 5 ( 9.8)                                    | 4 ( 7.7)                  | 3 ( 6.0)                  | 12 ( 7.8)       |
| Unknown                                                           | 1 ( 2.0)                                    | 0                         | 0                         | 1 ( 0.7)        |
| Prior Biologic Agent c , n (%)                                    |                                             |                           |                           |                 |
| Yes                                                               | 8 (15.7)                                    | 7 (13.5)                  | 13 (26.0)                 | 28 (18.3)       |
| 1                                                                 | 7 (13.7)                                    | 4 (7.7)                   | 12 (24.0)                 | 23 (15.0)       |
| 2                                                                 | 1 (2.0)                                     | 3 (5.8)                   | 1 (2.0)                   | 5 (3.3)         |
| No                                                                | 43 (84.3)                                   | 45 (86.5)                 | 37 (74.0)                 | 125 (81.7)      |
| Previous VEGF Targeted Therapy [a], n (%)                         |                                             |                           |                           |                 |
| • ANTINEOPLASTIC AGENTS                                           | 1 ( 2.0)                                    | 0                         | 1 ( 2.0)                  | 2 ( 1.3)        |
| • AXITINIB                                                        | 1 ( 2.0)                                    | 2 ( 3.8)                  | 0                         | 3 ( 2.0)        |
| • BEVACIZUMAB                                                     | 0                                           | 1 ( 1.9)                  | 4 ( 8.0)                  | 5 ( 3.3)        |
| • PAZOPANIB                                                       | 9 ( 17.6)                                   | 13 ( 25.0)                | 13 ( 26.0)                | 35 ( 22.9)      |
| • SORAFENIB                                                       | 1 ( 2.0)                                    | 0                         | 2 ( 4.0)                  | 3 ( 2.0)        |
| • SUNITINIB                                                       | 36 ( 70.6)                                  | 35 ( 67.3)                | 28 ( 56.0)                | 99 ( 64.7)      |
| • TIVOZANIB                                                       | 3 ( 5.9)                                    | 1 ( 1.9)                  | 2 ( 4.0)                  | 6 ( 3.9)        |
| Duration of Most Recent VEGF Targeted                             | Therapy                                     |                           |                           |                 |
| (Months)                                                          |                                             |                           |                           |                 |
| Mean (SD)                                                         | 17.2 (15.22)                                | 17.6 (14.21)              | 12.4 (10.94)              | 15.7 (13.72)    |
| Median                                                            | 9.8                                         | 14.5                      | 8.9                       | 11.5            |
| Q1, Q3                                                            | 5.6, 25.3                                   | 7.6, 25.6                 | 5.3, 15.8                 | 5.6, 21.9       |
| Time from End of Most Recent VEGF Targeted Therapy to Study Entry |                                             | (Months)                  |                           |                 |
| Mean (SD)                                                         | 2.3 ( 2.31)                                 | 2.2 ( 2.52)               | 3.2 ( 5.35)               | 2.6 ( 3.65)     |
| Median                                                            | 1.5                                         | 1.3                       | 1.4                       | 1.4             |
| Q1, Q3                                                            | 1.1, 2.3                                    | 0.9, 2.2                  | 1.2, 2.9                  | 1.0, 2.3        |
| Best Response for Most Recent VEGF Targeted therapy, n (%)        |                                             |                           |                           |                 |
| Complete Response                                                 | 1 ( 2.0)                                    | 0                         | 0                         | 1 ( 0.7)        |
| Partial Response                                                  | 14 ( 27.5)                                  | 10 ( 19.2)                | 10 ( 20.0)                | 34 ( 22.2)      |
| Stable Disease                                                    | 20 ( 39.2)                                  | 28 ( 53.8)                | 21 ( 42.0)                | 69 ( 45.1)      |
| Progressive Disease                                               | 7 ( 13.7)                                   | 10 ( 19.2)                | 15 ( 30.0)                | 32 ( 20.9)      |
| Not Evaluable                                                     | 3 ( 5.9)                                    | 1 ( 1.9)                  | 0                         | 4 ( 2.6)        |
| Not Applicable                                                    | 3 ( 5.9)                                    | 2 ( 3.8)                  | 2 ( 4.0)                  | 7 ( 4.6)        |
| Unknown                                                           | 3 ( 5.9)                                    | 1 ( 1.9)                  | 2 ( 4.0)                  | 6 ( 3.9)        |

A total of 47 subjects discontinued treatment for a reason other than progressive disease; of these 18 subjets received subsequent anticancer therapy. The type and and time to first subsequent anticancer therapy received are provided in table below.

Table 27: Post-treatment anticancer therapy for subjects who discontinued treatment for a reason other than progressive disease - FAS - Phase 2 - Study 205

<div style=\"page-break-after: always\"></div>

|                                                                               | Lenvatinib 18 mg + Everolimus 5 mg   | Lenvatinib 24 mg   | Everolimus 10 mg   |
|-------------------------------------------------------------------------------|--------------------------------------|--------------------|--------------------|
| Subjects who discontinued treatment for a reason other than PD, n (%) a       | 19 (37.3%)                           | 16 (30.8%)         | 12 (24.0%)         |
| Subjects who took anticancer therapy after treatment discontinuation, n (%) a | 7 (36.8)                             | 6 (37.5)           | 5 (41.7)           |
| Type of subsequent anticancer treatment received                              |                                      |                    |                    |
| mTOR Inhibitor:                                                               | 4 (21.1)                             | 2 (12.5)           | 1 (8.3)            |
| Everolimus                                                                    | 4 (21.1)                             | 2 (12.5)           | 1 (8.3)            |
| VEGF Inhibitor:                                                               | 2 (10.5)                             | 2 (12.5)           | 3 (25.0)           |
| Axitinib                                                                      | 2 (10.5)                             | 0                  | 2 (16.7)           |
| Bevacizumab                                                                   | 0                                    | 1 (6.3)            | 0                  |
| Cabozantinib                                                                  | 0                                    | 1 (6.3)            | 0                  |
| Sunitinib                                                                     | 0                                    | 0                  | 1 (8.3)            |
| Monoclonal Antibody b                                                         | 1 (5.3)                              | 2 (12.5)           | 0                  |
| Cytokine:                                                                     | 0                                    | 0                  | 1 (8.3)            |
| Interferon                                                                    | 0                                    | 0                  | 1 (8.3)            |
| Duration to start of subsequent therapy (days) c                              |                                      |                    |                    |
| Number of subjects                                                            | 7                                    | 6                  | 5                  |
| Mean (SD)                                                                     | 56.1 (58.5)                          | 54.2 (27.4)        | 68.0 (71.2)        |
| Median                                                                        | 29                                   | 47                 | 36                 |
| Q1, Q3                                                                        | 22, 91                               | 34, 76             | 13, 135            |
| Min, Max                                                                      | 16, 176                              | 25, 96             | 2, 154             |

AE = adverse event, max = maximum, min = minimum, mTOR = mammalian target of rapamycin, PD = progressive disease, Q1 = first quartile, Q3 = third quartile, SD = standard deviation, VEGF = vascular endothelial growth factor. a: Denominator includes all subjects who discontinued treatment for non-PD reasons.b:  Name of monoclonal antibody was not specified.c:  Duration from end of treatment = date of first dose of new therapy - date of last dose of study drug + 1.

## · Numbers analysed

All 153 subjects were treated. Data cut-off occurred as planned on 13 Jun 2014 following the occurrence of 101 PFS events among the 3 treatment arms, 63 PFS events in the combination versus everolimus arm, and 75 PFS events in the lenvatinib versus everolimus arm.

At the time of data cut-off, a higher number of subjects in the combination arm (13; 25.5%) were still on treatment than in the lenvatinib or everolimus arms (7; 13.5% and 3; 6.0%, respectively). Fewer subjects ended treatment due to disease progression in the combination arm (19; 37.3%) and lenvatinib arms (29; 55.8%) than in the everolimus arm (35; 70.0%).

As of the date of data cut-off, 69 (45.0%) subjects (31 in the combination arm, 23 in the lenvatinib arm, and 15  in  the  everolimus  arm)  remained  in  the  study,  including  23  (15.0%)  subjects  who  were  still  receiving study treatment.

<div style=\"page-break-after: always\"></div>

All 153 subjects who were randomized and treated were included in the FAS and the Safety Analysis Set.

## · Outcomes and estimation

## Primary endpoint

## Progression Free Survival

<!-- image -->

ArmA=E708018mg+Everolimus5mg:ArmB=E708024mg:ArmC=Everolimus10mg Hazardratiois based ona stratifiedCoxregression modelincluding treatment as a factor and hemoglobin and correctedserum calcium as strata.

Data cut-off date = 13 Jun 2014.

Hazard ratio is based on a stratified Cox regression model including treatment as a factor and haemoglobin and corrected serum calcium as strata.  The Efron method was used for correction for tied events.

Median PFS is based the Kaplan-Meier method and 95% CI is based on the Greenwood formula using log-log transformation.

Figure 7: Kaplan-Meier Plot of Progression-Free Survival - Full Analysis Set - Study 205 Phase 2 Investigator Assessment

At the data cutoff of 13 Jun 2014 for the primary analysis, 101 PFS events occurred among the 3 treatment arms. Per arm, the primary endpoint PFS analysis is based on 26 PFS events (51%) in the combination arm vs. 37 events (74%) for everolimus. For lenvatinib arm, 38 events (73%) were observed.

The lenvatinib/everolimus combination significantly prolonged PFS compared with everolimus (median 14.6 months [95% CI: 5.9, 20.1] vs. 5.5 months [95% CI: 3.5, 7.1]; HR=0.40, 95% CI: 0.24, 0.68; p=0.0005).

## Secondary endpoints

## Overall Survival

At the data cut-off for the final PFS analysis (13 Jun 2014), fewer subjects had died in the combination arm (19; 37.3%) than in the lenvatinib arm (26; 50.0%) and in the everolimus arm (26; 52.0%). At the date of the first OS update (10 Dec 2014), 24 (47.1%) subjects in the combination arm, 31 (59.6%) in the lenvatinib arm and 33 (66.0%) subjects in the everolimus arm had died. At the date of the second OS update (31 July 2015), 32 (62.7%) subjects in the combination arm, 34 (65.4%) in the lenvatinib arm and 37 (74.0%) subjects in the everolimus arm had died.

<div style=\"page-break-after: always\"></div>

Table 28: Summary of the results of the Overall Survival Analyses -Full Analysis Set

|                                     | Lenvatinib 18 mg + Everolimus 5 mg (N=51)   | Lenvatinib 24 mg (N=52)   | Everolimus 10 mg (N=50)   |
|-------------------------------------|---------------------------------------------|---------------------------|---------------------------|
| Primary Analysis                    |                                             |                           |                           |
| Median (months) (95% CI)            | 25.5 (20.8, 25.5)                           | 18.4 (13.3, NE)           | 17.5 (11.8, NE)           |
| Hazard Ratio (95% CI) vs everolimus | 0.55 (0.30, 1.01)                           | 0.74 (0.42, 1.31)         | 0.74 (0.40, 1.36)         |
| P-value vs everolimus               | 0.06                                        | 0.29                      | 0.30                      |
| First Update (10 Dec 2014)          |                                             |                           |                           |
| Median (months) (95% CI)            | 25.5 (16.4, NE)                             | 19.1 (13.6, 26.2)         | 15.4 (11.8, 19.6)         |
| Hazard Ratio (95% CI) vs everolimus | 0.51 (0.30, 0.88)                           | 0.68 (0.41, 1.14)         | 0.75 (0.43, 1.30          |
| P-value vs everolimus               | 0.02                                        | 0.12                      | 0.32                      |
| Second Update (31 Jul 2015)         |                                             |                           |                           |
| Median (months) (95% CI)            | 25.5 (16.4, 32.1)                           | 19.1 (13.6, 26.2)         | 15.4 (11.8, 20.6)         |
| Hazard Ratio (95% CI) vs everolimus | 0.59 (0.36, 0.96)                           | 0.75 (0.47, 1.20)         | 0.79 (0.48, 1.30)         |
| P-value vs everolimus               | 0.06                                        | 0.13                      | 0.31                      |

## A - Overall Survival at the planned time point (13 Jun 2014)

<!-- image -->

Hazardratioisbasedonastratified Coxregressionmodel includingtreatmentasafactorandhemoglobin andcortectedserumcalciumasstrata

ArmA=E708018mg+Everolimus5mg:ArmB=E708024mg:ArmC=Everolimus10mg

<div style=\"page-break-after: always\"></div>

## B - Overall Survival at the first updated time point (10 Dec 2014)

<!-- image -->

## C - Overall Survival at the second updated time point (31 Jul 2015)

Figure 8: Kaplan-Meier Plots of Overall Survival at the Planned (A), First updated (B) and Second Updated (C) Time points - Full Analysis Set

<!-- image -->

## Tumour Response (ORR, DCR, CBR and durable stable disease rate)

<div style=\"page-break-after: always\"></div>

Table 29: Summary of Tumour Response - Investigator Assessment - Full Analysis Set

|                                 | Lenvatinib 18 mg + Everolimus 5 mg (N=51)   | Lenvatinib 24 mg (N=52)   | Everolimus 10 mg (N=50)   |
|---------------------------------|---------------------------------------------|---------------------------|---------------------------|
| Complete response (CR), n (%)   | 1 (2.0)                                     | 0                         | 0                         |
| Partial response (PR), n (%)    | 21 (41.2)                                   | 14 a (26.9)               | 3 (6.0)                   |
| Stable disease (SD), n (%)      | 21 (41.2)                                   | 27 (51.9)                 | 31 (62.0)                 |
| Progressive disease (PD), n (%) | 2 (3.9)                                     | 3 (5.8)                   | 12 (24.0)                 |
| Not evaluable, n (%) a          | 0                                           | 2 (3.8)                   | 0                         |
| Not assessable, n (%) b         | 6 (11.8)                                    | 6 (11.5)                  | 4 (8.0)                   |

Data cut-off date = 13 Jun 2014.  Percentages are based on the total number of subjects in the Full Analysis Set within relevant treatment group.

CI = confidence interval, CSR = clinical study report, FAS = full analysis dataset, NE = not estimable.

a:  After database lock, it was discovered that 1 of the 14 subjects did not have a PR

Table 30: Summary of ORR, DCR, CBR and durable stable disease rate- Investigator Assessment - Full Analysis Set

|                                                         | Lenvatinib 18 mg + Everolimus 5 mg (N=51)   | Lenvatinib 24 mg (N=52)   | Everolimus 10 mg (N=50)   |
|---------------------------------------------------------|---------------------------------------------|---------------------------|---------------------------|
| Objective Response Rate (CR + PR), n (%)                | 22 (43.1)                                   | 14 (26.9)                 | 3 (6.0)                   |
| 95% CI of objective response rate c                     | (29.3, 57.8)                                | (15.6, 41.0)              | (1.3, 16.5)               |
| Rate Ratio, P Valued                                    |                                             |                           |                           |
| Lenvatinib 18 mg + Everolimus 5 mg vs. Everolimus 10 mg | 7.2 (2.3, 22.5), P<0.0001                   |                           |                           |
| Lenvatinib 24 mg vs. Everolimus 10 mg                   |                                             | 4.5 (1.4, 14.7), P=0.0067 |                           |
| Lenvatinib 18 mg + Everolimus 5 mg vs. lenvatinib 24 mg | 1.6 (0.9, 2.8), P=0.1007                    |                           |                           |
| Duration of Objective Response (months)e                | Duration of Objective Response (months)e    |                           |                           |
| Median (95% CI)                                         | 13.0 (3.7, NE)                              | 7.5 (3.8, NE)             | 8.5 (7.5, 9.4)            |
| 1st Quartile, 3rd Quartile                              | 3.7, NE                                     | 6.3, 12.9                 | 7.5, 9.4                  |
| Disease Control Rate (CR + PR + SD ≥7 weeks), n (%)     | 43 (84.3)                                   | 41 (78.8)                 | 34 (68.0)                 |
| 95% CI of disease control rate c                        | (71.4, 93.0)                                | (65.3, 88.9)              | (53.3, 80.5)              |
| Durable Stable Disease Rate (SD ≥23 weeks), n (%)       | 13 (25.5)                                   | 20 (38.5)                 | 18 (36.0)                 |
| 95% CI of durable stable disease rate c                 | (14.3, 39.6)                                | (25.3, 53.0)              | (22.9, 50.8)              |
| Clinical Benefit Rate (CR + PR + durable SD), n (%)     | 35 (68.6)                                   | 34 (65.4)                 | 21 (42.0)                 |
| 95% CI of clinical benefit rate c                       | (54.1, 80.9)                                | (50.9, 78.0)              | (28.2, 56.8)              |

Data cut-off date = 13 Jun 2014.  Percentages are based on the total number of subjects in the Full Analysis Set within relevant treatment group.

CI = confidence interval, CSR = clinical study report, FAS = full analysis dataset, NE = not estimable.

- a: Not Evaluable indicates best overall response of Not Evaluable or SD shorter than 7 weeks postrandomization.
- b: Not Assessable includes early deaths and subjects with progression who discontinued treatment or were censored prior to tumour assessment scans.  All of these subjects were counted as failures.
- c: 95% CI was constructed using the method of Clopper and Pearson.
- d: Analyses performed after database lock.  Rate ratio is based on the normal approximation and P value is based on the 2 sided Fisher's exact P value.

<div style=\"page-break-after: always\"></div>

e:  Point estimates are based on Kaplan-Meier method and 95% CIs are based on the Greenwood formula.

f:  After database lock, it was discovered that 1 of the 14 subjects (10222003) did not have a PR

A highly statistically significant and clinically meaningful increase in ORR (43.1% vs 6%; RR=7.2 [95% CI: 2.3,  22.5];  p&lt;0.001)  was  observed  for  the  lenvatinib/everolimus  combination  over  everolimus.  In  the combination  arm,  one  subject  was  achieving  a  CR  and  21  subjects  a  PR  versus  3  subjects  a  PR  in  the everolimus arm.

Three  responses,  all  PRs,  were  unconfirmed  in  the  combination  arm  in  the  primary  ORR  analysis;  thus, excluding these 3 responses, the confirmed ORR in the combination arm was 37% (n=19/51).

## · Ancillary analyses

## Retrospective analyses by blinded Independent Imaging Review (IIR)

As per request by and in agreement with the FDA and EMA, a retrospective analyses of the tumour scans was conducted to investigate whether the results of a blinded IIR supported the efficacy results (PFS, BOR) based on the investigator-assessed tumour responses.

The primary objective of this blinded IIR review was to compare the PFS of the combination arm versus the everolimus arm, and of the lenvatinib arm versus the everolimus arm as assessed by IIR tumour assessments, using the FAS. The secondary objectives were to assess BOR, including ORR, DCR, SD, durable SD, and CBR; and to compare PFS of the combination arm to the lenvatinib arm as assessed by IIR using the FAS.

Table 31: Summary of Key Efficacy Results Obtained by Investigator or Blinded Independent Imaging Review

|                                 | Investigator Assessment         | Investigator Assessment      | Independent Imaging Assessment   | Independent Imaging Assessment   |
|---------------------------------|---------------------------------|------------------------------|----------------------------------|----------------------------------|
|                                 | Lenvatinib 18mg +Everolimus 5mg | Everolimus 10mg              | Lenvatinib 18mg +Everolimus 5mg  | Everolimus 10mg                  |
| PFS - Primary Analysis          | PFS - Primary Analysis          | PFS - Primary Analysis       | PFS - Primary Analysis           | PFS - Primary Analysis           |
| Median (months) (95% CI) a      | 14.6 (5.9, 20.1)                | 5.5 (3.5, 7.1)               | 12.8 (7.4, 17.5)                 | 5.6 (3.6, 9.3)                   |
| Hazard Ratio (95% CI) b p-value | 0.40 (0.24, 0.68) 0.0005        | 0.40 (0.24, 0.68) 0.0005     | 0.45 (0.26, 0.79) 0.0029         | 0.45 (0.26, 0.79) 0.0029         |
| PFS - Sensitivity Analysis c    | PFS - Sensitivity Analysis c    | PFS - Sensitivity Analysis c | PFS - Sensitivity Analysis c     | PFS - Sensitivity Analysis c     |
| Median (months) (95% CI) a      | 10.7 (5.6, 17.5)                | 5.5 (3.6, 6.4)               | 11.1 (7.4, 13.0)                 | 5.3 (3.6, 6.4)                   |
| Hazard Ratio (95% CI) b p-value | 0.40 (0.25, 0.63) 0.0001        | 0.40 (0.25, 0.63) 0.0001     | 0.48 (0.30, 0.76) 0.0017         | 0.48 (0.30, 0.76) 0.0017         |
| ORR (CR+PR)                     | ORR (CR+PR)                     | ORR (CR+PR)                  | ORR (CR+PR)                      | ORR (CR+PR)                      |
| n (%) (95% CI) d                | 22 (43.1) (29.3, 57.8)          | 3 (6.0) (1.3, 16.5)          | 18 (35.3) (22.4, 49.9)           | 0 (0.0, 7.1)                     |
| Rate Ratio e (95%CI) p-value    | 7.2 (2.3, 22.5) <0.0001         | 7.2 (2.3, 22.5) <0.0001      | NE (NE, NE) <0.0001              | NE (NE, NE) <0.0001              |

<div style=\"page-break-after: always\"></div>

a: Point estimates are based on Kaplan-Meier method and 95% CIs are based on the Greenwood formula using log-log transformation; b: Stratified HR is based on a stratified Cox  regression mode including treatment as covariate factor and baseline ECOG scores, haemoglobin and corrected serum calcium as strata. The Efron method was used for correction for tied events. P-values based on stratified Log Rank test; c: All documented radiological disease progression or deaths prior to data cut-off date were used as events; d: 95% CI was constructed using the method of Clopper and Pearson. e: Rate ratio is based  on  the normal approximation and p-values is based on 2-sided Fisher's exact p-value.

|                                 | Investigator Assessment      | Investigator Assessment      | Independent Imaging Assessment   | Independent Imaging Assessment   |
|---------------------------------|------------------------------|------------------------------|----------------------------------|----------------------------------|
|                                 | Lenvatinib 24mg              | Everolimus 10mg              | Lenvatinib 24mg                  | Everolimus 10mg                  |
| PFS - Primary Analysis          | PFS - Primary Analysis       | PFS - Primary Analysis       | PFS - Primary Analysis           | PFS - Primary Analysis           |
| Median (months) (95% CI) a      | 7.4 (5.6, 10.2)              | 5.5 (3.5, 7.1)               | 9.0 (5.6, 10.2)                  | 5.6 (3.6, 9.3)                   |
| Hazard Ratio (95% CI) b p-value | 0.61 (0.38, 0.98) 0.0479     | 0.61 (0.38, 0.98) 0.0479     | 0.62 (0.37, 1.04) 0.1175         | 0.62 (0.37, 1.04) 0.1175         |
| PFS - Sensitivity Analysis c    | PFS - Sensitivity Analysis c | PFS - Sensitivity Analysis c | PFS - Sensitivity Analysis c     | PFS - Sensitivity Analysis c     |
| Median (months) (95% CI) a      | 7.4 (5.6, 9.2)               | 5.5 (3.6, 6.4)               | 9.0 (5.5, 10.2)                  | 5.3 (3.6, 6.4)                   |
| Hazard Ratio (95% CI) b p-value | 0.61 (0.40, 0.94) 0.0262     | 0.61 (0.40, 0.94) 0.0262     | 0.66 (0.42, 1.03) 0.0838         | 0.66 (0.42, 1.03) 0.0838         |
| ORR (CR+PR)                     | ORR (CR+PR)                  | ORR (CR+PR)                  | ORR (CR+PR)                      | ORR (CR+PR)                      |
| n (%) (95% CI) d                | 14 (26.9) (15.6, 41.0)       | 3 (6.0) (1.3, 16.5)          | 20 (38.5) (25.3, 53.0)           | 0 (0.0, 7.1)                     |
| Rate Ratio e (95%CI) p-value    | 4.5 (1.4, 14.7) 0.0067       | 4.5 (1.4, 14.7) 0.0067       | NE (NE, NE) <0.0001              | NE (NE, NE) <0.0001              |

|                                 | Investigator Assessment         | Investigator Assessment      | Independent Imaging Assessment   | Independent Imaging Assessment   |
|---------------------------------|---------------------------------|------------------------------|----------------------------------|----------------------------------|
|                                 | Lenvatinib 18mg +Everolimus 5mg | Lenvatinib 24mg              | Lenvatinib 18mg +Everolimus 5mg  | Lenvatinib 24mg                  |
| PFS - Primary Analysis          | PFS - Primary Analysis          | PFS - Primary Analysis       | PFS - Primary Analysis           | PFS - Primary Analysis           |
| Median (months) (95% CI) a      | 14.6 (5.9, 20.1)                | 7.4 (5.6, 10.2)              | 12.8 (7.4, 17.5)                 | 9.0 (5.6, 10.2)                  |
| Hazard Ratio (95% CI) b p-value | 0.66 (0.39, 1.10) 0.1209        | 0.66 (0.39, 1.10) 0.1209     | 0.72 (0.42, 1.24) 0.3194         | 0.72 (0.42, 1.24) 0.3194         |
| PFS - Sensitivity Analysis c    | PFS - Sensitivity Analysis c    | PFS - Sensitivity Analysis c | PFS - Sensitivity Analysis c     | PFS - Sensitivity Analysis c     |
| Median (months) (95% CI) a      | 10.7 (5.6, 17.5)                | 7.4 (5.6, 9.2)               | 11.1 (7.4, 13.0)                 | 9.0 (5.5, 10.2)                  |
| Hazard Ratio (95% CI) b p-value | 0.66 (0.41, 1.05) 0.0723        | 0.66 (0.41, 1.05) 0.0723     | 0.73 (0.46, 1.16) 0.1591         | 0.73 (0.46, 1.16) 0.1591         |
| ORR (CR+PR)                     | ORR (CR+PR)                     | ORR (CR+PR)                  | ORR (CR+PR)                      | ORR (CR+PR)                      |
| n (%) (95% CI) d                | 22 (43.1) (29.3, 57.8)          | 14 (26.9) (15.6, 41.0)       | 18 (35.3) (22.4, 49.9)           | 20 (38.5) (25.3, 53.0)           |
| Rate Ratio e (95%CI) p-value    | 1.6 (0.9, 2.8) 0.1007           | 1.6 (0.9, 2.8) 0.1007        | 0.9 (0.6, 1.5) 0.8388            | 0.9 (0.6, 1.5) 0.8388            |

<div style=\"page-break-after: always\"></div>

## Progression-free Survival by IIR

<!-- image -->

ArmA=E708018mg·Everolimus5mg:ArmB=E708024mg.ArmC=Everolimus10mg.*+meanscensoredsubjects

Figure 9: Kaplan-Meier Plot of Progression-Free Survival per Blinded Independent Imaging Review (IIR) - Full Analysis Set

## Concordance analyses of PFS and BOR

Table 32: Progression-Free Survival assessed by Investigator and Blinded Independent Imaging Review - Full Analysis Set

|                                           | Investigator   | Independent review, n (%)   | Independent review, n (%)   |
|-------------------------------------------|----------------|-----------------------------|-----------------------------|
|                                           | review         | PD                          | Non PD                      |
| Overall (N=153)                           | PD             | 73 (47.7)                   | 28 (18.3)                   |
|                                           | Non PD         | 12 (7.8)                    | 40 (26.1)                   |
| Lenvatinib 18 mg + Everolimus 5 mg (N=51) | PD             | 18 (35.3)                   | 7 (13.7)                    |
|                                           | Non PD         | 7 (13.7)                    | 19 (37.3)                   |
| Lenvatinib 24 mg (N=52)                   | PD             | 28 (53.8)                   | 8 (15.4)                    |
|                                           | Non PD         | 12 (7.8)                    | 40 (26.1)                   |
| Everolimus 10 mg (N=50)                   | PD             | 27 (54)                     | 13 (26)                     |
|                                           | Non PD         | 1 (2.0)                     | 9 (18.0)                    |

## PD=progressive disease

Percentages are based on the total number of randomised subjects in the relevant treatment group. Tumor response was based on RECIST 1.1. Independent Reviewer responses were per the review selected by the adjudicator.

Overall, the blinded independent and the investigator results agreed on 73.8% (47.7% + 26.1%) of cases, as to whether the subject had progressed or not. Agreement was not observed for PD versus non PD in 26.1% (18.3% + 7.8%) of subjects. For 18.3% of subjects, the investigator assessed progressive disease, but this was not observed by the independent reviewer. Conversely, in 7.8% of subjects, the independent reviewer observed PD, but the investigator did not.

<div style=\"page-break-after: always\"></div>

A high level of agreement in BOR was observed between the blinded IIR and investigator assessments. Results of the 3 treatment arms were consistent with that of the overall agreement (weighted Kappa range: 0.65 to 0.73).

## Sensitivity analyses for Progression-Free Survival

A pre-planned sensitivity analysis, decided to be done after database lock, was performed using ECOG PS (0 vs 1) as an additional stratum in the stratified Cox regression model used for the primary analysis.

Table 33: Progression-Free Survival based on Investigator Assessment: Pre-planned Sensitivity Analysis based on ECOG PS as a stratum - Full Analysis Set

|                                           | Lenvatinib 18 mg + Everolimus 5 mg (N=51)   | Everolimus 10 mg (N=50)   |
|-------------------------------------------|---------------------------------------------|---------------------------|
| Median PFS (95% CI)a                      | 14.6 (5.9, 20.1)                            | 5.5 (3.5, 7.1)            |
| P-value Based on Stratified Log-rank Test | 0.0012                                      |                           |
| Stratified Hazard Ratio (95% CI)          | 0.43 (0.25, 0.72)                           |                           |

## Ad hoc sensitivity analyses of PFS

Four ad hoc sensitivity analyses of PFS were performed to ensure that the results of the primary analysis were robust:

1. Inclusion of clinical progression as a PFS event,
2. Censored subjects with documented progression based solely on pleural effusion as a new lesion,
3. Included all subjects with disease progression and deaths as events even if a subject had missing assessments, received other anticancer therapy or treatment discontinuation due to reasons other than PD
4. Censored subjects based on the end of treatment with the last dose as entered on the study medication page of the CRF.

The results of the ad-hoc analyses were generally consistent with those of the primary PFS analysis.

Table 34: Progression-Free Survival: Ad hoc Sensitivity Analyses - Full Analysis Set

|                             | Sensitivity Analyses                  | Sensitivity Analyses                  | Sensitivity Analyses                                     | Sensitivity Analyses                                     | Sensitivity Analyses               | Sensitivity Analyses               | Sensitivity Analyses                       | Sensitivity Analyses                       |
|-----------------------------|---------------------------------------|---------------------------------------|----------------------------------------------------------|----------------------------------------------------------|------------------------------------|------------------------------------|--------------------------------------------|--------------------------------------------|
|                             | Clinical Progression as a PFS Event a | Clinical Progression as a PFS Event a | Censor Subjects with PD based only on Pleural Effusion b | Censor Subjects with PD based only on Pleural Effusion b | All PDs and Deaths as PFS Events c | All PDs and Deaths as PFS Events c | Last Dose Date from Study Medication CRF d | Last Dose Date from Study Medication CRF d |
|                             | Lenv 18 mg + Ever 5 mg                | Ever 10 mg                            | Lenv 18 mg + Ever 5 mg                                   | Ever 10 mg                                               | Lenv 18 mg + Ever 5 mg             | Ever 10 mg                         | Lenv 18 mg + Ever 5 mg                     | Ever 10 mg                                 |
| Median PFS months (95%CI) e | 11.1 (5.6,17.5)                       | 5.5 (3.6, 7.6)                        | 14.6 (5.9,20.1)                                          | 5.5 (3.5, 7.1)                                           | 10.7 (5.6,17.5)                    | 5.5 (3.6, 6.4)                     | 14.7 (5.6,20.5)                            | 5.5 (3.6, 9.3)                             |
| p-value                     | 0.0010                                | 0.0010                                | 0.0005                                                   | 0.0005                                                   | 0.0001                             | 0.0001                             | 0.0011                                     | 0.0011                                     |

<div style=\"page-break-after: always\"></div>

| based on Stratified Log Rank Test   |                   |                   |                   |                  |
|-------------------------------------|-------------------|-------------------|-------------------|------------------|
| Stratified HR (95% CI) f            | 0.44 (0.27, 0.72) | 0.40 (0.24, 0.67) | 0.40 (0.25, 0.63) | 0.41 (0.24, 071) |

Data cut-off date = 13 Jun 2014 Lenv - lenvatinib, Ever - everolimus

The tumour assessment was based on RECIST 1.1 criteria. Percentages are based on the total number of subjects in the Full Analysis Set within relevant treatment group. CRF = case report form.

- a: Included clinical progression as a PFS event.
- b: Censored subjects with documented progression based solely on pleural effusion as a new lesion (1 subject met this criterion).
- c: Included all subjects with disease progression and deaths as events even if a subject had missing assessments, received other anticancer therapy or treatment discontinuation due to reasons other than PD (Appendix Figure 2.7.3-1)
- d: Censored subjects based on the end of treatment with the last dose date as entered on the study medication page of the CRF, rather than the investigator's stated end of treatment date from the disposition page of the CRF (Appendix Figure 2.7.3-2).
- e: Point estimates are based on Kaplan-Meier method and 95% CIs are based on the Greenwood formula using log-log transformation.
- f: Stratified hazard ratio is based on a stratified Cox regression model including treatment as a covariate factor and baseline ECOG scores, haemoglobin, and corrected serum calcium as strata. The Efron method was used for correction for tied events.

## Planned Subgroup Analyses of Progression-Free Survival (Investigator)

Subgroup analyses of PFS were considered exploratory and are limited by the sample size within each subgroup.

<div style=\"page-break-after: always\"></div>

|                            | Events/N              | Events/N              |                       | Median (Months)       | Median (Months)       |                       |
|----------------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
|                            | ArmA                  | ArmC                  | HR (95% CI)           | AmA                   | ArmC                  |                       |
| Overall                    | 26/51                 | 37/50                 | 0.401(0.239,0.675)    | 14.6                  | 5.5                   |                       |
| Hemoglobin Group           |                       |                       |                       |                       |                       |                       |
| <=13 or 11.5(female) g/dL  | 18/33                 | 23/31                 | 0.456(0.244,0.851)    | 5.6                   | 5.3                   |                       |
| >13 or 11.5(female) g/dL   | 8/18                  | 14/19                 | 0.248(0.102,0.600)    | 20.1                  | 7.0                   |                       |
| Correctedserumcalcium      |                       |                       |                       |                       |                       |                       |
| >=10 mg/dL                 | 4/6                   | 6/8                   | 0.262(0.072,0.955)    | 12.9                  | 5.3                   |                       |
| <10 mg/dL                  | 22/45                 | 31/42                 | 0.395(0.227,0.686)    | 14.6                  | 5.5                   |                       |
| Age group                  |                       |                       |                       |                       |                       |                       |
| <=65 years                 | 15/31                 | 30/39                 | 0.333(0.178.0.625)    | 14.7                  | 5.5                   |                       |
| >65years                   | 11/20                 | 7/11                  | 0.399(0.153,1.039)    | 7.4                   | 5.6                   |                       |
| Sex                        |                       |                       |                       |                       |                       |                       |
| male                       | 16/35                 | 30/38                 | 0.312(0.169,0.577)    | 14.6                  | 5.3                   |                       |
| female                     | 10/16                 | 7/12                  | 0.610(0.230.1.617)    | 9.5                   | 9.3                   |                       |
| ECOG performance status    |                       |                       |                       |                       |                       |                       |
| 0                          | 11/27                 | 22/28                 | 0.271(0.130,0.562)    | 17.5                  | 5.5                   |                       |
| 1                          | 15/24                 | 15/22                 | 0.499(0.241,1.032)    | 5.6                   | 3.6                   |                       |
| Region                     |                       |                       |                       |                       |                       |                       |
| Europe                     | 23/46                 | 24/36                 | 0.385(0.215.0.692)    | 14.6                  | 5.5                   |                       |
| United States              | 3/5                   | 13/14                 | 0.464(0.132,1.637)    | 11.2                  | 5.3                   |                       |
| Baselinehypertensionstatus |                       |                       |                       |                       |                       |                       |
| yes                        | 18/36                 | 26/36                 | 0.502(0.273,0.920)    | 9.5                   | 5.7                   |                       |
| no                         | 8/15                  | 11/14                 | 0.140(0.054,0.360)    | 14.7                  | 2.3                   |                       |
| FavorsArmA FavorsArmC      | FavorsArmA FavorsArmC | FavorsArmA FavorsArmC | FavorsArmA FavorsArmC | FavorsArmA FavorsArmC | FavorsArmA FavorsArmC | FavorsArmA FavorsArmC |

0.01

0.1

1

10

HazardRatioand95%ConfidenceInterval

ArmA=E708018mg+EverolmusSmgArmB=E708024mg:ArmC=Everolimus10mg HazardratioisbasedonaCoxregressionmodelincluding treatment,subgroup and treatment-by-subgroupinteractionasfactors

Figure 10: Forest Plot of Hazard Ratio for Progression-Free Survival by Subgroup - Full Analysis Set

## Analyses by prior VEGF-targeted therapy

Based on the results of a post-hoc exploratory analysis in a limited number of patients per subgroup, the positive effect on PFS was seen regardless of which prior VEGF-targeted therapy was used: sunitinib (Hazard ratio [HR] = 0.356 [95% CI: 0.188, 0.674] or other therapies (HR = 0.350 [95% CI: 0.148, 0.828]). The results for OS also favored the combination arm over everolimus arm: sunitinib (Hazard ratio [HR] = 0.532 [95% CI: 0.303, 0.935] or other therapies (HR = 0.639 [95% CI: 0.255, 1.604]), with median OS: 21.8 and 32.1 months, with sunitinib and other therapy, respectively, in combination arm; and 12 and 21.4 months, with sunitinib and other therapy, respectively, in everolimus arm. When OS was calculated from the starting date of prior VEGF-targeted therapy, results for OS also favored the combination arm over everolimus arm.

<div style=\"page-break-after: always\"></div>

## A-Prior VEGF-targeted therapy: sunitinib

<!-- image -->

## B-Prior VEGR targeted therapy: Other therapy

Arm A - combination, Arm B - lenvatinib, Arm C - everolimus

<!-- image -->

Figure 11: Kaplan-Meier Plot for PFS in Subjects Who Received Prior Sunitinib or Prior Vascular Endothelial Growth Factor-Targeted Therapy Other than Sunitinib in the Combination and Everolimus Treatment Arms Study 205 Phase 2 (Full Analysis Set)

<div style=\"page-break-after: always\"></div>

In subjects who received prior sunitinib, the ORR was 41.7% (n=15/36) for the combination arm versus 3.6% (n=1/28) for the everolimus arm as of the 13 Jun 2014 cutoff date for the primary PFS analysis. In subjects who received a different prior VEGF-targeted therapy, the ORR again favored the combination arm (46.7%, n=7/15) compared with 9.1% (n=2/22) for everolimus.

The median duration of treatment in Study 205 was 5.0 months (min, max: 0.7, 33.0) and 4.1 months (0.3, 33.6) in subjects who received prior sunitinib in the combination (n=36) and everolimus (n=28) arms, respectively, and 11.0 months (1.0, 26.5) and 4.7 months (0.6, 29.9) in subjects who received prior VEGFtargeted therapy other than sunitinib in the combination (n=15) and everolimus (n=22) arms, respectively.

In subjects who received prior sunitinib, the median duration of response was 13.0 months (95% CI: 3.7, NE) for the 15 responders in the combination arm and 9.4 months for the single responder in the everolimus arm as of the 13 Jun 2014 cutoff date for the primary PFS analysis. In subjects who received a different prior VEGF-targeted therapy, the median duration of response was 12.8 months (95% CI: 2.7, NE) for the 7 responders in the combination arm and 7.5 months (95% CI: NE, NE) for the 2 responders in the everolimus arm.

## Clinical studies in special populations

|                       | Age 65-74 (Older subjects number /total number)   | Age 75-84 (Older subjects number /total number)   | Age 85+ (Older subjects number /total number)   |
|-----------------------|---------------------------------------------------|---------------------------------------------------|-------------------------------------------------|
| Controlled Trials     | 54/153                                            |                                                   |                                                 |
| Non Controlled trials |                                                   |                                                   |                                                 |

A total of 54 subjects &gt;65years of age was enrolled in the pivotal Phase 2 portion of Study 205.

A clear benefit from treatment with lenvatinib/everolimus relative to everolimus for PFS could be observed (HR:  0.399,  95%CI:  0.153-1.039).  However,  the  number  of  subjects  was  low  and  not  evenly  balanced between the lenvatinib/everolimus arm (n=20) and everolimus arm (n=11).

## Analysis performed across trials (pooled analyses AND meta-analysis)

NA

## Supportive study

Efficacy evaluation was an exploratory objective in the Phase 1b part of Study 205. The exploratory endpoint was the Best Overall Response (BOR). All 20 enrolled subjects were evaluated for objective response,

<div style=\"page-break-after: always\"></div>

assessed by the investigator using RECIST 1.1. A total of 4 subjects, 2 in Cohort 3 and 1 in each of Cohorts 1 and 2, had their BOR categorized as 'unknown.' These subjects discontinued study medication early due to AEs or subject withdrew.

Table 35: Best Overall Tumour Response (BOR) of all subjects per investigator assessment by cohort - Phase 1b - Study 205 (Safety Analysis Set)

| Objective Response (n, %)                | Cohort 1 Lenvatinib 12 mg + Everolimus 5 mg (N=7)   | Cohort 2 Lenvatinib 18 mg + Everolimus 5 mg (N=11)   | Cohort 3 Lenvatinib 24 mg + Everolimus 5 mg (N=2)   |
|------------------------------------------|-----------------------------------------------------|------------------------------------------------------|-----------------------------------------------------|
| Objective Response Rate (CR + PR), n (%) | 2 (28.6)                                            | 4 (36.4)                                             | 0                                                   |
| Complete Response (CR)                   | 0                                                   | 1 ( 9.1)                                             | 0                                                   |
| Partial Response (PR)                    | 2 (28.6)                                            | 3 (27.3)                                             | 0                                                   |
| Stable Disease (SD)                      | 4 (57.1)                                            | 5 (45.5)                                             | 0                                                   |
| Progressive Disease (PD)                 | 0                                                   | 1 (9.1)                                              | 0                                                   |
| Unknown a n (%)                          | 1 (14.3)                                            | 1 (9.1)                                              | 2 (100.0)                                           |

## · Summary of main efficacy results

The  following  tables  summarise  the  key  efficacy  results  from  the  study  205  supporting  the  present application. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment.

Table 36:  Summary of efficacy for phase 2 portion of trial E7080-G000-205

Title: An  Open-Label,  Multicenter  Phase  1b/2  Study  of  E7080  Alone,  and  in  Combination  With Everolimus  in  Subjects  With  Unresectable  Advanced  or  Metastatic  Renal  Cell  Carcinoma  Following One Prior VEGF-Targeted Treatment

| Study identifier   | E7080-G000-205                                                                 | E7080-G000-205                                                                                   |
|--------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| Design             | randomized, open-label, multicenter                                            | randomized, open-label, multicenter                                                              |
|                    | Duration of main phase: Duration of Run-in phase: Duration of Extension phase: | 16 March 2012 - 13 June 2014 (data cut-off date for the primary endpoint) Not applicable ongoing |
| Hypothesis         | superiority                                                                    | superiority                                                                                      |
| Treatments groups  | Lenvatinib/everolimus combination                                              | Lenvatinib 18 mg QD + everolimus 5 mg QD, orally, continuous 28-day cycles N=51                  |
| Treatments groups  | Lenvatinib                                                                     | Lenvatinib 24 mg QD, orally, continuous 28- day cycles N=52                                      |

<div style=\"page-break-after: always\"></div>

|                                    | Everolimus                         | Everolimus                                        | Everolimus                                        | Everolimus 10 mg QD, orally, continuous 28- day cycles                                                                                                                                                                                                                                  | Everolimus 10 mg QD, orally, continuous 28- day cycles                                                                                                                                                                                                                                  | Everolimus 10 mg QD, orally, continuous 28- day cycles                                                                                                                                                                                                                                  |
|------------------------------------|------------------------------------|---------------------------------------------------|---------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Endpoints and definitions          | Primary endpoint                   | Primary endpoint                                  | PFS                                               | N=50 The time from randomization to the date of the first documented tumour progression as determined by the investigator using RECIST 1.1 criteria, or death due to any cause. Comparison groups: - combination vs. single-agent everolimus - single-agent lenvatinib vs. single-agent | N=50 The time from randomization to the date of the first documented tumour progression as determined by the investigator using RECIST 1.1 criteria, or death due to any cause. Comparison groups: - combination vs. single-agent everolimus - single-agent lenvatinib vs. single-agent | N=50 The time from randomization to the date of the first documented tumour progression as determined by the investigator using RECIST 1.1 criteria, or death due to any cause. Comparison groups: - combination vs. single-agent everolimus - single-agent lenvatinib vs. single-agent |
|                                    | Secondary endpoint                 | Secondary endpoint                                | PFS                                               | The time from randomization to the date of the first documented tumour progression as determined by the investigator using RECIST 1.1 criteria, or death due to any cause. Comparison group: - combination vs. single-agent lenvatinib                                                  | The time from randomization to the date of the first documented tumour progression as determined by the investigator using RECIST 1.1 criteria, or death due to any cause. Comparison group: - combination vs. single-agent lenvatinib                                                  | The time from randomization to the date of the first documented tumour progression as determined by the investigator using RECIST 1.1 criteria, or death due to any cause. Comparison group: - combination vs. single-agent lenvatinib                                                  |
|                                    | Secondary                          | Secondary                                         | OS                                                | The time from the date of randomization until the date of death of any cause                                                                                                                                                                                                            | The time from the date of randomization until the date of death of any cause                                                                                                                                                                                                            | The time from the date of randomization until the date of death of any cause                                                                                                                                                                                                            |
|                                    | endpoint Secondary endpoint        | endpoint Secondary endpoint                       | ORR                                               | The proportion of subjects who had best overall response (BOR) of complete response (CR) or partial response (PR) as determined by the investigator using RECIST 1.1 criteria                                                                                                           | The proportion of subjects who had best overall response (BOR) of complete response (CR) or partial response (PR) as determined by the investigator using RECIST 1.1 criteria                                                                                                           | The proportion of subjects who had best overall response (BOR) of complete response (CR) or partial response (PR) as determined by the investigator using RECIST 1.1 criteria                                                                                                           |
| Database lock                      | 13 June 2014                       | 13 June 2014                                      | 13 June 2014                                      | 13 June 2014                                                                                                                                                                                                                                                                            | 13 June 2014                                                                                                                                                                                                                                                                            | 13 June 2014                                                                                                                                                                                                                                                                            |
| Results and Analysis               | Results and Analysis               | Results and Analysis                              | Results and Analysis                              | Results and Analysis                                                                                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                                                                                    | Results and Analysis                                                                                                                                                                                                                                                                    |
| Analysis description               | Analysis description               | Primary Analysis                                  | Primary Analysis                                  | Primary Analysis                                                                                                                                                                                                                                                                        | Primary Analysis                                                                                                                                                                                                                                                                        | Primary Analysis                                                                                                                                                                                                                                                                        |
| Analysis population and time point | Analysis population and time point | Intent to treat (=Full Analysis Set) 13 June 2014 | Intent to treat (=Full Analysis Set) 13 June 2014 | Intent to treat (=Full Analysis Set) 13 June 2014                                                                                                                                                                                                                                       | Intent to treat (=Full Analysis Set) 13 June 2014                                                                                                                                                                                                                                       | Intent to treat (=Full Analysis Set) 13 June 2014                                                                                                                                                                                                                                       |
| Descriptive statistics             | Descriptive statistics             |                                                   |                                                   |                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                         |
| description and estimate           | description and estimate           | Treatment group                                   | Lenvatinib 18 mg Everolimus 5 mg                  | Lenvatinib 18 mg Everolimus 5 mg                                                                                                                                                                                                                                                        | Lenvatinib 24 mg                                                                                                                                                                                                                                                                        | Everolimus 10 mg                                                                                                                                                                                                                                                                        |
| variability                        | variability                        | Number of subjects                                | 51                                                | 51                                                                                                                                                                                                                                                                                      | 52                                                                                                                                                                                                                                                                                      | 50                                                                                                                                                                                                                                                                                      |
|                                    |                                    | PFS (months) median                               | 14.6                                              | 14.6                                                                                                                                                                                                                                                                                    | 7.4                                                                                                                                                                                                                                                                                     | 5.5                                                                                                                                                                                                                                                                                     |
|                                    |                                    | 95% CI                                            | (5.9,20.1)                                        | (5.9,20.1)                                                                                                                                                                                                                                                                              | (5.6,10.2)                                                                                                                                                                                                                                                                              | (3.5,7.1)                                                                                                                                                                                                                                                                               |
|                                    |                                    | Number of deaths (%)                              | 19 (37.3)                                         | 19 (37.3)                                                                                                                                                                                                                                                                               | 26 (50.0)                                                                                                                                                                                                                                                                               | 26 (52.0)                                                                                                                                                                                                                                                                               |
|                                    |                                    | OS (months) median                                | 25.5                                              | 25.5                                                                                                                                                                                                                                                                                    | 18.4                                                                                                                                                                                                                                                                                    | 17.5                                                                                                                                                                                                                                                                                    |
|                                    |                                    | 95% CI                                            | (20.8,25.5)                                       | (20.8,25.5)                                                                                                                                                                                                                                                                             | (13.3,NE)                                                                                                                                                                                                                                                                               | (11.8,NE)                                                                                                                                                                                                                                                                               |
|                                    |                                    | ORR (%)                                           | 43.1                                              | 43.1                                                                                                                                                                                                                                                                                    | 26.9                                                                                                                                                                                                                                                                                    | 6.0                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|                                | 95% CI                 | (29.3,57.8)       | (15.6,41.0)       | (15.6,41.0)                | (1.3,16.5)                 |
|--------------------------------|------------------------|-------------------|-------------------|----------------------------|----------------------------|
| Effect estimate per comparison | Primary endpoint PFS   | Comparison groups | Comparison groups | Combination vs. Everolimus | Combination vs. Everolimus |
|                                | Primary endpoint PFS   | HR                | HR                | 0.40                       | 0.40                       |
|                                | Primary endpoint PFS   | 95% CI            | 95% CI            | (0.24,0.68)                | (0.24,0.68)                |
|                                | Primary endpoint PFS   | P-value           | P-value           | 0.0005                     | 0.0005                     |
|                                | Primary endpoint PFS   | Comparison groups | Comparison groups | Lenvatinib vs. Everolimus  | Lenvatinib vs. Everolimus  |
|                                | Primary endpoint PFS   | HR                | HR                | 0.61                       | 0.61                       |
|                                | Primary endpoint PFS   | 95% C             | 95% C             | (0.38,0.98)                | (0.38,0.98)                |
|                                | Primary endpoint PFS   | P-value           | P-value           | 0.0479                     | 0.0479                     |
|                                | Secondary endpoint PFS | Comparison groups | Comparison groups | Combination vs. Lenvatinib | Combination vs. Lenvatinib |
|                                | Secondary endpoint PFS | HR                | HR                | 0.66                       | 0.66                       |
|                                | Secondary endpoint PFS | 95% C             | 95% C             | (0.39,1.10)                | (0.39,1.10)                |
|                                | Secondary endpoint PFS | P-value           | P-value           | 0.1209                     | 0.1209                     |
|                                | Secondary endpoint OS  | Comparison groups | Comparison groups | Combination vs. Everolimus | Combination vs. Everolimus |
|                                | Secondary endpoint OS  | HR                | HR                | 0.55                       | 0.55                       |
|                                | Secondary endpoint OS  | 95% CI            | 95% CI            | (0.30,1.01)                | (0.30,1.01)                |
|                                | Secondary endpoint OS  | P-value           | P-value           | 0.0623                     | 0.0623                     |
|                                | Secondary endpoint OS  | Comparison groups | Comparison groups | Lenvatinib vs. Everolimus  | Lenvatinib vs. Everolimus  |
|                                | Secondary endpoint OS  | HR                | HR                | 0.74                       | 0.74                       |
|                                | Secondary endpoint OS  | 95% CI            | 95% CI            | (0.42,1.31)                | (0.42,1.31)                |
|                                | Secondary endpoint OS  | P-value           | P-value           | 0.2896                     | 0.2896                     |
|                                | Secondary endpoint OS  | Comparison groups | Comparison groups | Combination vs. Lenvatinib | Combination vs. Lenvatinib |
|                                | Secondary endpoint OS  | HR                | HR                | 0.70                       | 0.70                       |
|                                | Secondary endpoint OS  | 95% CI            | 95% CI            | (0.40,1.36)                | (0.40,1.36)                |
|                                | Secondary endpoint OS  | P-value           | P-value           | 0.3023                     | 0.3023                     |
|                                | Secondary endpoint ORR | Comparison groups | Comparison groups | Combination vs. Everolimus | Combination vs. Everolimus |
|                                | Secondary endpoint ORR | RR                | RR                | 7.2                        | 7.2                        |
|                                | Secondary endpoint ORR | 95% CI            | 95% CI            | (2.3,22.5)                 | (2.3,22.5)                 |
|                                | Secondary endpoint ORR | P-value           | P-value           | <0.0001                    | <0.0001                    |
|                                | Secondary endpoint ORR | Comparison groups | Comparison groups | Lenvatinib vs. Everolimus  | Lenvatinib vs. Everolimus  |
|                                | Secondary endpoint ORR | RR                | RR                | 4.5                        | 4.5                        |
|                                | Secondary endpoint ORR | 95% CI            | 95% CI            | (1.4,14.7)                 | (1.4,14.7)                 |

<div style=\"page-break-after: always\"></div>

|                                                 |                                                                                      | P-value                                                                              | 0.0067                                                                               |
|-------------------------------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
|                                                 |                                                                                      | Comparison groups                                                                    | Combination vs. Lenvatinib                                                           |
|                                                 |                                                                                      | RR                                                                                   | 1.6                                                                                  |
|                                                 |                                                                                      | 95% CI                                                                               | (0.9,2.8)                                                                            |
|                                                 |                                                                                      | P-value                                                                              | 0.1007                                                                               |
| Notes                                           |                                                                                      |                                                                                      |                                                                                      |
| Analysis description                            | Ancillary ad hoc analysis: Includes results of independent review (for PFS and ORR); | Ancillary ad hoc analysis: Includes results of independent review (for PFS and ORR); | Ancillary ad hoc analysis: Includes results of independent review (for PFS and ORR); |
| PFS combination vs. everolimus                  | Median (months); (95% CI)                                                            | 12.8 (7.4, 17.5) Vs. 5.6 (3.6, 9.3)                                                  | 12.8 (7.4, 17.5) Vs. 5.6 (3.6, 9.3)                                                  |
| PFS combination vs. everolimus                  | Hazard Ratio (95% CI)                                                                | 0.45 (0.26, 0.79)                                                                    | 0.45 (0.26, 0.79)                                                                    |
| PFS combination vs. everolimus                  | p-value                                                                              | 0.003                                                                                | 0.003                                                                                |
| ORR combination vs. everolimus                  | ORR: n (%) Rate Ratio (95% CI)                                                       | 18 (35.3) vs. 0 NE (NE, NE)                                                          | 18 (35.3) vs. 0 NE (NE, NE)                                                          |
| ORR combination vs. everolimus                  | p-value                                                                              | <0.0001                                                                              | <0.0001                                                                              |
| Analysis description                            | Updated analysis for OS: First Update                                                | Updated analysis for OS: First Update                                                | Updated analysis for OS: First Update                                                |
| Analysis population and time point description  | Intent to treat 10 Dec 2014                                                          | Intent to treat 10 Dec 2014                                                          | Intent to treat 10 Dec 2014                                                          |
| Descriptive statistics and estimate variability | Treatment group                                                                      | Lenvatinib 18 mg Everolimus 5 mg Combination                                         | Everolimus 10 mg                                                                     |
| Descriptive statistics and estimate variability | Number of subjects                                                                   | 51                                                                                   | 50                                                                                   |
| Descriptive statistics and estimate variability | Number of deaths (%)                                                                 | 24 (47.1)                                                                            | 33 (66.0)                                                                            |
| Descriptive statistics and estimate variability | OS (months) median                                                                   | 25.5                                                                                 | 15.4                                                                                 |
| Descriptive statistics and estimate variability | 95% CI                                                                               | (16.4,NE)                                                                            | (11.8,19.6)                                                                          |
| Effect estimate per comparison                  | Secondary endpoint OS                                                                | Comparison groups                                                                    | Combination vs. Everolimus                                                           |
| Effect estimate per comparison                  |                                                                                      | HR 0.51                                                                              | HR 0.51                                                                              |
| Effect estimate per comparison                  |                                                                                      | 95% CI (0.30,0.88)                                                                   | 95% CI (0.30,0.88)                                                                   |
| Effect estimate per comparison                  |                                                                                      | Comparison groups Lenvatinib vs. Everolimus                                          | Comparison groups Lenvatinib vs. Everolimus                                          |
| Effect estimate per comparison                  |                                                                                      | HR 0.68                                                                              | HR 0.68                                                                              |
| Effect estimate per comparison                  |                                                                                      | 95% C (0.41,1.14)                                                                    | 95% C (0.41,1.14)                                                                    |
| Effect estimate per comparison                  |                                                                                      | P-value 0.1181                                                                       | P-value 0.1181                                                                       |
| Effect estimate per comparison                  |                                                                                      | Comparison groups Combination vs. Lenvatinib                                         | Comparison groups Combination vs. Lenvatinib                                         |
| Effect estimate per comparison                  |                                                                                      | HR 0.75                                                                              | HR 0.75                                                                              |
| Effect estimate per comparison                  |                                                                                      |                                                                                      |                                                                                      |
| Effect estimate per comparison                  |                                                                                      |                                                                                      |                                                                                      |

<div style=\"page-break-after: always\"></div>

|                                                 |                                        | 95% C                                        | 95% C                                  | (0.43,1.30)                            |
|-------------------------------------------------|----------------------------------------|----------------------------------------------|----------------------------------------|----------------------------------------|
|                                                 |                                        | P-value                                      | P-value                                | 0.3157                                 |
| Analysis description                            | Updated analysis for OS: Second Update | Updated analysis for OS: Second Update       | Updated analysis for OS: Second Update | Updated analysis for OS: Second Update |
| Analysis population and time point description  | Intent to treat 31 Jul 2015            | Intent to treat 31 Jul 2015                  | Intent to treat 31 Jul 2015            | Intent to treat 31 Jul 2015            |
| Descriptive statistics and estimate variability | Treatment group                        | Lenvatinib 18 mg Everolimus 5 mg Combination | Lenvatinib 24 mg                       | Everolimus 10 mg                       |
| Descriptive statistics and estimate variability | Number of subjects                     | 51                                           | 52                                     | 50                                     |
| Descriptive statistics and estimate variability | Number of deaths (%)                   | 32 (62.7)                                    | 34 (65.4)                              | 37 (74.0)                              |
| Descriptive statistics and estimate variability | OS (months) median                     | 25.5                                         | 19.1                                   | 15.4                                   |
| Descriptive statistics and estimate variability | 95% CI                                 | (16.4,32.1)                                  | (13.6,26.2)                            | (11.8,20.6)                            |
| Effect estimate per comparison                  | Secondary endpoint OS                  | Comparison groups                            | Comparison groups                      | Combination vs. Everolimus             |
| Effect estimate per comparison                  | Secondary endpoint OS                  | HR                                           | HR                                     | 0.59                                   |
| Effect estimate per comparison                  | Secondary endpoint OS                  | 95% CI                                       | 95% CI                                 | (0.36,0.96)                            |
| Effect estimate per comparison                  | Secondary endpoint OS                  | P-value                                      | P-value                                | 0.0647                                 |
| Effect estimate per comparison                  | Secondary endpoint OS                  | Comparison groups                            | Comparison groups                      | Lenvatinib vs. Everolimus              |
| Effect estimate per comparison                  | Secondary endpoint OS                  | HR                                           | HR                                     | 0.75                                   |
| Effect estimate per comparison                  | Secondary endpoint OS                  | 95% C                                        | 95% C                                  | (0.47,1.20)                            |
| Effect estimate per comparison                  | Secondary endpoint OS                  | P-value                                      | P-value                                | 0.1299                                 |
| Effect estimate per comparison                  | Secondary endpoint OS                  | Comparison groups                            | Comparison groups                      | Combination vs. Lenvatinib             |
| Effect estimate per comparison                  | Secondary endpoint OS                  | HR                                           | HR                                     | 0.79                                   |
| Effect estimate per comparison                  | Secondary endpoint OS                  | 95% C                                        | 95% C                                  | (0.48,1.30)                            |
| Effect estimate per comparison                  | Secondary endpoint OS                  | P-value                                      | P-value                                | 0.3092                                 |

## 2.5.3. Discussion on clinical efficacy

The rationale for clinical evaluation of intended combination of multiple kinase inhibitor lenvatinib and mTOR inhibitor everolimus was based on biological rationale, the preliminary clinical experience with lenvatinib in metastatic  RCC,  established  efficacy  of  everolimus  in  2 nd line  treatment  after  VEGF-targeted  therapy  and expectation that combination therapy provides significant advantage over single-agent therapy.

## Design and conduct of clinical studies

The  pivotal  study  supporting  the  proposed  indication  is  a  Phase  1b/2  exploratory  study  E7080-G000-205. This  is  currently  the  only  study  conducted/ongoing  in  the  proposed  patient  population,  which  includes

<div style=\"page-break-after: always\"></div>

patients with metastatic or unresectable renal cell carcinoma after receiving at least 1 prior VEGF targeted therapy.  This  study  was  initially  designed  to  determine  whether  lenvatinib  and  its  combination  with everolimus are worthy of further investigation.

However, the impressive efficacy results of the study in terms of magnitude of PFS improvement, high ORR rates and associated trend to OS benefit in combination arm led to study re-consideration by the Applicant for a MAA purpose. The proposed treatment is the combination of lenvatinib with everolimus.

The Phase 1 part of Study 205 aimed to investigate different doses of both drugs within combination using a classical  designed  '3+3'  dose-escalation  stage  to  determine  the  DLTs  and  MTD  followed  by  a  cohort expansion  stage  to  confirm  the  MTD  and  to  establish  the  RP2  dose  for  lenvatinib  in  combination  with everolimus. Efficacy was an exploratory objective (BOR investigator-assessed using RECIST1.1).

The recommended dose/schedule of everolimus (10 mg once daily at continuous dosing; available as 2.5 mg, 5 mg and 10 mg tablets) is based on the dose-molecular marker responses (PD) in a Phase I trial in patients with advanced solid cancers (please refer to EPAR for Afinitor).

The MTD of single-agent lenvatinib (available as 4 mg and 10 mg hard capsules) using continuous dosing schedule was determined to be 25 mg QD in phase 1 program in advanced solid tumours and the dose 24 mg was further used for practical reasons. Importantly, concerns have been raised in regard to the starting dose of  24  mg  daily  (please  refer  to  EPAR  for  Lenvima  approved  in  orphan  RR-DTC  indication  in  2015).  Postapproval Study 211 aims to determine whether a starting dose of lenvatinib 20 mg or 14 mg QD will provide comparable efficacy (based on ORR at 6 months) with an improved safety profile to 24 mg QD (based on TEAE Grade 3 or higher in the first 6 months after randomization).

The principles of the CHMP guidance available at the time of the design of the Study 205 (initiated in 2010) have been employed for DLT/MTD/RP2D determination. The dose for initiating dose escalation in combination therapy was half of the full dose for each single-agent (12 mg lenvatinib QD and 5 mg everolimus QD). The Applicant gave priority to lenvatinib for dose escalation based on preliminary evidence of lenvatinib activity in 9 RCC patients. Due to the occurrence of DLTs in the first two subjects enrolled in the Cohort 3 (lenvatinib 24 mg + everolimus 5 mg), the Cohort 4 with a full dose of everolimus 10 mg in combination with lenvatinib 24 mg was not tested.  Therefore, full recommended dose of everolimus in RCC indication was not achieved. Alternative dosing schedules were not tested. The dose-finding principles for non-cytotoxic compounds are evolving, with consideration given to how the concepts of MTD and DLT are pre-defined, in order to capture relevant toxicities and arrive at a useful RP2D (EMA/CHMP/205/95 Rev.5).

## Efficacy data and additional analyses

In patients with advanced RCC and disease progression following 1 prior VEGF-targeted treatment, the combination of lenvatinib 18 mg with everolimus 5 mg demonstrated statistically significant (p=0.0005) improvement in PFS compared with treatment with everolimus alone (median 14.6 months vs 5.5 months, respectively). The improvement in PFS of 9.1 months is considered clinically significant. The combination's improvement in PFS over everolimus was noted for all subgroups analysed (HRs range from 0.14 to 0.61).

The combination arm showed a statistically significant (P&lt;0.0001) improvement in ORR (43.1%) compared with both single agent arms (26.9% for the lenvatinib arm, and 6.0% for the everolimus arm).

<div style=\"page-break-after: always\"></div>

The combination arm showed a trend towards prolonged survival (HR = 0.55) compared with the everolimus arm that reached statistical significance (P=0.0242) in the updated OS analysis based on a 10 Dec 2014 data cut-off (HR = 0.51). Median survival was 25.5 months for the combination arm and 15.4 months for the everolimus arm.

These  results  support  an  efficacy  claim  for  the  proposed  combination  of  lenvatinib  and  everolimus  in  the proposed indication.

The pre-planned and post hoc sensitivity analyses and the sub-group analyses produced results consistent with  and  supportive  of  the  primary  analyses  results  for  the  primary  endpoints.  The  post  hoc  blinded independent  review  showed  improvements  in  PFS  and  ORR  with  the  combination  over  everolimus  alone. Though  these  differences  were  lesser  than  that  calculated  in  the  primary  analysis,  the  results  are  still statistically and clinically significant.

## 2.5.4. Conclusions on the clinical efficacy

The  efficacy  of  the  combination  of  lenvatinib  with  everolimus  has  been  shown.  Lenvatinib/everolimus combination therapy demonstrated improved PFS compared to everolimus monotherapy with a median PFS of 14.6 months vs. 5.5 months. The HR was 0.40 (95% CI: 0.24, 0.68, p=0.0005). An independent imaging review (IIR) was conducted and the results obtained, for PFS and ORR, corroborated the improvements seen in the investigator analyses with a median PFS of 12.8 months vs. 5.6 months with everolimus alone (HR= 0.45, 95% CI= 0.26,0.79, p=0.003). Additional sensitivity analyses performed confirmed the robustness of observed PFS.

Furthermore,  encouraging  signs  of  a  prolonged  OS  were  seen  in  patients  treated  with  the  combination  of lenvatinib  and  everolimus  combination  therapy  as  per  the  primary  analysis  as  well  as  the  two  updated analyses that span a more than 1-year period. A similar trend towards prolonged OS was also observed in favour of lenvatinib monotherapy but less obvious than with combination therapy.

## 2.6. Clinical safety

The main source of safety data in support of lenvatinib-everolimus combination therapy in RCC patients is Study 205 conducted in 173 patients, of which 62 patients received treatment at the intended doses/schedule of lenvatinib 18 mg plus everolimus 5 mg administered orally once daily (QD) and additional 9 patients received different doses of lenvatinib in the dose-finding part of Study 205 (12 mg - 7 patients; 24 mg - 2 patients).

In  the  Phase  1b  part  of  Study  205,  lenvatinib 18 mg QD plus everolimus 5 mg QD, was identified as the maximum tolerated dose (MTD) and the recommended Phase 2 (RP2) dose for the subsequent Phase 2 part of the study.

In the Phase 2 part of Study 205, the lenvatinib + everolimus combination was compared with single-agent lenvatinib at the starting  dose of 24 mg QD (dose approved for the treatment of differentiated thyroid cancer [DTC]) and single-agent everolimus 10 mg QD (dose approved for the second-line treatment of advanced RCC).

The safety analysis groups within the RCC Safety Set from Study 205 are as follows:

<div style=\"page-break-after: always\"></div>

- RCC Phases 1b+2 combination group (N=62), hereafter referred to as the RCC combination group includes  all  subjects  who  received  at  least  1  dose  of  combination  study  drug  (lenvatinib  18  mg  QD  + everolimus 5 mg QD) in either the Phase 1b (n=11) or the Phase 2 portion of Study 205 (n=51, arm A).
- RCC  lenvatinib  group  (N=52,  arm  B):  all  subjects  who  received  at  least  1  dose  of  single-agent lenvatinib 24 mg QD in the Phase 2 portion of Study 205.
- RCC  everolimus  group  (N=50,  arm  C):  all  subjects  who  received  at  least  1  dose  of  single-agent everolimus 10 mg QD in the Phase 2 portion of Study 205.

Safety data for all treatment arms in Study 205 were presented in the CSR through the data cutoff date for the primary efficacy endpoint analysis of 13 Jun 2014. The safety data from Study 205 was updated with cutoff date 31 Jul 2015 to allow for the inclusion of additional safety data for the RCC Safety Set.

The clinical program for lenvatinib, which is not approved as monotherapy in the RCC indication, includes 33 clinical  studies  with  approximately  2150  subjects  with  different  cancer  types  and  292  healthy  volunteer enrolled with cutoff date 31 Jul 2015 and treated with lenvatinib either as monotherapy or as combination therapy.

The  comparisons  of  lenvatinib  safety  data  were  done  with  the  pooled  safety  data  from  the  monotherapy studies  of  lenvatinib  for  progressive  radioiodine-refractory  DTC  (RR-DTC),  with  additional  supportive comparisons with the Non-DTC Safety Set:

- All DTC Lenvatinib Monotherapy Safety Set (N=458): includes all lenvatinib-treated subjects from Studies E7080-G000-201 (DTC subjects only), E7080-J081-208 (DTC subjects only), and E7080-G000-303 (both the randomized and the optional open-label portions of the study) as of the 10 Dec 2014 data cutoff date.
- Non-DTC Monotherapy Safety Set (N=656): includes all subjects who received single-agent lenvatinib in studies conducted in subjects with cancer as of the 15 Sep 2013 data cutoff date. Because of the small number of subjects (n=26/656, ≈ 4%) ongoing as of this cutoff date, the Applicant did not provide an update from these 26 subjects.

## Patient exposure

As of the 31 Jul 2015 cut-off date for the RCC Safety Set, a total of 46 subjects (28.0%) were still ongoing in Study 205  (4 receiving  treatment  and  42 in  follow-up),  112 subjects  (68.3%)  had  died,  and  6 subjects (3.7%) had withdrawn from the study.

The  subject  disposition  status  and  primary  reasons  for  discontinuation  are  summarized  for  the  RCC,  the All DTC, and the Non-DTC Safety Sets in table 380 below.

Table 37: Subject Disposition and Reasons for Discontinuation - RCC, All DTC, and Non DTC Safety Sets

|                      | Renal Cell Carcinoma                                        | Renal Cell Carcinoma          | Renal Cell Carcinoma          | All DTC                  | Non-DTC                  |
|----------------------|-------------------------------------------------------------|-------------------------------|-------------------------------|--------------------------|--------------------------|
|                      | Lenvatinib 18 mg + Everolimus 5 mg Phases 1b+2 (N=62) n (%) | Lenvatinib 24 mg (N=52) n (%) | Everolimus 10 mg (N=50) n (%) | Lenvatinib (N=458) n (%) | Lenvatinib (N=656) n (%) |
| All Treated Subjects | 62 (100.0)                                                  | 52 (100.0)                    | 50 (100.0)                    | 458 (100.0)              | 656 (100)                |
| Treatment Ongoing a  | 2 (3.2)                                                     | 1 (1.9)                       | 1 (2.0)                       | 161 (35.2)               | 26 (4.0)                 |

<div style=\"page-break-after: always\"></div>

| Completed Treatment - Disease Progression b               | 34 (54.8)                                                 | 31 (59.6)                                                 | 37 (74.0)                                                 | 188 (41.0)                                                | 392 (59.8)                                                |
|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------------|
| Discontinued Prematurely                                  | 26 (41.9)                                                 | 20 (38.5)                                                 | 12 (24.0)                                                 | 109 (23.8)                                                | 238 (36.3)                                                |
| Primary Reason for Premature Discontinuation of Treatment | Primary Reason for Premature Discontinuation of Treatment | Primary Reason for Premature Discontinuation of Treatment | Primary Reason for Premature Discontinuation of Treatment | Primary Reason for Premature Discontinuation of Treatment | Primary Reason for Premature Discontinuation of Treatment |
| Adverse event                                             | 14 (22.6)                                                 | 13 (25.0)                                                 | 5 (10.0)                                                  | 81 (17.7)                                                 | 149 (22.7)                                                |
| Subject choice c                                          | 3 (4.8)                                                   | 0                                                         | 1 (2.0)                                                   | 11 (2.4)                                                  | 0                                                         |
| Lost to follow-up                                         | 0                                                         | 0                                                         | 0                                                         | 1 (0.2)                                                   | 2 (0.3)                                                   |
| Administrative/Other                                      | Administrative/Other                                      | Administrative/Other                                      | Administrative/Other                                      | Administrative/Other                                      | Administrative/Other                                      |
| Withdrawal of consent d                                   | 2 (3.2)                                                   | 0                                                         | 0                                                         | 7 (1.5)                                                   | 12 (1.8)                                                  |
| Pregnancy                                                 | 0                                                         | 0                                                         | 0                                                         | 0                                                         | 0                                                         |
| Study terminated by sponsor                               | 0                                                         | 0                                                         | 0                                                         | 0                                                         | 0                                                         |
| Other e                                                   | 7 (11.3)                                                  | 7 (13.5)                                                  | 6 (12.0)                                                  | 9 (2.0)                                                   | 75 (11.4)                                                 |

The safety data cut-off date was 31 Jul 2015 for the RCC Safety Set, 10 Dec 2014 for the All DTC Safety Set, and 15 Sep 2013 for the Non-DTC Safety Set.

CRF = case report form, DTC = differentiated thyroid cancer; RCC = renal cell carcinoma.

a:  Ongoing at safety data cut-off date.

b:  Disease progression was considered as completion of study treatment, as defined per protocol.

c:  Subject choice indicates that the subject elected to stop treatment with the investigational drug, but agreed to further data collection, including follow-up data.

d:  Withdrawal of consent indicates that the subject did not agree to allow collection of any additional data.

e:  'Other' was a category on the CRF.  For Study 205, this includes palliative therapy and withdrawal due to poor compliance; for the All DTC and the Non-DTC Safety Sets, no further information is available.

The overall exposure to lenvatinib by mean daily dose and duration of exposure, as of the 31 Jul 2015 safety data cut-off date for Study 205, is presented in the table 39 below.

Table 38: Summary of Study Drug Exposure for Lenvatinib - RCC, All DTC, and Non-DTC Safety Sets

| Parameter Statistic                        | Renal Cell Carcinoma                                  | Renal Cell Carcinoma                       | All DTC a                                  | Non-DTC b                                  |
|--------------------------------------------|-------------------------------------------------------|--------------------------------------------|--------------------------------------------|--------------------------------------------|
| Parameter Statistic                        | Lenvatinib 18 mg + Everolimus 5 mg Phases 1b+2 (N=62) | Lenvatinib 24 mg (N=52)                    | Lenvatinib (N=458)                         | Lenvatinib (N=656)                         |
| Number of Cycles Received, n               | Number of Cycles Received, n                          | Number of Cycles Received, n               | Number of Cycles Received, n               | Number of Cycles Received, n               |
| Mean (SD)                                  | 12.1 (9.57)                                           | 10.2 (7.72)                                | 17.8 (12.47)                               | 7.0 (8.98)                                 |
| Median                                     | 9.5                                                   | 8.5                                        | 16.0                                       | 4.0                                        |
| Q1, Q3                                     | 4.0, 18.0                                             | 4.0, 14.5                                  | 7.0, 29.0                                  | 2.0, 8.0                                   |
| Min, Max                                   | 1, 36                                                 | 1, 32                                      | 1.0, 66.0                                  | 1, 98                                      |
| Cumulative Dose of Lenvatinib, mg          | Cumulative Dose of Lenvatinib, mg                     | Cumulative Dose of Lenvatinib, mg          | Cumulative Dose of Lenvatinib, mg          | Cumulative Dose of Lenvatinib, mg          |
| Mean (SD)                                  | 4142 (3787.9)                                         | 4625 (3606.5)                              | 7402.5 (5781.24)                           | 3143.7 (4005.04)                           |
| Median                                     | 2731                                                  | 3898                                       | 6114.0                                     | 1784.0                                     |
| Q1, Q3                                     | 954.0, 6376                                           | 1886, 6291                                 | 2702.0, 11366.0                            | 816.0, 3932.0                              |
| Min, Max                                   | 252, 15462                                            | 96, 17032                                  | 60.0, 28224.0                              | 1.6, 32245.5                               |
| Lenvatinib Average Daily Dose, e mg/day    | Lenvatinib Average Daily Dose, e mg/day               | Lenvatinib Average Daily Dose, e mg/day    | Lenvatinib Average Daily Dose, e mg/day    | Lenvatinib Average Daily Dose, e mg/day    |
| Mean (SD)                                  | 13.2 (3.71)                                           | 18.9 (5.02)                                | 16.6 (5.24)                                | 18.8 (6.00)                                |
| Median                                     | 13.5                                                  | 20.3                                       | 16.1                                       | 20.5                                       |
| Q1, Q3                                     | 10.6, 16.9                                            | 15.1, 23.9                                 | 12.7, 21.0                                 | 15.2, 24.0                                 |
| Min, Max                                   | 6, 18                                                 | 7, 24                                      | 4.4, 25.5                                  | 0.2, 32.0                                  |
| Percentage of Intended Lenvatinib Dose, f% | Percentage of Intended Lenvatinib Dose, f%            | Percentage of Intended Lenvatinib Dose, f% | Percentage of Intended Lenvatinib Dose, f% | Percentage of Intended Lenvatinib Dose, f% |
| Mean (SD)                                  | 73.5 (20.62)                                          | 78.7 (20.91)                               | 69.9 (22.09)                               | 84.5 (18.82)                               |
| Median                                     | 75.0                                                  | 84.5                                       | 68.1                                       | 92.3                                       |
| Q1, Q3                                     | 58.9, 93.8                                            | 62.9, 99.5                                 | 53.3, 90.0                                 | 73.7, 100.0                                |
| Min, Max                                   | 31, 100                                               | 28, 100                                    | 22.3, 106.2                                | 2.8, 100.0                                 |

<div style=\"page-break-after: always\"></div>

The safety data cut-off date was 31 Jul 2015 for the RCC Safety Set, 10 Dec 2014 for the All DTC Safety Set, and 15 Sep 2013 for the Non-DTC Safety Set.

AE = adverse event, DTC = differentiated thyroid cancer, Max = maximum, Min = minimum, NAv = not available, Q1 = 1st quartile, Q3 = 3rd quartile, QD = once a day, RCC = renal cell carcinoma, SD = standard deviation, SY = subject-years, TEAE = treatment-emergent adverse event.

a:  The lenvatinib starting dose was 24 mg QD except for 32 subjects who had a starting dose of 20 mg QD.

b:  The lenvatinib starting dose was 24 mg QD for 508 subjects; it was &lt;14 mg QD for 93 subjects, 14 - &lt;20 mg QD for 12 subjects, 20 - &lt;24 mg QD for 12 subjects, and &gt;24 mg QD for 3 subjects.

c:  Duration of treatment (in months) is defined as (Last dose date - First dose date + 1)×12/365.25, and includes dose interruptions.

d:  SY of treatment = sum of duration of treatment (in years) for all subjects in each category.  These values are used for treatment adjustment of TEAEs to calculate the AE Rate of episodes/SY.

e:  Mean Daily Dose (mg/day) = Total cumulative dose (mg) / (last dose date - 1st dose date + 1).

f:  Percentage of Intended Dose = Mean daily dose / planned starting dose.

Duration of treatment was defined as the number of days the subject received treatment, including dose interruptions.

Table 39: Duration of treatment, months - RCC, All DTC, and Non DTC Safety Sets

|                                 | Renal Cell Carcinoma                                        | Renal Cell Carcinoma          | Renal Cell Carcinoma          | All DTC a                | Non-DTC b                |
|---------------------------------|-------------------------------------------------------------|-------------------------------|-------------------------------|--------------------------|--------------------------|
|                                 | Lenvatinib 18 mg + Everolimus 5 mg Phases 1b+2 (N=62) n (%) | Lenvatinib 24 mg (N=52) n (%) | Everolimus 10 mg (N=50) n (%) | Lenvatinib (N=458) n (%) | Lenvatinib (N=656) n (%) |
| Duration of Treatment, c months |                                                             |                               |                               |                          |                          |
| 0 - <6 months, n (%)            | 29 (46.8)                                                   | 22 (42.3)                     | 32 (64.0)                     | 142 (31)                 | 479 (73.0)               |
| ≥6 months, n (%)                | 33 (53.2)                                                   | 30 (57.7)                     | 18 (36.0)                     | 316 (69)                 | 177 (27.0)               |
| Mean (SD)                       | 10.7 (8.81)                                                 | 8.9 (7.21)                    | 6.7 (6.81)                    | 15.9 (11.46)             | 6.1 (8.25)               |
| Median                          | 8.0                                                         | 7.4                           | 4.1                           | 14.7                     | 3.5                      |
| Q1, Q3                          | 3.7, 16.6                                                   | 3.2, 13.0                     | 1.9, 10.0                     | 5.7, 26.6                | 1.6, 7.4                 |
| Min, Max                        | 0.5, 33.0                                                   | 0.1, 29.4                     | 0.3, 33.6                     | 0.1, 60.7                | 0.0, 89.6                |
| SY of Treatment d               | 55.2                                                        | 38.8                          | 27.7                          | 608.1                    | 331.1                    |

The safety data cut-off date was 31 Jul 2015 for the RCC Safety Set, 10 Dec 2014 for the All DTC Safety Set, and 15 Sep 2013 for the Non-DTC Safety Set.

AE = adverse event, DTC = differentiated thyroid cancer, Max = maximum, Min = minimum, NAv = not available, Q1 = 1st quartile, Q3 = 3rd quartile, QD = once a day, RCC = renal cell carcinoma, SD = standard deviation, SY = subject-years, TEAE = treatment-emergent adverse event.

a:  The lenvatinib starting dose was 24 mg QD except for 32 subjects who had a starting dose of 20 mg QD.

b:  The lenvatinib starting dose was 24 mg QD for 508 subjects; it was &lt;14 mg QD for 93 subjects, 14 - &lt;20 mg QD for 12 subjects, 20 - &lt;24 mg QD for 12 subjects, and &gt;24 mg QD for 3 subjects.

c:  Duration of treatment (in months) is defined as (Last dose date - First dose date + 1)×12/365.25, and includes dose interruptions.

d:  SY of treatment = sum of duration of treatment (in years) for all subjects in each category.  These values are used for treatment adjustment of TEAEs to calculate the AE Rate of episodes/SY

## Duration of exposure

Duration of exposure was defined as the number of days the subject received treatment, excluding dose interruptions.

Table 40: Patient exposure to lenvatinib by duration of exposure

|                        | Renal Cell Carcinoma                                   | Renal Cell Carcinoma                                   | Renal Cell Carcinoma                             | Renal Cell Carcinoma                             | Renal Cell Carcinoma   | Renal Cell Carcinoma   | All DTC            | All DTC            |
|------------------------|--------------------------------------------------------|--------------------------------------------------------|--------------------------------------------------|--------------------------------------------------|------------------------|------------------------|--------------------|--------------------|
|                        | Lenvatinib 18 mg + Everolimus 5 mg Phases Ib+II (N=62) | Lenvatinib 18 mg + Everolimus 5 mg Phases Ib+II (N=62) | Lenvatinib 18mg + Everolimus 5mg Phase II (N=51) | Lenvatinib 18mg + Everolimus 5mg Phase II (N=51) | Lenvatinib 24mg (N=52) | Lenvatinib 24mg (N=52) | Lenvatinib (N=656) | Lenvatinib (N=656) |
| Duration of Exposure   | n (%)                                                  | Subj- year                                             | n (%)                                            | Subj- year                                       | n (%)                  | Subj- year             | n (%)              | Subject- year      |
| 1 day to < 1 week      | 0                                                      | 0                                                      | 0                                                | 0                                                | 1 (1.9)                | 0                      | 3 (0.7)            | 0                  |
| 1 week to < 3 months   | 17(27.4)                                               | 2.1                                                    | 14 (27.5)                                        | 1.7                                              | 12(23.1)               | 1.4                    | 81(17.7)           | 10.3               |
| 3 months to < 6 months | 15(24.2)                                               | 5.3                                                    | 13 (25.5)                                        | 4.7                                              | 10(19.2)               | 3.7                    | 58(12.7)           | 21.8               |
| 6 months to < 1 year   | 8(12.9)                                                | 6.6                                                    | 5 (9.8)                                          | 3.9                                              | 15(28.8)               | 10.1                   | 84(18.3)           | 61.6               |
| 1 year to < 2 years    | 17(27.4)                                               | 24.3                                                   | 15 (29.4)                                        | 21.7                                             | 12(23.1)               | 16.2                   | 120(26.2)          | 182.2              |
| >= 2 years             | 5(8.1)                                                 | 12.0                                                   | 4 (7.8)                                          | 9.7                                              | 2(3.8)                 | 4.3                    | 112(24.5)          | 273.0              |
| Total                  | 62 (100.)                                              | 50.2                                                   | 51 (100.)                                        | 41.8                                             | 52 (100.)              | 35.8                   | 81(17.7)           | 10.3               |

<div style=\"page-break-after: always\"></div>

Table 41: Patient exposure to everolimus by duration of exposure

|                       | Lenvatinib 18 mg + Everolimus 5 mg Phases 1b + 2 (N=62) a   | Lenvatinib 18 mg + Everolimus 5 mg Phases 1b + 2 (N=62) a   | Lenvatinib 18 mg + Everolimus 5 mg Phase 2 (N=51)   | Lenvatinib 18 mg + Everolimus 5 mg Phase 2 (N=51)   | Everolimus 10 mg (N=50)   | Everolimus 10 mg (N=50)   |
|-----------------------|-------------------------------------------------------------|-------------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|---------------------------|---------------------------|
| Duration of Exposure  | n (%)                                                       | Subject- year                                               | n (%)                                               | Subject- year                                       | n (%)                     | Subject- year             |
| 1 week to <3 months   | 16 (25.8)                                                   | 1.9                                                         | 13 (25.5)                                           | 1.5                                                 | 19 (38.0)                 | 2.4                       |
| 3 months to <6 months | 15 (24.2)                                                   | 5.2                                                         | 13 (25.5)                                           | 4.7                                                 | 14 (28.0)                 | 5.1                       |
| 6 months to <1 year   | 9 (14.5)                                                    | 7.1                                                         | 6 (11.8)                                            | 4.5                                                 | 9 (18.0)                  | 7.0                       |
| 1 year to <2 years    | 17 (27.4)                                                   | 24.3                                                        | 15 (29.4)                                           | 21.7                                                | 6 (12.0)                  | 6.8                       |
| ≥2 years              | 5 (8.1)                                                     | 12.0                                                        | 4 (7.8)                                             | 9.7                                                 | 2 (4.0)                   | 5.1                       |
| Total                 | 62 (100.0)                                                  | 50.4                                                        | 51 (100.0)                                          | 42.1                                                | 50 (100.0)                | 26.4                      |

## Adverse events

The overall TEAE profile in all safety data sets is summarized below.

Table 42: Overview of Treatment-Emergent Adverse Events - RCC, All DTC, and Non DTC Safety Sets

|                                                                                | Renal Cell Carcinoma                                        | Renal Cell Carcinoma          | Renal Cell Carcinoma          | All DTC                  | Non-DTC                  |
|--------------------------------------------------------------------------------|-------------------------------------------------------------|-------------------------------|-------------------------------|--------------------------|--------------------------|
|                                                                                | Lenvatinib 18 mg + Everolimus 5 mg Phases 1b+2 (N=62) n (%) | Lenvatinib 24 mg (N=52) n (%) | Everolimus 10 mg (N=50) n (%) | Lenvatinib (N=458) n (%) | Lenvatinib (N=656) n (%) |
| TEAEs [a]                                                                      | 62 (100.0)                                                  | 52 (100.0)                    | 50 (100.0)                    | 457 (99.8)               | 647 (98.6)               |
| Treatment-related TEAEs [b]                                                    | 62 (100.0)                                                  | 51 ( 98.1)                    | 49 ( 98.0)                    | 4446 (97.4)              | 610 (93)                 |
| TEAEs with CTCAE Grade >=3                                                     | 49 ( 79.0)                                                  | 46 ( 88.5)                    | 27 ( 54.0)                    | 397 (56.7)               | 472 (72.0)               |
| Treatment-related TEAEs with CTCAE Grade >=3                                   | 43 ( 69.4)                                                  | 35 ( 67.3)                    | 21 ( 42.0)                    | 344 (75.1)               | 360 (54.9)               |
| Serious TEAEs [c]                                                              | 38 ( 61.3)                                                  | 28 ( 53.8)                    | 21 ( 42.0)                    | 263 (57.4)               | 314 (47.9)               |
| Deaths                                                                         | 1 ( 1.6)                                                    | 1 ( 2.0)                      | 3 ( 5.8)                      | 34 (7.4)                 | 54 (8.2)                 |
| Other SAEs                                                                     | 37 ( 59.7)                                                  | 29 ( 56.9)                    | 27 ( 51.9)                    | 257 (56.1)               | 331 (50.5)               |
| Life threatening                                                               | 2 ( 3.2)                                                    | 2 ( 3.9)                      | 2 ( 3.8)                      | 25 (5.5)                 | 22 (3.4.8)               |
| Requires inpatient hospitalization or prolongation of existing hospitalization | 36 ( 58.1)                                                  | 28 ( 54.9)                    | 25 ( 48.1)                    | 240 (52.4)               | 322 (49.1)               |
| Persistent or significant disability or incapacity                             | 0                                                           | 0                             | 0                             | 0                        | 0                        |
| Congenital anomaly / birth defect                                              | 0                                                           | 0                             | 0                             | 188 (41.0)               | 392 (59.8)               |
| Important medical events                                                       | 5 ( 8.1)                                                    | 3 ( 5.9)                      | 5 ( 9.6)                      | 35 (7.6)                 | 31 (4.7)                 |
| TEAEs leading to study drug dose adjustment [d]                                | 58 ( 93.5)                                                  | 47 ( 90.4)                    | 30 ( 60.0)                    | 427 (93.2)               | 477 (72.7)               |
| TEAEs leading to study drug withdrawal                                         | 18 ( 29.0)                                                  | 16 ( 30.8)                    | 6 ( 12.0)                     | 96 (21.0)                | 168 (25.6)               |
| TEAEs leading to study drug dose reduction                                     | 42 ( 67.7)                                                  | 30 ( 57.7)                    | 8 ( 16.0)                     | 298 (65.1)               | 186 (28.4)               |
| TEAEs leading to study drug interruption                                       | 47 ( 75.8)                                                  | 36 ( 69.2)                    | 25 ( 50.0)                    | 371 (81)                 | 364 (55.5)               |
| TEAEs leading to study drug dose reduction and/or interruption                 | 55 ( 88.7)                                                  | 41 ( 78.8)                    | 27 ( 54.0)                    | 403 (88.0)               |                          |

<div style=\"page-break-after: always\"></div>

The overall TEAE profile in in Phase 1b part of the Study 205 is summarized below.

Table 43: Overview of Treatment-Emergent Adverse Events - Safety Analysis Set -Phase 1b part of Study 205

|                                                                                | Lenvatinib 12 mg + everolimus 5 mg (N=7) n (%)   | Lenvatinib 18 mg + everolimus 5 mg (N=11) n (%)   | Lenvatinib 24 mg + everolimus (N=2) n (%)   |
|--------------------------------------------------------------------------------|--------------------------------------------------|---------------------------------------------------|---------------------------------------------|
| TEAEs                                                                          | 7 (100.0)                                        | 11 (100.0)                                        | 2 (100.0)                                   |
| TEAEs with CTCAE Grade >=3                                                     | 7 (100.0)                                        | 10 (90.9)                                         | 1 (50.0)                                    |
| Serious TEAEs                                                                  | 6 (85.7)                                         | 8 (72.7)                                          | 0                                           |
| Deaths [a]                                                                     | 1[a]                                             | 1[a]                                              | 2[a]                                        |
| Other SAEs [b]                                                                 | 6 (85.7)                                         | 8 (72.7)                                          | 0                                           |
| Requires inpatient hospitalization or prolongation of existing hospitalization | 5 (71.4)                                         | 8 (72.7)                                          | 0                                           |
| Important medical events                                                       | 1 (14.3)                                         | 2 (18.2)                                          | 0                                           |
|                                                                                | Lenvatinib 12 mg + everolimus 5 mg (N=7)         | Lenvatinib 18 mg + everolimus 5 mg (N=11)         | Lenvatinib 24 mg + everolimus (N=2)         |
| TEAEs leading to study drug dose adjustment [c]                                | 5 (71.4)                                         | 11 (100.0)                                        | 1 (50.0)                                    |
| TEAEs leading to study drug withdrawal                                         | 0                                                | 168 (25.6)                                        | 168 (25.6)                                  |
| TEAEs leading to study drug dose reduction                                     | 2 (28.6)                                         | 7 (63.6)                                          | 1 (50.0)                                    |
| TEAEs leading to study drug interruption                                       | 5 (71.4)                                         | 9 (81.8)                                          | 0                                           |

Percentages are based on the total number of subjects in the relevant treatment arm. Data cutoff date 13 Jun 2014. For each row category, a subject with 2 or more TEAEs in that category is counted only once.

a: Two subjects (10011005 and 70011001) died within 30 days of the last dose of study medication due to their underlying cancer (progressive disease), however, the investigator did not report the death as an adverse event. Therefore, these subjects are not included in the overall incidence of SAEs.

b: Subjects may have had more than 1 SAE or an SAE that met more than 1 criterion.

c: Study treatment adjustment includes study treatment withdrawal, dose reduction, and/or interruption.

## Common adverse events

In the RCC combination group  the most frequently reported TEAEs (any grade), occurring in at least 30% of subjects, were diarrhoea (80. 6%), fatigue (59.7%), decreased appetite (53.7%), vomiting (48.4%), nausea (45.2%), hypertension (40.3%), hypertriglyceridemia (40.3%), cough (37.1%), stomatitis (35.5%), peripheral  oedema  (33.9%),  decreased  weight  (33.9%),  dyspnea  (30.6%),  and  hypercholesterolemia (30.6%).

The most frequently reported Grade 3 or 4 TEAEs, occurring in at least 5% of subjects in the RCC combination group, were diarrhoea (19.4%), fatigue (12.9%), hypertension (12.9%), hypertriglyceridemia (12.9%), acute renal failure (8.1%), anaemia (8.1%), dehydration (8.1%), proteinuria (8.1%), and vomiting (6.5%).

<div style=\"page-break-after: always\"></div>

In a larger lenvatinib monotherapy safety data set the most commonly reported TEAEs ( ≥ 30% of subjects, any grade) (All DTC safety set), in descending order of frequency, were hypertension, diarrhoea, decreased appetite,  weight  decreased,  fatigue,  nausea,  proteinuria,  stomatitis,  vomiting,  dysphonia,  headache,  and palmar-plantar erythrodysesthesia (PPE) syndrome.

The overall safety profile of everolimus is also well established. The most frequently reported (≥10%) AEs with  everolimus  in  clinical  trials  were  stomatitis,  rash,  fatigue,  diarrhoea,  infections,  nausea,  decreased appetite, anaemia, dysgeusia, pneumonitis, hyperglycaemia, weight decreased, pruritus, asthenia, peripheral oedema, hypercholesterolemia, epistaxis, and headache.

Table 44: Per-Subject Incidence Rate of Treatment-Emergent Adverse Events Occurring in 10% or More of Subjects for Any AE Grade or at Least 5% for AE Grades 3 and 4

|                                                      | Renal Cell Carcinoma                                 | Renal Cell Carcinoma                                 | Renal Cell Carcinoma                                 | Renal Cell Carcinoma                                 | Renal Cell Carcinoma                                 | Renal Cell Carcinoma                                 | All DTC                                              | All DTC                                              | Non-DTC                                              | Non-DTC                                              |
|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|------------------------------------------------------|
| System Organ Class Preferred Term                    | Lenvatinib + Everolimus 18mg + 5mg (N = 62)*         | Lenvatinib + Everolimus 18mg + 5mg (N = 62)*         | Lenvatinib 24 mg (N = 52)                            | Lenvatinib 24 mg (N = 52)                            | Everolimus 10 mg (N= 50)                             | Everolimus 10 mg (N= 50)                             | Lenvatinib (N= 458) n (%)                            | Lenvatinib (N= 458) n (%)                            | Lenvatinib (N-656)                                   | Lenvatinib (N-656)                                   |
| System Organ Class Preferred Term                    | Grade Any                                            | Grade 3/4                                            | Grade Any                                            | Grade 3/4                                            | Grade Any                                            | Grade 3/4                                            | Grade Any                                            | Grade 3/4                                            | Grade Any                                            | Grade 3/4                                            |
| Subjects with Any TEAE                               | 62 (100.)                                            | 48 (77.4)                                            | 52 (100.0)                                           | 46 (88.5)                                            | 50 (100.0)                                           | 27 (54.0)                                            | 457 (99.8)                                           | 394 (86.0)                                           | 647 (98.6)                                           | 462 (70.4)                                           |
| Blood and lymphatic system disorders                 | Blood and lymphatic system disorders                 | Blood and lymphatic system disorders                 | Blood and lymphatic system disorders                 | Blood and lymphatic system disorders                 | Blood and lymphatic system disorders                 | Blood and lymphatic system disorders                 | Blood and lymphatic system disorders                 | Blood and lymphatic system disorders                 | Blood and lymphatic system disorders                 | Blood and lymphatic system disorders                 |
| Anaemia                                              | 11 (17.7)                                            | 5 (8.1)                                              | 4 (7.7)                                              | 1 (1.9)                                              | 13 (26.0)                                            | 6 (12.0)                                             | 37 (8.1)                                             | 7 (1.5)                                              | 50 (7.6)                                             | 15 (2.3)                                             |
| Thrombo- cytopenia                                   | 7 (11.3)                                             | 3 (4.8)                                              | 1 (1.9)                                              | 0                                                    | 4 (8.0)                                              | 0                                                    | 37 (8.1)                                             | 8 (1.7)                                              | 70 (10.7)                                            | 11 (1.7)                                             |
| Endocrine disorders                                  | Endocrine disorders                                  | Endocrine disorders                                  | Endocrine disorders                                  | Endocrine disorders                                  | Endocrine disorders                                  | Endocrine disorders                                  | Endocrine disorders                                  | Endocrine disorders                                  | Endocrine disorders                                  | Endocrine disorders                                  |
| Hypothyroidism                                       | 15 (24.2)                                            | 0                                                    | 19 (36.5)                                            | 1 (1.9)                                              | 1 (2.0)                                              | 0                                                    | 24 (5.2)                                             | 0                                                    | 110 (16.8)                                           | 7 (1.1)                                              |
| Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           | Gastrointestinal disorders                           |
| Abdominal Pain                                       | 15 (24.2)                                            | 2 (3.2)                                              | 12 (23.1)                                            | 2 (3.8)                                              | 1 (2.0)                                              | 0                                                    | 93 (20.3)                                            | 9 (2.0)                                              | 146 (22.3)                                           | 27 (4.1)                                             |
| Abdominal Pain Upper                                 | 9 (14.5)                                             | 1 (1.6)                                              | 7 (13.5)                                             | 0                                                    | 3 (6.0)                                              | 0                                                    | 85 (18.6)                                            | 3 (0.7)                                              | 88 (13.4)                                            | 6 (0.9)                                              |
| Constipation                                         | 10 (16.1)                                            | 0                                                    | 19 (36.5)                                            | 0                                                    | 9 (18.0)                                             | 0                                                    | 122 (26.6)                                           | 1 (0.2)                                              | 172 (26.2)                                           | 6 (0.9)                                              |
| Diarrhoea                                            | 50 (80.6)                                            | 12 (19.4)                                            | 37 (71.2)                                            | 6 (11.5)                                             | 17 (34.0)                                            | 1 (2.0)                                              | 307 (67.0)                                           | 46 (10.0)                                            | 270 (41.2)                                           | 33 (5.0)                                             |
| Dyspepsia                                            | 10 (16.1)                                            | 0                                                    | 6 (11.5)                                             | 1 (1.9)                                              | 6 (12.0)                                             | 0                                                    | 57 (12.4)                                            | 1 (0.2)                                              | 49 (7.5)                                             | 0                                                    |
| Nausea                                               | 28 (45.2)                                            | 3 (4.8)                                              | 32 (61.5)                                            | 4 (7.7)                                              | 8 (16.0)                                             | 0                                                    | 207 (45.2)                                           | 10 (2.2)                                             | 271 (41.3)                                           | 21 (3.2)                                             |
| Oral Pain                                            | 8 (12.9)                                             | 0                                                    | 5 (9.6)                                              | 0                                                    | 1 (2.0)                                              | 0                                                    | 38 (8.3)                                             | 1 (0.2)                                              | 43 (6.6)                                             | 2 (0.3)                                              |
| Stomatitis                                           | 22 (35.5)                                            | 1 (1.6)                                              | 13 (25.0)                                            | 1 (1.9)                                              | 21 (42.0)                                            | 1 (2.0)                                              | 169 (36.9)                                           | 12 (2.6)                                             | 141 (21.5)                                           | 10 (1.5)                                             |
| Vomiting                                             | 30 (48.4)                                            | 4 (6.5)                                              | 20 (38.5)                                            | 2 (3.8)                                              | 6 (12.0)                                             | 0                                                    | 163 (35.6)                                           | 11 (2.4)                                             | 209 (31.9)                                           | 18 (2.7)                                             |
| General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions | General disorders and administration site conditions |
| Asthenia                                             | 15 (24.2)                                            | 2 (3.2)                                              | 8 (15.4)                                             | 1 (1.9)                                              | 3 (6.0)                                              | 1 (2.0)                                              | 115 (25.1)                                           | 29 (6.3)                                             | 67 (10.2)                                            | 21 (3.2)                                             |

<div style=\"page-break-after: always\"></div>

| Fatigue                                         | 37 (59.7)                                       | 8 (12.9)                                        | 21 (40.4)                                       | 4 (7.7)                                         | 16 (32.0)                                       | 0                                               | 213 (46.5)                                      | 23 (5.0)                                        | 333 (50.8)                                      | 80 (12.2)                                       |
|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|-------------------------------------------------|
| Oedema Peripheral                               | 21 (33.9)                                       | 1 (1.6)                                         | 9 (17.3)                                        | 0                                               | 9 (18.0)                                        | 0                                               | 96 (21.0)                                       | 2 (0.4)                                         | 81 (12.3)                                       | 2 (0.3)                                         |
| Pyrexia                                         | 13 (21.0)                                       | 1                                               | 5 (9.6)                                         | 0                                               | 5                                               | 1                                               | 69 (15.1)                                       | 1 (0.2)                                         | 68 (10.4)                                       | 2 (0.3)                                         |
| (1.6) (10.0) (2.0) Infections and infestations  | (1.6) (10.0) (2.0) Infections and infestations  | (1.6) (10.0) (2.0) Infections and infestations  | (1.6) (10.0) (2.0) Infections and infestations  | (1.6) (10.0) (2.0) Infections and infestations  | (1.6) (10.0) (2.0) Infections and infestations  | (1.6) (10.0) (2.0) Infections and infestations  | (1.6) (10.0) (2.0) Infections and infestations  | (1.6) (10.0) (2.0) Infections and infestations  | (1.6) (10.0) (2.0) Infections and infestations  | (1.6) (10.0) (2.0) Infections and infestations  |
| Nasopharyngitis                                 | 7 (11.3)                                        | 0                                               | 4 (7.7)                                         | 0                                               | 6 (12.0)                                        | 0                                               | 46 (10.0)                                       | 0                                               | 27 (4.1)                                        | 0                                               |
| Investigations                                  | Investigations                                  | Investigations                                  | Investigations                                  | Investigations                                  | Investigations                                  | Investigations                                  | Investigations                                  | Investigations                                  | Investigations                                  | Investigations                                  |
| Blood Thyroid Stimulating Hormone Increased     | 7 (11.3)                                        | 0                                               | 2 (3.8)                                         | 0                                               | 1 (2.0)                                         | 0                                               | 28 (6.1)                                        | 0                                               | 55 (8.4)                                        | 1 (0.2)                                         |
| Weight Decreased                                | 21 (33.9)                                       | 2 (3.2)                                         | 26 (50.0)                                       | 3 (5.8)                                         | 4 (8.0)                                         | 0                                               | 241 (52.6)                                      | 55 (12.0)                                       | 144 (22.0)                                      | 22 (3.4)                                        |
| Metabolism and nutrition disorders              | Metabolism and nutrition disorders              | Metabolism and nutrition disorders              | Metabolism and nutrition disorders              | Metabolism and nutrition disorders              | Metabolism and nutrition disorders              | Metabolism and nutrition disorders              | Metabolism and nutrition disorders              | Metabolism and nutrition disorders              | Metabolism and nutrition disorders              | Metabolism and nutrition disorders              |
| Decreased Appetite                              | 33 (53.2)                                       | 3 (4.8)                                         | 30 (57.7)                                       | 2 (3.8)                                         | 9 (18.0)                                        | 0                                               | 246 (53.7)                                      | 24 (5.2)                                        | 238 (36.3)                                      | 15 (2.3)                                        |
| Dehydration                                     | 8 (12.9)                                        | 5 (8.1)                                         | 1 (1.9)                                         | 0                                               | 1 (2.0)                                         | 0                                               | 44 (9.6)                                        | 17 (3.7)                                        | 66 (10.1)                                       | 27 (4.1)                                        |
| Hypercholester- olaemia                         | 19 (30.6)                                       | 2 (3.2)                                         | 6 (11.5)                                        | 1 (1.9)                                         | 8 (16.0)                                        | 0                                               | 15 (3.3)                                        | 2 (0.4)                                         | 9 (1.4)                                         | 0                                               |
| Hyperglycaemia                                  | 11 (17.7)                                       | 0                                               | 3 (5.8)                                         | 0                                               | 12 (24.0)                                       | 5 (10.0)                                        | 23 (5.0)                                        | 1 (0.2)                                         | 29 (4.4)                                        | 10 (1.5)                                        |
| Hypertriglyc- eridaemia                         | 25 (40.3)                                       | 8 (12.9)                                        | 7 (13.5)                                        | 2 (3.8)                                         | 12 (24.0)                                       | 4 (8.0)                                         | 17 (3.7)                                        | 2 (0.4)                                         | 14 (2.1)                                        | 2 (0.3)                                         |
| Hypokalaemia                                    | 8 (12.9)                                        | 3 (4.8)                                         | 1 (1.9)                                         | 1 (1.9)                                         | 1 (2.0)                                         | 0                                               | 49 (10.7)                                       | 13 (2.8)                                        | 42 (6.4)                                        | 11 (1.7)                                        |
| Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders | Musculoskeletal and connective tissue disorders |
| Arthralgia                                      | 18 (29.0)                                       | 0                                               | 13 (25.0)                                       | 0                                               | 7 (14.0)                                        | 0                                               | 141 (30.8)                                      | 5 (1.1)                                         | 130 (19.8)                                      | 3 (0.5)                                         |
| Back Pain                                       | 15 (24.2)                                       | 2 (3.2)                                         | 11 (21.2)                                       | 0                                               | 7 (14.0)                                        | 0                                               | 91 (19.9)                                       | 10 (2.2)                                        | 104 (15.9)                                      | 7 (1.1)                                         |
| Musculoskeletal Chest                           | 11 (17.7)                                       | 1 (1.6)                                         | 8 (15.4)                                        | 2 (3.8)                                         | 2 (4.0)                                         | 0                                               | 57 (12.4)                                       | 1 (0.2)                                         | 38 (5.8)                                        | 2 (0.3)                                         |
| Pain                                            | Pain                                            | Pain                                            | Pain                                            | Pain                                            | Pain                                            | Pain                                            | Pain                                            | Pain                                            | Pain                                            | Pain                                            |
| Pain In Extremity                               | 10 (16.1)                                       | 0                                               | 6 (11.5)                                        | 1 (1.9)                                         | 3 (6.0)                                         | 0                                               | 83 (18.1)                                       | 5 (1.1)                                         | 79 (12.0)                                       | 7 (1.1)                                         |
| Nervous system disorders                        | Nervous system disorders                        | Nervous system disorders                        | Nervous system disorders                        | Nervous system disorders                        | Nervous system disorders                        | Nervous system disorders                        | Nervous system disorders                        | Nervous system disorders                        | Nervous system disorders                        | Nervous system disorders                        |
| Dizziness                                       | 7 (11.3)                                        | 0                                               | 4 (7.7)                                         | 0                                               | 2 (4.0)                                         | 0                                               | 74 (16.2)                                       | 1 (0.2)                                         | 88 (13.4)                                       | 0                                               |
| Headache                                        | 12 (19.4)                                       | 1 (1.6)                                         | 14 (26.9)                                       | 3 (5.8)                                         | 5 (10.0)                                        | 1 (2.0)                                         | 164 (35.8)                                      | 12 (2.6)                                        | 198 (30.2)                                      | 13 (2.0)                                        |
| Psychiatric disorders                           | Psychiatric disorders                           | Psychiatric disorders                           | Psychiatric disorders                           | Psychiatric disorders                           | Psychiatric disorders                           | Psychiatric disorders                           | Psychiatric disorders                           | Psychiatric disorders                           | Psychiatric disorders                           | Psychiatric disorders                           |
| Insomnia                                        | 10 (16.1)                                       | 1 (1.6)                                         | 8 (15.4)                                        | 0                                               | 1 (2.0)                                         | 0                                               | 62 (13.5)                                       | 0                                               | 57 (8.7)                                        | 1 (0.2)                                         |
| Renal and urinary disorders                     | Renal and urinary disorders                     | Renal and urinary disorders                     | Renal and urinary disorders                     | Renal and urinary disorders                     | Renal and urinary disorders                     | Renal and urinary disorders                     | Renal and urinary disorders                     | Renal and urinary disorders                     | Renal and urinary disorders                     | Renal and urinary disorders                     |
| Proteinuria                                     | 18 (29.0)                                       | 5 (8.1)                                         | 16 (30.8)                                       | 10 (19.2)                                       | 7 (14.0)                                        | 1 (2.0)                                         | 178 (38.9)                                      | 48 (10.5)                                       | 197 (30.0)                                      | 37 (5.6)                                        |
| Renal Failure Acute                             | 5 (8.1)                                         | 5 (8.1)                                         | 5 (9.6)                                         | 3 (5.8)                                         | 0                                               | 0                                               | 11 (2.4)                                        | 4 (0.9)                                         | 14 (2.1)                                        | 6 (0.9)                                         |
| Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders |
| Cough                                           | 23 (37.1)                                       | 0                                               | 9 (17.3)                                        | 1 (1.9)                                         | 15 (30.0)                                       | 0                                               | 124 (27.1)                                      | 1 (0.2)                                         | 104 (15.9)                                      | 4 (0.6)                                         |
| Dysphonia                                       | 11 (17.7)                                       | 0                                               | 19 (36.5)                                       | 0                                               | 2 (4.0)                                         | 0                                               | 163 (35.6)                                      | 4 (0.9)                                         | 192 (29.3)                                      | 1 (0.2)                                         |
| Dyspnoea                                        | 19 (30.6)                                       | 3 (4.8)                                         | 12 (23.1)                                       | 1 (1.9)                                         | 11 (22.0)                                       | 4 (8.0)                                         | 83 (18.1)                                       | 11 (2.4)                                        | 108 (16.5)                                      | 14 (2.1)                                        |

<div style=\"page-break-after: always\"></div>

| Epistaxis                              | 14 (22.6)                              | 0                                      | 4 (7.7)                                | 0                                      | 12 (24.0)                              | 0                                      | 75 (16.4)                              | 1 (0.2)                                | 67 (10.2)                              | 0                                      |
|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
| Oropharyngeal Pain                     | 7 (11.3)                               | 0                                      | 2 (3.8)                                | 0                                      | 2 (4.0)                                | 0                                      | 71 (15.5)                              | 1 (0.2)                                | 53 (8.1)                               | 1 (0.2)                                |
| Skin and subcutaneous tissue disorders | Skin and subcutaneous tissue disorders | Skin and subcutaneous tissue disorders | Skin and subcutaneous tissue disorders | Skin and subcutaneous tissue disorders | Skin and subcutaneous tissue disorders | Skin and subcutaneous tissue disorders | Skin and subcutaneous tissue disorders | Skin and subcutaneous tissue disorders | Skin and subcutaneous tissue disorders | Skin and subcutaneous tissue disorders |
| Dry Skin                               | 7 (11.3)                               | 0                                      | 3 (5.8)                                | 0                                      | 3 (6.0)                                | 0                                      | 52 (11.4)                              | 0                                      | 71 (10.8)                              | 0                                      |
| Pruritus                               | 8 (12.9)                               | 0                                      | 3 (5.8)                                | 0                                      | 7 (14.0)                               | 0                                      | 26 (5.7)                               | 0                                      | 34 (5.2)                               | 0                                      |
| Rash                                   | 14 (22.6)                              | 0                                      | 8 (15.4)                               | 0                                      | 11 (22.0)                              | 0                                      | 89 (19.4)                              | 1 (0.2)                                | 77 (11.7)                              | 0                                      |
| Vascular disorders                     | Vascular disorders                     | Vascular disorders                     | Vascular disorders                     | Vascular disorders                     | Vascular disorders                     | Vascular disorders                     | Vascular disorders                     | Vascular disorders                     | Vascular disorders                     | Vascular disorders                     |
| Hypertension                           | 25 (40.3)                              | 8 (12.9)                               | 25 (48.1)                              | 9 (17.3)                               | 5 (10.0)                               | 1 (2.0)                                | 321 (70.1)                             | 170 (37.1)                             | 347 (52.9)                             | 163 (24.8)                             |

Subjects with 2 or more TEAEs reported for the same preferred term were counted only once using the highest CTCAE grade. Percentages are based on the total number of subjects in the relevant treatment group or safety set.

The safety data cut-off date was 31 Jul 2015 for the RCC Safety Set, 10 Dec 2014 for the All DTC Safety Set, and 15 Sep 2013 for the Non-DTC Safety Set.

CTCAE = Common Terminology Criteria for Adverse Events, DTC = differentiated thyroid cancer, MedDRA = Medical Dictionary for Regulatory Activities, PPE = palmer-plantar erythrodysesthesia syndrome, RCC = renal cell carcinoma, TEAE = treatment-emergent adverse event, TSH = thyroid stimulating hormone.

## Clinically Significant Adverse Events (CSEs)

Clinically  significant  events  (CSEs)  previously  defined  for  the  DTC  MAA  included  hypertension,  proteinuria, arterial  and  venous  thromboembolic  events,  posterior  reversible  encephalopathy  syndrome  (PRES),  renal events,  liver  events,  gastrointestinal  (GI)  perforation  and  fistula  formation,  QTc prolongation,  decreased ejection fraction (EF), hypocalcemia, haemorrhage, and PPE. Weight loss and cytopenias were also evaluated.

The combination arm of study 205 had a higher level of clinically significant TEAE than everiolimus arm (79% and 62%, respectively).

Table 45: Summary of Clinically Significant Adverse Events

|                                             | RCC Lenvatinib 18 mg + Everolimus 5 mg Phases 1b+2 (N=62)   | RCC Lenvatinib 18 mg + Everolimus 5 mg Phases 1b+2 (N=62)   | RCC Lenvatinib 24 mg (N=52)   | RCC Lenvatinib 24 mg (N=52)   | RCC Everolimus 10 mg (N=50)   | RCC Everolimus 10 mg (N=50)   | All DTC Lenvatinib 24 mg (N=458)   | All DTC Lenvatinib 24 mg (N=458)   |
|---------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|------------------------------------|------------------------------------|
| TEAE, n (%)                                 | All Grades                                                  | Grade ≥3                                                    | All Grades                    | Grade ≥3                      | All Grades                    | Grade ≥3                      | All Grades                         | Grade ≥3                           |
| Subjects with any clinically significant AE | 49 (79.0)                                                   | 26 (41.9)                                                   | 49 (94.2)                     | 28 (53.8)                     | 31 (62.0)                     | 6 (12)                        | 423 (92.4)                         | 272 (59.4)                         |
| Hypertension                                | 26 (41.9)                                                   | 8 (12.9)                                                    | 25 (48.1)                     | 9 (17.3)                      | 5 (10)                        | 1 (2)                         | 336 (73.4)                         | 179 (39.1)                         |
| Arterial thromboembolic events              | 1 (1.6)                                                     | 1 (1.6)                                                     | 4 (7.7)                       | 4 (7.7)                       | 3 (6.0)                       | 2 (4.0)                       | 25 (5.5)                           | 14 (3.1)                           |
| Venous thromboembolic events                | 4 (6.5)                                                     | 2 (3.2)                                                     | 7 (13.5)                      | 3 (5.8)                       | 2 (4.0)                       | 1 (2.0)                       | 24 (5.2)                           | 18 (3.9)                           |
| QTc prolongation                            | 4 (6.5)                                                     | 0                                                           | 3 (5.8)                       | 0                             | 0                             | 0                             | 56 (12.2)                          | 5 (1.1)                            |
| Decreased EF and                            | 3                                                           | 2                                                           | 4                             | 1                             | 2                             | 1                             | 32                                 | 13                                 |

<div style=\"page-break-after: always\"></div>

|                                                     | RCC Lenvatinib 18 mg + Everolimus 5 mg Phases 1b+2 (N=62)   | RCC Lenvatinib 18 mg + Everolimus 5 mg Phases 1b+2 (N=62)   | RCC Lenvatinib 24 mg (N=52)   | RCC Lenvatinib 24 mg (N=52)   | RCC Everolimus 10 mg (N=50)   | RCC Everolimus 10 mg (N=50)   | All DTC Lenvatinib 24 mg (N=458)   | All DTC Lenvatinib 24 mg (N=458)   |
|-----------------------------------------------------|-------------------------------------------------------------|-------------------------------------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|------------------------------------|------------------------------------|
| TEAE, n (%)                                         | All Grades                                                  | Grade ≥3                                                    | All Grades                    | Grade ≥3                      | All Grades                    | Grade ≥3                      | All Grades                         | Grade ≥3                           |
| cardiac failure                                     | (4.8)                                                       | (3.2)                                                       | (7.7)                         | (1.9)                         | (4.0)                         | (2.0)                         | (7.0)                              | (2.8)                              |
| Hemorrhage                                          | 24 (38.7)                                                   | 5 (8.1)                                                     | 15 (28.8)                     | 1 (1.9)                       | 14 (28.0)                     | 1 (2)                         | 185 (40.4)                         | 13 (2.8)                           |
| PRES (posterior reversible encephalopathy syndrome) | 0                                                           | 0                                                           | 1 (1.6)                       | 1 (1.6)                       | 0                             | 0                             | 1 (0.2)                            | 1 (0.2)                            |
| Renal events                                        | 11 (17.7)                                                   | 6 (9.7)                                                     | 8 (15.4)                      | 3 (5.8)                       | 6 (12.0)                      | 1 (2.0)                       | 59 (12.9)                          | 12 (2.6)                           |
| Proteinuria                                         | 19 (30.6)                                                   | 5 (8.1)                                                     | 16 (30.8)                     | 10 (19.2)                     | 7 (14.0)                      | 1 (2.0)                       | 178 (38.9)                         | 48 (10.5)                          |
| Liver events                                        | 9 (14.5)                                                    | 2 (3.2)                                                     | 7 (13.5)                      | 1 (1.9)                       | 7 (14.0)                      | 1 (2.0)                       | 110 (24.0)                         | 25 (5.5)                           |
| Hypocalcemia                                        | 5 (8.1)                                                     | 2 (3.2)                                                     | 3 (5.8)                       | 0                             | 2 (4.0)                       | 0                             | 60 (13.1)                          | 20 (4.4)                           |
| PPE Palmar plantar erythro- dysesthesia             | 10 (16)                                                     | 0                                                           | 11 (21.2)                     | 0                             | 6 (12.0)                      | 0                             | 162 (35.4)                         | 15 (3.3)                           |
| GI perforation/ Fistula Formation                   | 1 (1.6)                                                     | 1 (1.6)                                                     | 3 (5.8)                       | 1 (1.9)                       | 0                             | 0                             | 11 (2.4)                           | 8 (1.7)                            |

## Cardiovascular events

Cardiovascular toxicity includes events such as hypertension, cardiac failure, arterial and venous thromboembolic events, QTc prolongation and haemorrage.  These are considered to be clinically significant events for lenvatinib+everolimus and are subject to routine Pharmacovigilance reporting.  A summary of the incidence of cardiovascular TEAEs in the lenvatinib RCC combination group and All DTC Safety Set is provided in Table above.

## Hypertension

Hypertension was experienced at a lower incidence rate and intensity in the RCC combination group (42%) than in the lenvatinib single arm (48%) and in the All DTC Safety set (73%) but was still higher than in the everolimus only arm (10%). AEs grade 3 or above occurred in 13% of the RCC combination group.

There  were  no  Grade  4  or  Grade  5  TEAEs,  no  SAEs,  and  no  discontinuations  due  to  AEs  related  to hypertension in the RCC combination group and thus hypertension was sufficiently manageable in the RCC combination group.

The median time to onset of hypertension was 4.9 weeks (any grade) and 6.9 weeks (Grade ≥ 3) in the RCC combination group, which is later than in the All DTC safety set (2 weeks). The highest proportion of subjects

<div style=\"page-break-after: always\"></div>

experienced an episode of hypertension in Cycle 1 in the RCC combination group (21.0%) as was the case in the All DTC Safety Set (45.6%).

## Thromboembolic events

Thromboembolic events are known to occur with VEGF/VEGFR-targeted therapies.

One Arterial thromboembolic events (ATE) per SGQ of grade 3 occurred in the RCC combination group to compare to 4 in the lenvatinib alone group (7.7%, 3 grade 3 and 1 grade 5) and in 5.5% of the DTC patients. There were no interruption, reduction or discontinuation due to ATE in the RCC combination group.

The time to onset of arterial thromboembolic events for the 1 subject in the RCC combination group was 69.6 weeks (Grade 3).  In the RCC combination group, the 1 episode of an arterial thromboembolic event occurred in Cycle 18.  Although episodes of arterial thromboembolic events per SGQ occurred throughout treatment in the All DTC Safety Set, a higher percentage tended to occur within the first 2 cycles of treatment.

Four venous thromboembolic events occurred in the RCC combination group (6.5%), one of each of grades 1, 2, 3 and 4, two being SAEs. One led to an interruption of the studied combination of drugs. The lenvatinib alone arm showed higher figures with 7 AEs ( 13.5%) of grade 1, 2 and 3  which is significantly higher than the profile of VTEs in DTC patients (at least for the grade 1 and 2 AEs). The median time to onset of venous thromboembolic events was 28.1 weeks (any grade) and 20.6 weeks (Grade ≥ 3) in the RCC combination group

Of the TEAEs contributing to the SGQ for venous thromboembolic events, deep vein thrombosis, pulmonary embolism,  thrombophlebitis,  and  venous  thrombosis  each  occurred  in  1  subject  in  the  RCC  combination group.  Pulmonary embolism was the most frequent event in the All DTC (2.8%) and the Non DTC (3.0%) Safety Sets.  The incidence rate and severity of venous thromboembolic events in the RCC combination group is consistent with the known safety profile of lenvatinib.

The median time to onset of venous thromboembolic events was 28.1 weeks (any grade) and 20.6 weeks (Grade ≥ 3) in the RCC combination group.

## QTc prolongation

In the RCC study in the subjects with baseline and postbaseline data avaliabale (92%), respectively 11.3% , 24% and 56% had increase of &gt;60 ms, between 30 and 61 ms,  and  below 31 ms in the RCC combination group. Data are similar for the RCC lenvatinib group but with a significantly lower number of patients with increase of &gt; 60 ms (2; 3.8%). The incidence of QTc interval greater than 500 ms was 6% in the lenvatinib plus  everolimus-treated  group.  No  reports  of  QTc  interval  prolongation  greater  than  500  ms  or  increases greater than 60 ms occurred in the everolimus-treated group.

The median time to onset of QTc prolongation was 35.1 weeks (any grade) in the RCC combination group.  In the RCC combination group, episodes occurred sporadically from Cycle 2 through Cycle 18.

## Decreased ejection fraction and cardiac failure

'Decreased ejection fraction and cardiac failure' occurred in 3 subjects (4.8%) in the RCC combination group, 4 subjects (7.7%) in the RCC lenvatinib group and 7% in the DTC safety set.  The only TEAE contributing to the  CSE  of  decreased  EF  and  cardiac  failure  that  occurred  in  more  than  2%  of  subjects  in  the  RCC

<div style=\"page-break-after: always\"></div>

combination  group  was  decreased  EF  (3.2%)  as  in  the  all-DTC  safety  set  (4.8%).  Cardiac  failure  was reported in 1 patient (1.6%) of the combination group.

So far  the  incidence  rate  and  severity  of  cardiac  failure  and  decreased  EF  events  in  the  RCC  combination group is consistent with the known safety profile of lenvatinib per the approved Lenvima SmPC.

The median time to onset of decreased EF and cardiac failure per SGQ was 15.7 weeks (any grade) and 32.8 weeks (Grade ≥ 3) in the RCC combination group.  Episodes of decreased EF and cardiac failure per SGQ tended  to  occur  sporadically  throughout  treatment  for  both  the  RCC  combination  group  and  the  All  DTC Safety Set.

## Haemorrhage

Haemorrhage is a well-known AE associated with treatment with TKIs. Two distinctive types of bleeding have been described:  mild spontaneous mucocutaneous bleeding and serious tumour related bleeding.

Haemorrhage  accounted  for  2  discontinuations,  2  drug  reductions  and  2  drug  interruptions  in  the  RCC combination arm, 1 discontinuation in the RCC lenvatinib arm and 1 dose reduction in the everolimus arm. One patient in both RCC combination and lenvatinib arms had a grade 5 event.

In the RCC study haemorrhage was reported in 38.7% (8.1% were Grade ≥ 3) of patients in the lenvatinib plus  everolimus-treated  group,  notably  epistaxis  (22.6%),  haematuria  (4.8%),  haematoma  (3.2%),  and gastric haemorrhage (3.2%). The median time to first onset of was 10.2 weeks (any grade) and 7.6 weeks (Grade ≥ 3) in the lenvatinib plus everolimus-treated group.  The rate of haemorrhage was the highest at the beginning  of  treatment  (12%  of  subjects)  then  decreased  to  a  plateau  after  3  cycles.  There  might  be  a second period of higher occurrence (5% of subjects) between the 6 th  and the 10 th  cycle. The chronology of the events is slightly different than the one of the DTC patients.

The incidence of serious haemorrhage was 4.8% (cerebral haemorrhage, gastric haemorrhage and haemarthrosis). Discontinuation due to haemorrhagic events occurred in 3.2% of patients in the lenvatinib plus everolimus-treated group. There was one case of fatal cerebral haemorrhage in the lenvatinib plus everolimus-treated group and one case of fatal intracranial haemorrhage in the lenvatinib-treated group.

## Renal and urinary disorders

Renal  events  including  renal  failure,  blood  creatinine  increased,  blood  urea  increased,  creatinine  renal clearance  decreased  and  toxic  nephropathy  toxic  were  reported  in  17.7%  of  patients  in  the  combination group  (11  events,  15  episodes,  0.27  episodes/SY)  in  the  RCC  combination  group,  12.9%  (8  events,  11 episodes, 0.14 episodes/SY) in the All DTC Safety Set, and 7.5% (0.25 episodes/SY) in the Non DTC Safety Set.  In the 11 subjects of the RCC combination group, no subjects discontinued treatment, 2 had a dose reduction and 3 a dose interruption. One subject discontinued treatment in the arm B/ RCC lenvatinib group.

There was a higher rate of SAEs for renal events in the RCC combination group (11.3%) compared with the All DTC (2.6%) and the Non DTC (2.1%) Safety Sets.  The incidence rate and severity of renal events was similar in the RCC combination group and the RCC lenvatinib group.

The median time to onset of renal events was 8.1 weeks (any grade and Grade ≥ 3) in the RCC combination group.  More than half of the episodes occurred within the first 3 cycles (RCC combination group, 7 of 12 episodes) or first 4 cycles (All DTC Safety Set, 35 of 76 episodes).  Thus, although episodes of renal events tended to occur throughout treatment, they more frequently did so early in treatment.

<div style=\"page-break-after: always\"></div>

Of the renal events, acute renal failure (8.1%) and increased blood creatinine (4.8%) were the most frequent for the RCC combination group.  In the All DTC Safety Set, acute renal failure and increased blood creatinine occurred in 2.4% and 6.6% of subjects, respectively.

## Renal failure and impairment

In the combination group 8.1% of patients developed renal failure and 3.2% developed renal impairment, (9.7% of patients had a Grade 3 event of renal failure or impairment). In the everolimus monotherapy group 2.0% of patients developed renal failure (2.0% were Grade 3).

In the DTC study, 5.0% of patients developed renal failure and 1.9% developed renal impairment, (3.1% of patients had a Grade ≥ 3 event of renal failure or impairment).

Grade 3 acute renal failure events occurred at a higher rate in the RCC combination group (5 subjects, 8.1%) than in the lenvatinib alone mRCC group (5.8%) or in the All DTC Safety Set (4 subjects, 0.9%). There were no Grade 4 or grade 5 acute renal failure events in the RCC safety.

Serious renal events occurred at a higher rate in the RCC combination group (11.3%) and the RCC lenvatinib group (7.7%) compared with the All DTC Safety Set (2.6%).

## Proteinuria

Proteinuria was reported in 30.6% of patients in the combination group (8.1% were Grade ≥ 3) and 14.0% of patients in the everolimus-treated group (2.0% were Grade ≥3). The median time to onset of proteinuria was 6.1 weeks (any grade) and 20.1 weeks (Grade ≥ 3) in the lenvatinib plus everolimus-treated group. Proteinuria led to permanent treatment discontinuation in 4.8% of patients. The highest proportion of subjects experienced an episode of proteinuria in the first 2 cycles of treatment.

## Liver Events

TEAEs occurred in 9 (14.5%), 7 (13.5%) and 5 (10%) of subjects of respectively the RCC combination, the RCC lenvatinib and the RCC everolimus arms to compare to 24% with the DTC patients. In the mRCC group 2 patients  discontinued  treatment,  and  one  each  had  an  interruption  or  a  dose  reduction.  In  the  mRCC lenvatinib group 1 patient had a dose reduction. SAEs occurred in 2 patients of the mRCC combination group: increased blood bilirubin (Grade 3) and increased transaminases (Grade 3). The median time to onset of liver events was 6.7 weeks (any grade) and 14.2 weeks (Grade ≥ 3) in the RCC combination group.  The worst grade and first  occurrence  of  the  event  generally occurred  within  the  first  7  treatment  cycles  in  a  similar pattern than with the all DTC safety group. The rate of liver event episodes per SY was slightly higher in the RCC combination group compared with that in the All DTC Safety.  SAEs and discontinuations due to liver events occurred for a slightly higher percentage of subjects in the RCC combination group than in the All DTC and the Non DTC Safety Sets, this difference representing a few subjects in the RCC group.  The episodes per SY and severity of liver events were higher in the RCC combination group than in the RCC lenvatinib group.

Of the TEAEs contributing to liver events in the RCC combination group, increased alanine aminotransferase (ALT)  was  the  most  frequent  (9.7%  any  Grade  and  1.6%  Grade ≥ 3),  followed  by  increased  aspartate aminotransferase  (AST;  4.8%  any  Grade  and  1.6%  Grade ≥ 3)  and  increased  blood  alkaline  phosphatase (ALP; 4.8% any Grade, no Grade ≥ 3).

There were no subjects identified in the safety database who met the criteria for possible Hy's Law.

<div style=\"page-break-after: always\"></div>

## Electrolyte disturbances

Table 46: Summary of electrolyte disturbances

| Parameter (CTCAE Preferred Term)   | Lenvatinib 18 mg + Everolimus 5 mg Phases 1b+2 (N=62)   | Lenvatinib 18 mg + Everolimus 5 mg Phases 1b+2 (N=62)   | Lenvatinib 24 mg Phase 2 (N=52)   | Lenvatinib 24 mg Phase 2 (N=52)   | Everolimus 10 mg Phase 2 (N=50)   | Everolimus 10 mg Phase 2 (N=50)   |
|------------------------------------|---------------------------------------------------------|---------------------------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| Grade of Lab Value:                | Any Grade n (%)                                         | Grade ≥3 n (%)                                          | Any Grade n (%)                   | Grade ≥3 n (%)                    | Any Grade n (%)                   | Grade ≥3 n (%)                    |
| Hypercalcemia                      | 1 (1.6)                                                 | 0                                                       | 0                                 | 0                                 | 1 (2.0)                           | 0                                 |
| Hypocalcemia                       | 5 (8.1)                                                 | 2 (3.2)                                                 | 3 (5.8)                           | 0                                 | 2 (4.0)                           | 0                                 |
| Hyperkalemia                       | 5 (8.1)                                                 | 3 (4.8)                                                 | 3 (5.8)                           | 0                                 | 1 (2.0)                           | 0                                 |
| Hypokalemia                        | 8 (12.9)                                                | 3 (4.8)                                                 | 1 (1.9)                           | 1 (1.9)                           | 1 (2.0)                           | 0                                 |
| Hyponatremia                       | 2 (3.2)                                                 | 2 (3.2)                                                 | 1 (1.9)                           | 0                                 | 0                                 | 0                                 |
| Hypermagnesemia                    | 0                                                       | 0                                                       | 0                                 | 0                                 | 1 (2.0)                           | 0                                 |
| Hypomagnesemia                     | 2 (3.2)                                                 | 1 (1.6)                                                 | 4 (7.7)                           | 1 (1.9)                           | 0                                 | 0                                 |
| Hypophosphatemia                   | 0                                                       | 0                                                       | 1 (1.9)                           | 0                                 | 1 (2.0)                           | 0                                 |

The incidence rate and episodes per SY of TEAEs for hypocalcemia per SGQ were comparable in the RCC combination group (5 subjects; 8.1%; 0.16), the RCC lenvatinib group (3 subjects; 5.8%; 0.08) and the Non DTC  (4.6%;  0.11)  Safety  Sets,  and  numerically  lower  than  that  in  the  All  DTC  Safety  Set  (60  subjects; 13.1%; 0.15).

No subjects required treatment interruptions or discontinued treatment because of abnormalities in sodium, magnesium or calcium.  One subject in the combination group required a dose reduction and discontinued treatment because of hypokalemia

Electrolyte disturbances such as hypokalaemia, hypocalcaemia, or hypomagnesaemia increase the risk of QT prolongation;  therefore  electrolyte  abnormalities  should  be  monitored  and  corrected  in  all  patients  before starting treatment.  Periodic monitoring of ECG and electrolytes (magnesium, potassium and calcium) should be  considered  during  treatment.  Blood  calcium  levels  should  be  monitored  at  least  monthly  and  calcium should be replaced as necessary during lenvatinib treatment. Lenvatinib dose should be interrupted or dose adjusted as necessary depending on severity, presence of ECG changes, and persistence of hypocalcaemia. (SmPC section 4.4). Hypocalcemia and hypokalemia are important identified risks in RMP.

## Palmar-Plantar Erythrodysesthesia Syndrome

The  incidence  rate  of  TEAEs  for  PPE  was  lower  in  the  RCC  combination  group  (16.1%)  and  in  the  RCC everolimus arm than that in the RCC lenvatinib arm (21%) and in the All DTC Safety Set (35.4%). There were no Grade 3 TEAEs in the RCC combination group; Grade 3 TEAEs were reported for 15 subjects (3.3%) in the All DTC Safety Set.  There were no SAEs and no treatment discontinuations due to PPE in the RCC or All  DTC  Safety  Sets.  Two  patients  (3.2%)  had  and  interruption  in  the  RCC  combination  arm,  1  in  the

<div style=\"page-break-after: always\"></div>

lenvatinib arm and 9% in the All-DTC safety set. Episodes of PPE tended to occur throughout treatment.  The median time to onset of PPE was 7.2 weeks in the RCC combination group.

## Gastrointestinal perforation and fistula formation

One case (1.6%; grade 3, perforated appendicitis) of gastrointestinal perforation and fistula formation occurred in the mRCC combination group, 3 in the mRCC lenvatinib group (6%) and 2.4% in the all-DTC safety group.

## Pancreatitis

Six  (9.7%)  subjects  of  the  RCC  combination  arm  had  a  potential  risk  of  pancreatitis.  One  had  a  dose reduction and one an interruption. No SAE was described. A higher incidence (9.7%) of 'Lipase increased' is observed in the RCC combination arm while 'Amylase increased', 'Hyperamylasaemia', 'hyperlipasaemia', 'pancreatic pseudocyst' and 'pancreatitis' are not different from the All DTC group.

## Interstitial Lung Disease

The  TEAEs  for  potential  risk  of  interstitial  lung  diseases  (ILD)  are  pneumonitis,  lung  infiltration,  acute respiratory distress syndrome and pulmonary sarcoidosis. In study 205 phase 2, pneumonitis occurred in 3 (6%) 1 and 6 patients of  the  RCC  combination,  lenvatinib  and  everolimus  groups  respectively.  While  the worst  grade  was  2  for  two  patients  of  the  combination  arm  (1  SAE),  it  was  3  for  three  patients  of  the everolimus arm. Lung infiltration occurred once in the everolimus arm (grade &lt; 3). Two (4.0%) subjects in the RCC everolimus group discontinued treatment because of pneumonitis.  The frequency of pneumonitis reported in the RCC everolimus group is not inconsistent with the known frequency reported in the approved AFINITOR SmPC.  The incidence (4, 6.5%) of ILD is higher in the RCC combination (phase 1b +2) than in the All DTC patients (6 events; 1.3%).

## Hypothyroidism

Thyroid dysfunction is a known class effect of TKIs due to the antiangiogenetic effect on the thyroid blood vessels of the drugs in this class. Hypothyroidism occurred in 24% of patients in the lenvatinib plus everolimus-treated group and 2% of patients in the everolimus-treated group. All events of hypothyroidism in the combination group were of Grade 1 or 2. There were no severe (Grade 3 or 4) TEAEs, SAEs, or treatment discontinuations associated with the important risk of hypothyroidism in the RCC combination group and the All DTC Safety Set; however, all 3 types of events were observed for the Non DTC Safety Set (1.2%, 0.6%, and 0.3%, respectively). In patients with a normal TSH at baseline, an elevation of TSH level was observed post baseline in 60.5% of lenvatinib plus everolimus-treated patients as compared with none in patients receiving everolimus alone.

## New or Worsening Safety Signals for Lenvatinib Plus Everolimus Combination Therapy

The potential for new or worsening safety signals with combination lenvatinib/everolimus therapy in RCC was evaluated in comparison with the known safety profiles of lenvatinib and everolimus as single agents.

<div style=\"page-break-after: always\"></div>

The  following  criteria  have  been  applied  in  order  to  make  a  meaningful  comparison  and  assessment  of potential new or worsening events based on the sample size in the RCC Safety Set:

-  Events  were  only  considered  for  evaluation  if  the  frequency  in  the  RCC  combination  group  was ≥ 10% subjects for any grade TEAE or ≥ 5% subjects for any Grade 3 or 4 TEAE.

·  These  events  were  only  considered  potential  new  or  worsening  signals  if  they  occurred  at ≥ 10% (any grade) AND there was a relative risk of 2 or greater when the RCC combination group was compared with the All DTC Safety Set OR if they occurred at ≥ 5% (Grade 3 or 4) AND there was a relative risk of 2 or greater when the  RCC  combination  group  was  compared  with  the  All  DTC  Safety  Set.  The  relative  risk  of  2  was chosen as the cutoff because a lower relative risk cutoff would likely result in many false signals due to the size of the RCC Safety Set.

Table 47: Summary of Potential New or Worsening Safety Signals for Lenvatinib Plus Everolimus Combination Therapy in the RCC Population

|                                                                  | Renal Cell                                                       | Carcinoma                                                        | Renal Cell                                                       | Renal Cell                                                       | Renal Cell                                                       | Renal Cell                                                       | All DTC                                                          | All DTC                                                          | Approved LENVIMA SmPC                                            | Approved AFINITOR SmPC                                           |
|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------|
| Preferred Term                                                   | Lenvatinib 18 mg + Everolimus 5 mg Phases 1b+2 (N=62) n (%)      | Lenvatinib 18 mg + Everolimus 5 mg Phases 1b+2 (N=62) n (%)      | Lenvatinib 24 mg (N=52) n (%) n                                  | Lenvatinib 24 mg (N=52) n (%) n                                  | Everolimus 10 mg (N=50) (%)                                      | Everolimus 10 mg (N=50) (%)                                      | Lenvatinib 24 mg (N=458) n (%)                                   | Lenvatinib 24 mg (N=458) n (%)                                   | Lenvatinib 24 mg (DTC) (N=452) %                                 | Everolimus 10 mg (all indications, including RCC) (N=2,470) %    |
| Grade of TEAE:                                                   | Any Grade                                                        | Grade 3 or 4                                                     | Any Grad e                                                       | Grad e 3 or 4                                                    | Any Grade                                                        | Grade 3 or 4                                                     | Any Grad e                                                       | Grade 3 or 4                                                     | Any Grade                                                        | Any Grade                                                        |
| Potential New Safety Signals                                     | Potential New Safety Signals                                     | Potential New Safety Signals                                     | Potential New Safety Signals                                     | Potential New Safety Signals                                     | Potential New Safety Signals                                     | Potential New Safety Signals                                     | Potential New Safety Signals                                     | Potential New Safety Signals                                     | Potential New Safety Signals                                     | Potential New Safety Signals                                     |
| Event not in Approved LENVIMA SmPC or Approved AFINITOR SmPC     | Event not in Approved LENVIMA SmPC or Approved AFINITOR SmPC     | Event not in Approved LENVIMA SmPC or Approved AFINITOR SmPC     | Event not in Approved LENVIMA SmPC or Approved AFINITOR SmPC     | Event not in Approved LENVIMA SmPC or Approved AFINITOR SmPC     | Event not in Approved LENVIMA SmPC or Approved AFINITOR SmPC     | Event not in Approved LENVIMA SmPC or Approved AFINITOR SmPC     | Event not in Approved LENVIMA SmPC or Approved AFINITOR SmPC     | Event not in Approved LENVIMA SmPC or Approved AFINITOR SmPC     | Event not in Approved LENVIMA SmPC or Approved AFINITOR SmPC     | Event not in Approved LENVIMA SmPC or Approved AFINITOR SmPC     |
| No events identified                                             | No events identified                                             | No events identified                                             | No events identified                                             | No events identified                                             | No events identified                                             | No events identified                                             | No events identified                                             | No events identified                                             | No events identified                                             | No events identified                                             |
| Hypertriglyceridae mia                                           | 25 (40.3)                                                        | 8 (12.9)                                                         | 7 (13.5)                                                         | 2 (3.8)                                                          | 12 (24.0)                                                        | 4 (8.0)                                                          | 17 (3.7)                                                         | 2 (0.4)                                                          | -                                                                | ≥1% to <10%                                                      |
| Anaemia                                                          | 11 (17.7)                                                        | 5 (8.1)                                                          | 4 (7.7)                                                          | 1 (1.9)                                                          | 13 (2 6.0)                                                       | 6 (12.0)                                                         | 37 (8.1)                                                         | 7 (1.5)                                                          | -                                                                | ≥10%                                                             |
| Hyperglycaemia                                                   | 11 (17.7)                                                        | 0                                                                | 3 (5.8)                                                          | 0                                                                | 12 (24.0)                                                        | 5 (10.0)                                                         | 23 (5.0)                                                         | 1 (0.2)                                                          | -                                                                | ≥10%                                                             |
| Pruritus                                                         | 8 (12.9)                                                         | 0                                                                | 3 (5.8)                                                          | 0                                                                | 7 (14.0)                                                         | 0                                                                | 26 (5.7)                                                         | 0                                                                | -                                                                | ≥10%                                                             |
| Potential Worsening Safety Signals                               | Potential Worsening Safety Signals                               | Potential Worsening Safety Signals                               | Potential Worsening Safety Signals                               | Potential Worsening Safety Signals                               | Potential Worsening Safety Signals                               | Potential Worsening Safety Signals                               | Potential Worsening Safety Signals                               | Potential Worsening Safety Signals                               | Potential Worsening Safety Signals                               | Potential Worsening Safety Signals                               |
| Event in Both Approved LENVIMA SmPC and Approved AFINITOR SmPC   | Event in Both Approved LENVIMA SmPC and Approved AFINITOR SmPC   | Event in Both Approved LENVIMA SmPC and Approved AFINITOR SmPC   | Event in Both Approved LENVIMA SmPC and Approved AFINITOR SmPC   | Event in Both Approved LENVIMA SmPC and Approved AFINITOR SmPC   | Event in Both Approved LENVIMA SmPC and Approved AFINITOR SmPC   | Event in Both Approved LENVIMA SmPC and Approved AFINITOR SmPC   | Event in Both Approved LENVIMA SmPC and Approved AFINITOR SmPC   | Event in Both Approved LENVIMA SmPC and Approved AFINITOR SmPC   | Event in Both Approved LENVIMA SmPC and Approved AFINITOR SmPC   | Event in Both Approved LENVIMA SmPC and Approved AFINITOR SmPC   |
| Diarrhoea a                                                      | 50 (80.6)                                                        | 12 (19.4)                                                        | 37 (71.2)                                                        | 6 (11.5)                                                         | 17 (34.0)                                                        | 1 (2.0)                                                          | 307 (67.0)                                                       | 46 (10.0)                                                        | ≥10%                                                             | ≥10%                                                             |
| Fatigue                                                          | 37 (59.7)                                                        | 8 (12.9)                                                         | 21 (40.4)                                                        | 4 (7.7)                                                          | 16 (32.0)                                                        | 0                                                                | 213 (46.5)                                                       | 23 (5.0)                                                         | ≥10%                                                             | ≥10%                                                             |
| Vomiting                                                         | 30 (48.4)                                                        | 4 (6.5)                                                          | 20 (38.5)                                                        | 2 (3.8)                                                          | 6 (12.0)                                                         | 0                                                                | 163 (35.6)                                                       | 11 (2.4)                                                         | ≥10%                                                             | ≥1% to <10%                                                      |
| Hypercholesterolem ia                                            | 19 (30.6)                                                        | 2 (3.2)                                                          | 6 (11.5)                                                         | 1 (1.9)                                                          | 8 (16.0)                                                         | 0                                                                | 15 (3.3)                                                         | 2 (0.4)                                                          | ≥1% to <10%                                                      | ≥10%                                                             |
| Dehydration                                                      | 8 (12.9)                                                         | 5 (8.1)                                                          | 1 (1.9)                                                          | 0                                                                | 1 (2.0)                                                          | 0                                                                | 44 (9.6)                                                         | 17 (3.7)                                                         | ≥1% to <10%                                                      | ≥1% to <10%                                                      |
| Renal Failure Acute                                              | 5 (8.1)                                                          | 5 (8.1)                                                          | 5 (9.6)                                                          | 3 (5.8)                                                          | 0                                                                | 0                                                                | 11 (2.4)                                                         | 4 (0.9)                                                          | ≥1% to <10%b                                                     | ≥10%c                                                            |
| Event in Approved LENVIMA SmPC but not in Approved AFINITOR SmPC | Event in Approved LENVIMA SmPC but not in Approved AFINITOR SmPC | Event in Approved LENVIMA SmPC but not in Approved AFINITOR SmPC | Event in Approved LENVIMA SmPC but not in Approved AFINITOR SmPC | Event in Approved LENVIMA SmPC but not in Approved AFINITOR SmPC | Event in Approved LENVIMA SmPC but not in Approved AFINITOR SmPC | Event in Approved LENVIMA SmPC but not in Approved AFINITOR SmPC | Event in Approved LENVIMA SmPC but not in Approved AFINITOR SmPC | Event in Approved LENVIMA SmPC but not in Approved AFINITOR SmPC | Event in Approved LENVIMA SmPC but not in Approved AFINITOR SmPC | Event in Approved LENVIMA SmPC but not in Approved AFINITOR SmPC |
| Hypothyroidism                                                   | 15 (24.2)                                                        | 0                                                                | 19 (36.5)                                                        | 1 (1.9)                                                          | 1 (2.0)                                                          | 0                                                                | 24 (5.2)                                                         | 0                                                                | ≥1% to <10%                                                      | -                                                                |

<div style=\"page-break-after: always\"></div>

All events that met the following criteria for a potential new or worsening event are shown in bold :  events were only considered for evaluation if the frequency in the RCC Phase 1b+2 combination group was ≥10% subjects for any grade TEAE or ≥5% subjects for any Grade 3 or 4 TEAE.  These events were only considered potential new or worsening signals if they occurred at ≥10% (any grade) AND there was a relative risk of 2 or greater when the RCC Phase 1b+2 combination group was compared with the All DTC Safety Set OR if they occurred at ≥5% (Grade 3 or 4) AND there was a relative risk of 2 or greater when the RCC Phase 1b+2 combination group was compared with the All DTC Safety Set. Subjects with 2 or more TEAEs reported for the same preferred term were counted only once using the highest CTCAE grade.

Percentages are based on the total number of subjects in the relevant treatment group or safety set.

The safety data cut-off date was 31 Jul 2015 for the RCC Safety Set, 10 Dec 2014 for the All DTC Safety Set, and 15 Sep 2013 for the Non-DTC Safety Set.

DTC = differentiated thyroid cancer, RCC = renal cell carcinoma, SmPC = Summary of Product Characteristics; TEAE = treatment-emergent adverse event, TKI = tyrosine kinase inhibitor, TSH = thyroid stimulating hormone.

a:  Diarrhoea is included for consideration because it occurred at a high frequency, although it did not meet the above criteria.

b:  Approved LENVIMA (lenvatinib) SmPC:  renal failure cases include acute prerenal failure, renal failure, renal failure acute, and renal tubular necrosis.

c:  Approved AFINITOR (everolimus) SmPC:  renal failure (≥10%) is shown for comparison to the approved LENVIMA SmPC, which includes combined terms (see above).  The frequency of acute renal failure reported in the approved AFINITOR SmPC is ≥0.1% to &lt;1%.

Eleven events were identified: diarrhea, hypercholesterolemia, hypothyroidism, hypertriglyceridemia, fatigue, vomiting,  acute  renal  failure,  dehydration,  anemia,  hyperglycemia  and  pruritus.  Diarrhea  has  also  been included  for  consideration  because  it  occurred  at  a  high  frequency,  although  it  did  not  meet  the  specified criteria.

## Potential new safety signals with the combination

No  new  safety  signals  have  been  identified  with  combination  therapy  in  the  RCC  Safety  Set  that  are  not already known for either lenvatinib or everolimus.

## New Safety Signals Not Known for Lenvatinib

Hypertriglyceridemia, anaemia, hyperglycaemia, and pruritus were reported with an increased frequency in the  RCC  combination  relative  to  All  DTC  Safety  set.    These  4  events  are  well  known  AEs  associated  with everolimus therapy and are all included in the approved AFINITOR SmPC.  There was an increased frequency in the RCC combination group relative to the All DTC Safety Set, which fulfilled the criteria for a new signal for  the  combination therapy.  However, the frequencies seen in the RCC everolimus group were generally higher than that in the RCC combination and RCC lenvatinib groups, which supports the conclusion that these events are attributable to everolimus and, therefore, not considered to be a new signal for the combination therapy.

## Hypertriglyceridemia

Hypertriglyceridemia  has  a  higher  incidence  in  mRCC  patients  (lenvatinib  arm;  13.5%)  than  in  the  DTC patients  (3.7%).  Although  single  agent everolimus  has  a  causal  effect  (24%);  the  combination  shows  the highest values (40.3%) suggesting a synergetic effect of everolimus and lenvatinib.

## Anaemia

Anaemia, described as 'very common' in the Afinitor SmPC, had the highest incidence in the RCC everolimus group (26%). Its incidence in the RCC lenvatinib group and in the DTC safety set is identical (8.1%), but it is twice as more frequent in the RCC combination group (17.7%). Of note the half AEs are of grade 3 or 4 AEs in the combination arm.

<div style=\"page-break-after: always\"></div>

Anaemia  was  the  most  frequently  reported  AE  that  led  to  dose  reduction  and/or  interruption  in  the everolimus arm. This event led to dose reduction and/or interruption in 1 subject in each of the combination (2.0%) and lenvatinib (1.9%) arms, and in 6 subjects (12.0%) in the everolimus arm. Anaemia resulting in dose reduction and/or interruption was Grade 3 or 4 in 1 subject in each of the combination and lenvatinib arms, and in 4 subjects (8.0%) in the everolimus arm.

## Hyperglycaemia

The incidence of hyperglycaemia is described as 'very common' in the SmPC of Afinitor. Its incidence (any grade) was much higher in the RCC combination group (17.7%) compared with that in the All DTC Safety Set (5.0%).  No Grade 3 or 4 events were reported in the RCC combination group.  Hyperglycaemia (any grade; Grade  3  or  4)  was  reported  in  the  RCC  lenvatinib  group  (5.8%;  0%)  and  in  the  RCC  everolimus  group (24.0%; 10.0%).

## Pruritus

The incidence of pruritus is described as very common in the SmPC of Afinitor. Its incidence (any grade) was much higher in the RCC combination group (12.9%) compared with that in the All DTC Safety Set (5.7%). No Grade 3 or 4 events were reported in the RCC combination group.  Pruritus Grade 1 or 2, but no grade 3 or 4 events have been reported in the RCC lenvatinib group (5.8%) and in the RCC everolimus group (14.0%).

## Safety signals already known for both lenvatinib and everolimus

Fatigue, vomiting, hypercholesterolemia, dehydration, and acute renal failure were reported with an increased frequency in the RCC combination group relative to the All DTC Safety Set.  Diarrhoea was added because of its high frequency.

## Diarrhoea

In the RCC study, diarrhoea was reported in 80.6% of patients in the combination group (21.0% were Grade ≥ 3) and in 34.0% of patients in the everolimus-treated group (2.0% were Grade ≥ 3). The median time to onset was 4.1 weeks (any grade) and 8.1 weeks (Grade ≥ 3) in the lenvatinib plus everolimus-treated group. Diarrhoea was the most frequent cause of dose interruption/reduction and recurred despite dose reduction. Diarrhoea resulted in discontinuation in one patient. The increased frequency of severe diarrhoea in the RCC combination group appears to represent an additive effect of the 2 therapies, a worsening safety signal for the combination therapy and can be managed with dose reductions and medical therapy, including prompt institution of antidiarrheal medication at the first onset of this TEAE.

## Vomiting

Vomiting showed a similar pattern with incidences of 12%, 38.5% and 48.4% in the everolimus, lenvatinib and combination groups. No discontinuation was due to this AE.  The incidence of vomiting that led to dose reduction and/or interruption was 19.6% (n=10) in the combination, 5.8% (n=3) in the lenvatinib and in 0% in the everolimus arm. Grade 3 or 4 vomiting led to dose reduction and/or interruption in 3 subjects (5.9%) in the combination and 2 subjects (3.8%) in the lenvatinib arms.

<div style=\"page-break-after: always\"></div>

## Fatigue

Similarly to diarrhoea but in a much lower extent, the combination appears to exert additional effects on fatigue according to the incidences of  32%, 40.4% but 59.7%  in the RCC everolimus, lenvatinib and combination groups respectively (incidences of 0%, 7.7% and 12.9 % for grade 3 and 4 AEs, respectively). No discontinuation was due to this AE.  Another constitutional symptom asthenia was reported in 24.2% of subjects in the combination group, 15.4% in the lenvatinib group, and 6.0% in the everolimus group.  There was only 1 event of Grade 4 asthenia, which occurred in the everolimus group (there were only 1 or 2 events of Grade ≥ 3 asthenia in each of the 3 groups).  Weight loss was reported in 33.9% of subjects in the combination group, 50.0% in the lenvatinib group, and 8.0% in the everolimus group.  Unlike the trend observed for fatigue and asthenia, lenvatinib and everolimus combination treatment did not demonstrate increase in the observed incidence of weight loss compared to the single agents alone.  There were no treatment discontinuations due to asthenia or weight loss in any of the 3 treatment groups.

Table 48: Summary of constitutional symptoms

| Parameter (CTCAE Preferred Term)   | Lenvatinib 18 mg + Everolimus 5 mg Phases 1b+2 (N=62)   | Lenvatinib 18 mg + Everolimus 5 mg Phases 1b+2 (N=62)   | Lenvatinib 24 mg Phase 2 (N=52)   | Lenvatinib 24 mg Phase 2 (N=52)   | Everolimus 10 mg Phase 2 (N=50)   | Everolimus 10 mg Phase 2 (N=50)   |
|------------------------------------|---------------------------------------------------------|---------------------------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| Grade of Lab Value:                | Any Grade n (%)                                         | Grade ≥3 n (%)                                          | Any Grade n (%)                   | Grade ≥3 n (%)                    | Any Grade n (%)                   | Grade ≥3 n (%)                    |
| Fatigue                            | 37 (59.7)                                               | 8 (12.9)                                                | 21 (40.4)                         | 4 (7.7)                           | 16 (32.0)                         | 0                                 |
| Asthenia                           | 15 (24.2)                                               | 2 (3.2)                                                 | 8 (15.4)                          | 1 (1.9)                           | 3 (6.0)                           | 1 (2.0)                           |
| Weight Loss                        | 21 (33.9)                                               | 2 (3.2)                                                 | 26 (50.0)                         | 3 (5.8)                           | 4 (8.0)                           | 0                                 |

## Hypercholesterolemia and dyslipedemia

The incidence rate of hypercholesterolemia (any grade) was much higher in the RCC combination group (30.6%) compared with that in the All DTC Safety Set (3.3%), with that of the RCC lenvatinib arm (11.5%) or with that of the RCC everolimus arm (16%) and the increased incidence is a worsening safety signal for the combination therapy.

The most frequent events within the dyslipidemia SMQ were hypertriglyceridemia (40.3% in the RCC combination group, 13.5% in the RCC lenvatinib group, and 24.0% in the RCC everolimus group), hypercholesterolemia (30.6%, 11.5%, and 16.0%, respectively), and increased blood cholesterol (8.1%, 3.8%, and 6.0%, respectively). Dyslipidemia caused 5 interruptions and 2 reductions of drug in the RCC combination group but only one drug reduction in the lenvatinib arm.

## Dehydration

The incidence of grade 3 or 4 dehydration (5 pts; 8.1%) in the combination arm is significantly higher than in the lenvatinib arm and the everolimus arm (both 0%).

## Acute renal failure

This AE is described above in the section on significant AEs.

<div style=\"page-break-after: always\"></div>

## Abdominal pain

Abdominal pain (upper) led to dose reduction and/or interruption in 9.8% (n=5), 3.8% (n=2) and 0% in the combination, lenvatinib, and everolimus arms, respectively. One subject (2.0%) in the combination arm had Grade 3 upper abdominal pain that led to dose reduction/interruption.

## Long-Term Safety

Long-term safety data for the combination are currently limited to the results available from Study 205.

Table 49:  Overall Adverse Event Profile for the Combination Arm by Study Drug Treatment Period - Study 205 (Phase 2 + Proposed Dose Pooled Safety Set)

| Category                                      | 0-6 mo N=62 n (%)   | >6-12 mo N=33 n (%)   | >12-18 mo N=24 n (%)   | >18-24 mo N=12 n (%)   | >24 mo N=7 n (%)   |
|-----------------------------------------------|---------------------|-----------------------|------------------------|------------------------|--------------------|
| TEAEs                                         | 62 (100.0)          | 33 (100.0)            | 23 (95.8)              | 12 (100.0)             | 6 (85.7)           |
| Treatment-related TEAEs                       | 62 (100.0)          | 32 (97.0)             | 23 (95.8)              | 12 (100.0)             | 6 (85.7)           |
| Grade ≥3 TEAEs                                | 44 (71.0)           | 8 (24.2)              | 10 (41.7)              | 3 (25.0)               | 2 (28.6)           |
| Treatment-related Grade ≥3 TEAEs a            | 38 (61.3)           | 8 (24.2)              | 8 (33.3)               | 2 (16.7)               | 2 (28.6)           |
| SAEs                                          | 28 (45.2)           | 5 (15.2)              | 7 (29.2)               | 2 (16.7)               | 0 (0.0)            |
| Deaths                                        | 1 (1.6)             | 0 (0.0)               | 0 (0.0)                | 0 (0.0)                | 0 (0.0)            |
| Nonfatal SAEs                                 | 27 (43.5)           | 5 (15.2)              | 7 (29.2)               | 2 (16.7)               | 0 (0.0)            |
| TEAEs leading to study drug dose adjustment b | 54 (87.1)           | 15 (45.5)             | 16 (66.7)              | 5 (41.7)               | 1 (14.3)           |
| TEAEs leading to study drug withdrawal        | 13 (21.0)           | 1 (3.0)               | 3 (12.5)               | 0 (0.0)                | 1 (14.3)           |
| TEAEs leading to study drug dose reduction    | 39 (62.9)           | 3 (9.1)               | 5 (20.8)               | 1 (8.3)                | 0 (0.0)            |
| TEAEs leading to study drug dose interruption | 43 (69.4)           | 13 (39.4)             | 11 (45.8)              | 4 (33.3)               | 1 (14.3)           |

For each row category, a subject with 2 or more AEs in that category in each interval is counted only once for that time interval. However, if a subject had more than 1 episode of the same AE across multiple intervals, episodes are counted separately  as  new  events  for  each  relevant  interval.  Only  subjects  with  a  specific  AE  reported  in  a  given  interval  are counted for that interval. Percentages are based on total number of subjects at risk in each period.

a: Treatment-related TEAEs include TEAEs that were considered by the Investigator to be possibly or probably related to study drug or TEAEs with a missing causality.

b:  Dose  adjustment  includes  study  drug  withdrawal,  dose  reduction,  and/or  interruption.  Subjects  may  be  counted  in multiple categories.

As of the 31 Jul 2015 cutoff date for the RCC Safety Set, a total of 46 subjects (28.0%) were still ongoing (4 receiving treatment and 42 in follow-up) in Study 205. The pharmacovigilance database was reviewed with the cutoff date of 27 Apr 2016. One of the 4 follow-up reports for SAEs pertained to a fatal event with the time to onset of 844 days after the subject's first dose. Based on additional follow-up information this was a case of myocardial infarction. The coroner's postmortem report confirmed the immediate cause of death as being  attributed  to  acute  plaque  haemorrhage  of  the  left  descending  artery.  The  subject  had  advanced atherosclerosis of the coronary vessels and a medical history of hypercholesterolemia and Type 2 diabetes.

<div style=\"page-break-after: always\"></div>

Given that long-term safey data with lenvatinib and its combination with everolimus are limited in the RCC patients, long-term safety data for lenvatinib monotherapy are of particular relevance to inform on lenvatinib safety at long term and to compare safety profiles of the combination versus single-agent therapies. In the lenvatinib  monotherapy  All  DTC  safety  set,  139  subjects  ( ≈ 30%)  received  lenvatinib  for  longer  than  24 months. Of these 139 subjects, 28.8% had a severe (Grade 3 or 4) TEAE after 24 months of treatment, most commonly  hypertension  (8  subjects,  5.8%)  and  diarrhea  (5,  3.6%).  The  most  frequently  reported  CSEs ( ≥ 10% of subjects) after 24 months of lenvatinib treatment in Lenvatinib either the All DTC (N=139) or NonDTC (N=26) safety sets were hypertension, proteinuria, hemorrhage, liver events, and PPE.

## Serious adverse event/deaths/other significant events

Table 50: Serious Adverse Events That Occurred in 3% or More of Subjects in the RCC Phases 1b+2 Combination Group - RCC, All DTC, and Non DTC Safety Sets

|                                         | Renal Cell Carcinoma                              | Renal Cell Carcinoma          | Renal Cell Carcinoma          | All DTC                   | Non-DTC                   |
|-----------------------------------------|---------------------------------------------------|-------------------------------|-------------------------------|---------------------------|---------------------------|
| Preferred Term                          | Lenvatinib + Everolimus 18mg + 5mg (N = 62)* n(%) | Lenvatinib 24mg (N = 52) n(%) | Everolimus 10mg (N = 50) n(%) | Lenvatinib (N = 458) n(%) | Lenvatinib (N = 656) n(%) |
| Subjects with at least One Serious TEAE | 38 (61.3)                                         | 28 (53.8)                     | 21 (42.0)                     | 263 (57.4)                | 314 (47.9)                |
| Dehydration                             | 6 (9.7)                                           | 0                             | 0                             | 15 (3.3)                  | 19 (2.9)                  |
| Renal Failure Acute                     | 5 (8.1)                                           | 4 (7.7)                       | 0                             | 6 (1.3)                   | 9 (1.4)                   |
| Anaemia                                 | 4 (6.5)                                           | 1 (1.9)                       | 4 (8.0)                       | 2 (0.4)                   | 2 (0.3)                   |
| Diarrhoea                               | 3 (4.8)                                           | 0                             | 0                             | 3 (0.7)                   | 14 (2.1)                  |
| Dyspnoea                                | 3 (4.8)                                           | 1 (1.9)                       | 2 (4.0)                       | 7 (1.5)                   | 9 (1.4)                   |
| Thrombocytopenia                        | 3 (4.8)                                           | 0                             | 0                             | 1 (0.2)                   | 3 (0.5)                   |
| Vomiting                                | 3 (4.8)                                           | 0                             | 0                             | 6 (1.3)                   | 19 (2.9)                  |
| Confusional State                       | 2 (3.2)                                           | 1 (1.9)                       | 0                             | 3 (0.7)                   | 7 (1.1)                   |
| General Physical Health Deterioration   | 2 (3.2)                                           | 0                             | 0                             | 8 (1.7)                   | 12 (1.8)                  |
| Hyperkalaemia                           | 2 (3.2)                                           | 0                             | 0                             | 0                         | 1 (0.2)                   |
| Musculoskeletal Chest Pain              | 2 (3.2)                                           | 1 (1.9)                       | 0                             | 2 (0.4)                   | 1 (0.2)                   |
| Pyrexia                                 | 2 (3.2)                                           | 0                             | 1 (2.0)                       | 3 (0.7)                   | 8 (1.2)                   |
| Renal Impairment                        | 2 (3.2)                                           | 0                             | 0                             | 1 (0.2)                   | 0                         |

## Deaths

Table 51: Table Listing of Fatal Adverse Events - Safety Analysis Set (Phase 2)

| Subject ID Age (yr), Sex, Race                      | Fatal Adverse Event Preferred term/ (Investigator Term)   | Relationship to Study Drug a                        | Study Day of AE Onset/ Death b                      | Last Dose Before Death (mg)                         | Duration of Treatment (days) c                      | Day of Death in Relation to Last Dose d             |
|-----------------------------------------------------|-----------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|
| Combination Arm (Lenvatinib 18mg + Everolimus 5 mg) | Combination Arm (Lenvatinib 18mg + Everolimus 5 mg)       | Combination Arm (Lenvatinib 18mg + Everolimus 5 mg) | Combination Arm (Lenvatinib 18mg + Everolimus 5 mg) | Combination Arm (Lenvatinib 18mg + Everolimus 5 mg) | Combination Arm (Lenvatinib 18mg + Everolimus 5 mg) | Combination Arm (Lenvatinib 18mg + Everolimus 5 mg) |
|                                                     | Cerebral haemorrhage (Brain hemorrhage)                   | Probably related                                    | 27 / 27                                             | 24 / 5e                                             | 26                                                  | 2                                                   |

<div style=\"page-break-after: always\"></div>

| Subject ID Age (yr), Sex, Race   | Fatal Adverse Event Preferred term/ (Investigator Term)   | Relationship to Study Drug a   | Study Day of AE Onset/ Death b   | Last Dose Before Death (mg)   | Duration of Treatment (days) c   | Day of Death in Relation to Last Dose d   |
|----------------------------------|-----------------------------------------------------------|--------------------------------|----------------------------------|-------------------------------|----------------------------------|-------------------------------------------|
| Lenvatinib 24 mg                 | Lenvatinib 24 mg                                          | Lenvatinib 24 mg               | Lenvatinib 24 mg                 | Lenvatinib 24 mg              | Lenvatinib 24 mg                 | Lenvatinib 24 mg                          |
|                                  | Myocardial infarction (Myocardial infarction)             | Possibly related               | 700 / 700                        | 10                            | 700                              | 1                                         |
|                                  | Haemorrhage intracranial (Intracranial hemorrhage)        | Not related                    | 195/ 195                         | 20                            | 168                              | 28                                        |
|                                  | Sepsis (Sepsis)                                           | Not related                    | 37 / 37                          | 24                            | 33                               | 5                                         |
| Everolimus 10 mg                 | Everolimus 10 mg                                          | Everolimus 10 mg               | Everolimus 10 mg                 | Everolimus 10 mg              | Everolimus 10 mg                 | Everolimus 10 mg                          |
|                                  | Acute respiratory failure (Acute respiratory failure) f   | Not related                    | 447 / 457                        | 10                            | 446                              | 12                                        |
|                                  | Escherichia sepsis (Sepsis E. coli)                       | Not related                    | 38 / 38                          | 10                            | 26                               | 13                                        |

Adverse event terms were coded using Medical Dictionary for Drug Regulatory Affairs (MedDRA) version 16.1. Includes treatment-emergent fatal AEs as of the data cutoff date (13 Jun 2014). Age is age at informed consent. AE = adverse event, F = female, M = male, W = white, yr = year.

- a: As assessed by the investigator.
- b: Study Day of Death = date of death - date of first dose of study drug +1
- c: Duration of Treatment = date of last dose of study drug - date of first dose of study drug +1
- d: Number of days between end of treatment with study drug and death.
- e: Lenvatinib dose / everolimus dose. Lenvatinib dose corrected post DBL to 18 mg in database (lenvatinib dosing in combination arm).
- f: Acute respiratory failure was secondary to pneumonia.

There  were  6  subjects  with  fatal  AEs:  1  in  the  combination  arm,  3  in  the  lenvatinib  arm  and  2  in  the everolimus  arm.  None  of  these  subjects  had  progressive  disease  reported  as  the  cause  of  death  by  the investigator. In 1 subject in the lenvatinib arm, the investigator did not specify whether progressive disease was present at the time of death.

The subject in the combination arm died of a cerebral haemorrhage that was considered probably related to study medication by the investigator. A 58-year-old White female diagnosed with metastatic clear cell renal cell carcinomahad medical history of anaemia, constipation and fatigue. Previous anticancer therapy included sunitinib.  Concomitant  medications  included  iron,  magnesium  and  senna  alexandrina.  ECOG  performance status at screening was 0. The subject was admitted to the hospital due to severe headache, hypertension and  vomiting.  Within  one  hour  of  admission,  the  subject  became  noncommunicative.  A  CT  of  the  brain showed cerebral haemorrhage. The study medication was withdrawn and the subject received the last dose of study medication. Later that day, one day after the last dose, the subject died due to cerebral haemorrhage. The Investigator considered this event serious and probably related to the study medication.

Of the 3 subjects that had fatal AEs in the lenvatinib group:

- 1 subject with a history of aortic arteriosclerosis and atherosclerotic calcification of coronary arteries died of a myocardial infarction that was considered possibly related to lenvatinib treatment by the investigator.
- 1 subject died of an intracranial haemorrhage that was considered not related to lenvatinib treatment; the investigator did not specify whether progressive disease was present at the time of death. This subject had a

<div style=\"page-break-after: always\"></div>

history of hypertension, craniotomy for microsurgical resection of brain metastases, and prior radiotherapy to the left frontal lobe.

- 1 subject died of sepsis that was considered not related to lenvatinib treatment by the investigator. The subject was hospitalized for both acute renal failure and sepsis (etiology unknown) at the time of death.

In the everolimus arm, one subject died of respiratory failure and the other subject died of E.coli sepsis. The first subject had pneumonia (Grade 3) that resulted in respiratory failure with pericardial effusion (Grade 3) and cardiac tamponade (Grade 4) as contributing factors.

One subject died of myocardial infarction in the combination arm after data cutoff date of 31July 2015 (see 'Long-term safety' section above).

## Laboratory findings

Table 52: Treatment Emergent Markedly Abnormal Laboratory Results - study 205 (Phase 2)

|                                                                   | RENAL Cell Carcinoma                                         | RENAL Cell Carcinoma                             | RENAL Cell Carcinoma   | RENAL Cell Carcinoma   | All DTC            |
|-------------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------|------------------------|------------------------|--------------------|
| Laboratory Test Statistic                                         | Lenvatinib 18mg + Everolimus 5mg Phase Ib + Phase II (N=62)* | Lenvatinib 18mg + Everolimus 5mg Phase II (N=51) | Lenvatinib 24mg (N=52) | Everolimus 10mg (N=50) | Lenvatinib (N=458) |
| HEMATOLOGY                                                        |                                                              |                                                  |                        |                        |                    |
| Hemoglobin                                                        |                                                              |                                                  |                        |                        |                    |
| Study Overall, n [a] Markedly Abnormal                            | 62                                                           | 51                                               | 51                     | 50                     | 447                |
| High                                                              | 1 (1.6)                                                      | 1 (2.0)                                          | 1 (2.0)                | 0                      | 5 (1.1)            |
| Markedly Abnormal Low                                             | 6 (9.7)                                                      | 5 (9.8)                                          | 2 (3.9)                | 12 (24.0)              | 21 (4.7)           |
| Platelets                                                         |                                                              |                                                  |                        |                        |                    |
| Study Overall, n [a]                                              | 61                                                           | 50                                               | 51                     | 50                     | 446                |
| Markedly Abnormal Low                                             | 9 (14.8)                                                     | 7 (14.0)                                         | 1 (2.0)                | 1 (2.0)                | 22 (4.9)           |
| Leukocytes                                                        |                                                              |                                                  |                        |                        |                    |
| Study Overall, n [a]                                              | 62                                                           | 51                                               | 51                     | 50                     | 447                |
| Markedly Abnormal Low                                             | 6 (9.7)                                                      | 5 (9.8)                                          | 2 (3.9)                | 5 (10.0)               | 33 (7.4)           |
| Neutrophils                                                       |                                                              |                                                  |                        |                        |                    |
| Study Overall, n [a]                                              | 61                                                           | 51                                               | 51                     | 50                     | 429                |
| Markedly Abnormal Low                                             | 6 (9.8)                                                      | 5 (9.8)                                          | 3 (5.9)                | 0                      | 34 (7.9)           |
| Lymphocytes                                                       |                                                              |                                                  |                        |                        |                    |
| Study Overall, n [a] Markedly Abnormal High Markedly Abnormal Low | 61                                                           | 51                                               | 51                     | 50                     | 423                |
| Study Overall, n [a] Markedly Abnormal High Markedly Abnormal Low | 3 (4.9)                                                      | 2 (3.9)                                          | 1 (2.0)                | 0                      | 9 (2.1)            |
| Study Overall, n [a] Markedly Abnormal High Markedly Abnormal Low | 20 (32.8)                                                    | 15 (29.4)                                        | 12 (23.5)              | 14 (28.0)              | 105 (24.8)         |
| CHEMISTRY                                                         |                                                              |                                                  |                        |                        |                    |
| Creatinine                                                        |                                                              |                                                  |                        |                        |                    |
| Study Overall, n [a]                                              | 62                                                           | 51                                               | 51                     | 50                     | 449                |
| Markedly Abnormal High                                            | 8 (12.9)                                                     | 7 (13.7)                                         | 5 (9.8)                | 6 (12.0)               | 57 (12.7)          |
| Aspartate Aminotransferase                                        |                                                              |                                                  |                        |                        |                    |
| Study Overall, n [a] Markedly Abnormal High                       | 62                                                           | 51                                               | 51                     | 50                     | 449                |
| Study Overall, n [a] Markedly Abnormal High                       | 5 (8.1)                                                      | 4 (7.8)                                          | 2 (3.9)                | 0                      | 26 (5.8)           |

<div style=\"page-break-after: always\"></div>

| Alanine Aminotransferase Study Overall, n [a]   | 62        | 51        | 51        | 48        | 449        |
|-------------------------------------------------|-----------|-----------|-----------|-----------|------------|
| Markedly Abnormal High                          | 6 (9.7)   | 4 (7.8)   | 2 (3.9)   | 2 (4.2)   | 32 (7.1)   |
| Alkaline Phosphatase                            |           |           |           |           |            |
| Study Overall, n [a]                            | 62        | 51        | 51        | 50        | 449        |
| Markedly Abnormal High                          | 5 (8.1)   | 4 (7.8)   | 3 (5.9)   | 1 (2.0)   | 17 (3.8)   |
| Bilirubin                                       |           |           |           |           |            |
| Study Overall, n [a]                            | 62        | 51        | 51        | 50        | 421        |
| Markedly Abnormal High                          | 1 (1.6)   | 1 (2.0)   | 1 (2.0)   | 0         | 24 (5.7)   |
| Potassium                                       |           |           |           |           |            |
| Study Overall, n [a]                            | 62        | 51        | 51        | 50        | 449        |
| Markedly Abnormal High                          | 5 (8.1)   | 5 (9.8)   | 6 (11.8)  | 3 (6.0)   | 25 (5.6)   |
| Markedly Abnormal Low                           | 4 (6.5)   | 4 (7.8)   | 4 (7.8)   | 1 (2.0)   | 27 (6.0)   |
| Sodium                                          |           |           |           |           |            |
| Study Overall, n [a]                            | 62        | 51        | 51        | 50        | 449        |
| Markedly Abnormal High                          | 0         | 0         | 1 (2.0)   | 0         | 4 (0.9)    |
| Markedly Abnormal Low                           | 7 (11.3)  | 5 (9.8)   | 3 (5.9)   | 3 (6.0)   | 27 (6.0)   |
| Calcium                                         |           |           |           |           |            |
| Study Overall, n [a]                            | 62        | 51        | 51        | 50        | 449        |
| Markedly Abnormal High                          | 1 (1.6)   | 1 (2.0)   | 1 (2.0)   | 1 (2.0)   | 17 (3.8)   |
| Markedly Abnormal Low                           | 8 (12.9)  | 6 (11.8)  | 7 (13.7)  | 3 (6.0)   | 101 (22.5) |
| Phosphate                                       |           |           |           |           |            |
| Study Overall, n [a]                            | 62        | 51        | 51        | 49        | 425        |
| Markedly Abnormal Low                           | 7 (11.3)  | 7 (13.7)  | 2 (3.9)   | 3 (6.1)   | 6 (1.4)    |
| Glucose Chemistry                               |           |           |           |           |            |
| Study Overall, n [a]                            | 61        | 50        | 51        | 48        | 425        |
| Markedly Abnormal High                          | 6 (9.8)   | 5 (10.0)  | 8 (15.7)  | 11 (22.9) | 30 (7.1)   |
| Markedly Abnormal Low                           | 1 (1.6)   | 0         | 1 (2.0)   | 1 (2.1)   | 14 (3.3)   |
| Triglycerides                                   |           |           |           |           |            |
| Study Overall, n [a]                            | 62        | 51        | 51        | 50        | 271        |
| Markedly Abnormal High                          | 18 (29.0) | 15 (29.4) | 11 (21.6) | 15 (30.0) | 20 (7.4)   |
| Cholesterol                                     |           |           |           |           |            |
| Study Overall, n [a]                            | 62        | 51        | 51        | 50        | 279        |
| Markedly Abnormal High                          | 19 (30.6) | 15 (29.4) | 6 (11.8)  | 6 (12.0)  | 36 (12.9)  |
| Albumin                                         |           |           |           |           |            |
| Study Overall, n [a]                            | 62        | 51        | 51        | 50        | 449        |
| Markedly Abnormal Low                           | 5 (8.1)   | 4 (7.8)   | 6 (11.8)  | 1 (2.0)   | 96 (21.4)  |
| Magnesium                                       |           |           |           |           |            |
| Study Overall, n [a]                            | 62        | 51        | 51        | 50        | 425        |
| Markedly Abnormal High                          | 0         | 0         | 0         | 0         | 4 (0.9)    |
| Markedly Abnormal Low                           | 3 (4.8)   | 3 (5.9)   | 6 (11.8)  | 0         | 17 (4.0)   |
| Creatine Kinase                                 |           |           |           |           |            |
| Study Overall, n [a]                            | 57        | 48        | 48        | 44        | 409        |
| Markedly Abnormal High                          | 8 (14.0)  | 6 (12.5)  | 3 (6.3)   | 6 (13.6)  | 24 (5.9)   |
| Triacylglycerol Lipase                          |           |           |           |           |            |
| Study Overall, n [a]                            | 57        | 48        | 48        | 44        | 362        |
| Markedly Abnormal High                          | 9 (15.8)  | 8 (16.7)  | 6 (12.5)  | 8 (18.2)  | 20 (5.5)   |

* Includes all subjects who received lenvatinib 18 mg + everolimus 5 mg dose from both Phase I and Phase II portion of study E7080-G000-205. [a] Indicates the number of subjects with nonmissing baseline and post-baseline data; this number is used to calculate percentages within each laboratory test. Markedly abnormal is defined as a value that is above or below the normal range and the CTCAE grade increased from baseline by 2 or more grades, except for phosphate which must have shifted by 3 or more grades. Subjects are counted only once for each row. Laboratory Results were graded using Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. The data cut off date for the RCC set is 31JUL2015, data cut off date for the All DTC set is 10DEC2014.

<div style=\"page-break-after: always\"></div>

## Safety in special populations

## Age

Overall there was no meaningful difference in the AE profile between the older ( ≥ 65 years)   and younger (&lt; 65  years)  subjects  for  the  RCC  combination  group.    The  findings  for  the  RCC  combination  group  were comparable with those for the All DTC and the Non DTC Safety Sets.

## Gender

No  meaningful  differences  between  male  and  female  subjects  for  the  RCC  combination  group  with  the exception  of  a  trend  toward  a  higher  rate  of  treatment  discontinuation  among  female  subjects  (44%) compared with male subjects (22.7%). However the numbers are low and no firm conclusion can be drawn.

## Race

The studied population was essentially white, other races were underrepresented.

## Weight

The RCC combination group showed similar mean decreases in body weight (maximum mean change: minus 15.83 kg) compared with that for the RCC lenvatinib group (maximum mean change:   minus 12.60 kg) at time points for which more than 2 subjects contributed data. The selected RCC patients had relatively high BMI and were not representative of  patients  with  lower  weight.  An  analysis  of  weight  loss  by  body  mass index done in the All DTC Safety Set indicated that weight loss was greater for subjects in the obese and overweight  categories  at  Baseline  than  for  subjects  in  the  underweight  or  normal  weight  categories.  The number of patients is too low to draw firm conclusions.

## Safety related to drug-drug interactions and other interactions

## Drug-drug interactions

Please refer to the PK assessment report and PD section (Section 2.4) of this report.

## Drug-disease interactions

The  safety  of  lenvatinib  in  combination  with  everolimus  was  evaluated  in  subjects  with  potential  baseline disease risk factors. These include renal impairment, hepatic impairment, hypertension, and diabetes.

The  CSE  of  Renal  Events  tended  to  occur  at  a  higher  incidence  rate  in  subjects  with  baseline  renal impairment compared with those without baseline renal impairment for the RCC combination group (27.8% vs. 13.6%). This difference was also observed for the All DTC Safety Set (24.5% vs. 11.5%); a similar trend was observed for the Non-DTC Safety Set 11.5% vs. 6.9%).

The  safety  of  lenvatinib  in  combination  with  everolimus  in  subjects  with  RCC  was  evaluated  by  baseline hepatic function: Not Impaired and Impaired subgroups. Subjects were considered to have baseline hepatic impairment  if  their  baseline  AST,  ALT,  or  bilirubin  levels  were  a  CTCAE  Grade  1  or  higher  (Impaired subgroup). For the RCC Safety Set groups, the number of subjects with impaired hepatic function at baseline

<div style=\"page-break-after: always\"></div>

was very small: 6 subjects overall; 3 (4.8%) of 62 subjects in the RCC combination group and 3 (5.8%) of 52 subjects in the RCC lenvatinib group. Because the percentage of subjects in the RCC combination group was less than 5%, no meaningful comparisons can be made. Therefore, baseline hepatic function was not further discussed.

Baseline hypertension (yes vs no subgroups) was evaluated as risk factor. The overall incidence rate of SAEs for the RCC Safety Set, were similar (63.0% vs. 56.3%) in subjects with and without baseline hypertension. Patients  with  baseline  hypertension  had  a  higher  incidence  of  Grade 3  or  4  dehydration,  fatigue,  and hypertension (SmPC section 4.8). The following higher incidence rate in subjects with baseline hypertension than in  those  without  in  the  RCC  combination  group  were  reported: dehydration  (10.9%  vs.  0%),  fatigue (15.2% vs. 6.3%), and hypertension (17.4% vs. 0%).

Subjects  were  considered  to  have  baseline  diabetes  if  they  had  a  medical  history  of  diabetes  or hyperglycaemia or received any prior diabetic medications. Although the number of subjects with baseline diabetes  was  small  (n=9)  in  the  RCC  combination  group,  severe  acute  renal  failure  (22.2%  vs.  5.7%), hypertension (22.2% vs. 11.3%), and hypertriglyceridemia (33.3% vs. 9.4%) tended to be reported at a higher  incidence  rate  in  subjects  with  baseline  diabetes  than  in  those  without  baseline  diabetes.  Of  note, severe diarrhea and fatigue occurred more frequently in subjects without baseline diabetes than in those with baseline  diabetes  in  the  RCC  combination  group.  The  following  common  TEAEs  were  reported  at  a  higher incidence  rate  in  subjects  with  baseline  diabetes  than  in  those  without  baseline  diabetes  for  the  RCC combination group: abdominal distension (22.2% vs. 5.7%), acute renal failure (22.2% vs. 5.7%), asthenia (33.3% vs. 22.6%), hyperglycaemia (33.3% vs. 15.1%), hyperkalemia (22.2% vs. 5.7%), hypertriglyceridemia (55.6% vs. 37.7%), musculoskeletal chest pain (33.3% vs. 15.1%), nausea (55.6% vs. 43.4%), and vomiting (66.7% vs. 45.3%). Therefore, the SmPC section 4.8 states that patients with baseline diabetes had a higher incidence of Grade 3 or 4 hypertension, hypertriglyceridemia and acute renal failure.

## Discontinuation due to adverse events

In the RCC study 18 (29%) of patients discontinued treatment due to adverse events. Most individual AEs leading to study treatment discontinuation were reported in not more than 1 subject; the only AEs that led to discontinuation in more than 1 subject were thrombocytopenia in 2 (3.9%) subjects in the combination arm, myocardial infarction/acute myocardial infarction in 2 (3.9%) subjects in the lenvatinib arm, and pneumonitis in  2  (4.0%)  subjects  in  the  everolimus  arm.  Five  (9.8%)  subjects  in  the  combination  arm,  8  (15.4%) subjects in the lenvatinib arm, and 3 (6.0%) subjects in the everolimus arm discontinued study medication as a result of Grade 3 or 4 AEs.

The rate of discontinuation due to TEAEs in the Phase 1b+2 combination arm as of 31 Jul 2015 was similar before Cycle 5 (5 subjects; 0.24/subject year [SY]) and after Cycle 5 (9 subjects; 0.26/SY).

Eight subjects, 3 in each of the combination and lenvatinib arms, and 2 in the everolimus arm, discontinued study medication due to 1 or more Grade 4 or 5 AEs. These events included a) Grade 4 hypokalemia, Grade 4 dyspnoea,  and  Grade  5  cerebral  haemorrhage  in  1  subject  each  in  the  combination  arm,  b)  Grade  5 myocardial  infarction,  Grade  4  intracranial  haemorrhage,  and  Grade  4  sepsis  in  1  subject  each  in  the lenvatinib arm and c) Grade 4 pulmonary embolism and Grade 4 Escherichia sepsis in 1 subject each in the everolimus arm.

<div style=\"page-break-after: always\"></div>

Table 53: Adverse Events Leading to Study Treatment Discontinuation by Preferred Term - Study 205 (Phase 2)

| MedDRA Preferred Term                                          | Lenvatinib + Everolimus 18mg + 5mg (N = 51) n (%)   | Lenvatinib + Everolimus 18mg + 5mg (N = 51) n (%)   | Lenvatinib + Everolimus 18mg + 5mg (N = 51) n (%)   | Lenvatinib 24 mg (N = 52) n (%)   | Lenvatinib 24 mg (N = 52) n (%)   | Lenvatinib 24 mg (N = 52) n (%)   | Everolimus 10 mg (N = 50) n (%)   | Everolimus 10 mg (N = 50) n (%)   | Everolimus 10 mg (N = 50) n (%)   |
|----------------------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| MedDRA Preferred Term                                          | All Grade                                           | Gr 3                                                | Gr 4                                                | All Grade                         | Gr 3                              | Gr 4                              | All Grade                         | Gr 3                              | Gr 4                              |
| Subjects with any TEAEs Leading to Treatment Discontinuation a | 13 (25.5)                                           |                                                     |                                                     | 16 (30.8)                         |                                   |                                   | 6 (12.0)                          |                                   |                                   |
| Thrombocytopenia                                               | 2 (3.9)                                             |                                                     |                                                     |                                   |                                   |                                   |                                   |                                   |                                   |
| Alanine Aminotransferase Increased                             | 1 (2.0)                                             | 1 (2.0)                                             |                                                     | 1 (2.0)                           |                                   |                                   |                                   |                                   |                                   |
| Arthralgia                                                     | 1 (2.0)                                             |                                                     |                                                     |                                   |                                   |                                   |                                   |                                   |                                   |
| Aspartate Aminotransferase Increased                           | 1 (2.0)                                             | 1 (2.0)                                             |                                                     |                                   |                                   |                                   |                                   |                                   |                                   |
| Cerebral Haemorrhage b                                         | 1 (2.0)                                             |                                                     |                                                     |                                   |                                   |                                   |                                   |                                   |                                   |
| Confusional State                                              | 1 (2.0)                                             | 1 (2.0)                                             |                                                     |                                   |                                   |                                   |                                   |                                   |                                   |
| Convulsion                                                     | 1 (2.0)                                             | 1 (2.0)                                             |                                                     |                                   |                                   |                                   |                                   |                                   |                                   |
| Diarrhoea                                                      | 1 (2.0)                                             | 1 (2.0)                                             |                                                     |                                   |                                   |                                   |                                   |                                   |                                   |
| Dyspnoea                                                       | 1 (2.0)                                             |                                                     | 1 e (2.0)                                           |                                   |                                   |                                   | 1 (2.0)                           |                                   |                                   |
| Gastric Haemorrhage                                            | 1 (2.0)                                             | 1 (2.0)                                             |                                                     |                                   |                                   |                                   |                                   |                                   |                                   |
| Hepatic Pain                                                   | 1 (2.0)                                             |                                                     |                                                     |                                   |                                   |                                   |                                   |                                   |                                   |
| Hyperkalaemia                                                  | 1 (2.0)                                             |                                                     | 1 (2.0)                                             |                                   |                                   |                                   |                                   |                                   |                                   |
| Hypokalaemia                                                   | 1 (2.0)                                             |                                                     |                                                     |                                   |                                   |                                   |                                   |                                   |                                   |
| Hypomagnesaemia                                                | 1 (2.0)                                             | 1 (2.0)                                             |                                                     |                                   |                                   |                                   |                                   |                                   |                                   |
| Penile Oedema                                                  | 1 (2.0)                                             |                                                     |                                                     |                                   |                                   |                                   |                                   |                                   |                                   |
| Proteinuria                                                    | 2 (3.9)                                             |                                                     |                                                     | 3 (5.8)                           | 1 (1.9)                           |                                   |                                   |                                   |                                   |
| Weight Decreased                                               | 1 (2.0)                                             |                                                     |                                                     | 1 (1.9)                           |                                   |                                   |                                   |                                   |                                   |
| Acute Myocardial Infarction                                    |                                                     |                                                     |                                                     | 1 (1.9)                           | 1 (1.9)                           |                                   |                                   |                                   |                                   |
| Back Pain                                                      |                                                     |                                                     |                                                     | 1 (1.9)                           |                                   |                                   |                                   |                                   |                                   |
| Cholecystitis                                                  |                                                     |                                                     |                                                     | 1 (1.9)                           |                                   |                                   |                                   |                                   |                                   |
| Ejection Fraction Decreased                                    |                                                     |                                                     |                                                     | 1 (1.9)                           |                                   |                                   |                                   |                                   |                                   |
| Escherichia Sepsis                                             |                                                     |                                                     |                                                     |                                   |                                   |                                   | 1 (2.0)                           |                                   | 1 (2.0)                           |
| Haemorrhage Intracranial                                       |                                                     |                                                     |                                                     | 1 (1.9)                           |                                   | 1 (1.9)                           |                                   |                                   |                                   |
| Inappropriate Antidiuretic Hormone Secretion                   |                                                     |                                                     |                                                     | 1 (1.9)                           | 1 (1.9)                           |                                   |                                   |                                   |                                   |
| Metastatic Pain c                                              |                                                     |                                                     |                                                     | 1 (1.9)                           |                                   |                                   |                                   |                                   |                                   |
| Myocardial Infarction b                                        |                                                     |                                                     |                                                     | 1 (1.9)                           |                                   |                                   |                                   |                                   |                                   |
| Osteolysis                                                     |                                                     |                                                     |                                                     | 1 (1.9)                           | 1 (1.9)                           |                                   |                                   |                                   |                                   |
| Pneumonitis                                                    |                                                     |                                                     |                                                     |                                   |                                   |                                   | 2 (4.0)                           | 1 (2.0)                           |                                   |
| Posterior Reversible Encephalopathy Syndrome                   |                                                     |                                                     |                                                     | 1 (1.9)                           | 1 (1.9)                           |                                   |                                   |                                   |                                   |
| Pulmonary Embolism                                             |                                                     |                                                     |                                                     |                                   |                                   |                                   | 1 (2.0)                           |                                   | 1 (2.0)                           |
| Renal Failure Acute                                            |                                                     |                                                     |                                                     | 1 (1.9)                           | 1 (1.9)                           |                                   |                                   |                                   |                                   |
| Sepsis                                                         |                                                     |                                                     |                                                     | 1 (1.9) b                         |                                   | 1 (1.9)                           |                                   |                                   |                                   |
| Spinal Cord Compression d                                      |                                                     |                                                     |                                                     |                                   |                                   |                                   | 1 (2.0)                           |                                   |                                   |

Data cutoff date = 13 Jun 2014 and 31 jul 2015 (yellow) . Percentages are based on the total number of subjects in the Safety Analysis Set within relevant treatment group. Display is in decreasing order of frequency of TEAEs in the (lenvatinib + everolimus) arm. Adverse Events terms were coded using Medical Dictionary for Regulatory Activities (MedDRA) version 16.1. Gr = grade, TEAE = treatment-emergent adverse event.

<div style=\"page-break-after: always\"></div>

- a: Subjects with 2 or more adverse events in the same preferred term are counted only once for that preferred term.
- b: Grade 5. See Table 32 for a listing of subjects with fatal adverse events.
- c: Subject had clinical progression (rib lesion) at the time of the event.
- d: Subject had progressive disease (L2 vertebral body lesion) at the time of the event.
- e: Investigator reported term was shortness of breath due to disease progression.

## Dose modifications (reductions and interruptions)

Table 54: Time to First Dose Reduction among Subjects with Dose Reduction

|                                            | Renal Cell Carcinoma                                           | Renal Cell Carcinoma                               | Renal Cell Carcinoma            | Renal Cell Carcinoma            | All DTC                         |
|--------------------------------------------|----------------------------------------------------------------|----------------------------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                            | Lenvatinib 18mg + Everolimus 5mg Phase Ib + Phase II (N = 62)* | Lenvatinib 18mg + Everolimus 5mg Phase II (N = 51) | Lenvatinib 24mg (N = 52)        | Everolimus 10mg (N = 50)        | Lenvatinib (N = 458)            |
| Subjects with Any Dose Reduction[1], n (%) | 44 (71.0)                                                      | 36 (70.6)                                          | 32 (61.5)                       | 13 (26.0)                       | 357 (77.9)                      |
| Time to Dose Reduction (Months)            | Time to Dose Reduction (Months)                                | Time to Dose Reduction (Months)                    | Time to Dose Reduction (Months) | Time to Dose Reduction (Months) | Time to Dose Reduction (Months) |
| Median (95% CI)                            | 1.8 (1.3, 2.5)                                                 | 1.7 (1.1, 2.5)                                     | 2.3 (1.8, 3.3)                  | 2.5 (1.9, 7.8)                  | 2.3 (1.8, 2.8)                  |
| Q1, Q3                                     | 1.1 ,3.7                                                       | 1.0 ,3.6                                           | 1.5 ,4.0                        | 2.1 ,7.8                        | 0.9 ,5.1                        |

* Includes all subjects who received lenvatinib 18 mg + everolimus 5 mg dose from both Phase I and Phase II portion of study E7080-G000-205. [1] Includes subjects with dose reduction in either lenvatinib or everolimus. [2] Includes subjects with dose reduction in lenvatinib. [3] Includes subjects with dose reduction in everolimus. 95% CI was estimated using the log-log transformation from Kaplan-Meier method. Percentages are based on total number of subjects in each treatment group within each safety analysis set. The data cut off date for the RCC set is 31JUL2015, data cut off date for the All DTC set is 10DEC2014.

## · Lenvatinib

Table 55: Summary of Last Dose Levels for Lenvatinib - Safety Analysis Set

| Last Dose Levels [a]   | Lenvatinib 18mg + Everolimus 5mg Phase Ib + Phase II (N=62)* n(%)   | Lenvatinib 18mg + Everolimus 5mg Phase II (N=51) n(%)   | Lenvatinib 24mg (N=52) n(%)   |
|------------------------|---------------------------------------------------------------------|---------------------------------------------------------|-------------------------------|
| 24 mg                  | 0 ( 0.0)                                                            | 0 ( 0.0)                                                | 20 ( 38.5)                    |
| 20 mg                  | 0 ( 0.0)                                                            | 0 ( 0.0)                                                | 15 ( 28.8)                    |
| 18 mg                  | 18 ( 29.0)                                                          | 15 ( 29.4)                                              | 0 ( 0.0)                      |
| 14 mg                  | 19 ( 30.6)                                                          | 15 ( 29.4)                                              | 6 ( 11.5)                     |
| 10 mg                  | 14 ( 22.6)                                                          | 12 ( 23.5)                                              | 8 ( 15.4)                     |
| 8 mg                   | 10 ( 16.1)                                                          | 8 ( 15.7)                                               | 2 ( 3.8)                      |
| 4 mg                   | 1 ( 1.6)                                                            | 1 ( 2.0)                                                | 1 ( 1.9)                      |

<div style=\"page-break-after: always\"></div>

Table 55: Summary of Last Dose Levels for Lenvatinib - Safety Analysis Set

| Last Dose Levels [a]   | Lenvatinib 18mg + Everolimus 5mg Phase Ib + Phase II (N=62)* n(%)   | Lenvatinib 18mg + Everolimus 5mg Phase II (N=51) n(%)   | Lenvatinib 24mg (N=52) n(%)   |
|------------------------|---------------------------------------------------------------------|---------------------------------------------------------|-------------------------------|

* Includes all subjects who received lenvatinib 18 mg + everolimus 5 mg dose from both Phase I and Phase II portion of study E7080-G000-205.

Percentages are based on the total number of subjects in the safety analysis set within relevant treatment group.

[a] This is the last non-zero dose.

Table 56: Dose reductions and interruptions in lenvatinib (data cutoff 31Jul2015)

|                                                   | Renal Cell Carcinoma                                                 | Renal Cell Carcinoma                                     | Renal Cell Carcinoma           | All DTC                    |
|---------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------|--------------------------------|----------------------------|
|                                                   | Lenvatinib 18mg + Everolimus 5mg Phase Ib + Phase II (N = 62)* n (%) | Lenvatinib 18mg + Everolimus 5mg Phase II (N = 51) n (%) | Lenvatinib 24mg (N = 52) n (%) | Lenvatinib (N = 458) n (%) |
| Dose Reduction                                    | Dose Reduction                                                       | Dose Reduction                                           | Dose Reduction                 | Dose Reduction             |
| Total Number of Subjects with Dose Reduction      | 44 (71.0)                                                            | 36 (70.6)                                                | 32 (61.5)                      | 357 (77.9)                 |
| Cycle of First Dose Reduction (until cycle 10)    |                                                                      |                                                          |                                |                            |
| Cycle 1                                           | 6 (9.7)                                                              | 6 (11.8)                                                 | 4 (7.7)                        | 92 (20.1)                  |
| Cycle 2                                           | 16 (25.8)                                                            | 13 (25.5)                                                | 6 (11.5)                       | 70 (15.3)                  |
| Cycle 3                                           | 8 (12.9)                                                             | 6 (11.8)                                                 | 10 (19.2)                      | 29 (6.3)                   |
| Cycle 4                                           | 3 (4.8)                                                              | 2 (3.9)                                                  | 3 (5.8)                        | 35 (7.6)                   |
| Cycle 5                                           | 1 (1.6)                                                              | 1 (2.0)                                                  | 3 (5.8)                        | 28 (6.1)                   |
| Cycle 6                                           | 4 (6.5)                                                              | 3 (5.9)                                                  | 2 (3.8)                        | 21 (4.6)                   |
| Cycle 7                                           | 1 (1.6)                                                              | 1 (2.0)                                                  | 1 (1.9)                        | 24 (5.2)                   |
| Cycle 8                                           | 2 (3.2)                                                              | 2 (3.9)                                                  | 2 (3.8)                        | 7 (1.5)                    |
| Cycle 9                                           | 1 (1.6)                                                              | 1 (2.0)                                                  | -                              | 9 (2.0)                    |
| Cycle 10                                          | -                                                                    | -                                                        | -                              | 6 (1.3)                    |
| Frequency of Dose Reductions [1]                  |                                                                      |                                                          |                                |                            |
| 1                                                 | 19 (30.6)                                                            | 15 (29.4)                                                | 15 (28.8)                      | 98 (21.4)                  |
| 2                                                 | 14 (22.6)                                                            | 12 (23.5)                                                | 6 (11.5)                       | 115 (25.1)                 |
| 3                                                 | 10 (16.1)                                                            | 8 (15.7)                                                 | 8 (15.4)                       | 94 (20.5)                  |
| >=4                                               | 1 (1.6)                                                              | 1 (2.0)                                                  | 3 (5.8)                        | 50 (10.9)                  |
| Dose Interruptions                                | Dose Interruptions                                                   | Dose Interruptions                                       | Dose Interruptions             | Dose Interruptions         |
| Total Number of Subjects with Dose Interruptions  | 50 (80.6)                                                            | 41 (80.4)                                                | 39 (75.0)                      | 282 (61.6)                 |
| Cycle of First Dose Interruption (until cycle 10) |                                                                      |                                                          |                                |                            |
| Cycle 1                                           | 18 (29.0)                                                            | 16 (31.4)                                                | 11 (21.2)                      | 54 (11.8)                  |

<div style=\"page-break-after: always\"></div>

| Cycle 2                                        | 15 (24.2)   | 11 (21.6)            | 10 (19.2)   | 39 (8.5)   |
|------------------------------------------------|-------------|----------------------|-------------|------------|
| Cycle 3                                        | 6 (9.7)     | 6 (11.8)             | 5 (9.6)     | 39 (8.5)   |
| Cycle 4                                        | 3 (4.8)     | 2 (3.9)              | 6 (11.5)    | 33 (7.2)   |
| Cycle 5                                        | 2 (3.2)     | 2 (3.9)              | 3 (5.8)     | 18 (3.9)   |
| Cycle 6                                        | 4 (6.5)     | 3 (5.9)              | -           | 12 (2.6)   |
| Cycle 7                                        | 2 (3.2)     | 1 (2.0)              | 3 (5.8)     | 9 (2.0)    |
| Cycle 8                                        | -           | -                    | -           | 5 (1.1)    |
| Cycle 9                                        | -           | -                    | -           | 15 (3.3)   |
| Cycle 10                                       | -           | -                    | 1 (1.9)     | 11 (2.4)   |
| Frequency of Dose Interruptions                |             |                      |             |            |
| 1                                              | 17 (27.4)   | 13 (25.5)            | 10 (19.2)   | 83 (18.1)  |
| 2                                              | 9 (14.5)    | 7 (13.7)             | 10 (19.2)   | 50 (10.9)  |
| 3                                              | 4 (6.5)     | 4 (7.8)              | 8 (15.4)    | 37 (8.1)   |
| >=4                                            | 20 (32.3)   | 17 (33.3)            | 11 (21.2)   | 112 (24.5) |
|                                                |             | Dose Discontinuation |             |            |
| Drug Discontinuation due to AE                 | 18 (29.0)   | 13 (25.5)            | 16 (30.8)   | 96 (21.0)  |
| Cycle of Drug Discontinuation (until cycle 10) |             |                      |             |            |
| Cycle 1                                        | 1 (1.6)     | 1 (2.0)              | 2 (3.8)     | 16 (3.5)   |
| Cycle 2                                        | 1 (1.6)     | 1 (2.0)              | 1 (1.9)     | 10 (2.2)   |
| Cycle 3                                        | 1 (1.6)     | 1 (2.0)              | 2 (3.8)     | 10 (2.2)   |
| Cycle 4                                        | 2 (3.2)     | 1 (2.0)              | 1 (1.9)     | 10 (2.2)   |
| Cycle 5                                        | 2 (3.2)     | 1 (2.0)              | -           | 7 (1.5)    |
| Cycle 6                                        | 3 (4.8)     | 2 (3.9)              | 1 (1.9)     | 4 (0.9)    |
| Cycle 7                                        | 3 (4.8)     | 3 (5.9)              | 2 (3.8)     | 7 (1.5)    |
| Cycle 8                                        | -           | -                    | -           | 1 (0.2)    |
| Cycle 9                                        | 1 (1.6)     | 1 (2.0)              | 1 (1.9)     | 5 (1.1)    |
| Cycle 10                                       | -           | -                    | 2 (3.8)     | 4 (0.9)    |
| Cycle 11                                       | -           | -                    | -           | 1 (0.2)    |
| Cycle 13                                       | -           | -                    | -           | 1 (0.2)    |
| Cycle 14                                       | -           | -                    | -           | 1 (0.2)    |
| Cycle 15                                       | 1 (1.6)     | -                    | -           | 1 (0.2)    |
| Cycle 16                                       | -           | -                    | -           | 2 (0.4)    |
| Cycle 18                                       | 1 (1.6)     | -                    | -           | 1 (0.2)    |
| Cycle 19                                       | -           | -                    | -           | 1 (0.2)    |
| Cycle 20                                       | 1 (1.6)     | 1 (2.0)              | 1 (1.9)     | -          |
| Cycle 21                                       | -           | -                    | -           | 2 (0.4)    |
| Cycle 22                                       | -           | -                    | 1 (1.9)     | 3 (0.7)    |
| Cycle 23                                       | -           | -                    | -           | 1 (0.2)    |
| Cycle 25                                       | -           | -                    | 2 (3.8)     | 2 (0.4)    |
| Cycle 30                                       | 1 (1.6)     | 1 (2.0)              | -           | -          |
| Cycle 32                                       | -           | -                    | -           | 3 (0.7)    |
| Cycle 33                                       | -           | -                    | -           | 2 (0.4)    |
| Cycle 45                                       | -           | -                    | -           | 1 (0.2)    |

* Includes all subjects who received lenvatinib 18 mg + everolimus 5 mg dose from both Phase I and Phase II portion of study E7080-G000-205. [1] Dose reductions calculated directly from the dosing record (based on the planned dose). Drug discontinuation is based on AE data. Percentages are based on total number of subjects in each treatment group within each safety analysis set. The data cut off date for the RCC set is 31JUL2015, data cut off date for the All DTC set is 10DEC2014.

<div style=\"page-break-after: always\"></div>

## · Everolimus.

In the RCC combination group, 77.4% of subjects had 1 or more dose interruptions of everolimus compared to 54% of subjects in everolimus arm. Drug discontinuation occurred in 12% of patients in the everolimus group and it was 29% in the combination group.

Table 57: Dose interruptions in everolimus (data cutoff 31Jul2015)

|                                                   | Renal Cell Carcinoma                                                 | Renal Cell Carcinoma                                     | Renal Cell Carcinoma            |
|---------------------------------------------------|----------------------------------------------------------------------|----------------------------------------------------------|---------------------------------|
|                                                   | Lenvatinib 18mg + Everolimus 5mg Phase Ib + Phase II (N = 62)* n (%) | Lenvatinib 18mg + Everolimus 5mg Phase II (N = 51) n (%) | Everolimus 10 mg (N = 50) n (%) |
| Total Number of Subjects with Dose Reduction      | 1 (1.6)                                                              | 1 (2.0)                                                  | 13 (26)                         |
| Cycle of First Dose Reduction (until cycle 10)    |                                                                      |                                                          |                                 |
| Cycle 2                                           | 0                                                                    | 6 (11.8)                                                 | 2 (4.0)                         |
| Cycle 3                                           | 0                                                                    | 13 (25.5)                                                | 5 (10.0)                        |
| Cycle 6                                           | 1 (1.6)                                                              | 1 (2.0)                                                  | 1 (2.0)                         |
| Cycle 7                                           | 0                                                                    | 2 (3.9)                                                  | 1 (2.0)                         |
| Cycle 9                                           | 0                                                                    | 1 (2.0)                                                  | 1 (2.0)                         |
| Cycle 11                                          | 0                                                                    | 3 (5.9)                                                  | 2 (4.0)                         |
| Cycle 12                                          | 0                                                                    | 1 (2.0)                                                  | 1 (2.0)                         |
| Frequency of Dose Reductions [1]                  |                                                                      |                                                          |                                 |
| 1                                                 | 1 (1.6)                                                              | 1 (2.0)                                                  | 13 (26.0)                       |
| 2                                                 | 0                                                                    | 0                                                        | 0                               |
| 3                                                 | 0                                                                    | 0                                                        | 0                               |
| >=4                                               | 0                                                                    | 0                                                        | 0                               |
| Total Number of Subjects with Dose Interruptions  | 48 (77.4)                                                            | 39 (76.5)                                                | 27 (54.0)                       |
| Cycle of First Dose Interruption (until cycle 10) |                                                                      |                                                          |                                 |
| Cycle 1                                           | 18 (29.0)                                                            | 16 (31.4)                                                | 4 (8.0)                         |
| Cycle 2                                           | 14 (22.2)                                                            | 10 (19.6)                                                | 8 (16.0)                        |
| Cycle 3                                           | 4 (6.5)                                                              | 4 (7.8)                                                  | 6 (12.0)                        |
| Cycle 4                                           | 3 (4.8)                                                              | 2 (3.9)                                                  | 3 (6.0)                         |
| Cycle 5                                           | 2 (3.2)                                                              | 2 (3.9)                                                  | 1 (2.0)                         |
| Cycle 6                                           | 4 (6.5)                                                              | 3 (5.9)                                                  | 1 (2.0)                         |
| Cycle 7                                           | 2 (3.2)                                                              | 1 (2.0)                                                  | 1 (2.0)                         |
| Cycle 8                                           | 0                                                                    | 0                                                        | 1 (2.0)                         |
| Cycle 9                                           | 1 (1.6)                                                              | 1 (2.0)                                                  | 0                               |
| Cycle 10                                          | 0                                                                    | 0                                                        | 1 (2.0)                         |
| Cycle 11                                          | 0                                                                    | 0                                                        | 1 (2.0)                         |
| Frequency of Dose Interruptions                   |                                                                      |                                                          |                                 |
| 1                                                 | 16 (25.8)                                                            | 12 (23.5)                                                | 15 (30.0)                       |

<div style=\"page-break-after: always\"></div>

| 2                               | 9 (14.5)   | 7 (13.7)   | 8 (16.0)   |
|---------------------------------|------------|------------|------------|
| 3                               | 3 (4.8)    | 3 (5.9)    | 1 (2.0)    |
| >=4                             | 20 (32.3)  | 17 (33.3)  | 3 (6.0)    |
| Drug discontinuation due to AEs | 18 (29.0)  | 13 (25.5)  | 6 (12.0)   |

## Adverse events that required dose reduction or interruption

The  treatment-emergent adverse  event  (TEAE)  that  most  frequently  led  to  dose  reduction  was  diarrhoea. Dose reductions for diarrhoea occurred at a higher frequency in the RCC combination arm (21.0%) compared with the RCC lenvatinib arm (13.5%) as well as for the All DTC (10.5%) and Non-DTC (3.5%) safety sets.

Table 58: Treatment-Emergent Adverse Events That Led to Dose Reduction in Greater Than 3% of Subjects for the RCC Phases 1b+2 Combination Group - RCC, All DTC, and Non DTC Safety Sets

|                                                          | Renal Cell Carcinoma                               | Renal Cell Carcinoma           | Renal Cell Carcinoma           | All DTC                    | Non-DTC                    |
|----------------------------------------------------------|----------------------------------------------------|--------------------------------|--------------------------------|----------------------------|----------------------------|
| Preferred Term                                           | Lenvatinib + Everolimus 18mg + 5mg (N = 62)* n (%) | Lenvatinib 24mg (N = 52) n (%) | Everolimus 10mg (N = 50) n (%) | Lenvatinib (N = 458) n (%) | Lenvatinib (N = 656) n (%) |
| Subjects with at least 1 TEAE that led to dose reduction | 42 (67.7)                                          | 30 (57.7)                      | 8 (16.0)                       | 298 (65.1)                 | 186 (28.4)                 |
| Diarrhoea                                                | 13 (21.0)                                          | 7 (13.5)                       | -                              | 48 (10.5)                  | 23 (3.5)                   |
| Thrombocytopenia                                         | 4 (6.5)                                            | -                              | -                              | 8 (1.7)                    | 6 (0.9)                    |
| Vomiting                                                 | 4 (6.5)                                            | 1 (1.9)                        | -                              | 13 (2.8)                   | 7 (1.1)                    |
| Fatigue                                                  | 3 (4.8)                                            | 3 (5.8)                        | 1 (2.0)                        | 42 (9.2)                   | 35 (5.3)                   |
| Nausea                                                   | 3 (4.8)                                            | 4 (7.7)                        | -                              | 23 (5.0)                   | 8 (1.2)                    |
| Proteinuria                                              | 3 (4.8)                                            | 3 (5.8)                        | 1 (2.0)                        | 50 (10.9)                  | 21 (3.2)                   |
| Abdominal Pain Upper                                     | 2 (3.2)                                            | -                              | -                              | 4 (0.9)                    | -                          |
| Asthenia                                                 | 2 (3.2)                                            | 2 (3.8)                        | 1 (2.0)                        | 21 (4.6)                   | 9 (1.4)                    |
| Decreased Appetite                                       | 2 (3.2)                                            | 3 (5.8)                        | -                              | 36 (7.9)                   | 18 (2.7)                   |
| Hypertriglyceridaemia                                    | 2 (3.2)                                            | -                              | -                              | -                          | -                          |
| Stomatitis                                               | 2 (3.2)                                            | 1 (1.9)                        | -                              | 20 (4.4)                   | 13 (2.0)                   |
| Weight Decreased                                         | 2 (3.2)                                            | 1 (1.9)                        | -                              | 37 (8.1)                   | 13 (2.0)                   |

Adverse events leading to dose reduction and/or interruption as an action occurred with frequency of 88.7%, 78.8%  and  54%  respectively  in  the  combination  group,  lenvatinib  and  everolimus  arms.  Gastrointestinal events, including diarrhea, vomiting and upper abdominal pain, resulted in dose reduction and/or interruption more often in the combination than in the lenvatinib and everolimus arms. Grade 3 or 4 diarrhea led to dose reduction and/or interruption in 7 subjects (11.3%) in the combination, 5 subjects (9.6%) in the lenvatinib, and 1 subject (2.0%) in the everolimus arm.

<div style=\"page-break-after: always\"></div>

Table 59: Treatment-Emergent Adverse Events Leading to Dose Reduction and/or Dose Interruption in at Least 2 subjects in the Phase 2 part of Study 205 or 2% of All DTC Lenvatinib Safety Set.

|                                                                       | Renal Cell Carcinoma                                         | Renal Cell Carcinoma                                         | Renal Cell Carcinoma         | Renal Cell Carcinoma         | Renal Cell Carcinoma         | Renal Cell Carcinoma         | All DTC                      | All DTC                      |
|-----------------------------------------------------------------------|--------------------------------------------------------------|--------------------------------------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|------------------------------|
|                                                                       | Lenvatinib 18mg + Everolimus 5mg Phase Ib + Phase II (N=62)* | Lenvatinib 18mg + Everolimus 5mg Phase Ib + Phase II (N=62)* | Lenvatinib 24mg              | Lenvatinib 24mg              | Everolimus 10mg              | Everolimus 10mg              | Lenvatinib                   | Lenvatinib                   |
| Preferred Term                                                        | All Grade                                                    | Grade 3 or 4                                                 | All Grade                    | Grade 3 or 4                 | All Grade                    | Grade 3 or 4                 | All Grade                    | Grade 3 or 4                 |
| Subjects with any TEAEs Leading to Dose Reduction and/or Interruption | 55 (88.7)                                                    | 39 (62.9)                                                    | 41 (78.8)                    | 29 (55.8)                    | 27 (54.0)                    | 15 (30.0)                    | 403 (88.0)                   | 293 (64.0)                   |
| Diarrhoea                                                             | 24(38.7)                                                     | 7(11.3)                                                      | 15(28.8)                     | 5 (9.6)                      | 1 (2.0)                      | 1 (2.0)                      | 104(22.7)                    | 33(7.2)                      |
| Vomiting                                                              | 11(17.7)                                                     | 3 (4.8)                                                      | 3 (5.8)                      | 2 (3.8)                      | -                            | -                            | 36 (7.9)                     | 5 (1.1)                      |
| Fatigue                                                               | 9 (14.5)                                                     | 2 (3.2)                                                      | 6 (11.5)                     | 3 (5.8)                      | 4 (8.0)                      | -                            | 61(13.3)                     | 20(4.4)                      |
| Decreased Appetite                                                    | 7 (11.3)                                                     | 3 (4.8)                                                      | 7(13.5)                      | 2 (3.8)                      | -                            | -                            | 65(14.2)                     | 21 (4.6)                     |
| Proteinuria                                                           | 6 (9.7)                                                      | 3 (4.8)                                                      | 8 (15.4)                     | 7(13.5)                      | 1 (2.0)                      | 1 (2.0)                      | 87(19.0)                     | 43 (9.4)                     |
| Abdominal Pain Upper                                                  | 5 (8.1)                                                      | 1 (1.6)                                                      | 2 (3.8)                      | -                            | -                            | -                            | 12 (2.6)                     | 1 (0.2)                      |
| Asthenia                                                              | 5 (8.1)                                                      | 1 (1.6)                                                      | 5 (9.6)                      | 1 (1.9)                      | 1 (2.0)                      | 1 (2.0)                      | 46(10.0)                     | 20 (4.4)                     |
| Nausea                                                                | 5 (8.1)                                                      | 2 (3.2)                                                      | 7 (13.5)                     | 2 (3.8)                      | -                            | -                            | 52(11.4)                     | 7 (1.5)                      |
| Stomatitis                                                            | 5 (8.1)                                                      | 1 (1.6)                                                      | 1 (1.9)                      | 1 (1.9)                      | -                            | -                            | 33 (7.2)                     | 10 (2.2)                     |
| Thrombocytopenia                                                      | 5 (8.1)                                                      | 3 (4.8)                                                      | -                            | -                            | 1 (2.0)                      | -                            | 14 (3.1)                     | 7 (1.5)                      |
| Hypertriglyceridaemia                                                 | 4 (6.5)                                                      | 4 (6.5)                                                      | -                            | -                            | -                            | -                            | 1 (0.2)                      | -                            |
| Pyrexia                                                               | 4 (6.5)                                                      | 1 (1.6)                                                      | -                            | -                            | 2 (4.0)                      | 1 (2.0)                      | 4 (0.9)                      | -                            |
| Renal Failure Acute                                                   | 4 (6.5)                                                      | 3 (4.8)                                                      | -                            | -                            | -                            | -                            | 3 (0.7)                      | 1 (0.2)                      |
| Weight Decreased                                                      | 4 (6.5)                                                      | 1 (1.6)                                                      | 3 (5.8)                      | 1 (1.9)                      | -                            | -                            | 72(15.7)                     | 28 (6.1)                     |
| Dehydration                                                           | 3 (4.8)                                                      | 3 (4.8)                                                      | -                            | -                            | -                            | -                            | 15 (3.3)                     | 9 (2.0)                      |
| Hypertension                                                          | 3 (4.8)                                                      | 2 (3.2)                                                      | 6 (11.5)                     | 4 (7.7)                      | -                            | -                            | 97(21.2)                     | 68 (14.8)                    |
| Abdominal Discomfort                                                  | 2 (3.2)                                                      | -                                                            | -                            | -                            | -                            | -                            | -                            | -                            |
| Abdominal Pain                                                        | 2 (3.2)                                                      | 1 (1.6)                                                      | 5 (9.6)                      | 2 (3.8)                      | -                            | -                            | 18(3.9)                      | 3 (0.7)                      |
|                                                                       | Renal Cell Carcinoma All DTC                                 | Renal Cell Carcinoma All DTC                                 | Renal Cell Carcinoma All DTC | Renal Cell Carcinoma All DTC | Renal Cell Carcinoma All DTC | Renal Cell Carcinoma All DTC | Renal Cell Carcinoma All DTC | Renal Cell Carcinoma All DTC |
| Preferred Term                                                        | Lenvatinib 18mg + Everolimus 5mg Phase Ib + Phase II (N=62)* | Lenvatinib 18mg + Everolimus 5mg Phase Ib + Phase II (N=62)* | Lenvatinib 24mg              | Lenvatinib 24mg              | Everolimus 10mg              | Everolimus 10mg              | Lenvatinib                   | Lenvatinib                   |
|                                                                       | All                                                          | Grade                                                        | All                          | Grade                        | All                          | Grade                        | All                          | Grade                        |
| Blood Creatine Phosphokinase Increased                                | 2 (3.2)                                                      | 2 (3.2)                                                      | -                            | -                            | 1 (2.0)                      | 1 (2.0)                      | 5 (1.1)                      | 1 (0.2)                      |
| Dyspnoea                                                              | 2 (3.2)                                                      | -                                                            | 1 (1.9)                      | -                            | 2 (4.0)                      | 1 (2.0)                      | 8 (1.7)                      | -                            |
| Gingivitis                                                            | 2 (3.2)                                                      | -                                                            | -                            | -                            | -                            | -                            | 1 (0.2)                      | -                            |
| Hypercholesterolaemia                                                 | 2 (3.2)                                                      | 2 (3.2)                                                      | 1 (1.9)                      | 1 (1.9)                      | -                            | -                            | -                            | -                            |
| Hypotension                                                           | 2 (3.2)                                                      | -                                                            | -                            | -                            | -                            | -                            | 12 (2.6)                     | 6 (1.3)                      |

<div style=\"page-break-after: always\"></div>

| Lethargy                                    | 2 (3.2)   | 1 (1.6)   | 1 (1.9)   | -       | 1 (2.0)   | -       | 1 (0.2)   | -        |
|---------------------------------------------|-----------|-----------|-----------|---------|-----------|---------|-----------|----------|
| Pneumonitis                                 | 2 (3.2)   | -         | -         | -       | 3 (6.0)   | 2 (4.0) | 1 (0.2)   | -        |
| Anaemia                                     | 1 (1.6)   | 1 (1.6)   | 1 (1.9)   | 1 (1.9) | 6 (12.0)  | 4 (8.0) | 4 (0.9)   | 1 (0.2)  |
| Arthralgia                                  | 1 (1.6)   | -         | 1 (1.9)   | -       | -         | -       | 22 (4.8)  | 1 (0.2)  |
| Cough                                       | 1 (1.6)   | -         | -         | -       | 2 (4.0)   | -       | 6 (1.3)   | -        |
| Dysphonia                                   | 1 (1.6)   | -         | -         | -       | -         | -       | 15 (3.3)  | 4 (0.9)  |
| Ejection Fraction Decreased                 | 1 (1.6)   | -         | 3 (5.8)   | 1 (1.9) | -         | -       | 6 (1.3)   | 2 (0.4)  |
| Hypothyroidism                              | 1 (1.6)   | -         | 2 (3.8)   | 1 (1.9) | -         | -       | -         | -        |
| Lipase Increased                            | 1 (1.6)   | 1 (1.6)   | 2 (3.8)   | 2 (3.8) | -         | -       | 6 (1.3)   | 6 (1.3)  |
| Lower Respiratory Tract Infection           | 1 (1.6)   | -         | -         | -       | 4 (8.0)   | 1 (2.0) | 2 (0.4)   | 2 (0.4)  |
| Palmar-Plantar Erythrodysaesthesia Syndrome | 1 (1.6)   | -         | 1 (1.9)   | -       | 1 (2.0)   | -       | 60 (13.1) | 15 (3.3) |
| Pneumonia                                   | 1 (1.6)   | -         | 1 (1.9)   | 1 (1.9) | -         | -       | 13 (2.8)  | 8 (1.7)  |
| Dizziness                                   | -         | -         | -         | -       | -         | -       | 9 (2.0)   | 1 (0.2)  |
| Electrocardiogram Qt Prolonged              | -         | -         | -         | -       | -         | -       | 9 (2.0)   | 5 (1.1)  |
| Headache                                    | -         | -         | 1 (1.9)   | 1 (1.9) | -         | -       | 19 (4.1)  | 7 (1.5)  |
| Hypocalcaemia                               | -         | -         | -         | -       | -         | -       | 9 (2.0)   | 6 (1.3)  |
| Malaise                                     | -         | -         | 1 (1.9)   | -       | -         | -       | 9 (2.0)   | -        |
| Mouth Ulceration                            | -         | -         | -         | -       | 2 (4.0)   | 1 (2.0) | -         | -        |
| Myalgia                                     | -         | -         | 1 (1.9)   | 1 (1.9) | -         | -       | 12 (2.6)  | 3 (0.7)  |
| Oedema Peripheral                           | -         | -         | -         | -       | -         | -       | 10 (2.2)  | 1 (0.2)  |
| Pain In Extremity                           | -         | -         | 1 (1.9)   | -       | -         | -       | 9 (2.0)   | 1 (0.2)  |
| Upper Respiratory Tract Infection           | -         | -         | 3 (5.8)   | -       | 2 (4.0)   | -       | 5 (1.1)   | -        |

* Includes all subjects who received lenvatinib 18 mg + everolimus 5 mg dose from both Phase I and Phase II portion of study E7080-G000-205. Any TEAEs leading to dose reduction and/or dose interruption not having at least 2 subjects in any treatment arm in the RCC safety set are listed only if the incidence is &gt;=2% in the All DTC set. TEAE = Treatment-emergent adverse event. Dose reduction and/or dose interruption in (Lenvatinib + Everolimus) arm refer to dose reduction and/or interruption in Lenvatinib or Everolimus or both. Percentages are based on the total number of subjects in the safety analysis set within relevant treatment group. Display is in decreasing order of frequency of TEAEs in the (Lenvatinib + Everolimus) Phase Ib + Phase II pooled group. Subject with two or more adverse events in the same preferred term is counted only once for that preferred term. Adverse Events terms were coded using Medical Dictionary for Regulatory Activities (MedDRA) version 17.1. The data cut off date for the RCC set is 31JUL2015, data cut off date for the All DTC set is 10DEC2014.

## Post marketing experience

Lenvatinib has been approved for marketing in over 35 countries for the indication of RR-DTC and is sold under the brand name, LENVIMA®. Approximately 1000 new patients have been exposed to lenvatinib since the  International  Birth  Date  of  13  Feb  2015  through  12  Aug  2015,  the  cut-off  date  for  the  most  recent Periodic Safety Update Report (Oct 2015).

Most of the exposure has been in patient support programs in the US and in a post-marketing surveillance study  in  Japan.  The  most  frequently  reported  adverse  reactions  post-marketing  have  been  dehydration, hypertension, diarrhoea, fatigue, and nausea. These are consistent with the adverse reactions observed in the clinical studies included in the original MAA for DTC and are consistent with the safety profile of lenvatinib as reflected in the current product information.

<div style=\"page-break-after: always\"></div>

## 2.6.1. Discussion on clinical safety

From  the  safety  database  all  the  adverse  reactions  reported  in  clinical  trials  have  been  included  in  the Summary of Product Characteristics.

The assessment of clinical safety is based on the results of the phase 1b/2 study 205 which enrolled overall 62 patients with RCC treated with the intended dosing regimen of lenvatinib-everolimus combination. Data for  lenvatinib  monotherapy  was  provided  from  studies  in  other  indications  and  is  supported  by  data  from lenvatinib monotherapy arm of Study 205. The safety profile of everolimus is well-established in the secondline RCC patients. The open-label nature of Study 205, in addition to its relatively small sample size, further diminished the value of safety data analysis from randomised treatment arms. Comparison exercise between combination  arm  and  respective  monotherapy  arms  is  further  complicated  by  lower  doses  of  components used within combination than in single-agent arms. The submitted data did not allow evaluation of potential PD and/or PK interactions that could result in higher toxicity in certain patient subgroups.

Safety data from the randomised part of Study 205 were supported by safety data coming from the dosefinding part of the same study.

The most frequently reported TEAEs (any grade), occurring in at least 30% of subjects in the combination group were diarrhoea (80. 6%), fatigue (59.7%),  decreased appetite (53.7%), vomiting (48.4%), nausea (45.2%), hypertension (40.3%), hypertriglyceridemia (40.3%), cough (37.1%), stomatitis (35.5%), peripheral  oedema  (33.9%),  decreased  weight  (33.9%),  dyspnoea  (30.6%),  and  hypercholesterolemia (30.6%).  There is an overlap with safety profiles of both lenvatinib (associated with hypertension, diarrhoea, decreased  appetite, weight decreased, fatigue,  nausea, proteinuria, stomatitis, vomiting, dysphonia, headache, and palmar-plantar erythrodysesthesia (PPE) syndrome) and everolimus (stomatitis, rash, fatigue, diarrhoea, infections, nausea, decreased appetite, anaemia, dysgeusia, pneumonitis, hyperglycemia, weight decreased, pruritus, asthenia, peripheral edema, hypercholesterolemia, epistaxis, and headache).

The  most  frequently  reported  Grade  3  or  4  TEAEs,  occurring  in  at  least  5%  of  subjects  in  the  RCC combination group, were diarrhoea (19.4%), fatigue (12.9%), hypertension (12.9%), hypertriglyceridemia (12.9%), acute renal failure (8.1%), anaemia (8.1%), dehydration (8.1%), proteinuria (8.1%), and vomiting (6.5%).  In  the  lenvatinib  arm,  the  most  common  grade  3  or  4  treatment-emergent  adverse  event  was proteinuria (19%) and in patients assigned to single-agent everolimus it was anaemia (12%).

Grade 3 and 4 events occurred in higher proportion of patients allocated to lenvatinib plus everolimus arm (71%) and single-agent lenvatinib arm (79%) compared to single-agent everolimus (50%).

SAEs were reported in 38 subjects (61.3%) in the combination group (n=62), in 28 subjects (53.8%) in the lenvatinib arm, and in 21 subjects (42.0%) in the everolimus arm. Among the most frequent SAEs (&gt;5% subjects) reported in the combination arm were dehydration (9.7%) and renal failure (8.1%). Other most serious  adverse  events  include  dyspnea,  gastrointestinal  AEs  (diarrhea  and  vomitig)  and  haematological events  (anaemia  and  thrombocytopenia).  Anaemia  was  more  frequently  reported  in  the  combination  and everolimus arms (in 4 subjects each).

Six  fatal  AEs  were  reported,  including  one  cerebral  haemorrhage  in  the  combination  group  and  one myocardial  infarction  with  single-agent  lenvatinib.  Longer  follow-up  data  in  patients  with  RCC  reported additional SAE of myocardial infaction with fatal outcome one day post-treatment.

Clinically  significant  events  (CSEs)  previously  defined  for  the  DTC  MAA  included  hypertension,  proteinuria, arterial  and  venous  thromboembolic  events,  posterior  reversible  encephalopathy  syndrome  (PRES),  renal events,  liver  events,  gastrointestinal  (GI)  perforation  and  fistula  formation,  QTc  prolongation,  decreased

<div style=\"page-break-after: always\"></div>

ejection  fraction  (EF),  hypocalcaemia,  haemorrhage,  and  PPE.  Weight  loss  and  cytopenias  were  also evaluated.

For  the  majority  of  CSEs,  there  was  no  significant  change  to  the  known  safety  profiles  of  lenvatinib  or everolimus, but the available data do not allow to make definitive conclusions since some events are rarer and would not be adequately addressed by available safety database. No Hy's Law cases occurred. However, the frequency of renal events and cytopenias (anaemia, thrombocytopenia), did increase in the RCC safety set. Renal failure, renal impairment and proteinuria were reported in substantial proportion of patients, with about 10% incidence of grade 3 or greater.

## Consistency with safety profile of VEGFi and mTORi

The  AEs  observed  with  combination  lenvatinib/everolimus  in  Study  205  are  consistent  with  the  known toxicities of each individual agent.

Furthermore,  lenvatinib  has  a  safety  profile  that  is  consistent  with  other  VEGF/VEGFR-targeted  therapies, although the nature and extent of various AEs differ among the approved compounds, described as follows.

Combination lenvatinib/everolimus tends to be associated most frequently with hypertension; GI events such as  diarrhoea,  nausea,  and  vomiting;  hypothyroidism;  and  hypercholesterolemia.  These  events  can  be controlled with dose modifications and prompt medical treatment.

Everolimus  was  also  associated  with  high  rates  of  hyperglycaemia  as  well  as  anaemia,  lymphopenia,  and dyslipidaemia,  and  the  SmPC  contains  special  precautions  for  non-infectious  pneumonitis,  renal  failure events, stomatitis, and wound healing complications.

## Safety in comparison to other TKIs use in second line treatment of mRCC

Common  treatment-related  adverse  events  associated  with  VEGF-targeted  therapies  and  TKIs  in  general include  fatigue  and  asthenia,  GI  symptoms  (e.g.,  diarrhoea,  stomatitis),  skin  toxicities  (e.g.,  hand-foot syndrome,  hair  depigmentation,  rash),  cardiovascular  toxicities  (e.g.,  hypertension),  and  a  variety  of metabolic and laboratory abnormalities (Schmidinger, 2013). Although there are a number of known class effects,  targeted  agents  differ  regarding  their  individual  side  effect  profiles.  These  differences  may  be attributed to the drug's mode of action, the number of targets inhibited, the type of inhibited target(s) (e.g., VEGF vs. PDGF vs.Flt-3), and the strength of target inhibition (affinity to the tyrosine kinase, 'on-' and 'off-' target toxicities) (Chen and Cleck, 2009; Haraldsdottir and Shah, 2014; Schmidinger, 2013).

Some toxicities have been linked to the inhibition of a specific target, e.g., hypertension and VEGF; however, the  association  of  other  side  effects  with  a  particular  target  is  less  clear  (e.g.,  stomatitis,  diarrhoea). Moreover,  single-nucleotide  polymorphisms  may  influence  the  incidence  and  severity  of  side  effects  in different patient populations (Schmidinger, 2013).

Events  regarded  as  class  effects  that  occurred  infrequently,  rarely,  or  not  at  all  with  combination lenvatinib/everolimus included arterial and venous thromboembolic events, interstitial lung disease, cardiac failure, PRES, PPE, and impaired wound healing. However, the number of patients was limited and serious adverse events should be closely monitored.

Hypertension  was  commonly  reported  with  all  of  the  approved  agents  and  appears  to  be  dose-dependent (Schmidinger, 2013). Axitinib was also associated with high rates of elevated TSH and GI events such as nausea  and  diarrhoea.  Sorafenib  was  associated  with  higher  rates  of  PPE,  rash,  alopecia,  and  bleeding

<div style=\"page-break-after: always\"></div>

events.  Pazopanib  was  associated  with  higher  rates  of  hyperglycaemia,  haemorrhagic  events,  and  liver events (including elevations in liver transaminase values).

In  clinical  trials  of  TKIs,  amylase  and  lipase elevations  were  also  reported  frequently  (often  by  more than 30% of subjects) and are considered a class effect, whereas acute pancreatitis occurred in fewer than 5% of subjects (Pezzilli, et al., 2010). Another review of clinical trials of TKIs reported increased amylase and lipase levels in approximately 50% of subjects (Schmidinger, 2013). In Study 205, elevations in lipase and amylase concentrations occurred in approximately 10% and 3% of subjects in the RCC combination arm, respectively, but there were no cases of pancreatitis.

## Potential for new or worsening safety

The potential for new or worsening safety signals with combination lenvatinib/everolimus therapy in RCC was evaluated in comparison with the known safety profiles of lenvatinib and everolimus as single agents.

No new safety signals have been identified with combination therapy in the RCC Safety Set, which was not already known for either lenvatinib or everolimus.

Hypertriglyceridemia, anaemia, hyperglycaemia, and pruritus were reported with an increased frequency in the  RCC combination group relative to the All DTC  Safety Set and fulfilled the criteria  for  a  potential new safety signal with combination therapy in the RCC population that is not already known for lenvatinib.

Fatigue,  vomiting,  hypercholesterolemia,  dehydration,  and  acute  renal  failure  were  reported  with  an increased frequency in the RCC combination group relative to the All DTC Safety Set.

Diarrhoea  has  also  been  included  for  consideration  because  it  occurred  at  a  high  frequency  (81%  in  the combination arm), although it did not meet one of the prespecified criteria (relative risk of 2 or greater when the RCC combination group was compared with the All DTC Safety Set). Grade 3 or 4 diarrhea occurred in about 19% of patients. It also triggered dose adjustments being the most frequent cause of dose reductions and/or  interruptions  and  resulting  in  discontinuation  of  treatment  in  one  patient.  Although  not  studied directly,  the  MOA  for  the worsening of diarrhea with the combination is postulated to be mediated by the impairment  of  intestinal  function  related  to  the  MOAs  for  the  individual  agents  -  VEGF/VEGFR  and  c-KIT inhibition by lenvatinib coupled with mTOR/NHE3 inhibition by everolimus.

Electrolyte  imbalance,  mucocutaneous  toxicities  and  constitutional  symptoms  are  observed,  although  at varying  frequencies  with  both  VEGFR  TKIs  and  mTOR  inhibitors  and,  in  some  cases  the  combination treatment may alter the frequencies of observed toxicities with the single agents. Drugs that act on the VEGF pathway  may  induce  renal  abnormalities,  as  a  consequence  of  their  intrinsic  mode  of  action  and nephrotoxicity associated with everolimus has been reported (Launay-Vacher et al., 2015).  The renal toxicity of VEGF inhibitors is mainly renovascular in nature, including hypertension (HTN), proteinuria, and decreased glomerular  filtration  rate  (GFR).    Renal  events  were  observed  in  higher  proportion  of  patients  in  the combination group (17.7%) than in lenvatinib arm (15.4%) and everolimus arm (12%), with higher rate of grade 3 and more events (9.7%, 5.8% and 2%, respectively). Grade 3 acute renal failure events occurred at a  higher  rate  in  the  RCC  combination  group  (5  subjects,  8.1%)  than  in  the  lenvatinib  alone  mRCC  group (5.8%) or in the All DTC Safety Set (4 subjects, 0.9%).

The incidence rate of hypothyroidism (any grade) was much higher in the RCC combination group (24.2%) compared with that in the everolimus group (2%). In addition, the incidence rate of increased blood TSH (any  grade)  in  the  RCC  combination  group  (11.3%)  was  higher  than  that  in  the  All  DTC  Safety  Set. Impairment  of  exogenous  thyroid  suppression  is  included  in  the  Warnings  and  Precautions  section  of  the

<div style=\"page-break-after: always\"></div>

approved LENVIMA SmPC.  The rate of hypothyroidism for combination lenvatinib/everolimus was within the range reported for other agents in the same class.

Both hypothyroidism and increased blood TSH are known class effects of TKIs (Haraldsdottir and Shah, 2014; Pezzilli, et al., 2010).  The rate of hypothyroidism may be dose dependent as it was reported at a higher rate in the RCC lenvatinib group (24 mg lenvatinib:  36.5%) compared with the RCC combination group (18 mg lenvatinib:  24.2%). Furthermore, 75% of patients in the lenvatinib plus everolimus-treated group were not receiving  exogenous  thyroid  replacement,  and  of  these,  71%  had  normal  baseline  thyroid  stimulating hormone (TSH) levels. In patients with a normal TSH at baseline, an elevation of TSH level was observed post  baseline  in  63%  of  lenvatinib  plus  everolimus-treated  patients  as  compared  with  none  in  patients receiving everolimus alone.

Unexpected onset of AEs due to potential pharmacokinetic and/or pharmacodynamic interactions and their late detection is not excluded given that experience with VEGFi-mTORi combinations is limited to date mainly to early phase studies, with few data at long term.

Investigation of safety data from Studies 307 and 218 in regard to potentially worsening AEs will be further conducted in a manner similar to that applied to the data from Study 205.  The frequency of all treatmentemergent adverse events (TEAEs) (any grade) and Grade 3 or 4 TEAEs. The first review to be conducted will be  of  first-line  data  in  Study  307  (which  is  estimated  to  be  available  by  2020)  against  the  known  safety profile of treated subjects in DTC and second-line RCC, followed, in 2021, by a comparison of the secondand third-line data in RCC Study 218.  The Study 218 data will also be pooled with the 2 previous data sets in support of the addition of these data to the SmPC.  This will allow analysis of safety data across the breadth of  the  RCC  population covered in Studies 307, 218, and 205, and will provide a useful view of the safety profile  across  the  proposed  range  of  use  from  first-line  through  third-line  settings.  Any  differences  in incidence or severity from the existing AE profile or between different subgroups will be identified, discussed, and if warranted, proposed for inclusion in the SmPC.

The following methodology was proposed to further characterise potential worsening of AEs. Events will be considered potential new or worsening signals if: they occur at ≥ 5% (any grade) AND there is a relative risk of 2 or greater when the RCC combination group is compared either with the everolimus EPAR pooled data set  or  the  incidences  of  the  events  which  are  ADRs  in  the  Kisplyx  SmPC;-OR  for  Grade  3  or  4  events,  or clinically significant adverse events, if they occur at ≥ 1% AND there is a relative risk of 2 or greater when the RCC combination group is compared either with the everolimus EPAR pooled data set or the incidences of the events which are ADRs in the Kisplyx SmPC.

## Long-term safety

Long-term safety data for the combination are currently available from Study 205 and are limited by the number of subjects in the study and, consequently, by the number of patients who received treatment for more than one year. The combination treatment appear to prolong overall survival in patients in the pivotal study, with median OS of about 2 years observed. Of the 62 subjects in the combination arm, 22 subjects (35.5%) had 1 year or more of treatment (36.3 SY) and 5 subjects (8.1%) had ≥ 2 years of treatment (12.0 SY).  However,  long-term  safety  will  be  more  comprehensively  assessed  in  a  lager  safety  database  in  the planned  studies.  In  particular,  potential  cumulative  toxicity  and  time-dependent  intolerability  and  toxicity could emerge at longer term. Additional combination-therapy trials (Studies 218, 307 and 221) are planned, which  will  provide  additional  data  on  longer-term  safety  and  allow  comparison  with  single  agent  safety profiles.  Moreover,  real-world  data  will  become  available  from  the  EU  and  US  upon  approval  of  the combination.

<div style=\"page-break-after: always\"></div>

Given the limited number of patients treated with combination, no meaningful conclusions in regard to longterm  toxicity  can  be  drawn.  Higher  proportion  of  all  types  of  AEs  appears  to  be  observed  within  first  6 months, but some increase in toxicity might occur at more than 1 year of exposure. Collection of long-term safety  data  is  of  continuous  importance  also  for  lenvatinib  monotherapy  and  several  studies  are  ongoing. Long-term data with other VEGF-targeted therapies (eg Rini et al, 2015) indicate increase in cardiovascular toxicity, which is a key element in B/R of these agents (Shah et al, 2015). Long-term data on the safety profiles of the TKIs axitinib and sunitinib used as monotherapy in RCC have been analysed.  Of a total of 108 patients had received axitinib for ≥ 2 years, and interval analysis showed that most AEs occurred during the first 6 months of treatment, with rates stable or decreased over time.  However, incidence rates increased over time for proteinuria, peripheral edema, and increased blood creatinine.  Common Grade ≥ 3 AE rates declined or plateaued over time, except for increased amylase and myocardial infarction.  The median times to  onset  for  increased  amylase  and  myocardial  infarction  were  8.1  months  and  22.1  months,  respectively (Rini, et al., 2015). In regard to long-term safety of sunitinib, hypothyroidism increased by interval analysis from 6% at 0 &lt;6 months to 42% at 5-&lt;6 years and by cumulative analysis from 14% at 0-&lt;1 year to 36% over 6 years.  Grade 3/4 treatment-related AEs in patients during long-term treatment peaked during the first year and then steadily decreased (Porta, et al., 2016).

Based  upon  review  of  the  available  literature  on  long-term  use  of  TKIs  as  single  agents  in  mRCC,  the majority of AEs occurred within the first 6-12 months, and the incidence of most AEs decreased or remained stable over time.  The exceptions to these observations were proteinuria, peripheral oedema, increased blood creatinine,  and  hypothyroidism.    The  severe  (Grade ≥ 3)  AEs  that  increased  in  incidence  over  time  were increased  amylase  and  myocardial  infarction,  and  these  AEs  tended  to  occur  later  on  in  treatment  (&gt;8 months).

## Dose

When therapeutic goal is prolongation of survival, it is important to reduce toxicities and to maximize overall time  on  treatment.  The  duration  of  treatment  (including  dose  interruptions)  was  8.0  months  in  the combination  group  (n=62)  (7.6  months  in  the  combination  arm  in  the  Study  205),  7.4  months  in  the lenvatinib group (n=52) and 4.1 months in the everolimus group. Most of the AEs observed up to now with the combination treatment are manageable and further optimisation of strategies to reduce rate of premature discontinuation of treatment due to toxicity is encouraged to allow patients to benefit from highly effective treatment.

The  results  from  the  study  205  show  efficacy  in  mRCC  patients  with  the  starting  dose  of  18  mg  QD  of lenvatinib  and  5  mg  everolimus,  however  88.7%  of  patients  require  dose  modifications  (dose  reduction and/or interruption) and 29% of patients discontunied treatment due to AEs, indicating poor tolerability of the combination. Similarly, overall 89.7% of lenvatinib-treated patients had dose modifications of lenvatinib in  DTC  Study  303.  Data  on  safety  and  activity  of  lower  starting  doses  for  lenvatinib  monotherapy  will  be provided through a randomised dose-finding trial E7080-G000-211 (Study 211) looking at safety and activity of three starting doses (24 mg, 20 mg and 14 mg once daily) (see RMP). Primary endpoints will pertain to safety  (rate  of  TEAE  with  CTCAE  grades  of  3  or  higher  within  6  months  after  randomization),  but  also  to efficacy (Objective response rate (ORR) at 6 months (ORR6M) as assessed by the investigator according to RECIST 1.1).

In the RCC indication, a study comparing lower dose of lenvatinib within combination is requested. Study 218 is a randomised dose-finding phase 2 trial in advanced RCC patients which aims to compare lower dose of

<div style=\"page-break-after: always\"></div>

lenvatinib- 14 mg, with possibility to increase the dose up to 18 mg if well tolerated. The 14-mg starting dose will be escalated to 18 mg if no Grade 2 (intolerable) or any Grade ≥ 3 treatment-emergent adverse events  that  require  dose  reduction  are  observed  in  the  first  cycle  (4  weeks)  of  treatment.    Further characterisation and use of appropriate biomarkers and PK/PD models is also expected (see discussion on clinical pharmacology and RMP).

In order to investigate correctly the potential of lenvatinib for CYP3A4 inhibition/induction, an in vivo study with midazolam as a probe substrate for CYP3A4, the applicant is requested to conduct a drug-drug interaction study to investigate the potential of lenvatinib for CYP3A4 inhibition/induction (study 109).

Further, in order to further charactrerise the combination safety profile, Study 307, 218 and study 221 are planned in addition to the ongoing safety studies for lenvatinib monotherapy (Studies 303, 208 and 211).

Study  218  will  further  evaluate  the  safety  of  lenvatinib-everolimus  combination  and  further  contribute  to knowledge  on  PK  and  PK/PD  of  lenvatinib  and  everolimus  and  their  PK  and  PD  interactions  It  will  also establish  exposure-safety  and  exposure-efficacy  relationships  and  better  inform  the  choice  of  the  optimal starting dose, the results of the integrated and mechanism-based PK/PD modelling should be submitted at the time of submission of the CSR.

Study 307 is requested to further characterise the safety and tolerability profile of the combination therapy and  further  contribute  to  knowledge  on  PK  and  PK/PD  of  lenvatinib  and  everolimus  and  their  PK  and  PD interactions.

Study 221 will continue to characterize safety for the combination treatment in patients with non clear cell renal carcinoma.

The studies requested for Lenvima will also provide relevant safety information for this application. Study 303 will  evaluate  the  long-term  safety  of  lenvatinib  in  patients  with  RR-DTC  in  a  randomized,  double-blind, placebo-controlled Phase 3 study. This will enable to continue to characterize/ confirm current and long-term safety profile of lenvatinib in monotherapy in another indication (DTC). Study 208 will contribute to the longterm safety profile of lenvatinib in patients with advanced thyroid cancer. Study 211 will determine whether a starting  dose  of  lenvatinib  20  mg  or  14  mg  QD  will  provide  comparable  efficacy  (based  on  Objective Response Rate at 6 months [ORR6M]) with an improved safety profile to 24 mg QD (based on TEAE Grade 3 or higher in the first 6 months after randomization).

For further details on the above mentioned studies, please see RMP section 2.7 below.

## 2.6.2. Conclusions on the clinical safety

The overall safety profile of lenvatinib-everolimus combination is consistent with known safety profiles of its components  observed  either  in  other  indications (for lenvatinib) or in the intended  indication (for everolimus). The reported toxicity was in general predictable and manageable. No new safety signal has been reported. The incidences and severity of some of the adverse events are increased due to an additive and/or synergic  effect  of  the  combination.  However,  most  of  these  were  well  managed  by  dose  reduction, interruption or by additional medical treatment.

However, precaution is warranted given a small size of safety database, a limited information on long-term toxicity, and a limited data on PK/PD interactions together with indication on potential for worsening toxicity for VEGFRi -mTOR inhibitor combinations in general. Although toxicity appears to be manageable with the

<div style=\"page-break-after: always\"></div>

intended combination, an onset of more frequent or severe toxicity may occur in a larger database and/or at longer term.

Poor  tolerability  of  the  combination  is  manifest  with  high  rates  of  discontinuations  due  to  AEs  and  dose modifications.

Therefore, further studies need to be conducted in relevant clinical setting in order to provide comprehensive data  and  to  improve  tolerability  profile  of  the  combination  in  view  of  a  limited  safety  database  for  the combination  treatment  at  intended  doses/schedule,  related  uncertainties  and  poor  tolerability  of  the combination (high rate of treatment discontinuation and dose modifications).

The CHMP considers the following measures necessary to address issues related to safety (please see section 2.7 of the RMP):

Study 307 is requested to further characterise the safety and tolerability profile of the combination therapy and  further  contribute  to  knowledge  on  PK  and  PK/PD  of  lenvatinib  and  everolimus  and  their  PK  and  PD interactions.

Study 218 will further evaluate the safety of lenvatinib-everolimus combination and contribute to knowledge on  PK  and  PK/PD  of  lenvatinib  and  everolimus  and  their  PK  and  PD  interactions.  It  will  also  establish exposure-safety and exposure-efficacy relationships and better inform on the choice of the optimal starting dose. The results of the integrated and mechanism-based PK/PD modelling should be submitted at the time of submission of the CSR.

Study 221 will continue to characterize safety for the combination treatment in patients with non clear cell renal carcinoma.

Study 010 will assess in vitro lenvatinib protein binding, determine the unbound drug concentrations in order to define correctly the dose-adjustment in patients with severe hepatic and renal impairment.

Studies requested for Lenvima will also provide relevant safety information for this application (please see section 2.7 of the RMP). Study 303 will evaluate the long-term safety of lenvatinib in patients with RR-DTC in a randomized, double-blind, placebo-controlled Phase 3 study. Study 208 will determine the long-term safety profile  of  lenvatinib  in  patients  with  advanced  thyroid  cancer.  Study  211  will  determine  whether  a  lower starting dose of lenvatinib will provide comparable efficacy (based on Objective Response Rate at 6 months [ORR6M]) with an improved safety profile  to  24  mg  QD  (based  on  TEAE  Grade  3 or  higher  in  the  first  6 months  after  randomization).  Study  109  will  investigate  correctly  the  potential  of  lenvatinib  for  CYP3A4 inhibition/induction.

## 2.7. Risk Management Plan

## Safety concerns

| Summary of safety concerns   | Summary of safety concerns                           |
|------------------------------|------------------------------------------------------|
| Important identified risks   | Hypertension Proteinuria Renal failure or impairment |

<div style=\"page-break-after: always\"></div>

| Summary of safety concerns   | Summary of safety concerns                                                                                                                                                                                                                                                                                                                                                                                                                              |
|------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                              | Hypokalaemia Cardiac failure Posterior reversible encephalopathy syndrome (PRES) Hepatotoxicity Haemorrhagic events Arterial thromboembolic events (ATEs) QTc prolongation Hypocalcemia                                                                                                                                                                                                                                                                 |
| Important potential risks    | Gastrointestinal perforation and fistula formation Venous thromboembolic events (VTEs) Abnormal pregnancy outcome, excretion of lenvatinib in milk Male and female fertility Pancreatitis Bone and teeth abnormalities in the paediatric population Impaired wound healing Interstitial Lung Disease (ILD)-like conditions Potential of lenvatinib for induction/inhibition of CYP-3A4 Mediated Drug Metabolism Overdose (concomitant everolimus) (RCC) |
| Missing information          | Use in the paediatric population Use in severe hepatic impairment Use in severe renal impairment Use in patients from ethnic origins other than Caucasian or Asian Use in patients aged ≥ 75 years Long-term use                                                                                                                                                                                                                                        |

## Pharmacovigilance plan

| Study/activity Type, title and category (1-3)   | Objectives                                                                         | Safety concerns addressed                                                             | Status (planned, started)   | Date for submission of interim or final reports (planned or actual   |
|-------------------------------------------------|------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------|-----------------------------|----------------------------------------------------------------------|
| Study 109 (Interventional Clinical Study:       | A drug-drug interaction (DDI) study to investigate the potential of lenvatinib for | To investigate correctly the potential of lenvatinib for CYP3A4 inhibition/induction, | Planned                     | Mar 2018                                                             |

<div style=\"page-break-after: always\"></div>

| Study/activity Type, title and category (1-3)                     | Objectives                                                                                                                                                                                                                                                                                                                                                                                                              | Safety concerns addressed                                                                                                             | Status (planned, started)                                     | Date for submission of interim or final reports (planned or actual   |
|-------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------|----------------------------------------------------------------------|
| Category 3)                                                       | CYP3A4 inhibition/induction                                                                                                                                                                                                                                                                                                                                                                                             | an in vivo study with midazolam as a probe substrate for CYP3A4.                                                                      |                                                               |                                                                      |
| Study E7080- A001-010 (Interventional Clinical Study: Category 3) | A Multicenter Phase 0 Study In Healthy Subjects As Well As Subjects With Either Hepatic Or Renal Impairment To Obtain Plasma To Assess In Vitro Lenvatinib Protein Binding                                                                                                                                                                                                                                              | To define correctly the dose-adjustment in patients with severe hepatic and renal impairment and determine unbound drug concentration | Planned                                                       | 30 June 2019                                                         |
| DTC                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                       |                                                               |                                                                      |
| Study 201 (Interventional Clinical Study: Category 3)             | To evaluate the long-term safety of lenvatinib in Medullary and Iodine-131 Refractory, Unresectable DTC, Stratified by Histology                                                                                                                                                                                                                                                                                        | Continue to characterize/ confirm current safety profile of lenvatinib in DTC                                                         | Completed*                                                    | Feb 2014                                                             |
| Study 207 (Interventional Clinical Study: Category 3)             | To evaluate PK, PD, tolerability, and safety of lenvatinib in children from 2 to less than 18 years of age with a relapsed or refractory solid malignant tumor (including RAI-refractory DTC) and in patients with osteosarcoma, an extension phase to evaluate lenvatinib in combination with two chemotherapy agents. To assess bone growth and height during and after discontinuation of treatment with lenvatinib. | Use in paediatric population aged 2 to <18 years                                                                                      | Start date: 29 Dec 2014, first dose of lenvatinib 15 Jan 2015 | 30 Jun 2018                                                          |
| Study 208 (Interventional Clinical Study: Category 3)             | To determine the long-term safety profile of lenvatinib in Japanese patients with advanced thyroid cancer.                                                                                                                                                                                                                                                                                                              | Continue to characterize/ confirm current safety profile of lenvatinib in DTC                                                         | Completed*                                                    | Final CSR: 2016                                                      |
| Study 303 (Interventional Clinical Study: Category 3)             | To evaluate long-term safety of lenvatinib in patients with RR-DTC in a randomized, double-blind, placebo- controlled Phase 3 study.                                                                                                                                                                                                                                                                                    | Continue to characterize/ confirm current safety profile of lenvatinib in DTC                                                         | Completed*                                                    | Ongoing                                                              |

<div style=\"page-break-after: always\"></div>

| Study/activity Type, title and category (1-3)         | Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | Safety concerns addressed                                                                                                                                                                                | Status (planned, started)   | Date for submission of interim or final reports (planned or actual   |
|-------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|----------------------------------------------------------------------|
| Study 211 (Interventional Clinical Study: Category 3) | Primary Objective • To determine whether a starting dose of lenvatinib 20 mg or 14 mg once daily (QD) will provide comparable efficacy (based on objective response rate [ORR] at 6 months [ORR6M]) with an improved safety profile compared to 24 mg QD (based on treatment-emergent adverse events [TEAEs] of Grade 3 or higher in the first 6 months after randomization). Secondary Objectives: • To evaluate PFS • To evaluate PFS2 • To evaluate safety and tolerability • To evaluate PK-PD relationship between exposure and biomarkers /efficacy/safety • To evaluate impact on HR QOL Exploratory Objectives: • To explore OS •To explore TSH, and other serum biomarkers as potential biomarkers for tumor response • To explore DNA sequence variants in genes that may influence PK, safety, or | Characterize/ confirm safety profile of lenvatinib in DTC at lower doses, to determine whether a lower dose starting dose of lenvatinib will provide comparable efficacy with an improved safety profile | Planned                     | 31 Aug 2020                                                          |
| RCC                                                   | RCC                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | RCC                                                                                                                                                                                                      | RCC                         | RCC                                                                  |

<div style=\"page-break-after: always\"></div>

| Study/activity Type, title and category (1-3)          | Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | Safety concerns addressed                                                                                                                             | Status (planned, started)   | Date for submission of interim or final reports (planned or actual                                                                                                                         |
|--------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study 205 (Interventional Clinical Study: Category 3)* | An Open-Label, Multicenter Phase Ib/2 Study of Lenvatinib Alone, and in Combination with Everolimus in subjects with unresectable advanced or metatstatic renal cell carcinoma following one prior VEGF targeted treatment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | To continue to characterize/confirm the current safety profile of lenvatinib either as monotherapy or in combination with everolimus in advanced RCC. | Ongoing                     | Dec 2018                                                                                                                                                                                   |
| Study 218 (Interventional Clinical Study: Category 3)  | Primary objective: •To assess whether a starting dose of lenvatinib 14 mg in combination with everolimus 5 mg once daily (QD) will provide comparable efficacy (based on objective response rate [ORR] at 24 weeks [ORR24W]) with an improved safety profile compared to lenvatinib 18 mg in combination with everolimus 5 mg (based on treatment-emergent intolerable Grade 2 or any ≥Grade 3 adverse events in the first 24 weeks after randomization). Secondary objectives: •To assess PFS •To assess ORR •To determine the tolerability and safety profile of lenvatinib in combination with everolimus •To assess proportion of subjects who discontinued treatment due to toxicity •To assess time to treatment failure •To assess PK profiles of lenvatinib and everolimus during combination therapy and to assess PK and PD drug-drug interactions •To evaluate OS •To evaluate impact on QOL | To continue to characterize/confirm the current safety profile of lenvatinib either as monotherapy or in combination with everolimus in advanced RCC  | Planned                     | Final protocol and data analysis plan submission: Nov 2016 Study completion: Nov 2020 Periodic interim analyses by independent Data Monitoring Committee Final report submission: Jul 2021 |
| Study 221 (Interventional Clinical Study:              | Primary Objective: •To evaluate objective                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | To characterize the safety profile of lenvatinib + everolimus                                                                                         | Final protocol 13           | Final report submission:                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

| Study/activity Type, title and category (1-3)         | Objectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Safety concerns addressed                                                                                      | Status (planned, started)   | Date for submission of interim or final reports (planned or actual   |
|-------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------|-----------------------------|----------------------------------------------------------------------|
| Category 3)                                           | response rate (ORR) of lenvatinib in combination with everolimus in subjects with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any chemotherapy for advanced disease Secondary Objectives: •To assess safety and tolerability of lenvatinib in combination with everolimus •To evaluate progression- free survival (PFS) •To evaluate overall survival (OS) •To assess the pharmacokinetic (PK) profiles of lenvatinib and everolimus during combination therapy in subjects with nccRCC. Exploratory Objectives: • To explore clinical benefit rate (CBR) • To explore disease control rate (DCR) • To explore duration of response (DOR) •To identify and explore tumor and blood biomarkers that correlate with clinical outcomes, including efficacy •To explore the relationship of population PK derived exposure parameters to biomarker, safety, and efficacy data using a model- based approach | in subjects with nccRCC who have not received any chemotherapy for advanced disease                            | May 2016                    | Q4 2019                                                              |
| Study 307 (Interventional Clinical Study: Category 3) | Primary Objective: • To demonstrate that lenvatinib in combination with everolimus (Arm A) or                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | To continue to characterize/confirm the current safety profile of lenvatinib in combination with everolimus in | Planned                     | The protocol and the data analysis plan for PK/PD should be          |

<div style=\"page-break-after: always\"></div>

| Study/activity Type, title and category (1-3)   | Objectives                                                                                                                                                                                                                                                                                                                                                                                                   | Safety concerns addressed   | Status (planned, started)   | Date for submission of interim or final reports (planned or actual                                                                                 |
|-------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                 | pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression-free survival (PFS) (by independent imaging review [IIR] using Response Evaluation Criteria In Solid Tumors [RECIST 1.1]) as first-line treatment in subjects with advanced renal cell carcinoma (RCC). Secondary Objectives: [The secondary objectives are under review and will be updated when finalized]. | advanced RCC                |                             | submitted by: 30/11/2016 Periodic interim analyses by independent Data Monitoring Committee Final report submission of study results: 15 July 2020 |

Category 3 are required additional PhV activity (to address specific safety concerns or to measure effectiveness of risk minimisation measures)

The PRAC, having considered the data submitted, was of the opinion that the proposed post-authorisation PhV development plan is sufficient to identify and characterise the risks of the product.

The PRAC also considered that routine PhV is sufficient to monitor the effectiveness of the risk minimisation measures.

## Risk minimisation measures

| Safety Concern              | Routine Risk Minimization Measures                                                                                                                     | Additional Risk Minimization Measures   |
|-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| Hypertension                | SmPC sections 4.2, 4.4 and 4.8 Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies. | None planned                            |
| Proteinuria                 | SmPC sections 4.4 and 4.8 Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.      | None planned                            |
| Renal failure or impairment | SmPC sections 4.2, 4.4 and 4.8 Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies. | None planned                            |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                      | Routine Risk Minimization Measures                                                                                                                | Additional Risk Minimization Measures   |
|-----------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| Hypokalaemia                                        | SmPC section 4.8 Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.          | None planned                            |
| Cardiac failure                                     | SmPC sections 4.4 and 4.8 Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies. | None planned                            |
| Posterior reversible encephalopathy syndrome (PRES) | SmPC sections 4.4 and 4.8 Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies. | None planned                            |
| Hepatotoxicity                                      | SmPC sections 4.4 and 4.8 Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies. | None planned                            |
| Hemorrhagic events                                  | SmPC sections 4.4 and 4.8 Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies. | None planned                            |
| Arterial thromboembolic events (ATEs)               | SmPC sections 4.4 and 4.8 Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies. | None planned                            |
| QTc prolongation                                    | SmPC sections 4.4 and 4.8 Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies. | None planned                            |
| Hypocalcemia                                        | SmPC sections 4.4 and 4.8                                                                                                                         | None planned.                           |
| Hypothyroidism                                      | SmPC sections 4.4 and 4.8 Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies. | None planned                            |
| Gastrointestinal perforation and fistula formation  | SmPC sections 4.4 and 4.8 Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies. | None planned.                           |
| Venous thromboembolic events (VTEs)                 | SmPC section 4.8                                                                                                                                  | None planned.                           |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                                       | Routine Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                   | Additional Risk Minimization Measures   |
|--------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| Abnormal pregnancy outcome, excretion in breast milk                                 | SmPC section 4.6 Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.                                                                                                                                                                                                                             | None planned                            |
| Male and female fertility                                                            | SmPC sections 4.6 and 5.3 Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.                                                                                                                                                                                                                    | None planned                            |
| Pancreatitis                                                                         | No risk minimization measures are recommended at present as there is insufficient clinical evidence to establish this as an identified risk. The need for risk minimization measures will be revisited on review of pharmacovigilance data . Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies. | None planned                            |
| Bone and teeth abnormalities in the pediatric population                             | SmPC sections 4.2 and 5.3 Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.                                                                                                                                                                                                                    | None planned                            |
| Impaired Wound Healing                                                               | No risk minimization measures are recommended at present as there is insufficient clinical evidence to establish this as an identified risk. The need for risk minimization measures will be revisited on review of pharmacovigilance data .                                                                                                                         | None planned                            |
| Interstitial Lung Disease (ILD)-like conditions                                      | No risk minimization measures are recommended at present as there is insufficient clinical evidence to establish this as an identified risk. The need for risk minimization measures will be revisited on review of pharmacovigilance data . Prescription only medicine.                                                                                             | None planned                            |
| Potential of lenvatinib for induction/inhibition of CYP-3A4 mediated drug metabolism | No risk minimization measures are recommended at present as there is insufficient clinical evidence to establish this as an identified risk. The need for risk minimization measures will be revisited on review of pharmacovigilance data . Prescription only medicine.                                                                                             | None planned                            |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                    | Routine Risk Minimization Measures                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | Additional Risk Minimization Measures   |
|-------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------|
| Overdose (concomitant everolimus) (RCC)                           | No risk minimization measures are recommended at present as there is insufficient clinical evidence to establish this as an identified risk. The need for risk minimization measures will be revisited on review of pharmacovigilance data . Prescription only medicine.                                                                                                                                                                                                                                                                                                                                                                                | None planned                            |
| Use in the paediatric population                                  | SmPC section 4.2 Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | None planned                            |
| Use in severe hepatic impairment                                  | SmPC section 4.2 Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | None planned                            |
| Use in severe renal impairment                                    | SmPC section 4.2 Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | None planned                            |
| Use in patients from ethnic origins other than Caucasian or Asian | SmPC sections 4.2 and 4.4 Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | None planned                            |
| Use in patients aged ≥75 years                                    | SmPC sections 4.2, 4.4 and 4.8 Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | None planned                            |
| Long-term use                                                     | AEs such as cardiovascular events may emerge during long-term treatment, and continuous collection of long- term safety data is relevant for all indications. In RCC, no risk minimization measures are recommended at present as the duration of exposure to the combination covers the lifespan of the treated patient population: 72% of total subject-years of exposure were contributed by patients treated for at least 12 months, whilst median survival for mRCC patients treated with this comibination is 25.5 months. Prescription only medicine. Use restricted to health care professionals experienced in the use of anticancer therapies | None planned                            |

The PRAC, having considered the data submitted, was of the opinion that the proposed risk minimisation measures are sufficient to minimise the risks of the product in the proposed indication(s).

<div style=\"page-break-after: always\"></div>

## Conclusion

The CHMP and PRAC considered that the risk management plan version 8.0 is acceptable.

## 2.8. Pharmacovigilance

## Pharmacovigilance system

The  CHMP  considered  that  the  pharmacovigilance  system  summary  submitted  by  the  applicant  fulfils  the requirements of Article 8(3) of Directive 2001/83/EC.

## 2.9. Product information

## 2.9.1. User consultation

The results of the user consultation with target patient groups on the package leaflet submitted by the applicant show that the package leaflet meets the criteria for readability as set out in the Guideline on the readability of the label and package leaflet of medicinal products for human use.

## 2.9.2. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Lenvatinib (lenvatinib) is included in the additional monitoring list as it contains a new active substance which, on 1 January 2011, was not contained in any medicinal product authorised in the EU.

Therefore the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

The initially claimed indication is:

'Lenvatinib  is  indicated  in  combination  with  everolimus  for  the  treatment  of  patients  with  unresectable advanced  or  metastatic  renal  cell  carcinoma  (RCC)  following  one  prior  vascular  endothelial  growth  factor (VEGF)-targeted therapy'.

The agreed indication is:

<div style=\"page-break-after: always\"></div>

'Kisplyx is indicated in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted prior therapy'.

Renal cell carcinoma is the third leading urologic cancer. About 30% of patients with RCC have metastatic disease at the time of diagnosis, and a significant proportion of patients with localized disease treated with curative nephrectomy relapse subsequently with metastatic disease. Metastatic RCC is associated with a high quality-of-life burden. About 8% to 22.5% of mRCC patients survive for five years or more as compared to 90% of patients with localized renal cancer, but survival rates increase with the use of new therapies and depend  on  several  prognostic  factors.  Patient  population  is  heterogeneous  in  terms  of  clinical  (prognostic factors) and molecular determinants.

The  incidence  of  mRCC  is  increasing,  and  the  disease  is  still  considered  incurable.  The  most  frequent locations of metastases are the lungs, mediastinum, bone, liver, and brain.

In  patients  with  advanced  RCC,  the  aim  of  therapy  is  to  prolong  PFS,  to  achieve  high  response  rate,  to prolong  survival  and  to  improve  quality  of  life.  In  second  line  setting  only  few  agents  could  demonstrate benefit in terms of OS (e.g. nivolumab) and most of therapies approved in second line could show PFS benefit in randomised phase 3 trials, although with different magnitude of effect (median PFS ranging from 4 to 7 months).

## 3.1.2. Available therapies and unmet medical need

Current approved treatments for metastatic RCC in the first-line setting comprise targeted therapies, either tyrosine kinase inhibitors (TKI; sunitinib; pazopanib) or mammalian target of rapamycin (mTOR) inhibitors (temsirolimus) administered as single agents, bevacizumab + interferon, or high-dose interleukin-2.

Approved  second-line  agents  include  TKIs:  sorafenib,  sunitinib,  axitinib,  and  pazopanib  and  the  mTOR inhibitor everolimus.

A novel immunotherapeutic agent, belonging to a class of immune checkpoint inhibitors (PD-1/PD-L1), has been recently granted approval by the EC. Opdivo (nivolumab) as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults.

Afinitor, intended to be used at a half of the recommended dose in combination with lenvatinib, is indicated for the treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy. The recommended dose is 10 mg everolimus once daily. Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs.

## 3.1.3. Main clinical studies

The application is based on a Phase 1b/2 study 205 (n=173) consisting of dose-finding part to determine DLTs/MTD/RP2D  (n=20)  and  randomised  open-label  3-arm  part  (n=153),  with  lenvatinib-everolimus combination (18mg/5mg), single-agent lenvatinib (24mg QD) and single-agent everolimus (10mg QD) arms.

<div style=\"page-break-after: always\"></div>

## 3.2. Favourable effects

## Beneficial effects

The  combination  of  lenvatinib  plus  everolimus  significantly  prolonged  PFS  compared  to  single-agent everolimus with a median PFS of 14.6 months (95% CI: 5.9, 20.1) for the combination versus 5.5 months (95% CI: 3.5, 7.1) for everolimus (HR=0.40, 95% CI: 0.24, 0.68, p=0.0005), by investigator assessment and analysis. An independent imaging review (IIR) was conducted and the results obtained, for PFS and ORR, corroborated the improvements seen in the investigator analyses. The IIR results showed PFS of 12.8 months with  the  proposed  combination  compared  to  5.6  months  with  everolimus  alone  (HR=  0.45,  95%  CI= 0.26,0.79, p=0.003).

The observed PFS benefit was consistent with results for secondary endpoints of OS and ORR.

At 3 different time points, the combination of lenvatinib plus everolimus consistently showed a trend towards prolonged survival compared with everolimus, with HRs (95%CI; p-value) of 0.55 (0.30, 1.01; p=0.06), 0.51 (0.30, 0.88; p=0.02), and 0.59 (0.36, 0.96; p=0.06), respectively.

The ORR for the combination was greater than the ORR for everolimus with 43.1% (1 CR and 21 PRs) and 6%  (3  PRs),  respectively.  The  independent  imaging  review  analyses  showed  an  ORR  of  35.3%  for  the combination compared to 0% in the everolimus arm.

## 3.3. Uncertainties and limitations about favourable effects

The Study 205 is of modest size (153 patients) and was not powered to demonstrate OS benefit. Due to a small sample size the benefit in subgroups could not be comprehensively assessed. Of note, patient reported outcomes have not been collected and impact on quality of life is uncertain.

## 3.4. Unfavourable effects

Diarrhoea,  hypercholesterolemia,  and  hypothyroidism  were  identified  as  worsening  safety  signals  with  the combination treatment compared with lenvatinib and everolimus as monotherapy.

Grade 3 and 4 events occurred in higher proportion of patients allocated to lenvatinib plus everolimus arm (79%) compared to single-agent everolimus (54%).

SAEs were reported in 38 subjects (61.3%) in the combination safety group and in 21 subjects (42.0%) in the everolimus arm.

The rate of discontinuations due to AEs was reported as 29% in pooled safety data set with intended dosing regimen and as 12 % in the everolimus arm.

Adverse events leading to dose reductions, interruptions and modifications (redaction and/or interruptions) were reported respectively in 68%, 76% and 89 % of patients in combination group and in 16 %, 50 and 54% of patients in the everolimus arm.

The  overall  safety  profile  of  the  combination  was  consistent  with  known  safety  profiles  of  individual components, toxicity was predictable and in general manageable. No new safety signals were identified to date.

<div style=\"page-break-after: always\"></div>

## 3.5. Uncertainties and limitations about unfavourable effects

The safety database is limited in terms of sample size (62 patients treated in the intended indication with the intended dose regimen, including 11 in dose-finding part of the study) and in terms of duration of exposure.

It is unknown whether worsening of toxicity, earlier onset or higher severity of ADRs might occur in larger sample size population and whether underlying PK and/or PD interactions could contribute to such worsening.

Insufficient knowledge on PK and PD drug-drug interactions between lenvatinib and everolimus confers risk of potentially higher toxicity. With regard to potential interactions between lenvatinib and everolimus, further exploration is still needed.

In order to better understand the combination safety profile, including long-term toxicity, Studies 307, 218 and 221 are planned in addition to the already ongoing safety studies for lenvatinib monotherapy (Studies 303, 208 and 211).

It is unknown whether alternative dose/regimen will result in better tolerability of the combination. Study 218 will assess whether a starting dose of lenvatinib 14 mg in combination with everolimus 5 mg once daily (QD) will provide comparable efficacy with an improved safety profile compared to lenvatinib 18 mg in combination with everolimus 5 mg, and to assess PK and PK/PD of the two drugs and related interactions. It will also establish  exposure-safety  and  exposure-efficacy  relationships  and  better  inform  the  choice  of  the  optimal starting dose, the results of the integrated and mechanism-based PK/PD modelling should be submitted at the time of submission of the CSR.

Study 307 is requested to further characterise the safety profile and tolerability of the combination therapy and will contribute to understanding of PK, PK/PD of both drugs and their interactions.

Study 221 will assess the safety and efficacy of the combination therapy in non-clear cell RCC patients, the MAH should conduct and submit the results of this Phase 2 Trial.

The level of lenvatinib protein binding is yet not known while the assessment of renal and hepatic impairment should  be  based  on  free  fraction.  Study  010  will  provide  data  to  better  define  the  dose-adjustments  in patients with severe hepatic and renal impairment.

## 3.6. Effects Table

Table 60: Effects Table for Lenvatinib in combination with everolimus.

| Effect             | Short Description                      | Unit    | Treatment Combination LEV+EVE       | Control EVE   | Uncertainties/ Strength of evidence                                                                                       | References                               |
|--------------------|----------------------------------------|---------|-------------------------------------|---------------|---------------------------------------------------------------------------------------------------------------------------|------------------------------------------|
| Favourable Effects | Favourable Effects                     |         |                                     |               |                                                                                                                           |                                          |
| PFS (median)       | Patients alive and free of progression | Month s | 14.5 HR=0.40 95% CI: 0.24, p=0.0005 | 5.5 0.68,     | Open label design, but consistent and significant effect among primary (data cutoff 13 Jun 2014) and sensitivity analyses | See clinical efficacy section of this AR |

<div style=\"page-break-after: always\"></div>

| Effect                                           | Short Description                                | Unit                 | Treatment Combination LEV+EVE   | Control EVE          | Uncertainties/ Strength of evidence                                                            | References                         |
|--------------------------------------------------|--------------------------------------------------|----------------------|---------------------------------|----------------------|------------------------------------------------------------------------------------------------|------------------------------------|
| ORR                                              | Anti-tumour activity (CR+PR)                     | %                    | 43.1                            | 6.0                  | Significant effect                                                                             |                                    |
| OS (median) Cut-off 13 June 2014                 | Gain in survival                                 | Month s              | 25.5                            | 17.5                 | Not powered for OS, but trend towards prolonged survival confirmed by from two successive more |                                    |
| OS (median) Cut-off 13 June 2014                 | Gain in survival                                 | Month s              | HR=0.548 (0.298, 1.009)         | 0.0623               | data mature analyses (10 Dec 2014 and 31 Jul 2015)                                             |                                    |
| Unfavourable Effects                             | Unfavourable Effects                             | Unfavourable Effects | Unfavourable Effects            | Unfavourable Effects | Unfavourable Effects                                                                           | Unfavourable Effects               |
| At least                                         |                                                  | %                    | 100                             | 100                  | Open label design, small sample size                                                           | See clinical safety AR table 4.3.1 |
| AE grade                                         |                                                  | %                    | 79                              | 54                   | \"                                                                                              | \"                                  |
| Serious AE                                       | Serious AE                                       | %                    | 61.3                            | 21                   | \"                                                                                              | \"                                  |
| AE leading to dose interruption                  | AE leading to dose interruption                  | %                    | 75.8                            | 50                   | \"                                                                                              | \"                                  |
| AE leading to dose reduction                     | AE leading to dose reduction                     | %                    | 67.7                            | 16                   | \"                                                                                              | \"                                  |
| AE leading to dose reduction and/or interruption | AE leading to dose reduction and/or interruption | %                    | 87.7                            | 54                   | \"                                                                                              | \"                                  |
| AE leading to discontinuation                    | AE leading to discontinuation                    | %                    | 29.0                            | 12                   | \"                                                                                              | \"                                  |
| Number of AE with fatal outcome                  | Number of AE with fatal outcome                  | %                    | 1.6                             | 4                    | \"                                                                                              | \"                                  |
| Diarrhoea                                        | Diarrhoea                                        | %                    | 80.6                            | 34.0                 | \"                                                                                              | \"                                  |
| Hypertension                                     | Hypertension                                     | %                    | 41.9                            | 10.0                 | \"                                                                                              | \"                                  |
| Proteinuria                                      | Proteinuria                                      | %                    | 30.6                            | 14.0                 | \"                                                                                              | \"                                  |
| Renal failure                                    | Renal failure                                    | %                    | 8.1                             | 2.0                  | \"                                                                                              | \"                                  |
| Cardiac dysfunction                              | Cardiac dysfunction                              | %                    | 4.8                             | 4.0                  | \"                                                                                              | \"                                  |

<div style=\"page-break-after: always\"></div>

| Effect                                                                                         | Short Description                                                                              | Unit   | Treatment Combination LEV+EVE                      |   Control EVE | Uncertainties/ Strength of evidence   | References   |
|------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|--------|----------------------------------------------------|---------------|---------------------------------------|--------------|
| Posterior reversible encephalopathy syndrome (PRES) / Reversible posterior leucoencephalopathy | Posterior reversible encephalopathy syndrome (PRES) / Reversible posterior leucoencephalopathy | event  | 1 PRES                                             |             0 | \"                                     | \"            |
| Arterial thromboembolisms                                                                      | Arterial thromboembolisms                                                                      | %      | 1.6                                                |             6 | \"                                     | \"            |
| Venous thromboembolisms                                                                        | Venous thromboembolisms                                                                        | %      | 6.5                                                |             4 | \"                                     | \"            |
| Haemorrhage                                                                                    | Haemorrhage                                                                                    | %      | 38.7                                               |            28 | \"                                     | \"            |
| QTc prolongation                                                                               | QTc prolongation                                                                               | %      | - 11(greater than 60 ms) - 6 (greater than 500 ms) |             0 | \"                                     | \"            |
| Hypothyroidism                                                                                 |                                                                                                | %      | 24                                                 |             2 | \"                                     | \"            |
| Hypocalcemia                                                                                   | Hypocalcemia                                                                                   | %      | 8.1                                                |             4 | \"                                     | \"            |
| Perforated appendicitis                                                                        | Perforated appendicitis                                                                        | %      | 1.6                                                |             0 | \"                                     | \"            |

Abbreviations: HR: hazard ratio, NA: not applicable, Mo: months, LEN: lenvatinib, EVE: everolimus

Notes: Unfavourable effect rates are from the pooled safety dataset (n=62) for the lenvatinib-everolimus combination.

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The observed magnitude of the PFS gain and the magnitude of ORR in the combination arm compared to everolimus arm are statistically significant and clinically relevant in the second-line treatment of advanced RCC, a disease with currently evolving unmet medical need. New therapeutic options are needed to improve outcomes,  particularly  in  terms  of  overall  survival,  and  also  PFS.  The  intended  combination  showed improvement in PFS compared to standard treatment. Blinded independent imaging review and conducted sensitivity  analyses  provide  reassurance  regarding  the  robustness  of  data.  OS  data  are  supportive  and consistent with PFS/ORR data. The magnitude of PFS benefit is of particular value in this clinical setting in patients that have already received prior VEGF-targeted therapy. The overall safety profile of combination observed was consistent with known safety profiles of individual components, was predictable and in general manageable. No new safety signals were identified to date. This observation is reassuring and of importance for a combination therapy in view of unacceptable toxicities observed with other similar combinations.

However, the small safety database represents a limitation in the assessment of the safety profile. There are several  post-authorisation  studies  (study  218,  307,  221,  205)  which  will  further  characterise  the  safety profile of lenvatinib in combination with everolimus.

<div style=\"page-break-after: always\"></div>

A full understanding of the safety profile will be investigated in planned or on-going studies.

## 3.7.2. Balance of benefits and risks

An improvement in PFS benefit with the combination everolimus+lenvatinib treatment compared with everolimus monotherapy was observed in a single, small, open-label study. The benefits of Kisplyx in combination with everolimus outweigh the risks.

## 3.7.3. Additional considerations on the benefit-risk balance

The CHMP considers the following measures necessary to address issues related to safety: further studies and collection of real-life data are recommended to further address uncertainties.

## 3.8. Conclusions

The overall B/R of lenvatinib in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy is considered positive.

The CHMP recommends the approval of lenvatinib in combination with everolimus for the treatment of adult patients  with  advanced  renal  cell  carcinoma  (RCC)  following  one  prior  vascular  endothelial  growth  factor (VEGF)-targeted therapy.

## 4. Recommendations

## Similarity with authorised orphan medicinal products

The  CHMP  by  consensus  is  of  the  opinion  that  Kisplyx  is  not  similar  to  Nexavar  (sorafenib  tosylate)  and Torisel  (temsirolimus)  within  the  meaning  of  Article  3  of  Commission  Regulation  (EC)  No.  847/200.  See Annex 7.

## Outcome

Based on the CHMP review of data on quality, safety and efficacy, the CHMP considers by consensus that the risk-benefit balance of Kisplyx is positive in the following indication:

Kisplyx is indicated in combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy.

The CHMP therefore recommends the granting of the marketing authorisation subject to the following conditions:

<div style=\"page-break-after: always\"></div>

## Other conditions or restrictions regarding supply and use

## Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States.

Not applicable.